<SEC-DOCUMENT>0001104659-20-040118.txt : 20200330
<SEC-HEADER>0001104659-20-040118.hdr.sgml : 20200330
<ACCEPTANCE-DATETIME>20200330121048
ACCESSION NUMBER:		0001104659-20-040118
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200330
DATE AS OF CHANGE:		20200330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		20755313

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tm205388-1_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, DC 20549</B>&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the fiscal year ended: <U>December
31, 2019</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings"><B><FONT STYLE="font-family: Wingdings">&#168;</FONT></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from _________________
to ______________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMISSION FILE NUMBER: <U>001-38365</U>&nbsp;</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 14pt">EYENOVIA,
INC.</FONT><FONT STYLE="font-size: 10pt"><BR>
(Exact name of Registrant as Specified in Its Charter)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 40%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DELAWARE</B></FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 40%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-1178401</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>295 Madison Avenue, Suite 2400</B><BR>
<B>NEW YORK, NY</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10017</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: <U>(917) 289-1117</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 20%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock, $0.0001 Par Value</B></FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EYEN</B></FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(g) of the Act: none</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes<FONT STYLE="font-family: Wingdings">&#168;</FONT>  No
</FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes<FONT STYLE="font-family: Wingdings">&#168;</FONT>
No </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </FONT><FONT STYLE="font-family: Wingdings">&#120; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes </FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT><FONT STYLE="font-family: Wingdings"> </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 48%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes<FONT STYLE="font-family: Wingdings">&#168;</FONT>  No </FONT><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold
as of June 30, 2019 (based on the closing price of $4.30 on June 28, 2019, the last trading day of the registrant&rsquo;s most
recently completed second fiscal quarter), was approximately $31,000,000. Common stock held by each officer and director and by
each person known to the registrant who owned 10% or more of the outstanding common stock have been excluded in that such persons
may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of outstanding shares of the
registrant&rsquo;s common stock was 19,776,019 as of March 25, 2020.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DOCUMENTS INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Portions of the registrant&rsquo;s proxy
statement for its 2020 Annual Meeting of Stockholders currently scheduled to be held on June 11, 2020 are incorporated by reference
into Part III hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="padding-left: 0.5in; vertical-align: top; width: 1.25in; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I </B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#e_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#e_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#e_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3<FONT STYLE="color: blue"><U>2</U></FONT></FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#g1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#g1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#g1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#g2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#g2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#g2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#g3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#g3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#g3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#g4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#g4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#g4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II</B></FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#h8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#h8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#h8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="#i01"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART III</B></FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i01"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers, and Corporate Governance</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions and Director Independence</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><A HREF="#i07"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART IV</B></FONT></A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i07"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i08"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i08"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i08"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top"><A HREF="#i09"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</FONT></A></TD>
    <TD STYLE="vertical-align: top"><A HREF="#i09"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#i09"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><A HREF="#i10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: bottom"><A HREF="#i10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report contains
a number of &ldquo;forward-looking statements.&rdquo; Specifically, all statements other than statements of historical facts included
in this report regarding our financial position, business strategy and plans and objectives of management for future operations
are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements
were made, as well as assumptions made by and information available to management at that time. When used in this report and the
documents incorporated by reference herein, the words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;continue&rdquo; and &ldquo;intend,&rdquo;
and words or phrases of similar import, as they relate to our financial position, business strategy and plans, or objectives of
management, are intended to identify forward-looking statements. These statements reflect our view, as of the date hereof, with
respect to future events and are subject to risks, uncertainties and assumptions related to various factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should understand
that the following important factors, in addition to those discussed in our periodic reports to be filed with the Securities and
Exchange Commission, or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, could affect our future
results and could cause those results to differ materially from those expressed in such forward-looking statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fluctuations in our financial results
and stock price, particularly given market conditions and the potential economic impact of COVID 19;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our need to raise additional money to
fund our operations for the next twelve months as a going concern;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">risks of our clinical trials including,
but not limited to, the costs, design, initiation and enrollment (which could be adversely impacted by the coronavirus pandemic
and resulting social distancing), timing, progress and results of such trials; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations related to the use of
proceeds from our financings;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations regarding our ability
to fund our operating expenses and capital expenditure requirements with our cash on hand and proceeds from our financings;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates regarding expenses, future
revenue, timing of any future revenue, capital requirements and needs for additional financing;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the potential advantages of our reprioritized
pipeline; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates regarding cost savings related
to our reprioritized pipeline; </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates regarding the potential
market opportunity for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to develop and implement our
anticipated commercialization, marketing and manufacturing capabilities and strategies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the potential advantages of our product
candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the rate and degree of market acceptance
and clinical utility of our products;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our intellectual property position;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to identify additional products,
product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to attract and retain key
personnel;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of government laws and regulations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our competitive position;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developments relating to our competitors
and our industry;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain and establish
collaborations or obtain additional funding;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">general or regional economic conditions;
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in U.S. GAAP; and </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in the legal, regulatory and legislative
environments in the markets in which we operate, including impacts of United States government shut-downs on our ability to raise
money and obtain regulatory approval for our products.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe
that our expectations (including those on which our forward-looking statements are based) are reasonable, we cannot assure you
that those expectations will prove to be correct. Should any one or more of these risks or uncertainties materialize, or should
any underlying assumptions prove incorrect, actual results may vary materially from those described in our forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for our ongoing
obligations to disclose material information under the federal securities laws, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events or any other reason. All subsequent
forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the
cautionary statements contained or referred to herein. In light of these risks, uncertainties and assumptions, the forward-looking
events discussed in this report and the documents incorporated by reference herein might not occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; text-align: justify"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were organized as
a corporation under the laws of the State of Florida on March 12, 2014 under the name &ldquo;PGP Holdings V, Inc.&rdquo; On May
5, 2014, we changed our name to Eyenovia, Inc. On October 6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia,
Inc., a Delaware corporation. Our principal executive office is located at 295 Madison Avenue, Suite 2400, New York, NY 10017,
and&nbsp;our phone number is 917-289-1117. Our website is&nbsp;<I>http://www.eyenoviabio.com</I>. Information contained on, or
that can be accessed through, our website is not incorporated by reference into this report, and you should not consider information
on our website to be part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage
ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing our patented piezo-print delivery
technology, branded the Optejet<SUP>TM</SUP>. Eyenovia aims to achieve clinical microdosing of next-generation formulations of
well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential
to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success
for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication
with a success rate significantly higher than that of traditional eye drops (~90% vs. ~ 50%). Eyenovia&rsquo;s technology also
can deliver up to a 75% reduction in ocular drug and preservative exposure and has demonstrated significant improvement in the
therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and two Phase III trials. Using the Optejet,
Eyenovia is developing the next generation of smart ophthalmic therapeutics which target new indications or new combinations where
there are currently no comparable drug therapies approved by the United States Food and Drug Administration, or the FDA. Eyenovia&rsquo;s
microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified
by the FDA as drugs, and not medical devices or drug-device combination products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 29, 2019,
we announced that we were advancing the development of our MicroLine program for the improvement in the near vision in patients
with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with our MicroPine (progressive
myopia) and MicroStat (mydriasis) programs, Eyenovia deferred development activities for its MicroProst (glaucoma and ocular hypertension)
and MicroTears (red eye and itch relief lubrication) programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Presbyopia is a non-preventable,
age-related hardening of the lens, which causes the gradual loss of the eye&rsquo;s ability to focus on nearby objects. There currently
are no known FDA-approved drugs for the improvement of near vision in patients with presbyopia, although other companies have related
therapies in their pipeline. Eyenovia plans to initiate and complete its Phase III VISION trials for MicroLine in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroPine is the Company&rsquo;s
first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic
axial elongation and sclero-retinal stretching affecting approximately five million people in the United States. In February 2019,
the FDA accepted Eyenovia&rsquo;s investigational new drug application, or IND, to initiate its Phase III registration trial of
MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. Eyenovia enrolled its first patient in the CHAPERONE
study in June 2019 and expects to complete enrollment in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroStat is Eyenovia&rsquo;s
fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated 80
million office-based comprehensive and diabetic eye exams performed every year in the United States. Eyenovia has completed its
Phase III trials for MicroStat and announced positive results from these studies, known as MIST-1 and MIST-2. With the primary
objectives of its Phase III program for MicroStat met, Eyenovia plans to submit a new drug application, or NDA, to the FDA in 2020
for marketing approval in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Results from Eyenovia&rsquo;s
previous Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating mydriatic agents demonstrated
how the Optejet consistently delivered precision dosing at the volume of the eye&rsquo;s natural tear film capacity of 6-8 &micro;L,
which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional
eye drops with fewer side effects. In the third study, Eyenovia evaluated usability, patient tolerability and IOP lowering of microdosed
latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent
with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in
more than 90% of cases. Based on the results from these clinical trials, we are advancing MicroLine, MicroPine, MicroStat, and
MicroProst (should we resume the program) utilizing the 505(b)(2) pathway. Where possible, we also intend to use this pathway for
future clinical trials in new indications with significant unmet needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
our product pipeline and anticipated milestones:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 23%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product&nbsp;</B><BR>
<B>Candidate</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 41%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indication</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Next Expected Milestones</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MicroLine </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presbyopia</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate and Complete Phase III VISION Trials (2020)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MicroPine</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pediatric Myopia Progression
        (Near-Sightedness)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complete CHAPERONE Trial Enrollment (2020)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MicroStat</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mydriasis (Eye Dilation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File NDA (2020)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become
a leading ophthalmic biopharmaceutical company focused on developing and commercializing a strong pipeline of first-in-class microdose
therapeutics and a digital health platform for interactive patient care. The key elements of our strategy to achieve this goal
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Establish a portfolio
of first-in-class piezo-print micro-therapeutic products for multiple eye treatments through the 505(b)(2) pathway with the FDA.</I></B>&nbsp;We
are focused on integrating our next-generation technology with therapeutic compounds already well established in the topical treatment
of ophthalmic indications. We believe that the 505(b)(2) registration pathway, which reduces development risk compared to new molecular
entity programs by working with known compounds with well-established safety and efficacy profiles, will be available for our development
pipeline. We believe our pipeline of patented micro-therapeutic product candidates will be highly differentiated by our improved
tolerability and enhanced compliance profile and that our late-stage development programs could lead to NDA submissions in novel
indications where the products can have unique dosing and therapeutic profiles. We believe that this could lead to favorable pricing
and a reduced risk of generic substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Improve clinical
outcomes and patient experiences while providing an improved tolerability profile with our microdose therapeutics.</I></B>&nbsp;We
believe the Optejet will allow for high precision targeted microdosing for multiple eye treatments, while eliminating ophthalmic
over-dosing and reducing ocular exposure to toxic preservatives and pharmacologic ingredients compared to conventional eye drop
delivery mechanisms. Our clinical trials have demonstrated similar efficacy to eye drops, improved side effect profile and enhanced
patient experience with the Optejet as compared to conventional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Leverage our
electronic, smartphone-enabled &ldquo;e-health&rdquo; technology to introduce and develop patient-specific compliance monitoring
program.</I></B>&nbsp;The Optejet&rsquo;s mobile e-health technology is designed to track when a patient administers treatments,
allowing physicians to monitor patient compliance more accurately. We believe this could enhance patient compliance and improve
compliance monitoring by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for
a more intelligent, informed and personalized therapeutic paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Develop microdose
treatments for other ophthalmic diseases independently or in collaboration with third parties.</I></B>&nbsp;The Optejet also may
be suitable for new molecular entities and applications. Leveraging our existing platform technology, Eyenovia plans to continue
developing, either independently or through strategic relationships with third parties, other product candidates for various eye
diseases that can be administered using the Optejet and additional applications for the Optejet. We have entered into an exclusive
agreement with Senju Pharmaceuticals Co., Ltd., a leading ophthalmology company in Japan, for the Asian development and commercial
rights of our therapies and technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Develop solutions
for ophthalmic conditions with high unmet needs and no approved therapy.</I></B>&nbsp;We plan to target chronic ophthalmic conditions
with a high unmet medical need. By leveraging our piezo-print microdosing technology, we aim to reach conditions where there are
no approved drug therapies. For example, our MicroPine program involves a proprietary formulation of low-dose atropine intended
to slow myopia progression in the pediatric population. There are currently no commercially-available therapies in the United States
to treat this indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitations of Conventional Eye Therapies
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our microdosing platform
technology aims to address the following issues associated with conventional eye drop-based therapies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;<B>Dosing,
administration and waste of medication </B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Multiple third-party
studies have confirmed challenges with administering conventional eye drops, which include overdosing, poor compliance, imprecise
dosing, variability in drop size, and difficulty with self-administration. One study in patients who were experienced in using
eye drops and undergoing treatment for glaucoma for at least six&nbsp;months documented that nine out of 10 patients were unable
to administer treatment correctly at the end of the six-month study. Patients on average administered almost twice the necessary
number of drops with a mean number of drops instilled at 1.8 (+/1 1.2) and one patient administered up to 8 drops at one time.
In addition, approximately 75% of patients risked bottle contamination or potential ocular trauma by having the eye drop container
touch their eyes. Another larger study in 139 patients demonstrated that the proportion of patients who were able to correctly
administer their eye drops was only 22%&ndash;30%. Similarly, other studies have demonstrated that the vast majority of patients
either overdose or do not administer the required therapy to the eye correctly, which leads to unnecessary waste of medication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<I>&nbsp;<B>Side
effects associated with conventional macrodose therapies </B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Topical eye therapies
are administered using traditional eye drop pipette approaches. While average tear volume of the eye is 6&ndash;8 &micro;L, current
eyedrop therapies can involve administration of 30&ndash;50 &micro;L of liquid containing preservatives and pharmaceutical ingredients.
Thus, traditional drops can severely overdose the eye, which, depending on the ingredients, can be associated with ocular side
effects including hyperemia, or increased blood flow to the eye, redness, discomfort, stinging, blurred vision, burning, itching,
excessive tearing, eye pain, iris pigment changes, foreign body sensation, pigment discoloration, periorbital dermatitis and sunken
eye. For some topical medications, there also can be cardiovascular side effects such as changes in heart rate and arrhythmia that
are caused when medications are absorbed into the circulation system from overdosing both through conjunctiva absorption and when
drugs flow into the nose through the naso-lacrimal duct and are absorbed into the systemic circulation or swallowed. For example,
phenylephrine can cause cardiovascular adverse reactions including an increase in blood pressure, syncope, myocardial infarction,
tachycardia, arrhythmia and subarachnoid hemorrhage. Severe respiratory reactions and cardiac reactions, including death due to
bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic
or ophthalmic administration of timolol maleate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroStat contains
phenylephrine and tropicamide. However, as demonstrated in our Phase III study for this product candidate, patients administering
MicroStat reported few ocular adverse events and no systemic adverse events when they administered our microdosed product candidate.
Compared with historical data for traditional eye drops, MicroStat appeared to be much better tolerated, with low systemic absorption
of phenylephrine alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the Optejet, we
believe that the known adverse event profile of pilocarpine, including headaches, also may be moderated to make MicroLine the preferred
choice for presbyopia over potential pilocarpine drop options. The same is true with MicroPine, where we believe that microdosing
may result in a better tolerated product for children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Solution: The Optejet</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg01.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Optejet dispenser
delivers doses of 6&#8201;&ndash;&#8201;8 &micro;L, directly coating the corneal surface where 80% of intraocular drug penetration
occurs. We believe that microdosing may reduce drug and toxic preservative exposure by more than 75%, thus reducing ocular irritation,
and resulting in potentially gentler treatments without compromising the desired clinical effect. Our approach could also reduce
inadvertent waste associated with poor administration of conventional macrodose drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we
are one of the only companies with clinical stage technology for targeted microdosing of ophthalmic investigational therapies having
fully completed the Phase III clinical studies needed to serve as the basis for an NDA submission. The Optejet is based on piezo-print
technology, which is also used for pixel-sharp high-precision inkjet printing. The technology is optimized for and applied in ophthalmic
delivery to achieve microdosing that can be many times more precise than conventional eye droppers. In addition, our smart, electronic
system provides the capability to track when patients administer their medications and deliver this information to patients and
physicians via Bluetooth connectivity. Thus, physicians can make decisions regarding therapeutic regimens with knowledge of patient
compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has provided
written feedback that our clinical development activities will be treated as drug development programs, because only the drug comes
into contact with the eye. Consequently, we do not anticipate needing separate FDA approval for the Optejet dispenser or being
required to comply with FDA medical device regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Microdose administration
of topical ophthalmic drugs with the Optejet has been tested in preclinical models and clinical trials and shown to provide many
advantages over administrations of eye drops. Key advantages of the Optejet include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Dose reduction:</I></B> Our microdose
delivery technology is designed to achieve precise volumetric control at the microliter level to deliver 6&ndash;8 &micro;L, which
is the physiologic capacity of the tear film. This compares favorably to the volume of an eye drop (30&ndash;50 &micro;L), which
can result in overdosing, ocular toxicity and systemic leaching into the plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg02.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Targeted dose
instillation:</I></B> The Optejet allows for targeted delivery to the ocular surface and cornea, avoiding the conjunctival cul-de-sac.
The micro-jet spray created by the piezo-electric vibrations is columnated and focused to provide accurate delivery to the corneal
surface where the majority of ocular penetration occurs. Additionally, the Optejet is designed with an LED targeting mechanism
to facilitate proper positioning and objective alignment, thus increasing the likelihood of successful dose delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg03.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Speed of delivery:</I></B>
Our piezo-print technology is similar to high-precision ink-jet printing. Unlike a simple aerosolized mechanism, the Optejet is
designed with ejection control that creates a fast and targeted micro-jet delivery. Solution is dispensed to the ocular surface
in less than 100 milliseconds between the time the first droplet hits the corneal surface to the completion of dose delivery, which
is faster than the average involuntary blink response time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm205388-1_10kimg04.jpg" ALT="" STYLE="height: 141.75pt; width: 387.75pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;<B>Smart electronics:</B></I>
A key feature of the Optejet is the embedded electronic, smartphone enabled &ldquo;e-health&rdquo; system, which we believe is
the first intelligent electronic delivery system for ophthalmic therapies. Our electronic functions are designed to enable patients
and physicians to track when doses are administered. We believe this technology will improve compliance and chronic disease management
by empowering patients and physicians with access to dynamic, real time monitoring and compliance data for a more intelligent and
personalized therapeutic paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Trial Results </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an established
platform for microdose administration of ophthalmic solutions. Our preclinical and clinical studies suggest that a microdose of
approximately 8 &micro;L of medication results in clinical efficacy comparable to that of traditional eye drops, with the advantages
of fewer ocular side effects and less systemic exposure. We can use our platform technology with either new or existing molecular
entities. We have chosen the latter path for our initial pipeline product candidates.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to initiation
of our Phase III clinical studies, we conducted multiple preclinical and early phase studies to validate our piezo-print microdose
delivery platform. Data from a canine model of glaucoma demonstrated more than 40% IOP lowering effect at microdose of 8&ndash;9
 &micro;L latanoprost. Another independent microdose study published in the Journal of Investigative Ophthalmology and Visual Science
in 2014 further demonstrated that 3 &micro;L microdose with timolol 0.5% can reduce systemic plasma levels of the drug by a factor
of 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Diurnal IOP Lowering Effect of a Microdose
of Latanoprost Delivered by Pipette vs. Piezo-Print Dispenser in a Canine Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg05.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IOP Lowering Effect of Micro-Therapeutic
Dose of Latanoprost in Canine Model</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg06.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The
Phase II EYN-1601 clinical trial compared the mydriatic effect of phenylephrine 10% microdosed (~7 &micro;L in volume) with the
Optejet (EYN) to phenylephrine 10% (PE 10%) and phenylephrine 2.5% (PE 2.5%) eye drops (each ~32 &micro;L in volume) in 24 eyes.
At 75-minute peak dilation, our microdose provided similar mydriatic results (at approximately 1/4 of the dose exposure) to the
10% phenylephrine drops, and superior activity compared to 2.5% phenylephrine drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shown below is mean
pupil diameter change from baseline for the 24 eyes studied. The asterisk at t=75 min indicates EYN is statistically better than
PE 2.5% (p=0.009).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Pupil
Diameter, Increase from Baseline, MM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg07.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study was also
informative with regard to systemic drug exposure of these topical treatments. As shown below, microdosed phenylephrine 10% (EYN1)
demonstrated 35&ndash;40% lower plasma levels as compared with phenylephrine 10% eye drops (PE 10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg08.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown in the table
below, there were also fewer ocular adverse events in the microdosed group (EYN) suggesting an improvement in tolerability as compared
to 10% phenylephrine eye drops (PE 10%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">OCULAR ADVERSE EVENTS BY TREATMENT</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Adverse Event Description</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PE 10%</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Eyedrops)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYN</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(PE 10% microdose)</B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Ocular blurriness</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ocular burning/stinging/irritation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ocular dryness</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Subtotal by Treatment Group</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EYE-103 study investigated
a combination of phenylephrine and tropicamide microdose treatment administered using the Optejet compared to conventional eye
drops in 102 subjects (204 eyes). In this study, microdosing produced equivalent pupil dilation to eye drops and 91% of participants
preferred medication administration with the Optejet versus eye drops (6% preferred eye drops, while 3% expressed no preference
[p &lt; 0.0001]). On a scale of 1 to 10, with 10 being most favorable, general satisfaction scores were higher with Optejet administration
versus eye drops (9.8 &plusmn; 0.6 for Optejet vs 5.8 &plusmn; 3.0 for eye drops). Ocular comfort scores were nearly two times
better with the Optejet than with eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm205388-1_10kimg09.jpg" ALT="" STYLE="height: 118.5pt; width: 351pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, Eyenovia completed
a third early phase trial (EYN-POC-PG-21) to extend the findings of the two previous trials evaluating Optejet administration of
mydriatic agents. This study was a single-center, open-label, prospective, crossover design evaluating the usability, patient tolerability,
and proof-of-concept of microdose administration of commercial latanoprost 0.005% using the Optejet. Thirty healthy volunteer subjects
(60 eyes) were evaluated for eligibility and consented to study participation. Subsequently, at each of three treatment visits,
IOP was measured in the morning. Afterwards, on Treatment Days 1 and 2, a single 8-&micro;L microdose of latanoprost 0.005% ophthalmic
solution was administered to each eye using the Optejet. On the morning of Treatment Day 3, each subject received 2 &times; 8-&micro;L
Optejet microdoses (administered approximately 5 minutes apart) in one eye and the other eye received a single eye drop of latanoprost
0.005% ophthalmic solution. For each treatment day, IOP was measured 1, 7, 12, and 24 hours after receiving medication and a mean
diurnal IOP (DIOP) was calculated from the four readings. As shown below, mean DIOP after medication administration on Days 1 and
2 was lowered by 25.0% and 28.7%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg10.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Mean bilateral DIOP and percent change
in DIOP in eyes dosed using the Optejet through</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Treatment Day 2 (N = 29 pairs of eyes
from 29 evaluable subjects)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As shown below, on
Day 3, mean DIOP was 35.5% lower than baseline for eyes receiving microdose latanoprost 0.005% using the Optejet, and 35.0% lower
than baseline for eyes receiving a single drop of latanoprost 0.005%.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg11.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>DIOP
at Day 3 (N=29 Eyes of 29 Subjects per Treatment)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No clinically significant
changes were noted in slit lamp observations (including hyperemia) for any subjects who received study treatment and no adverse
events were reported. Subjects reported no-to-negligible ocular discomfort after medication administration using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.65in; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investigator-administered
medication using the Optejet was evaluated in 60 eyes (1 spray/eye) on Days 1 and 2, and in 30 eyes (2 sprays/eye) on Day 3. Optejet
administration was successful on the first attempt in 172 of the 180 cases (96%). Subject head movement and/or blinking and investigator
proficiency with Optejet use resulted in the need for additional administration in the remaining 4% of cases, the majority of which
(6/8) occurred on Day 1. Administration success was achieved on the first attempt on all Day 3 cases. There were no reports of
unintentional overdosing, tear fluid overflow, or the dispenser nozzle touching the eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a separate evaluation,
subjects were trained on Optejet self-administration with sterile water and then asked to demonstrate Optejet use in each eye during
the afternoon of each treatment day. By the afternoon of Day 3, qualified Eyenovia representatives judged that almost 90% of subjects
were able to demonstrate accurate self-administration using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This study demonstrated
Optejet medication administration to be easy to perform, safe, and comfortable to study subjects. Additionally, Optejet microdose
administration of 0.005% latanoprost resulted in mean DIOP reduction similar to reported literature for use of latanoprost 0.005%
ophthalmic solution administered as traditional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results
of these studies further validating microdose delivery of ophthalmic medication, we initiated Phase III programs in mydriasis in
late 2018 and progressive myopia in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Product Candidates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, Eyenovia advanced
the development of its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical
studies. As a result of prioritizing MicroLine, in tandem with its MicroPine (progressive myopia) and MicroStat (mydriasis) programs,
the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch
relief lubrication) programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MicroLine </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroLine is our proprietary
microdosed version of pilocarpine, a common ophthalmic medication that can dose-dependently induces miosis, or a contraction of
the pupil. It is a direct acting cholinergic parasympathomimetic agent that stimulates muscarinic acetylcholine receptors present
on smooth muscles, including those in the iris and ciliary body. As a result, pilocarpine causes contraction of the iris sphincter
muscle, which causes miosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reducing pupil size
with pilocarpine has been shown to improve near visual acuity in individuals who have presbyopia. In Benozzi et al, 2012, subjects
aged 45&#8210;50 years who bilaterally self-administered both pilocarpine 1% and diclofenac 0.1% eyedrops every 6 hours during
the day for up to 5 years reported good improvement in near vision without compromising distance vision. Thus, pilocarpine&rsquo;s
miotic effect may be useful in treating the increasingly compromised near vision that parallels the development of presbyopia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Background of
Presbyopia and Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Presbyopia is the gradual
decrease in the ability of the eye&rsquo;s natural lens to accommodate in near vision, resulting in a loss of focus on near objects.
In general, onset is around age 40 and is almost universal in adults over the age of 60. In the United States, there are approximately
113 million people with presbyopia; 20 million of them are between the ages of 45 and 65.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For many people, presbyopia
is among the first overt signs of aging. There are psychological factors accompanying the use of spectacles and bifocals for the
first time, as well as situational inconvenience for either not being able to see well or having to use a vision aiding device.
With MicroLine, we plan to introduce a pharmaceutical option for improving near vision that can work as a companion to spectacles,
for when patients wish not to use their reading glasses. Our market research indicates high interest in the product concept among
people aged 45 &ndash; 60 years, representing a potential market of presbyopes of up to 15 million people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase III Clinical
Development Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to evaluate
whether topical ocular microdosing of pilocarpine using the Optejet dispenser in presbyopic individuals can effectively improve
near vision without compromising distance vision and without causing the undesirable side effects of traditionally administered
pilocarpine. Our two Phase III studies, VISION-1 and VISION-2, are planned to enroll and complete in 2020. These studies will evaluate
the safety, tolerability, and efficacy of an Optejet-administered microdosing of pilocarpine 1% (approximately 0.080 mg/dose) and
2% (approximately 0.160 mg/dose) ophthalmic solutions versus placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MicroPine </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A key therapeutic program
for Eyenovia is our first-in-class topical treatment for progressive myopia, a back-of-the-eye disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Background of
Progressive Myopia and Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Myopia is an ocular
disorder that results in blurry vision when looking at distant objects. This happens when the eyeball is too long or corneal curvature
is too steep causing light entering the eye to be incorrectly focused. Myopia is one of the most common refractive errors seen
in children. Myopia that is present in young children tends to increase through the school years. As myopia progresses, so does
the risk of retinal detachment, cataracts, myopia maculopathy and even blindness. It is estimated that there are over 80 million
children diagnosed with myopia worldwide and over 12 million in the United States between the ages of 5 and 13. Progressive myopia
is estimated to affect close to half of these children in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Examples of Retinal Changes Due to Myopia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm205388-1_10kimg12.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Progressive Myopia with Retinal Atrophy
Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg17.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While currently there are no FDA-approved
therapies for myopia progression, there is growing evidence of the therapeutic benefit of topical atropine ophthalmic solution,
an anticholinergic agent used for pupil dilation and treatment of lazy eye, as a treatment to slow progression. Academic groups
have demonstrated that low dose atropine solution reduces myopia progression 60-70%, with sustained effect through three years.
A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology, indicates Level 1 (highest) evidence
of efficacy for low dose atropine for reduction of progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2)
391:399)). While atropine 1% ophthalmic solution is FDA-approved and commercially available in the United States for pupil dilation
and treatment of lazy eye, commonly reported side effects such as burning and stinging during drop administration, and blurred
vision and light sensitivity associated with its use make it undesirable for the treatment of progressive myopia in the pediatric
population, thus impeding the drug&rsquo;s clinical utility and adoption for myopia progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm205388-1_10kimg13.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our MicroPine program involves the development
of a micro-formulation (dilute and low volume) of atropine ophthalmic solution for reduction of myopia progression in children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Phase III Clinical
Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA accepted Eyenovia&rsquo;s
IND to initiate our single Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia
in children. Eyenovia enrolled its first patient in the CHAPERONE study in June 2019 and expects to complete enrollment in 2020.
The trial is a U.S.-based, multi-center, randomized, double-masked study enrolling more than 400 children and adolescents. Participants
will be equally randomized to receive nightly treatment with either of two MicroPine treatment concentrations or a placebo control
arm. The primary assessment of efficacy is based on reduction in myopia progression after 3 years of medication use. If the primary
objectives of our Phase III study are met, we plan to submit an NDA based on this study as well as existing literature demonstrating
the efficacy of low-dose atropine to reduce the progression of myopia in children to the FDA for marketing approval of MicroPine
to slow the progression of myopia under the 505(b)(2) pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MicroStat </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroStat is the potentially
first-in-class fixed combination micro-formulation product candidate for mydriasis (eye dilation) intended to facilitate the estimated
80 million office-based comprehensive and diabetic eye exams and four million ophthalmic surgical dilations performed every year
in the United States. Our fixed combination product has been developed to facilitate efficient pupil dilation with the potential
to reduce unintended effects of conventionally administered mydriatic agents. We believe the market for MicroStat exceeds $250
million in the United States alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Background of Mydriasis and Market
Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are more than
an estimated 80 million topical mydriatic applications performed every year as a required part of the comprehensive dilated eye
exam and standard retina fundoscopy for diabetic retinopathy screening, macular degeneration evaluation, glaucoma optic disc evaluation
and many other back-of-the-eye conditions. There are an additional estimated four million applications for ocular surgery. Most
optometrist and ophthalmologist offices maintain bottles of both phenylephrine and tropicamide eyedrops and use the drops in combination.
Each bottle is used on multiple patients, which carries a risk of contamination and ocular infection. The bottles are purchased
directly from suppliers and are not subject to insurance reimbursement. Our combination therapy, if approved, will allow the purchase
of one product for eye dilation. Additionally, the Optejet does not come in direct contact with the eye, thus minimizing the risk
of infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most dilated eye
exams require two separate topical pharmacologic agents/drops be administered sequentially (tropicamide, followed by
phenylephrine). All current mydriatic formulations use conventional macrodose drop delivery (30&ndash;50 &micro;L), which can
significantly overdose the ocular surface whose physiologic capacity is only 6&ndash;8 &micro;L. Studies demonstrate that
standard macrodosed pharmacologic dilation is associated with significant ocular discomfort and mild-moderate eye pain. On
the standard visual analogue scale for pain, such discomfort can exceed the levels of pain associated with a flu vaccine
subcutaneous injection. Additionally, there are systemic safety concerns with mydriatic macrodosing for retinopathy of
prematurity retinal screening and pediatric dilated eye exams. Studies comparing microdosed phenylephrine and cyclopentolate
to traditional eye drops (30&ndash;50 &micro;L drop size) in premature babies and in full-term infants have shown equivalent
pupil dilation with drop sizes ranging from 5&ndash;8 &micro;L while reducing systemic levels by more than 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With millions of patients
exposed to mydriatic pharmacologic agents every year, we are developing a microdose alternative whereby the Optejet can be deployed
to reduce ocular and systemic exposure by more than 75%. This potential improvement stems from lowering the dose from the 30&ndash;50
 &micro;L in standard drops to just 8 &micro;L with MicroStat combined with targeted delivery to the ocular surface. We expect to
achieve similar mydriatic activity as drops without the high incidence of unwanted side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pharmacologic mydriasis: dilated pupil
after application</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm205388-1_10kimg14.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Phase III Clinical Development Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We initiated Phase
III clinical trials of fixed-combination phenylephrine 2.5% and tropicamide 1% administered using the Optejet for mydriasis in
November 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MicroStat program
consisted of two Phase III randomized, controlled, cross-over clinical studies evaluating pupil dilation with our fixed combination
product (MicroStat) in comparison with the individual drug components (phenylephrine 2.5% and tropicamide 1%, respectively) (the
MIST-1 study), and with a placebo (the MIST-2 study). The primary endpoint for each study was the mean change in pupil diameter
at 35 minutes post-drug administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-1 study was
a double-masked, active-controlled, three-period cross-over superiority study evaluating MicroStat ophthalmic solution versus the
two individual drug components contained in MicroStat (phenylephrine 2.5% and tropicamide 1% ophthalmic solutions). All study drugs
were administered using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Volunteer participants
were evaluated for study eligibility during a screening visit and enrolled after providing study consent. Subjects meeting all
inclusion/exclusion criteria were scheduled for three treatment visits, which occurred at least two days, but no more than seven
days apart. At each treatment visit, baseline measurements were taken, then one of the three study drugs was administered to both
eyes in two separate instances, approximately five minutes apart. Afterwards, efficacy and safety assessments were performed at
specific time intervals, including pupil diameter measured by digital pupillometry in highly photopic conditions established by
using a fully-charged transilluminator at the brightest setting. Subjects were equally randomized to receive all three treatments
according to one of the six possible sequences of study drug administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-1 study was
double-masked so that there were no differences in drug presentation. Study drug administration was performed by seven different
trained personnel during the trial. To maintain masking, personnel who administered study drug were not allowed to perform post-drug
administration ophthalmic assessments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 64 subjects
were randomized to receive the study drug. Two subjects withdrew after the first treatment visit; therefore, the resulting per-protocol
analysis population consisted of 62 subjects (124 eyes). Mean pupil diameter for each eye at baseline and at 35 minutes post-drug
administration is shown graphically below. At 35 minutes, the treatment group difference between MicroStat and tropicamide 1% was
0.440 mm (SE 0.1839), which was statistically significant (p = 0.0183). The treatment group difference between MicroStat and phenylephrine
2.5% at the same timepoint was 3.638 mm (SE 0.1817), which was also statistically significant (p &lt;0.0001). Since the null hypothesis
was rejected for both sets of comparisons, the primary endpoint was met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pupil Diameter by Treatment at Baseline
and 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg15.jpg" ALT="">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">Mean &plusmn; Standard Deviation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">Tx A = phenylephrine 2.5%-tropicamide
1%; Tx B = tropicamide 1%; Tx C = phenylephrine 2.5%.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As
shown below, at 35 minutes post-drug administration, MicroStat achieved a clinically meaningful pupil diameter &#8805; 6.0 mm in
95.2% of right eyes and 93.5% of left eyes compared to a lower proportion for tropicamide 1% (79.0% and 77.4% of right and left
eyes, respectively) and for phenylephrine 2.5% (1.6% for both right and left eyes). MicroStat also achieved a pupil diameter &#8805;
7.0 mm in 67.7% of right and left eyes compared to a lower proportion for tropicamide 1% (43.5% and 41.9% or right and left eyes,
respectively) and for phenylephrine 2.5% (0% for right and left eyes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proportion of Eyes Achieving Pupil Diameter
 &#8805; 6.0 mm and &#8805; 7.0 mm at 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>35 Min Post Dose</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MicroStat</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tropicamide 1%</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phenylephrine 2.5%</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Combined
Visits</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1, 2, 3)</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OS</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N=62)</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil diameter &ge; 6.0 mm</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59 (95.2</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58 (93.5</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49 (79.0</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48 (77.4</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 (1.6</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 (1.6</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil diameter &lt; 6.0 mm</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 (4.8</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4 (6.5</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13 (21.0</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14 (22.6</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61 (98.4</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61 ( 98.4</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil diameter &ge; 7.0 mm</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42 (67.7</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42 (67.7</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27 (43.5</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26 (41.9</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil diameter &lt; 7.0 mm</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 (32.3</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 (32.3</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35 (56.5</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36 (58.1</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62 (100.0</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62 (100.0</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rate of treatment
emergent adverse events, or TEAEs, was low, and consistent with those observed with commercially available dilating eye drops (e.g.
blurry vision and stinging). Two TEAEs were reported in the MicroStat eyes, while four TEAEs were reported in each of the other
two treatment groups. All events were mild in nature. No non-ocular adverse events were reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MIST-2 Study was
a multi-center, double-masked, placebo-controlled, three-period crossover superiority study evaluating MicroStat ophthalmic solution
versus placebo. Both study drugs were administered using the Optejet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Volunteer participants
were evaluated for study eligibility during a screening visit and enrolled after providing study consent. Subjects meeting all
inclusion/exclusion criteria were scheduled for three treatment visits, which occurred at least two days, but no more than seven
days apart. A two-sequence, three-period crossover design was used. At each treatment visit, baseline measurements were taken,
then either the investigational drug or the placebo was administered to both eyes in two separate instances, approximately five
minutes apart. Only one study drug was administered per treatment visit, and subjects were equally randomized to one of two sequences,
ABB and BAA, where A was the Eyenovia fixed combination and B was placebo. Afterwards, efficacy and safety assessments were performed
at specific time intervals, including pupil diameter measured by digital pupillometry in highly photopic conditions established
by using a fully-charged transilluminator at the brightest setting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Like MIST-1, this study
was double-masked so that there were no differences in drug presentation. Study drug administration was performed by five different
trained personnel and, to maintain masking, personnel who administered study drug were not allowed to perform post-drug administration
ophthalmic assessments.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A total of 70 subjects
at two investigational sites were randomized to receive study drug. One subject withdrew after the first treatment visit; therefore,
the resulting per-protocol analysis population consisted of 69 subjects (138 eyes). Mean pupil diameter for each eye at baseline
and at 35 minutes post-drug administration is shown graphically below. At 35 minutes, the treatment group difference between MicroStat
and placebo was 4.63 mm (SE 0.0544), which was highly statistically significant (p &lt; 0.0001); consequently, the null hypothesis
was rejected and the primary endpoint was met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pupil Diameter by Eye and Treatment at
Baseline and 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm205388-1_10kimg16.jpg" ALT="">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 27pt">Mean &plusmn; Standard Deviation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As shown in the table below, at 35 minutes
post-drug administration, MicroStat achieved a clinically meaningful pupil diameter &#8805; 6.0 mm in 92.8%% of right eyes and
94.2% of left eyes and pupil diameter &#8805; 7.0 mm in 69.6% of right and 68.1% of left eyes. None of the eyes in the placebo
group achieved similar dilation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proportion of Eyes Achieving Pupil Diameter
 &#8805; 6.0 mm and &#8805; 7.0 mm at 35 Minutes<BR>
(PP Population)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>35
    Min Post Dose</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MicroStat</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Placebo</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Combined
    Visits&nbsp;&nbsp;(1, 2, 3)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OD
    (N=69)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OS
    (N=69)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OD
    (N=69)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OS
    (N=69)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil
    diameter &ge; 6.0 mm</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;64
    (92.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;65
    (94.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil
    diameter &lt; 6.0 mm</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;5
    (7.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;4
    (5.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;69
    (100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;69
    (100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil
    diameter &ge; 7.0 mm</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;48
    (69.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;47
    (68.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pupil
    diameter &lt; 7.0 mm</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;21
    (30.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;22
    (31.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;69
    (100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;69
    (100.0</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Two TEAEs (one event of mild instillation
site pain and one event of moderate photophobia) were reported in the MicroStat group, while none were reported with the use of
placebo. No non-ocular adverse events were reported. Essentially pain-free mydriasis was achieved without the use of a topical
anesthetic, which is often the practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outcomes of MIST-1
and MIST-2 are consistent. As shown below, in both studies, MicroStat achieved a mean change in pupil size between 4.6 mm and 4.8
mm at 35 minutes post-dose. In both studies, between 93% and 95% of eyes treated with the fixed combination mydriatic drug achieved
a pupil diameter &#8805; 6.0 mm at this same timepoint. Additionally, in MIST-1, the median time to maximum post-baseline pupil
diameter with &#8805; 1.0 mm increase from baseline for fixed combination solution was 73.0 minutes, while in MIST-2, it was 71.0
minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Efficacy of MicroStat in MIST-1 and MIST-2
Studies (PP Populations)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MIST-1</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MIST-2</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mean change in pupil diameter from baseline at 35 minutes</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 mm right eyes<BR>
4.7 mm left eyes</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7 mm right eyes<BR>
4.8 mm left eyes</FONT></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proportion of eyes with pupil diameter &#8805; 6.0 mm at 35 minutes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95.2% of right eyes <BR>
93.5% of left eyes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92.8% of right eyes <BR>
94.2% of left eyes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Median time to maximum post-baseline pupil diameter with &#8805; 1.0 mm increase from baseline</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73.0 minutes </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">71.0 minutes </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consistency of
these results validates the robustness of the study designs and demonstrates the impressive treatment effect of MicroStat. More
generally, these outcomes serve to further validate the bioavailability and efficacy of Optejet drug administration to the ocular
surface.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the primary objectives
of our Phase III program met, we plan to submit an NDA to the FDA for marketing approval in the United States in 2020. Outside
the United States, we have entered into a licensing partnership for MicroStat with Senju Pharmaceuticals for commercialization
in Asia, including China, Japan and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Technology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Optejet comes in
two parts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the base contains the electronic components which enable generation of control signals designed to ensure consistent, accurate columnated arrays of micro-droplets, as well as dose tracking via Bluetooth connectivity; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the disposable cartridge which contains the drug formulation in a primary drug container, targeted dosing system and piezo-driven ejector nozzle, and comes in one-month doses.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For
administration of our product candidates, the patient receives both the base and the disposable cartridge. For refills, the
patient receives only the disposable cartridge. Patients deliver their dose by attaching the cartridge to the base, pressing
an activation button which loads a single drug dose, then, holding it between one and two inches from the eye while looking
directly into an illuminated circle, pressing a second button to emit the micro-droplet delivered medication. The
micro-droplets are emitted in a quickly repeating array, that in aggregate form a micro-jet. Solution is dispensed to the
ocular surface in less than 100 milliseconds between the time the first droplet hits the corneal surface to the completion of
dose delivery, which is faster than the average involuntary blink response time. The patient feels&nbsp;a wet sensation on
the eye, but does not experience any pain, as demonstrated in studies to date. Several acute clinical trials have been
performed to date that demonstrate the Optejet&rsquo;s usability. As a precise and quick-delivered microdose, it does not
drip down the face or drain down the naso-lacrimal duct thereby minimizing delivery of extra product or preservatives to the
eye. The rechargeable base has intelligent power management and precision designed circuitry that maximizes battery life
allowing for infrequent recharging, while providing consistent dose delivery over the life of each cartridge.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our system is based
on piezo-driven printer technology, which is also used for high-precision ink jet printing. In ink jet printing, piezo technology
enables ink to be sprayed with precision to form letters and numbers on paper. Our patented system takes aspects of piezo driven
printer technology, and applies it to the delivery of therapeutics to the eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of our development
stage, our commercial organization is focused on establishing relationships with potential strategic partners, key opinion leaders
and medical organizations. These relationships will be important to the rapid acceptance and uptake of our products once they become
available. We are also assessing sales, reimbursement and distribution strategies to maximize the value of our assets in development.
We have licensed commercialization rights in Asia to Senju Pharmaceuticals and have retained global commercial rights for our product
candidates in all other regions. As partial consideration, Senju Pharmaceuticals purchased $5 million of our Series A preferred
stock in April 2015 (which subsequently converted to shares of our common stock in connection with our initial public offering).
Pursuant to the exclusive license agreement, Senju Pharmaceuticals also agreed to pay us royalties equal to 5% of the net sales
(excluding manufacturing costs, rebates and other charges) for the licensed products sold by Senju Pharmaceuticals on a semi-annual
basis until the expiration of all patents or pending patent applications covering such licensed product, at which time the royalty
rate will be reduced to 1%. The royalty payment will continue, on a country-by-country basis, until the latter of the 10th year
of the first commercial sale of a licensed product in any country or the expiration of the licensed patents. Upon expiration of
the agreement, Senju Pharmaceuticals will own an exclusive, fully paid up, irrevocable and perpetual license. The exclusive license
agreement may be terminated by either party for any material breach by the other party that is not cured within 90 If so terminated
by Senju Pharmaceuticals, the license will survive the termination with no further payment obligations to us. days of receipt of
written notice by the breaching party. If so terminated by us, the license will terminate and Senju Pharmaceuticals will transfer
all rights to regulatory approvals to us, with no refund or recovery of any development costs. Senju Pharmaceuticals may also terminate
the exclusive license agreement without cause upon 60 days written notice on a country-by-country basis, in which event Senju Pharmaceuticals
will transfer all rights to regulatory approvals pertaining to any licensed product to us.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
receive marketing approval, we plan to commercialize them in the United States through a combination of distributors, specialty
pharmacies and our own specialty sales force. We expect to work with distribution companies or through other marketing arrangements
in the European Union and other regions outside the United States We believe that the U.S. commercial organization will initially
consist of approximately 15 sales and marketing professionals and, upon approval of MicroPine, grow to approximately 100 individuals
calling on ophthalmologists and optometrists. We expect to make hires and sign distribution agreements for commercialization following
NDA approval of any of our product candidates. Our management team and directors, which would lead the commercialization planning
of our lead product candidates, have substantial experience in the commercialization of ophthalmic therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely on
a combination of limited internal manufacturing capacity and third-party manufacturers located in the United States and abroad
to produce the product candidates for our clinical trials. We manage such production with all our vendors on a purchase order basis.
Relationships with vendors of critical components are governed by applicable service and supply agreements or purchase order terms.
We do not currently have long-term agreements with these manufacturers or any other third-party suppliers. We intend to procure
quantities on a purchase order basis for our clinical and initial commercial production. If any of our existing third-party suppliers
should become unavailable to us for any reason, we believe that there are a number of potential replacements, although we might
experience a delay in our ability to obtain alternately sourced quantities of materials or services due to their unique and specialized
nature. We also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates
if they are approved. With respect to commercial production of our product candidates in the future, we plan to outsource production
of the majority of the product candidates if they are approved for marketing by the applicable regulatory authorities.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and
pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages,
we face potential competition from many different sources. Any product candidates that we successfully develop and commercialize
may also compete with existing therapies and new therapies that may become available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our potential competitors
include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic or biosimilar drug companies.
Many of our competitors have significantly greater financial and human resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller
and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product
candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MicroStat, we are
not aware of any micro-therapeutics nor of any existing FDA-approved phenylephrine-tropicamide topical fixed combination even in
standard macrodose. There are competitive macrodose drop formulations of individual therapeutics such as phenylephrine and tropicamide
for mydriasis by companies such as Akorn, Alcon and others, as well as pharmacies that compound the combination on an individual
basis for physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MicroLine, we are
not aware of FDA-approved drugs for the improvement of near vision in patients with presbyopia. There are other pharmaceutical
companies developing therapies for presbyopia, none of which makes use of microdosing technology or deliver medication as a spray.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that both
MicroStat and MicroLine would be &ldquo;cash pay&rdquo; products, as MicroStat is purchased directly by offices and used routinely
in eye exams, and MicroLine would be considered an &ldquo;aesthetic&rdquo; prescription product not generally covered by third
party insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For MicroPine, we are
not aware of any FDA-approved drugs to slow the progression of myopia. There are other versions of traditional eye drop atropine
under development by other pharmaceutical companies for this indication. There also are versions of compounded topical atropine
that have not been tested for their safety or efficacy that are dispensed on an individual basis to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success may depend
on our ability to obtain, maintain and enforce our proprietary rights related to our products and other technologies. We must also
operate without infringing the proprietary rights of others while preventing others from infringing our proprietary rights. We
will seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications. We may also
rely on trade secrets and know-how for some proprietary methods, methods of manufacture, and systems and devices. We continue innovating
our technologies, and will file appropriate U.S. and foreign patent applications for our future innovations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, we owned nine U.S. issued and allowed utility patents, one issued design patent, and eight pending U.S. patent applications,
as well as 53 issued foreign patents, 31 pending foreign patent applications, and one pending international PCT application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent coverage within
the portfolio includes issued and pending patent applications disclosing and claiming the following devices and methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A piezoelectric device configured to generate an ejected stream of droplets is the subject of one patent family. The device ejects droplets having an average ejected droplet diameter greater than 20 microns and an average initial droplet ejecting velocity between 0.5 m/s and 10 m/s. Furthermore, the stream of droplets is generated with low entrained airflow so that at least 75% of the mass is deposited on the eye. U.S. patents for these devices are expected to expire in 2031.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A method of delivering a medicament or solution to an eye with a piezo-ejector device is the subject of another patent family. The method involves delivering an average droplet size of 20 microns to 100 microns in diameter with an average initial droplet ejecting velocity between 1 m/s and 10 m/s to the eye. About 85% to 100% of the ejected mass of droplets is deposited on the eye. U.S. patents for these methods are expected to expire in 2031.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A device having a piezo-ejector that generates a directed stream of droplets through specially shaped openings in the piezo-ejector is the subject of still another patent family. The openings provide laminar flow through the openings. Laminar flow is provided by shaping the openings with a gradual slope change so that an external entry radius has a circular shape which reduces airflow while providing laminar flow through the openings. U.S. patents related to these devices are expected to expire in 2033.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A piezo-electric ejector device having a microcontroller which auto-tunes the ejector mechanism is the subject of another patent family. The device generates at least one cycle in a range of drive signal frequencies and obtains time-energy product feedback from a decay signal emitted by the actuator. U.S. patents related to these devices are expected to expire in 2033.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A method of monitoring the treatment of ophthalmic subjects by capturing images of the eye is the subject of another patent family. Images of the eye are taken which are sufficient to obtain information about the diagnosis or health of the eye. The data is stored and analyzed to monitor treatment. U.S. patents related to this method are expected to expire in 2031.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fluid ejector having a fluid loading plate in parallel arrangement with an ejector mechanism is the subject of patent family patented in Europe. The fluid loading plate forms a capillary separation with the ejector mechanism to generate capillary fluid flow. The fluid loading plate is also attached to the reservoir (at a fluid reservoir interface) and to the ejector mechanism (at an ejector mechanism interface) and may have one or more fluid channels from the fluid reservoir interface to the ejector mechanism interface. The ejector produces a stream of droplets having a droplet diameter greater than 15 microns with the stream having low entrained airflow so that the pressure of the stream will be substantially imperceptible.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expiry of any patent
depends upon the legal term for patents in that particular country. In the United States, the patent term is generally 20 years
from the earliest claimed filing date of a non-provisional patent application. In the United States, a patent&rsquo;s term may
be lengthened by patent term adjustment which compensates a patentee for administrative delays by the United States Patent and
Trademark Office, or the USPTO, in examining and granting a patent. A patent term may also be shortened if a patent is terminally
disclaimed over another patent or application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Drug Price Competition
and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the
expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent
is in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent term extension
cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable
to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method
for manufacturing it may be extended. We cannot provide any assurance that any patent term extension with respect to any U.S. patent
will be obtained and, if obtained, the duration of such extension. Similar patent term extension/reduction provisions are available
in the European Union and other jurisdictions. In the future, if and when our product candidates receive approval by the FDA or
foreign regulatory authorities, we will apply for patent term extensions on issued patents covering our products to the extent
available under the applicable law, depending upon the length of any such clinical trials for any product and other factors. The
expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be
available to us. However, we cannot provide any assurances that any such patent term extension of a foreign patent will be obtained
and, if obtained, the duration of such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Asia, we have been
granted a patent in each of China and South Korea and two patents in Japan that describe a piezoelectric device configured to generate
an ejected stream of droplets with a particular droplet diameter and ejection velocity. We also have seven additional patents granted
in China, five additional patents granted in Japan, and four patents granted in Singapore, all related to aspects of the piezoelectric
device and methods of using the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are marketed
under trademarks and service marks that are owned by us. The following words are trademarks in our Company&rsquo;s trademark portfolio
and are the subject of either registration, or application for registration, in the United States: EYENOVIA&reg;, OPTEJET&trade;,
EYELATOVA&trade;, EYETANO&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
trademarks noted above, we will file trademark applications for new trademarks registrations to protect our market positions in
the United States and other jurisdictions on an ongoing basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Proprietary Technology</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents,
we may rely on trade secrets and proprietary know-how to protect our technology. We endeavor to protect our proprietary technology
and processes in the appropriate manner to maintain their secrecy including confidentiality agreements when dealing with third
parties. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. We also require invention assignment
agreements with our employees, consultants, and contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation and Product Approvals
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities
in the United States, at federal, state and local levels, and in other countries and jurisdictions, including the European Union,
extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging,
storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and
import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign
countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities,
require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Review and Approval of Drugs in the
United States </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the FDA regulates drug products under the Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. The failure to comply with applicable requirements under
the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject
an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending
applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters,
voluntary product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals
of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the
FDA and the Department of Justice or other governmental entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An applicant seeking
approval to market and distribute a new drug product in the United States must typically undertake the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&rsquo;s good laboratory practice, or GLP, regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND which must take effect before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an institutional review board, or IRB, an independent committee charged with protecting the rights and welfare of human research subjects participating in clinical trials, before each clinical trial site may initiate clinical trial enrollment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trial(s) in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation and submission to the FDA of an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">review of the product by an FDA advisory committee, where appropriate or if applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of FDA audits of selected clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of user fees, with few exceptions, and securing FDA approval of the NDA; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Preclinical Studies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies
include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient
and the formulated drug or drug product, as well as&nbsp;<I>in vitro</I>&nbsp;and animal studies to assess the safety and activity
of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies
is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with
manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other
things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse
events and carcinogenicity, may continue after the IND is submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The IND and IRB
Processes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An IND is an exemption
from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial
and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to
interstate shipment and administration of any new drug that is not the subject of an approved NDA. In support of a request for
an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the
FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical
data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as
part of an IND. The FDA requires a 30-day waiting period after the acceptance of each IND before clinical trials may begin. This
waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable
health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the clinical
trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding
concerns before clinical trials can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following
commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that
clinical trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to
suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work
requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other
protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide
the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold,
an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base
that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise
satisfying the FDA that the investigation can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor may choose,
but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND,
all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with FDA certain regulatory requirements in order to use the study as support for an IND or
application for marketing approval. Specifically, such studies must be conducted in accordance with good clinical practice, or
GCP, including review and approval by an independent ethics committee, or IEC, and informed consent from subjects. The FDA&rsquo;s
regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well
as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner
comparable to that required for IND studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the
plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the
study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information
to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval
of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance
with the IRB&rsquo;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, some
clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides authorization for whether or not a clinical trial may move forward at designated
check points based on access that only the group maintains to available data from the study. Suspension or termination of development
during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable
health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive
climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information about certain
clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination
on its ClinicalTrials.gov website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Human Clinical
Trials in Support of an NDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve
the administration&nbsp;of the investigational product to human subjects under the supervision of qualified investigators in accordance
with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent
in writing before their participation in any clinical trial. Clinical trials are conducted in accordance with written study protocols
detailing, among other things, study objectives, participant inclusion and exclusion criteria, the parameters to be used in monitoring
safety and the effectiveness criteria to be evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are typically conducted in three sequential phases, which may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase I. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase II. The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Progress reports
detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious
adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and
unexpected suspected adverse reactions; findings from other studies or animal or&nbsp;<I>in vitro</I>&nbsp;testing that
suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious
suspected adverse reaction over that listed in the protocol or investigator brochure. Phase I, Phase II and Phase III
clinical trials might not be completed successfully within any specified period, or at all. Furthermore, the FDA or the
sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with
the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will
typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data
submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical
trials, companies often complete additional animal studies and must also develop additional information about the chemistry and
physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate
and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the
drug candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Submission of
an NDA to the FDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming successful
completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together
with detailed information relating to the product&rsquo;s chemistry, manufacture, controls and proposed labeling, among other things,
are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal
law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2019 is $2,588,478 for an
application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug program fee,
which for fiscal year 2019 is $309,915. Certain exceptions and waivers are available for some of these fees, such as an exception
from the application fee for drugs with orphan designation and a waiver for certain small businesses. Eyenovia is currently eligible
for a waiver of the application fees under the small business provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA conducts a
preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&rsquo;s receipt
of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional
information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to certain performance goals in the review
process of NDAs. Most such applications are meant to be reviewed within 10 months from the date of filing, and most applications
for &ldquo;priority review&rdquo; products are meant to be reviewed within six months of filing. For applications of drug products
that are not new molecular entities, FDA aims to conduct standard reviews within 10 months of receipt of the NDA and priority reviews
within six months of receipt of the NDA. The review process may be extended by the FDA for three additional months to consider
new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following
the original submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before approving an
NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval
inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such as active
pharmaceutical ingredients),&nbsp;finished drug product manufacturing, and control testing laboratories. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and
adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA,
the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a condition
of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional
labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA
will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product,
expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity.
REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use,
or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing
only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval
or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially
affect the potential market and profitability of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may refer an
application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee
is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The FDA&rsquo;s
Decision on an NDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the basis of the
FDA&rsquo;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities,
the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product
with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies
in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application.
If and when those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue
an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information
included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy
the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA approves
a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions
be included in the product labeling, require that post-approval studies, including Phase IV clinical trials, be conducted to further
assess the drug&rsquo;s safety after approval, require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can
materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product
based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product,
such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements
and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Post-Approval
Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drugs manufactured
or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion
and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, drug manufacturers
and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments
with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an approval is
granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events
of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials
to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences
include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on post-approval clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved
indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the distribution
of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution
of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors
by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements
to ensure accountability in distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Section 505(b)(2)
NDAs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NDAs for most new drug
products are based on two full clinical trials which must contain substantial evidence of the safety and efficacy of the proposed
new product. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an
alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on
the FDA&rsquo;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section
505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective
in use and relied upon by the applicant for approval of the application &ldquo;were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thus, Section 505(b)(2)
authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed
under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations
or new uses of previously approved products. If the Section 505(b)(2) applicant can establish that reliance on the FDA&rsquo;s
previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical studies or
clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements to support
the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications
for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Abbreviated New
Drug Applications for Generic Drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 1984, with passage
of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously
approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an
abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the
preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed
drug, or RLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, in order
for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients,
the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that
the generic drug is &ldquo;bioequivalent&rdquo; to the innovator drug. Under the statute, a generic drug is bioequivalent to an
RLD if&#8201; &ldquo;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent
of absorption of the listed drug.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon approval of an
ANDA, the FDA indicates whether the generic product is &ldquo;therapeutically equivalent&rdquo; to the RLD in its publication Approved
Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. Clinicians and pharmacists consider
a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and
numerous health insurance programs, the FDA&rsquo;s designation of therapeutic equivalence often results in substitution of the
generic drug without the knowledge or consent of either the prescribing clinicians or patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Hatch-Waxman
Amendments, the FDA might not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The
FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes
of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by
the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of
the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration
of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its
application four years following the original product approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDCA also
provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations,
other than bioavailability or bioequivalence&nbsp;studies, that were conducted by or for the applicant and are essential to
the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug
product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be
available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new
clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the
FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug
product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Hatch-Waxman Patent Certification
and the 30-Month Stay</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon approval of an
NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&rsquo;s
product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book.
When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents
listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is
not seeking approval. To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved
product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book
to the same extent that an ANDA applicant would.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, the applicant
must certify with respect to each patent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the required patent information has not been filed;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the listed patent has expired;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the listed patent is invalid, unenforceable or will not be infringed by the new product.&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A certification that
the new product will not infringe the already approved product&rsquo;s listed patents or that such patents are invalid or unenforceable
is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking
approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced
product have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the ANDA applicant
has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to
the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate
a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement
lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA
until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement
case that is favorable to the ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that
the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify
to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant
would. As a result, approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product
have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in
the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent
infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable
to the Section 505(b)(2) applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Pediatric Studies
and Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Pediatric
Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness
of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration
Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those
plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives
and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&rsquo;s
internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The
FDA or the applicant may request an amendment to the plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may, on its
own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and
procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required
by regulation, the pediatric data requirements do not apply to products with orphan designation.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pediatric exclusivity
is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional
six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity.
This six-month&nbsp;exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request
from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather,
if the clinical trial is deemed to fairly respond to the FDA&rsquo;s request, the additional protection is granted. If reports
of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or
regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term
extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Patent Term Restoration
and Extension</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A patent claiming a
new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration
period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the
time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product&rsquo;s approval date. Only one patent applicable to an approved
drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of
the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with
one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation
with the FDA. We cannot provide any assurance that any patent term extension with respect to any U.S. patent will be obtained and,
if obtained, the duration of such extension, in connection with any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The 21st Century
Cures Act </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 13, 2016,
President Obama signed the 21st Century Cures Act, or the Cures Act, into law. The Cures Act is designed to modernize and personalize
healthcare, spur innovation and research, and streamline the discovery and development of new therapies through increased federal
funding of particular programs. It authorizes increased funding for the FDA to spend on innovation projects. The new law also amends
the Public Health Service Act, or the PHSA, to reauthorize and expand funding for the NIH. The Act establishes the NIH Innovation
Fund to pay for the cost of development and implementation of a strategic plan, early stage investigators and research. It also
charges NIH with leading and coordinating expanded pediatric research. Further, the Cures Act directs the Centers for Disease Control
and Prevention to expand surveillance of neurological diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With amendments to
the FDCA and the PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines
and medical technologies. To that end, and among other provisions, the Cures Act reauthorizes the existing priority review voucher
program for certain drugs intended to treat rare pediatric diseases until 2020; creates a new priority review voucher program for
drug applications determined to be material national security threat medical countermeasure applications; revises the FDCA to streamline
review of combination product applications; requires FDA to evaluate the potential use of&#8201; &ldquo;real world evidence&rdquo;
to help support approval of new indications for approved drugs; provides a new &ldquo;limited population&rdquo; approval pathway
for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorizes FDA to designate a
drug as a &ldquo;regenerative advanced therapy,&rdquo; thereby making it eligible for certain expedited review and approval designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Review and Approval of Drug Products
in the European Union</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market
any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing
authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, the company
would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions
and can involve additional product testing and additional administrative review periods. The time required to obtain approval in
other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval
in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval
in one country or jurisdiction may negatively impact the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Procedures Governing
Approval of Drug Products in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the
European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented
through national legislation of the member states. Under this system, an applicant must obtain approval from the competent
national authority of a European Union member state in which the clinical trial is to be conducted. Furthermore, the
applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial
application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the
European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable
guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain marketing
approval of a product under European Union regulatory systems, an applicant must submit a marketing authorization application,
or MAA, either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing
authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory
for specific&nbsp;products, including for medicines produced by certain biotechnological processes, products designated as orphan
medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases.
For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative
or for which a centralized process is in the interest of patients, the centralized procedure may be optional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized
procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA,
is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization
and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under
the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock
stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of
the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest
from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the
EMA ensures that the opinion of the CHMP is given within 150 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decentralized procedure
is available to applicants who wish to market a product in various European Union member states where such product has not received
marketing approval in any European Union member states before. The decentralized procedure provides for approval by one or more
other, or concerned, member states of an assessment of an application performed by one member state designated by the applicant,
known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and
related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference
member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the related
materials within 210 days after receipt of a valid application. Within 90 days of receiving the reference member state&rsquo;s
assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related
materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a member state cannot
approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points
are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding
on all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within this framework,
manufacturers may seek approval of hybrid medicinal products under Article 10(3) of Directive 2001/83/EC. Hybrid applications rely,
in part, on information and data from a reference product and new data from appropriate preclinical tests and clinical trials.
Such applications are necessary when the proposed product does not meet the strict definition of a generic medicinal product, or
bioavailability studies cannot be used to demonstrate bioequivalence, or there are changes in the active substance(s), therapeutic
indications, strength, pharmaceutical form or route of administration of the generic product compared to the reference medicinal
product. In such cases the results of tests and clinical trials must be consistent with the data content standards required in
the Annex to the Directive 2001/83/EC, as amended by Directive 2003/63/EC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hybrid
medicinal product applications have automatic access to the centralized procedure when the reference product was authorized for
marketing via that procedure. Where the reference product was authorized via the decentralized procedure, a hybrid application
may be accepted for consideration under the centralized procedure if the applicant shows that the medicinal product constitutes
a significant therapeutic, scientific or technical innovation, or the granting of a community authorization for the medicinal product
is in the interest of patients at the community level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Clinical Trial
Approval in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Requirements for the
conduct of clinical trials in the European Union including Good Clinical Practice, or GCP, are set forth in the Clinical Trials
Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a
system for the approval of clinical trials in the European Union has been implemented through national legislation of the E.U.
member states. Under this system, approval must be obtained from the competent national authority of each E.U. member state in
which a study is planned to be conducted. To this end, a clinical trial application is submitted, which must be supported by an
investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive
2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics
committee has issued a favorable opinion on the clinical trial application in that country.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2014, the
E.U. passed the new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive 2001/20/EC.
To ensure that the rules for clinical trials are identical throughout the European Union, the new E.U. clinical trials legislation
was passed as a regulation that is directly applicable in all E.U. member states. All clinical trials performed in the European
Union are required to be conducted in accordance with the Clinical Trials Directive 2001/20/EC until the new Clinical Trials Regulation
(EU) No 536/2014 becomes applicable. According to the current plans of EMA, the new Clinical Trials Regulation will become applicable
in 2019. The Clinical Trials Directive 2001/20/EC will, however, still apply three years from the date of entry into application
of the Clinical Trials Regulation to (i) clinical trials applications submitted before the entry into application and (ii) clinical
trials applications submitted within one year after the entry into application if the sponsor opts for old system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The new Clinical Trials
Regulation aims to simplify and streamline the approval of clinical trial in the European Union. The main characteristics of the
regulation include:&nbsp;a streamlined application procedure via a single entry point, the E.U. portal; a single set of documents
to be prepared and submitted for the application as well as simplified reporting procedures that will spare sponsors from submitting
broadly identical information separately to various bodies and different member states; a harmonized procedure for the assessment
of applications for clinical trials, which is divided in two parts (Part I is assessed jointly by all member states concerned,
and Part II is assessed separately by each member state concerned); strictly defined deadlines for the assessment of clinical trial
applications; and the involvement of the ethics committees in the assessment procedure in accordance with the national law of the
member state concerned but within the overall timelines defined by the Clinical Trials Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Periods of Authorization
and Renewals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing authorization
is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation
of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing
authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality,
safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before
the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless
the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with
one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the European Union
market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization
ceases to be valid (the so-called sunset clause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Data and Market
Exclusivity in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union,
new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market
exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&rsquo;s
data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted,
and the innovator&rsquo;s data may be referenced, but not approved for two years. The overall 10-year period will be extended to
a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization
for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring
a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity
and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another
version of the product if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical tests
and clinical trials and obtain marketing approval of its product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Regulatory Requirements
after Marketing Authorization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As in the United States,
both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight
by the EMA and the competent authorities of the individual E.U. Member States both before and after grant of the manufacturing
and marketing authorizations. The holder of an E.U. marketing authorization for a medicinal product must, for example, comply with
E.U. pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting pharmacovigilance,
or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European
Union is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations.
Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements
set out in the applicable E.U. laws, including compliance with E.U. cGMP standards when manufacturing medicinal products and active
pharmaceutical ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European
Union, the advertising and promotion of approved products are subject to E.U. Member States&rsquo; laws governing promotion
of medicinal products, interactions with clinicians, misleading and comparative advertising and unfair commercial practices.
In addition, other legislation adopted by individual E.U. Member States may apply to the advertising and promotion of
medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply
with the product&rsquo;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of
a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion, which is prohibited
in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pharmaceutical Coverage, Pricing and
Reimbursement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant uncertainty
exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products
will depend, in part, on the extent to which third-party payors, including government health programs in the United States such
as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement
levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from
the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party
payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of
medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products
on an approved list, or formulary, which might not include all of the approved products for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to secure
coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic
studies in order to demonstrate&nbsp;the medical necessity and cost-effectiveness of the product, in addition to the costs required
to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates might not be considered medically necessary
or cost effective. Additionally, a payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&rsquo;s determination to provide coverage for a drug product does not assure
that other payors will also provide coverage for the drug product. Third-party reimbursement might not be sufficient to maintain
price levels high enough to realize an appropriate return on investment in product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The containment of
healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus
in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a
company&rsquo;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates
may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company
or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in
the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United
States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals
is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond
the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost
effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be
expensive and result in delays in our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Union,
pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed
only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare
the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the European Union provides
options for its member states to restrict the range of drug products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific
price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing
the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and
control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense.
As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price
controls or reimbursement limitations for drug products might not allow favorable reimbursement and pricing arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Law and Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Arrangements with healthcare
providers, pharmacists, consultants, third-party payors and customers are subject to broadly applicable healthcare laws and regulations
that may constrain our business and/or financial arrangements. Applicable federal and state healthcare laws and regulations include
without limitation the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, if one purpose of the remuneration is to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willingly executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which amended HIPAA to impose additional obligations, including mandatory contractual terms regarding the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, information related to payments and other transfers of value to clinicians and teaching hospitals and clinician ownership and investment interests; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some state laws require
pharmaceutical companies&nbsp;to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related
to payments to clinicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy
and security of health information in some circumstances, many of which differ from each other in significant ways and often are
not preempted by HIPAA, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in the Healthcare Marketplace
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A primary trend in
the U.S. healthcare industry and elsewhere is cost containment. There have been several federal and state proposals during the
last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for
drugs and other medical products, government control, and other changes to the healthcare system in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patient Protection
and Affordable Care Act of 2010, or ACA, included provisions related to the coverage of and payment for prescription drugs under
government healthcare programs. With regard to pharmaceutical products, among other things, the ACA was designed to expand and
increase industry rebates for drugs covered under Medicaid programs, impose an annual fee on branded pharmaceutical manufacturers
and make changes to the coverage requirements under the Medicare Part D program. Although the ACA has been the target of numerous
repeal efforts, cost containment for prescription drugs remains a priority under the current administration and the elements of
the ACA intended to curb drug prices have higher levels of political support than some other aspects of the law. Among the provisions
of the ACA of importance to our potential drug candidates are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&rsquo;s Medicaid rebate liability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded manufacturers&rsquo; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &ldquo;average manufacturer price,&rdquo; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded the types of entities eligible for the 340B drug discount program;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part D;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been clearly defined. The ACA provided that under certain circumstances, IPAB recommendations will become law unless Congress enacts legislation that will achieve the same or greater Medicare cost savings; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmaceutical pricing
has been a focus of the Trump administration, which has also continued efforts to repeal the ACA. It remains to be seen, however,
what impact new legislation, if passed, will have on the availability of healthcare and containing or lowering the cost of healthcare.
The elimination of the ACA&rsquo;s individual mandate, which imposed penalties to individuals who failed to obtain insurance coverage,
could ultimately result in fewer individuals having health insurance coverage, which changes to the ACA&rsquo;s minimum coverage
requirements may lead to policies with less generous benefits. While the timing and scope of any potential future legislation to
repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that
generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 25, 2020,
we had 27 full-time and two part-time employees. We also engage various consultants and contractors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Exchange Act, are available free of charge on our website at www.eyenoviabio.com as soon as reasonably
practicable after electronically filing or furnishing such material to the SEC. The SEC maintains a website (www.sec.gov) that
includes our reports, proxy statements and other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="e_001"></A><B>Item 1A.</B></TD><TD><B>Risk Factors.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our
common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information
in this report, including our financial statements and the related notes and &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; before deciding whether to invest in our common stock. The occurrence
of any of the events or developments described below could harm our business, financial condition, results of operations and growth
prospects. In such an event, the market price of our common stock could decline and you might lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR FINANCIAL POSITION
AND NEED FOR ADDITIONAL CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to continue
as a going concern which would likely cause our stockholders to lose most or all of their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audited financial
statements for the year ended December 31, 2019 were prepared under the assumption that we would continue as a going concern. However,
our independent registered public accounting firm included a &ldquo;going concern&rdquo; explanatory paragraph in its report on
our financial statements for the year ended December 31, 2019, indicating that, without additional sources of funding, our cash
at December 31, 2019 is not sufficient for us to operate as a going concern for a period of at least one year from the date that
the financial statements included in this Annual Report on Form 10-K are issued. Management&rsquo;s plans concerning these matters,
including our need to raise additional capital, are described in Note 2 &ndash; Summary of Significant Accounting Policies &ndash;
Liquidity and Going Concern of our financial statements included within this Annual Report on Form 10-K, however, management cannot
assure you that its plans will be successful. In light of the foregoing, there is substantial doubt about our ability to continue
as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment
in us.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We need to raise additional capital
in order to continue developing our product candidates into next year. Such funding might not be available on acceptable terms,
or at all. Failure to obtain this necessary capital may force us to delay, limit or terminate certain of our product development
efforts to continue operations. </I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We require substantial
additional funding to continue our research and development activities into next year. We also need substantial funding to advance
our commercialization efforts, and fund our operating expenses and other activities. If additional capital is not available when
needed, including because of general market conditions, we may need to significantly scale back or reprioritize our research and
development activities or cease our operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will require substantial
funds to discover, develop, protect and conduct research and development for our product candidates, including preclinical testing
for future product candidates and clinical trials of any of our product candidates, and to manufacture and market any such product
that may be approved for commercial sale. Even if we are successful in raising additional capital, such funds may prove to be insufficient
for these activities. Our financing needs may change substantially because of research and development costs, competition, clinical
trials and costs arising from additional regulatory approvals. We might not succeed in raising needed additional funds. The timing
of our need for additional funds will depend on a number of factors, which factors are difficult to predict or may be outside of
our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the resources, time and costs required
to initiate and complete our research and development, to initiate and complete preclinical studies and clinical trials and to
obtain regulatory approvals for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">progress in our research and development
programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing, receipt and amount of milestone,
royalty and other payments from future collaborators, if any; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs necessary to protect our intellectual
property.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our estimates and
predictions relating to any of these factors are incorrect, we may need to modify our operating plan. Additional funds might not
be available to us on acceptable terms, or at all, when needed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raising additional capital may cause
dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until such time as
we can generate substantial product revenues, we may attempt to finance our cash needs through equity offerings (such as our recent
approximately $6 million private placement), debt financings, government and/or other third-party grants or other third-party funding,
marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, our investors&rsquo; ownership interest
will be diluted. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable
to obtain funding on a timely basis, we may be required to significantly curtail one or more clinical research or development programs,
which would adversely impact potential revenues, results of operations and financial condition.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we raise additional
capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable
rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms
that might not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have incurred operating losses
since our inception. We expect to continue to incur losses for the foreseeable future and might never achieve or maintain profitability.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred net
losses of&thinsp;approximately $57.7 million since inception, have not generated any product sales revenue and have not achieved
profitable operations. Our net losses were approximately $21.2 million and $17.3 million for the years ended December 31, 2019
and 2018, respectively. We expect to continue to incur substantial losses in future periods while we continue to test and prepare
our product candidates for the market. It could be several years, if ever, before we have a commercialized drug. The net losses
we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially
if, and as, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">continue the ongoing and clinical development
of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">initiate preclinical studies and clinical
trials for any additional product candidates that we may pursue in the future;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">seek marketing approvals for our current
and future product candidates that successfully complete clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">continue to develop a sales, marketing
and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">develop, maintain, expand and protect
our intellectual property portfolio;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">implement operational, financial and management
systems; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">attract, hire and retain additional administrative,
clinical, regulatory and scientific personnel.</FONT></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are able to generate revenues
from the sale of our potential products, we might not become profitable and may need to obtain additional funding to continue operations.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we might not be able
to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease
the value of our company and could impair our ability to raise capital, expand our business or continue our operations. In addition,
because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount
of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relatively short operating history
may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage
company which commenced active operations in 2014. Our operations to date have been limited to organizing and staffing our company,
business planning, raising capital and developing our product candidates. We have not yet demonstrated our ability to obtain regulatory
approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing
activities necessary for successful product commercialization. Consequently, any predictions about our future success or viability
might not be as accurate as they could be if we had a longer operating history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a new
business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will
need to transition from a company with a product development focus to a company capable of supporting commercial and manufacturing
activities. We might not be successful in such a transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to use carryforward
tax losses or benefit from favorable tax legislation to reduce our taxes, our business, results of operations and financial condition
may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant
net operating losses since our inception in July 2014. As of December 31, 2019, we had federal net operating loss carry-forwards
of approximately $45.0 million, of which, approximately $10.8 million will expire at various dates from 2034 to 2037 for federal
purposes. If we are unable to use carryforward tax losses to reduce our future taxable basis for corporate tax purposes, our business,
results of operations and financial condition may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net operating
loss and tax credit carry-forwards are subject to review and possible adjustment by the Internal Revenue Service and state
tax authorities and may become subject to an annual limitation in the event of certain cumulative changes in the ownership
interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the
Internal Revenue Code of 1986, as amended, as well as similar state provisions. This could limit the amount of tax attributes
that can be utilized annually to offset future taxable income or tax liabilities. Pre-July 15, 2019, net operating loss
carryforwards of approximately $35,000,000 are subject to an annual limitation of approximately $918,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal and state
income tax returns are generally subject to tax examinations. To the extent we have tax attribute carryforwards, the tax years
in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities
to the extent utilized in a future period. Any unfavorable tax adjustment could have a significant impact on our results of operations
and future cash flows. Furthermore, if the United States government decides to eliminate, or reduce the scope or the rate of any
tax benefit, either of which it could decide to do at any time, our results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO DEVELOPMENT AND COMMERCIALIZATION
OF OUR&nbsp;PRODUCT&nbsp;CANDIDATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may encounter substantial delays
in or failure of our clinical trials. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical trials
that we are required to conduct to gain regulatory approval are delayed or unsuccessful, we might not be able to market our product
candidates. Additionally, because our product candidates are based on new technologies, we expect that our human clinical trials
will require extensive research and development and have substantial manufacturing and processing costs. Accordingly, our clinical
trial costs could be significantly higher than other conventional therapeutic technologies or drug products and could be delayed
if we do not have adequate means to fund them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience delays
in any phase of the development and commercial launch of product candidates, including during research and development and clinical
trials. Implementing a clinical trial is time-consuming and expensive, particularly human clinical trials, and the outcome of any
clinical trial is uncertain. The completion of any of these clinical trials may be delayed or halted for numerous reasons, including,
but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patients do not enroll in our clinical
trials (including due to any adverse impacts of the coronavirus pandemic and resulting social distancing and shelter in place orders)
or results from patients are not received at the expected rate;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patients discontinue participation in
a clinical trial prior to the scheduled endpoint set forth in the clinical protocol at a higher than expected rate, especially
if such discontinuations interfere with our ability to assess the efficacy of our drug candidate;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patients experience adverse events from
our treatment;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patients get hurt during a clinical trial
for a variety of reasons that might not be related to our product candidates, including the advanced stage of their disease and
other medical problems;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">third-party clinical investigators do
not perform the clinical trials in accordance with the anticipated schedule or consistent with the clinical trial protocol and
good clinical practices or other third-party organizations do not perform data collection and analysis in a timely or accurate
manner;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the FDA, IRBs, European Union regulatory
authorities, or the European Medicines Agency, and national authorities, or other regulatory authorities do not approve a clinical
trial protocol or place a clinical trial on hold;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">enrollment and sample size of our clinical
trials may be substantially different than estimated which may lead to longer timelines and larger expenses;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">third-party clinical investigators engage
in activities that, even if not directly associated with our clinical trials, result in their debarment, loss of licensure, or
other legal or regulatory sanction;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory inspections of manufacturing
facilities, which may, among other things, require us to undertake corrective action or suspend the clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in governmental regulations or
administrative actions;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the interim results of the clinical trial,
if any, are inconclusive or negative; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the study design, although approved and
completed, is inadequate to demonstrate effectiveness and safety.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our dependence upon
clinical trials in developing product candidates may impede them from reaching advanced stages of development and might prevent
all or part of our commercial operations. To date, the situations regarding potential delays in research and development activities
and clinical trials have yet to occur in a manner which adversely affects our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may find it difficult to enroll
or maintain participation of an adequate number of patients in our clinical trials, which could delay or prevent us from proceeding
with clinical trials of our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Identifying and qualifying
patients to participate in our clinical trials is critical to our success. Patient enrollment depends on many factors, including
the size and nature of the patient population, eligibility criteria for the clinical trial, the proximity of patients to clinical
sites and their ability and willingness to participate in our trials (which may be adversely affected due to personal or environmental
factors, including pandemics like COVID-19 and the resulting social distancing and shelter in place orders), the design of the
clinical protocol, the availability of competing clinical trials, the availability of new drugs approved for the indication the
clinical trial is investigating, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug
being studied in relation to other available therapies. Any inability to locate, enroll and maintain participation of a sufficient
number of patients in our clinical trials would result in significant delays, could require us to abandon one or more clinical
trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Delays in our clinical trials may also
result in increased development costs for our product candidates, which would cause the value of our company to decline and limit
our ability to obtain additional financing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any negative
results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients
in other clinical trials of that same product candidate. Delays in the enrollment for any clinical trial of our product candidates
will increase our costs, slow down our product development and approval process and delay or potentially jeopardize our ability
to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement
or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to develop marketable
products utilizing our technology and we might not be able to identify and successfully implement an alternative product development
strategy. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approach we have
adopted to discover and develop product candidates is new and may never lead to marketable products. We have concentrated our efforts
on developing therapeutic product candidates utilizing new advanced technology for drug delivery. To our knowledge, no person or
company has developed any therapeutic product utilizing the same technology and no such ophthalmic micro-therapeutic product has
been approved for marketing to date. We are leading a new field of ophthalmic micro-therapeutic research and development and the
scientific discoveries that form the basis for our efforts to develop products are relatively new. The scientific evidence to support
the feasibility of developing such products and treatments based on these discoveries is limited. Our focus solely on developing
products utilizing our proprietary technology, as opposed to more traditional technology, increases the risks associated with investing
in our stock. If we are unsuccessful in developing product candidates utilizing our technology or finding additional applications
for our technology, we may be required to change the scope and direction of our product development activities. If we are not able
to identify and successfully implement an alternative product development strategy, our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ophthalmic micro-therapeutic research
and development is a highly uncertain undertaking. Our development efforts may be delayed for any number of reasons, in which case
potential marketing approval or commercialization of our proprietary technology could be delayed or prevented. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities to develop ophthalmic microdose therapeutics utilizing our proprietary technology may be impeded due to scientific or
technological difficulties or our lack of complete understanding of the challenges. Our research and development activities might
not give rise to a marketable product and we might not succeed in developing a marketable product in a timely manner or in accordance
with our estimated budgets. Even if we are successful in developing such products, there is no certainty that our products, when
developed, will be found to be sufficiently effective and safe for use to receive regulatory approval for marketing, which would
adversely impact our potential revenues, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we complete the necessary
preclinical studies for any new product candidates and clinical trials for existing product candidates, the marketing approval
process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some
or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals,
we will not be able to commercialize our product candidates, and our ability to generate revenue would be materially impaired.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business depends
on the success of our lead research and development programs which will require additional clinical testing before we can seek
regulatory approval and potentially launch commercial sales. In addition, we do not have any products that have gained regulatory
approval. Our business and future success depends on our ability to obtain regulatory approval of and then successfully commercialize
our lead product candidates. We are currently preparing for Phase III clinical trials for MicroLine and MicroPine and our ability
to develop, obtain regulatory approval for, and successfully commercialize, current and any future product candidates will depend
on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">further ascertaining the FDA&rsquo;s expectations
with respect to the nonclinical and clinical testing requirements across the development programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successful completion of our current clinical
trials or other clinical trials, which will depend substantially upon the satisfactory performance of third-party contractors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successful achievement of the objectives
of planned clinical trials, including manufacturability qualification of devices;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">receipt of marketing approvals from the
FDA, and similar regulatory authorities outside the United States;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing commercial manufacturing
and supply arrangements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing a manufacturing and commercial
infrastructure;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">acceptance of the products by patients,
the medical community and third-party payors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing market share while competing
with other therapies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successfully executing any pricing and/or
reimbursement strategy;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a continued acceptable safety and adverse
event profile of the products following regulatory approval; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">qualifying for, identifying, registering,
maintaining, enforcing and defending intellectual property rights and claims covering the products.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy
includes developing several pipeline product candidates over the next approximately 3-4 years which will require additional clinical
development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial
manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We are not permitted
to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory
authorities, and we may never receive such regulatory approval for any of our product candidates. If we are unable to develop or
receive marketing approval in a timely manner or at all, we could experience significant delays or an inability to commercialize
the product, which would materially and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates may cause
undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential
or result in significant negative consequences following any potential marketing approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon our development
or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. Any serious adverse or undesirable side effects identified
during the development of our product candidates could interrupt, delay or halt clinical trials and could result in the denial
of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from
commercializing our product candidates and generating revenues from their sale. In addition, if any of our product candidates receive
regulatory approval and we or others later identify undesirable adverse effects caused by the product, we could face one or more
of the following consequences:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may require the
addition of labeling statements, such as a boxed warning or a contraindication, or other safety labeling changes;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may require a Risk
Evaluation and Mitigation Strategy;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may withdraw their
approval of the product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory authorities may seize the product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we may be required to change the way that
the product is administered, or conduct additional clinical trials or we may need to recall the product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we may be subject to litigation or product
liability claims fines, injunctions or criminal penalties; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our reputation may suffer.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the market opportunities for our
product candidates are smaller than we believe they are, our product revenues may be adversely affected and our business may suffer.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently focusing
our research and product development efforts on our MicroLine, MicroPine and MicroStat products. Our understanding of both the
number of people who have needs for these products, as well as the subset of people who have the potential to benefit from current
product candidates, are based on estimates in published literature. While we believe these estimates are reasonable, they may prove
to be incorrect and new studies may reduce the estimated incidence or prevalence of presbyopia, progressive myopia and mydriasis.
The number of patients in the United States and elsewhere may turn out to be lower than expected or these patients might not be
otherwise amenable to our product candidates or may become increasingly difficult to identify and access, all of which would adversely
affect our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The commercial success of our product
candidates will depend on the degree of market acceptance among ophthalmologists and optometrists, patients, patient advocacy groups,
third-party payors and the medical community. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive
regulatory approval to market our product candidates, our product candidates might not gain market acceptance upon their commercial
introduction, which could prevent us from becoming profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may have difficulties
convincing the medical community, third-party payors and consumers to accept and use any of our product candidates that may be
approved for commercialization in the future. Other factors that we believe will affect market acceptance of our product candidates
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing of our receipt of any marketing
approvals, the terms of any approvals and the countries in which approvals are obtained;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">safety, efficacy and ease of administration
of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the success of physician education programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability of any government and
third-party payor reimbursement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the pricing of our product candidates,
particularly as compared to alternative treatment methods and medications;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which alternative treatment
methods and medications are more readily available as compared to the availability of any product candidates that we may develop
in the future; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the prevalence and severity of any adverse
effects.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face significant competition in
an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us
or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our
ability to successfully market or commercialize our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The specialty pharma
market is highly competitive. If we are unable to compete effectively with any existing products, new treatment methods and new
technologies, we may be unable to commercialize therapeutic products that we may develop in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The specialty pharma
market is subject to rapid technological change and is significantly affected by existing rival products and medical procedures,
new product introductions and the market activities of other participants. Pharmaceutical and biotechnology companies, academic
institutions, governmental agencies and other public and private research organizations may pursue the research and development
of technologies, drugs or other therapeutic products for the treatment of some or all of the diseases we are targeting. We may
also face competition from products which have already been approved and accepted by the medical community for the treatment of
these same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of any
of the foregoing factors, our competitors may develop or commercialize products with significant advantages over any therapeutic
products that we may develop. If our competitors are more successful in commercializing their products than we are, their success
could adversely affect our competitive position and harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish an effective
distribution process our business may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited resources
for the sale, marketing and distribution of drug products. To achieve commercial success for the product candidates for which we
obtain marketing approval, we will need to establish and maintain an adequate sales force, and marketing and distribution capabilities,
either ourselves or through collaborations or other arrangements with third parties. In addition, failure to secure contracts with
wholesalers, retailers, or specialty pharmacies could negatively impact the distribution of our potential products, and failure
to coordinate financial systems could negatively impact our ability to accurately report product revenue. If we are unable to effectively
establish and manage the distribution process, the commercial launch and sales of our potential products may be delayed or severely
compromised and our results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are exposed to the risk of claims
seeking monetary damages by individuals and the risk of investigations by regulatory authorities, which could cause us to incur
substantial liabilities and to limit commercialization of any products that we develop. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the
risk of claims seeking monetary damages being filed against us for loss or harm suffered by participants of our clinical trials
or for loss or harm suffered by users of any drug that may receive approval for commercialization in the future. In either event,
the FDA or the regulatory authorities of other countries or regions may commence investigations of the safety and effectiveness
of any such clinical trial or commercialized drug, the manufacturing processes and facilities or marketing programs utilized in
respect of any such clinical trial or drug. Such investigations may result in mandatory or voluntary recalls of any commercialized
drug or other significant enforcement action such as limiting the indications for which any such drug may be used, or suspension
or withdrawal of approval for any such drug. Investigations by the FDA or any other regulatory authority in other countries or
regions also could delay or prevent the completion of any of our other clinical development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product liability lawsuits against
us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products
that we develop. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face an inherent
risk of product liability exposure related to the use of our product candidates that we develop in human clinical trials. We face
an even greater risk if we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims
that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual
outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">decreased demand for any product candidates
or products that we develop;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">injury to our reputation and significant
negative media attention;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawal of clinical trial participants;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant costs to defend the related
litigation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">substantial monetary awards to clinical
trial participants or patients;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">loss of revenue;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">reduced time and attention of our management
to pursue our business strategy; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the inability to commercialize any products
that we develop.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our insurance policies
might not fully cover the risk of loss associated with our operations. We may need to increase our insurance coverage as we expand
or undertake new our clinical trials for existing and future product candidates. We will need to further increase our insurance
coverage if we commence commercialization of any of the product candidates for which we obtain marketing approval. Insurance coverage
is increasingly expensive. We might not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to
satisfy any liability that may arise. In the event that we are required to pay damages for any such claim, we may be forced to
seek bankruptcy or to liquidate because our asset and revenue base may be insufficient to satisfy the payment of damages and any
insurance that we have obtained or may obtain for product or clinical trial liability might not provide sufficient coverage against
potential liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO REGULATORY APPROVAL
OF OUR PRODUCT CANDIDATES AND </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER LEGAL COMPLIANCE MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are not able to obtain, or
if there are delays in obtaining, required regulatory approvals, we might not be able to commercialize our product candidates,
and our ability to generate revenue would be materially impaired. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates
are subject to extensive and burdensome governmental regulations relating to product development, manufacturing, marketing and
commercialization, and sale, in addition to the laws and regulations applicable to clinical trials. Rigorous preclinical testing
and clinical trials and related regulatory approval processes are required in the United States and in many foreign jurisdictions
before a new product may be offered or sold. Satisfaction of these and other regulatory requirements is costly, time-consuming,
uncertain and subject to unanticipated delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the product candidates we intend to develop and market are regulated by the FDA under its drug development and review process.
The time required to obtain FDA and other approvals for our product candidates is unpredictable. Before such product candidates
can be marketed, we must obtain FDA approval of an IND permitting the conduct of clinical trials, then we must successfully complete
human testing, and the FDA must approve our NDA. Even after successful completion of clinical testing, there is a risk that the
FDA may request further information from us, disagree with our findings or otherwise undertake a lengthy review of our submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that
FDA will not approve any application we submit. It is possible that none of the product candidates that we may develop will obtain
the appropriate regulatory approvals necessary for us to commence the offer and sale of such products. Any delay or failure in
obtaining required approvals could have a material adverse effect on our ability to generate revenues from a particular prospective
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to obtain marketing approval
in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we intend to
market any therapy that we may develop in jurisdictions in addition to the United States, such as the European Union and Asia,
we will likely incur the same costs or more in satisfying foreign regulatory requirements governing the conduct of clinical trials,
manufacturing and marketing and commercialization of our product candidates. Approval by the FDA by itself does not assure approval
by regulatory authorities outside the United States and approval by one regulatory authority outside the United States does not
ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Each of these foreign regulatory approval
processes includes all of the risks associated with the FDA approval process, as well as risks attributable to having to satisfy
local regulations within each of these foreign jurisdictions. In addition, any failure or delay in obtaining regulatory approval
in one country may negatively affect the regulatory process in other countries. Our inability to obtain regulatory approval outside
the United States may adversely compromise our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of approvals, ongoing regulations
and post-marketing restrictions for our products may limit how we manufacture and market our products, which could materially impair
our ability to generate revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once marketing approval
has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation.
The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved
indications and in accordance with the provisions of the approved labeling and regulatory requirements. The FDA imposes stringent
restrictions on manufacturers&rsquo; communications regarding off-label use and if we do not restrict the marketing of our products
only to their approved indications, we may be subject to enforcement action for off-label marketing. We, and any potential collaborators
we may have in the future, must therefore comply with requirements concerning advertising and promotion for any of our products
for which we or our collaborators obtain marketing approval. Thus, if any of our product candidates receive marketing approval,
the accompanying label may limit the approved use of our product, which could limit sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition,
manufacturers of approved products and those manufacturers&rsquo; facilities are required to comply with extensive FDA
requirements, including ensuring that quality control and manufacturing procedures conform to cGMP requirements applicable to
drug manufacturers, which include requirements relating to quality control and quality assurance as well as the corresponding
maintenance of records and documentation and reporting requirements. We, any contract manufacturers we may engage in the
future, our future collaborators and their contract manufacturers will also be subject to other regulatory requirements,
including submissions of safety and other post-marketing information and reports, registration and listing requirements,
requirements regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or
clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a risk
evaluation and mitigation strategy. Our third party manufacturers&rsquo; inability to satisfy the chemistry, manufacturing
and control concerns of regulatory bodies such as the FDA would either prevent us from completing clinical trials or prevent
us from obtaining regulatory approval for marketing, either of which would significantly compromise our business
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to substantial
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Violations of the Food
Drug and Cosmetics Act (&ldquo;FDCA&rdquo;) relating to the promotion or manufacturing of drug products may lead to investigations
by the FDA, Department of Justice, and/or state Attorneys General alleging violations of federal and state healthcare fraud and
abuse laws, as well as state consumer protection laws. In addition, later discovery of previously unknown adverse events or other
problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield
various results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on such products, manufacturers
or manufacturing processes;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on the labeling or marketing
of a product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on product distribution or
use;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">requirements to conduct post-marketing
studies or clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">warning letters;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawal of the products from the market;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal to approve pending applications
or supplements to approved applications that we submit;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">recall of products;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">fines, restitution or disgorgement of
profits or revenues;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">suspension or withdrawal of marketing
approvals;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal to permit the import or export
of our products;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">product seizure or detention; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">injunctions or the imposition of civil
or criminal penalties.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to federal and state
healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply,
or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to U.S.
federal and state and also foreign healthcare fraud and abuse laws and regulations. Any finding of our failure to comply with such
laws and regulations could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations may
be directly or indirectly affected by various broad U.S. federal and state healthcare fraud and abuse laws. These include the U.S.
federal anti-kickback statute, which prohibits any person from knowingly and willfully offering, paying, soliciting or receiving
remuneration, directly or indirectly, in return for or to induce the referring, ordering, leasing, purchasing or arranging for
or recommending the ordering, purchasing or leasing of an item or service for which payment may be made under U.S. federal healthcare
programs, such as the Medicare and Medicaid programs. The U.S. federal anti-kickback statute is very broad in scope, and many of
its provisions have not been uniformly or definitively interpreted by existing case law or regulations. In addition, many states
have adopted laws similar to the U.S. federal anti-kickback statute, and some of these laws are broader than that statute in that
their prohibitions are not limited to items or services paid for by a U.S. federal healthcare program but, instead, apply regardless
of the source of payment. Violations of these laws could result in fines, imprisonment or exclusion from government-sponsored programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our relationships
with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and
regulations, which may expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm
and diminished profits and future earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers,
physicians and third-party payors play a primary role in the recommendation of any product candidates for which we obtain marketing
approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and
other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which
we plan to market, sell and distribute products for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some state laws require
pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government and federal and state laws may require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State
and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each
other in significant ways and often are not preempted by the Health Insurance Portability and Accountability Act, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that
our business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs.
It is possible that governmental authorities will conclude that our business practices might not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs,
such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers
or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal,
civil or administrative sanctions, including exclusions from government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recently enacted and future legislation
may affect our ability to commercialize our products and the prices we obtain for any products that are approved in the United
States or foreign jurisdictions, which would harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States
and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could affect our ability to profitably sell or commercialize our product candidates for which we obtain
marketing approval. The pharmaceutical industry has been a particular focus of these efforts and have been significantly affected
by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result
in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States Medicare
Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers
and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced
a new reimbursement methodology based on average sales prices for clinician administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives in this and
similar legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization
Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from changes in laws
applicable to federal and state healthcare programs may result in similar reduction in payment from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is discussed above,
several provisions of the ACA are important to our business, including, without limitation, our ability to commercialize our product
candidates and the prices we may obtain for any of our product candidates that are approved for sale. Provisions of the ACA that
are potentially important to our business include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an annual, nondeductible fee on any entity
that manufactures or imports specified branded prescription drugs and biologic products;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an increase in the statutory minimum rebates
a manufacturer must pay under the Medicaid Drug Rebate Program;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a new Medicare Part D coverage gap discount
program, in which participating manufacturers must agree to offer 50% point-of-sale discounts off negotiated drug prices during
the coverage gap period as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">expansion of healthcare fraud and abuse
laws, including the federal False Claims Act and the federal Anti-Kickback Statute, and the addition of new government investigative
powers, and enhanced penalties for noncompliance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">extension of manufacturers&rsquo; Medicaid
rebate liability;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">expansion of eligibility criteria for
Medicaid programs; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">expansion of the entities eligible for
discounts under the Public Health Service pharmaceutical pricing program.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, other legislative changes have
been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, for instance, included measures for spending
reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of
at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&rsquo;s
automatic reduction to several government programs (&ldquo;Sequestration&rdquo;) . These changes included aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through
2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare
payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. These and similar laws, including ongoing legislative efforts to promote transparency and contain costs
related to pharmaceutical prices, may result in additional reductions in Medicare and other third-party rates and otherwise affect
the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which
any such product candidate is prescribed or used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Continued efforts to
repeal or replace the ACA and other efforts to reform the healthcare marketplace and delivery system, could have an adverse effect
on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval
and may affect our overall financial condition and ability to develop or commercialize product candidates. We expect that future
reform efforts will continue to prioritize reductions in Medicare and other healthcare spending, more rigorous coverage criteria,
new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level
of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement
levels may negatively impact the prices we receive or the frequency with which any products we may develop are prescribed or administered.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private
payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The costs of prescription
pharmaceuticals has also been the subject of considerable discussion in the United States, and members of Congress and the Administration
have stated that they will address such costs through new legislative and administrative measures. To date, there have been several
laws passed under the new administration aimed at curbing the cost of drugs, and additional legislation has been proposed on this
subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pricing of prescription
pharmaceuticals is also subject to governmental controls outside the United States, which vary widely from country to country.
As a result, we might obtain regulatory approval for a product in a particular country, but then be subjected to pricing regulations
in that country that delay the commercial launch of the product and negatively impact the revenues able to be generated from the
sale of the product in that country. In these countries, pricing negotiations with governmental authorities can take considerable
time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may
be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies.
If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our
ability to generate revenues and become profitable could be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to anti-corruption
laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply
with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from
developing manufacturing and selling products outside the United States or be required to develop and implement costly compliance
programs, which could adversely affect our business, results of operations and financial condition. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations are
subject to anti-corruption laws, including the United Kingdom Bribery Act 2010, or Bribery Act, the United States Foreign Corrupt
Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in the
future. The Bribery Act, FCPA and these other laws generally prohibit us, our officers, and our employees and intermediaries from
bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business
or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries
in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry,
because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign
officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments
to government officials and have led to FCPA enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the
future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in
collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery
Act, FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory
requirements to which our international operations might be subject or the manner in which existing laws might be
administered or interpreted. If we expand our operations outside of the United States, we will need to dedicate additional
resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject
to other laws and regulations governing our international operations, including regulations administered by the governments of
the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions on countries and persons, customs requirements and currency exchange regulations, collectively referred to as
the Trade Control laws. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside
of the United States, or the sharing with certain non-United States nationals, of information classified for national security
purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing,
manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential
and increase our development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might not be completely
effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal
requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption
laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures,
and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity.
The SEC also may suspend or bar issuers from trading securities on United States exchanges for violations of the FCPA&rsquo;s accounting
provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control
laws by U.K., U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR BUSINESS OPERATIONS
AND MANAGING GROWTH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are highly dependent on the services
of our senior management team, including our Chief Executive Officer and Chief Medical Officer, Dr. Ianchulev, and if we are not
able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel,
our business will be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent
on our senior management team, including our Chief Executive Officer and Chief Medical Officer, Dr. Ianchulev. The employment agreements
we have with our executive officers do not prevent such persons from terminating their employment with us at any time. The loss
of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific
personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary
for the continued development of our business, we might not be able to sustain our operations or grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might not be able
to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology,
pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel
and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we
do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may
be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract,
retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which
we can discover and develop drug candidates and our business will be limited and we may experience constraints on our development
objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future performance
will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and
our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and
create effective working relationships among.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited corporate infrastructure
and may experience difficulties in managing growth. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 25, 2020,
we had only 27 full time employees and we rely on third-party contractors for the provision of professional and other services.
As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales,
marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away
from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We might not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of our
current and potential future drug candidates. If our management is unable to effectively manage our growth, our expenses may increase
more than expected, our ability to generate and grow revenue could be reduced and we might not be able to implement our business
strategy. Our future financial performance, our ability to commercialize drug candidates, develop a scalable infrastructure and
compete effectively will depend, in part, on our ability to effectively manage any future growth.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees, third-party clinical
investigators, consultants, licensors and strategic partners may engage in misconduct or other improper activities, including non-compliance
with regulatory standards and requirements and insider trading.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the
risk of fraud or other misconduct by our employees, third-party clinical investigators, consultants, licensors and strategic partners.
Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in
other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and
abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized
activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and
regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course
of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and
cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions
we take to detect and prevent this activity might not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions
could have a negative impact on our business, financial condition, results of operations and prospects, including the imposition
of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely upon information technology
and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm
our ability to operate our business effectively. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business operations
could suffer in the event of system failure. Despite the implementation of security measures, our internal computer systems and
those of our contract research organizations, and other contractors and consultants are vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to
occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For
example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and further development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR DEPENDENCE ON THIRD
PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited clinical trial experience.
We may rely upon third parties in conducting our clinical trials, and those third parties might not perform satisfactorily, including
failing to meet deadlines for the completion of such clinical trials. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in conducting and managing the clinical trials necessary to obtain regulatory approvals for our product candidates. We rely on
third parties for certain clinical development activities. Reliance on third parties reduces our control over these activities
and does not relieves us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials
is conducted in accordance with the general investigational plan and protocols for the clinical trial. Moreover, the FDA requires
us to comply with standards, commonly referred to as good clinical practices for conducting, recording and reporting the results
of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of clinical trial participants are protected. We are also required to register ongoing clinical trials and post the results of
completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so
can result in fines, adverse publicity and civil and criminal sanctions. If any third parties we engage do not successfully carry
out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements
or our stated protocols, we might not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates
and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. If these third
parties do not successfully carry out their contractual duties or meet expected deadlines, we may be required to replace them,
which may delay the affected clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We contract with third parties for
the manufacture of our product candidates including to provide materials required for the production of the Optejet and for our
research and development activities. This reliance on third parties increases the risk that we will not have sufficient quantities
of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
operate adequate internal manufacturing facilities for clinical or commercial production of our product candidates. We rely on
a number of third parties for the supply of parts, formulations, active pharmaceutical ingredients, and other materials required
for our manufacturing, research and development activities. If we were unable to reach agreements with these third parties, or
if we were unable to maintain contractual relationships with these third parties, our research and development activities would
be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third parties
to provide the materials required for our research and development activities. Obtaining these materials can require various approvals
as well as reaching a purchase or commercial agreement on acceptable terms with the provider of the materials. We might not be
able to reach agreements with a sufficient number of suppliers or do so on acceptable terms. If we are unable to reach acceptable
agreements with a sufficient number of suppliers of materials, our research and development activities will be delayed and our
ability to implement our business plan will be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our manufacturing process
is a complicated and expensive and it requires months of advance planning. We rely on a limited number of manufacturers for our
supply. If we were unable to acquire the necessary amount of deliverables to complete our clinical trials, our progress could be
delayed substantially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional potential
risks related to reliance on third-party manufacturers include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">manufacturing delays if our third-party manufacturers are compromised
due to environmental or political factors or health epidemics such as the coronavirus, they do not satisfactorily perform according
to the terms of their agreements with us, or they give greater priority to the supply of other products over our product candidates
or otherwise;&nbsp;</P>



<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in obtaining regulatory approval
for our product candidates, if our third-party manufacturers fail to satisfy or comply with regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the possible termination or nonrenewal
of the agreement by the third party at a time that is costly or inconvenient for us;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the possible breach of the manufacturing
agreement by the third party;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">product loss due to contamination, equipment
failure or improper installation or operation of equipment or operator error;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the failure of the third-party manufacturer
to comply with applicable regulatory requirements; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the possible misappropriation of our proprietary
information, including our trade secrets and know-how.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we, our service providers or our
third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third-party manufacturers fail to comply with laws regulating the protection of the environment and health and
human safety, we could be subject to enforcement actions and our business prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
activities, and the research and development activities of our service providers and third-party manufacturers, may involve the
use of hazardous materials and chemicals or the maintenance of various flammable and toxic chemicals. Failure to adequately handle
and dispose of these materials could lead to liabilities for resulting damages, which could be substantial. We also may be subject
to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure
to blood-home pathogens and the handling of bio-hazardous materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we, our service
providers, or any third-party manufacturers fail to comply with applicable federal, state or foreign laws or regulations, we could
be subject to enforcement actions, which could adversely affect our ability to develop, market and sell our product candidates
successfully and could harm our reputation and lead to reduced acceptance of our product candidates. These enforcement actions
may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on, or prohibitions against,
marketing our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions on importation of our product
candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">suspension of review or refusal to approve
new or pending applications;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">suspension or withdrawal of product approvals;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">product seizures;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">injunctions; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">civil and criminal penalties and fines.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR INTELLECTUAL PROPERTY
AND POTENTIAL LITIGATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our success depends on our ability
to protect our intellectual property and proprietary technology. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
in large part on our ability to obtain and maintain patent, trade secret and other intellectual property protection in the United
States and other countries with respect to our proprietary product candidates. If we do not adequately protect our intellectual
property rights, competitors may be able to erode, negate or preempt any competitive advantage we may have, which could harm our
business and ability to achieve profitability. To protect our proprietary position, we file patent applications in the United States
and abroad related to our novel product candidates that are important to our business. The patent application and approval process
is expensive and time-consuming and we might not be able to file and prosecute all necessary or desirable patent applications at
a reasonable cost or in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the scope of the
patent protection we obtain is not sufficiently broad, we might not be able to prevent others from developing and commercializing
technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the
marketplace may be unavailable or severely limited in some cases and might not adequately protect our rights or permit us to gain
or keep any competitive advantage. Although we enter into non-disclosure and confidentiality agreements with parties who have access
to confidential or patentable aspects of our research and development output, such as our employees, contractors and other third
parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby
jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often
lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions
claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position
of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and
has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights may be uncertain. Our pending and future patent applications might not result in patents being issued
which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies
and product candidates. In addition, the coverage claimed in a patent application can be significantly reduced before the patent
is issued, and its scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they might not
issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing
with us, or otherwise provide us with any competitive advantage. In addition, changes in either the patent laws or interpretation
of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection. In addition, the laws of foreign countries might not protect our rights to the same extent or in the same manner as
the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such
as Europe, restrict the patentability of methods of treatment of the human body more than United States law does.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our future
patents and patent applications may be co-owned with third parties. If we are unable to obtain an exclusive license to any such
third-party co-owners&rsquo; interest in such patents or patent applications, such co-owners may be able to license their rights
to other third parties, including our competitors, and our competitors could market competing products and technology. In addition,
we would need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and
such cooperation might not be provided to us. Furthermore, we, or any future partners, collaborators, or licensees, may fail to
identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late
to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. Any of the
foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our patents covering our proprietary
technology maybe subject to challenge, narrowing, circumvention and invalidation by third parties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our patents
may be challenged, narrowed, circumvented, or invalidated by third parties. The issuance of a patent is not conclusive as to its
inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United
States and abroad. We may be subject to a third party preissuance submission of prior art to the USPTO or become involved in opposition,
derivation, revocation, reexamination, post-grant and <I>inter partes</I> review, or interference proceedings challenging our patent
rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the
scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly
with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party
patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of
invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention
or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims
being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates.
Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the
eventual outcome is favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our competitors
and other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in
a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to our product
candidates but that uses a technology that falls outside the scope of our patent protection. Our competitors may also seek approval
to market generic versions of any approved products and in connection with seeking such approval may claim that our patents are
invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including
by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction
may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if
we have valid and enforceable patents, these patents still might not provide protection against competing products or processes
sufficient to achieve our business objectives. If the patent protection provided by the patents and patent applications we hold
or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully
commercialize our product candidates could be negatively affected, which could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We cannot be sure that we were the
first to make the technologies claimed in our patents or patent applications or that we were the first to file for patent protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the other
requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent.
However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first
to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection
of such inventions. Similarly, we cannot be certain that parties from whom we may license or purchase patent rights were the first
to make relevant claimed inventions or were the first to file for patent protection for them. If third parties have filed patent
applications on inventions claimed in our patents or applications on or before March 15, 2013, an interference proceeding in the
United States can be initiated by such third parties to determine the first to invent any of the subject matter covered by the
patent claims of our applications. If third parties have filed such applications after March 15, 2013, a derivation proceeding
in the United States can be initiated by such third parties to determine whether our invention was derived from theirs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The patent application process is
subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pending patent applications
cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues
from such applications. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance
that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending
patents. These risks and uncertainties include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the USPTO and various foreign governmental
patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent
process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter
the market earlier than would otherwise have been the case;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the coverage claimed in a patent application
can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patent applications might not result in
any patents being issued;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">patents that may be issued or in-licensed
may be challenged, invalidated, modified, revoked, circumvented, narrowed, found to be unenforceable or otherwise might not provide
any competitive advantage;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our competitors, many of whom have substantially
greater resources and many of whom have made significant investments in competing technologies, may seek or may have already obtained
patents that will limit, interfere with or eliminate our ability to make, use, and sell our potential product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">there may be significant pressure on the
U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United
States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">countries other than the United States
may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better
opportunity to create, develop and market competing product candidates.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the foregoing
events could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is difficult and costly to protect
our intellectual property and our proprietary technologies, and we might not be able to ensure their protection. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend in part on obtaining and maintaining patent protection and trade secret protection for the composition, use and structure
of our products and product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods
of treatment as well as on successfully defending these patents against potential third-party challenges. Our ability to protect
our products and product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is
dependent on the extent to which we have rights under valid and enforceable patents that cover these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ultimate determination
by the USPTO or by a court or other trier of fact in the United States, or corresponding foreign national patent offices or courts,
on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party
publications, patents and other information that may affect the patentability of claims in our various patent applications and
patents, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of
claims that may be allowed or enforced in our patents or patent applications, in our licensed patents or patent applications or
in third-party patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide assurances
that any of our patent applications will be found to be patentable, including over our own prior art patents, or will issue as
patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent applications
nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability
of our patents and patent applications in the United States or foreign jurisdictions. Any such challenge, if successful, could
limit patent protection for our products and product candidates and/or materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future
protection for our proprietary rights is uncertain because legal means afford only limited protection and might not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we might not be able to generate sufficient
data to support full patent applications that protect the entire breadth of developments in one or more of our programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">it is possible that one or more of our
pending patent applications will not become an issued patent or, if issued, that the patent(s) will be insufficient to protect
our technology, provide us with a basis for commercially viable products or provide us with any competitive advantages;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if our pending applications issue as patents,
they may be challenged by third parties as not infringed, invalid or unenforceable under United States or foreign laws; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if issued, the patents under which we
hold rights might not be valid or enforceable.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, to the
extent that we are unable to obtain and maintain patent protection for one of our products or product candidates or in the event
that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development
of a product or product candidate for follow-on indications. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining patent
protection of our technologies depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance
fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the
USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents
and applications. The USPTO and various non- U.S. governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There
are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. Under the terms of some of our licenses or future licenses, we
may not have the ability to maintain or prosecute patents in the portfolio, and must therefore rely on third parties to comply
with these requirements. Failure by us or our licensors to maintain protection of our patent portfolio could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, it is
possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the
future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments.
If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
eliminated. If any of our present or future partners, collaborators, licensees, or licensors, are not fully cooperative or disagree
with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there
are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents
may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes
could impair our ability to prevent competition from third parties, which may have a material adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to
protect our competitive position on our products for an adequate amount of time and if we do not obtain protection under the Hatch-Waxman
Amendments and similar non- U.S. legislation for extending the term of patents covering each of our product candidates, our business
may be materially harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents have a limited
lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions
may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for
the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our patent portfolio might not provide us with adequate and continuing
patent protection sufficient to exclude others from commercializing products similar to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the
timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the
Hatch-Waxman Amendments and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension
of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development
and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14
years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method
for using it, or a method for manufacturing it may be extended. However, we might not receive an extension if we fail to apply
within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements.
Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term
of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be
shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable
products could be reduced and could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes to the patent law in the
United States or other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves
both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. The Leahy-Smith America
Invents Act, or the America Invents Act, reformed U.S. patent law in part by changing the U.S. patent system from a &ldquo;first
to invent&rdquo; system to a &ldquo;first inventor to file&rdquo; system, expanding the definition of prior art, and developing
a post-grant review system. This legislation changed U.S. patent law in a way that may weaken our ability to obtain patent protection
in the United States for those applications filed after March 16, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the America
Invents Act created new procedures to challenge the validity of issued patents in the United States, including post-grant review
and <I>inter partes</I> review proceedings, which some third parties have been using to cause the cancellation of selected or all
claims of issued patents of competitors. For a patent with an effective filing date of March 16, 2013 or later, a petition for
post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for <I>inter partes</I>
review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to March 16,
2013. A petition for <I>inter partes</I> review can be filed after the nine-month period for filing a post-grant review petition
has expired for a patent with an effective filing date of March 16, 2013 or later. Post-grant review proceedings can be brought
on any ground of invalidity, whereas <I>inter partes</I> review proceedings can only raise an invalidity challenge based on published
prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded
to U.S. patents in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts.
Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant
review or <I>inter partes</I> review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents
are challenged by a third party in such a USPTO proceeding, there is no guarantee that we, our licensors or collaborators will
be successful in defending the patent, which would result in a loss of the challenged patent right to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, recent
court rulings in cases such as <I>Association for Molecular Pathology v. Myriad Genetics, Inc., BRCA1- &amp; BRCA2-Based Hereditary
Cancer Test Patent Litigation, Promega Corp. v. Life Technologies Corp. and Abbvie Deutschland GmbH v. Janssen Biotech, Inc.</I>
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination
of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress,
the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could
change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents
that we might obtain in the future. Any changes to patent law in the United States or other jurisdictions that impairs our ability
to protect our product candidates could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to enforce our
intellectual property rights throughout the world. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting,
enforcing and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some foreign countries can be less extensive than those in the United States. The requirements
for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue
patent protection, there can be no assurance that any patents will issue with claims that cover our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, our ability
to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual
property laws. Many companies have encountered significant problems in protecting and defending intellectual property rights in
certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, do not
favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement
of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory
licensing laws under which a patent owner must grant licenses to third parties. Consequently, we might not be able to prevent third
parties from practicing our inventions in certain foreign countries. Competitors may use our technologies in jurisdictions where
we have not obtained patent protection to develop and market their own products and, further, may export otherwise infringing products
to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate.
These products may compete with our products, and our patents or other intellectual property rights might not be effective or sufficient
to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Agreements through
which we license patent rights might not give us sufficient rights to permit us to pursue enforcement of our licensed patents or
defense of any claims asserting the invalidity of these patents (or control of enforcement or defense) of such patent rights in
all relevant jurisdictions as requirements may vary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proceedings to enforce
our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts
and resources from other aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated
or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against
us. We might not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, might not be commercially
meaningful. Furthermore, while we intend to protect our intellectual property rights in major markets for our products, we cannot
ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products.
Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. Any of the foregoing
could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are sued for infringing, misappropriating,
or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could
prevent or delay us from developing or commercializing our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating,
or otherwise violating the intellectual property and other proprietary rights of third parties. Third parties may have U.S. and
non- U.S. issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods
of use for the treatment of the disease indications for which we are developing our product candidates that may cover our product
candidates or approach to complement inhibition. If any third-party patents or patent applications are found to cover our product
candidates or their methods of use or manufacture, or our approach to complement inhibition, we might not be free to manufacture
or market our product candidates as planned without obtaining a license, which might not be available on commercially reasonable
terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is a substantial
amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened
with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates,
including interference and post-grant proceedings before the USPTO. There may be third-party patents or patent applications with
claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture
of our product candidates. We cannot guarantee that any of our patent searches or analyses including, but not limited to, the identification
of relevant patents, the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain
that we have identified each and every patent and pending application in the United States and abroad that is relevant to or necessary
for the commercialization of our product candidates in any jurisdiction. Because patent applications can take many years to issue,
there may be currently pending patent applications which may later result in issued patents that our product candidates may be
accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes
upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights
that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot
be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents,
and it might not always be clear to industry participants, including us, which patents cover various types of products or methods
of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation
is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates, products
or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable,
and we might not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires
a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful
in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could
be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we might
not have sufficient resources to bring these actions to a successful conclusion. Further, the outcome of intellectual property
litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility
of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the
testimony of experts as to technical facts upon which experts may reasonably disagree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are found to
infringe, misappropriate, or otherwise violate a third party&rsquo;s intellectual property rights, we could be forced, including
by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively,
we may be required to obtain a license from such third party in order to use the infringing technology and continue developing,
manufacturing or marketing the infringing product candidate or product. However, we might not be able to obtain any required license
on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving
our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede
or destroy our ability to compete successfully in the commercial marketplace. In addition, we could be found liable for monetary
damages, including treble damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent. A finding of
infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations,
which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims by third
parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard
as our own intellectual property and proprietary technology. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our current
and former employees and our licensors&rsquo; current and former employees, including our senior management, were previously employed
at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors.
Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us,
we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or
other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel
or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license
from such third party to commercialize our technology or products. Such a license might not be available on commercially reasonable
terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be
a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while
we typically require our employees, consultants and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each
party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related
to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such
claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. Any
of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become involved in lawsuits
to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe,
misappropriate, or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement
or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time
and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these
parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that
our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide
that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party
from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe
the patent&rsquo;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at
issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving
one or more of our patents could limit our ability to assert those patents against those parties or other competitors, and may
curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if
we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or
that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case,
we could ultimately be forced to cease use of such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the outcome
of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the
demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases
that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we establish
infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary
damages, which might not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could adversely affect the price of
our common shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue
such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims,
the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh
any benefit we receive as a result of the proceedings. Any such litigation could have a material adverse effect on our business,
financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important
to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be reliant upon
licenses to certain patent rights and proprietary technology form third parties that are important or necessary to the development
of our product candidates. These and other licenses might not provide exclusive rights to use such intellectual property and technology
in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products
in the future. As a result, we might not be able to prevent competitors from developing and commercializing competitive products
in territories included in all of our licenses. Our licensors may have relied on third party consultants or collaborators or funds
from third parties such that our licensors are not the sole and exclusive owners of the patents we in-license. This could have
a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we license patent rights might not give us control over patent prosecution or maintenance, so that we might not be
able to control which claims or arguments are presented and might not be able to secure, maintain, or successfully enforce necessary
or desirable patent protection from those patent rights. We cannot be certain that patent prosecution and maintenance activities
by our licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.
Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors, and cannot guarantee
that we would receive it and on what terms. We cannot be certain that our licensors will allocate sufficient resources or prioritize
their or our enforcement of such patents or defense of such claims to protect our interests in any licensed patents. If we cannot
obtain patent protection, or enforce existing or future patents against third parties, it could have a material adverse effect
on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the agreements
under which we currently license intellectual property or technology to or from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that
may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse
effect on our business, financial conditions, results of operations, and prospects. Moreover, if disputes over intellectual property
that we license prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on
our business, financial conditions, results of operations, and prospects. Disputes may arise regarding intellectual property subject
to a licensing agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the scope of rights granted under the
license agreement and other interpretation-related issues;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the extent to which our technology and
processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the sublicensing of patent and other rights
under current and any future collaborative development relationships;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our diligence obligations under any license
agreement and what activities satisfy such obligations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the inventorship and ownership of inventions
and know-how resulting from the joint creation or use of intellectual property by our license counterparties and us and our partners;
and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the priority of invention of patented
technology.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In spite of our efforts,
our license counterparties might conclude that we have materially breached our license agreements and might therefore terminate
the license agreements, which may remove our ability to develop and commercialize the product candidates and technology covered
by these license agreements. If any in-licenses are terminated, competitors would have the freedom to seek regulatory approval
of, and to market, products identical to ours. It is possible that we may be unable to obtain any additional licenses that we require
at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources
to redesign our product candidates, technology, or the methods for manufacturing them or to develop or license replacement technology,
all of which might not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or
commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects
significantly. Any of these events could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, the value of our technology could be negatively impacted and our business would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
protection afforded by patents, we also rely on trade secret protection for certain aspects of our intellectual property. However,
trade secrets are difficult to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality
agreements with parties who have access to them, such as our employees, consultants, independent contractors, advisors, contract
manufacturers, suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements
with employees and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose
our proprietary information, including our trade secrets, and we might not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may
have insufficient recourse against third parties for misappropriating the trade secret. Further, if any of our trade secrets were
to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those
to whom they communicate such technology or information, from using that technology or information to compete with us. If any of
our trade secrets were to be disclosed to or independently developed by a competitor, it could have a material adverse effect on
our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our trademarks and trade names
are not adequately protected, then we might not be able to build name recognition in our marks of interest and our business may
be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our trademarks or trade
names, including Optejet<SUP>TM</SUP>, may be challenged, infringed, circumvented or declared generic or determined to be infringing
on other marks. We rely on both registration and common law protection for our trademarks. We might not be able to protect our
rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential
partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although
we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in
the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark
applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks,
and our trademarks might not survive such proceedings. If we are unable to establish name recognition based on our trademarks and
trade names, we might not be able to compete effectively and our business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OWNERSHIP OF OUR COMMON
STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management and members of our
Board of Directors have the ability to substantially influence all matters submitted to stockholders for approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 25,
2020, our management and members of our Board of Directors, in the aggregate, beneficially owned shares representing
approximately 23% of our capital stock. As a result, they can substantially influence all matters submitted to our
stockholders for approval, as well as our management and affairs. For example, these persons would substantially influence
the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This
concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders desire or
result in management of our company that our public stockholders disagree with.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A significant portion of our total
outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop
significantly, even if our business is performing well.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of a substantial
number of shares of our common stock in the public market could occur at any time, subject to certain restrictions. These sales,
or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price
of our common stock. As of March 25, 2020, we had 19,776,019 shares of common stock outstanding, including 2,675,293 shares of
common stock that were issued in our recent private placement. The shares of common stock issued in our private placement and
3,344,154 shares of common stock issuable upon exercise of warrants also issued in that private placement may be resold without
restriction upon effectiveness of the resale registration statement regarding such securities that we are required to file with
the SEC within the next 30 days.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may
be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market historically
has experienced extreme price and volume fluctuations, such as those seen in February 2020 as a result of concerns the coronavirus
will impact the economy worldwide. As a result of this volatility and because the public market for our stock is new, you might
not be able to sell your common stock at or above the price at which you purchase it. From our IPO in January 2018 through March
25, 2020, the per share trading price of our common stock has been as high as $10.74 and as low as $1.77. It might continue to
fluctuate significantly in response to various factors, some of which are beyond our control. These factors include:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">general economic, industry and market
conditions, including as a result of the coronavirus pandemic;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to successfully conduct clinical
trials and submit NDAs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">results of clinical trials of our product
candidates or those of our competitors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the success of competitive products or
technologies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">commencement or termination of collaborations;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory or legal developments in the
United States and other countries;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developments or disputes concerning patent
applications, issued patents or other proprietary rights;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the recruitment or departure of key personnel;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the level of expenses related to any of
our product candidates or clinical development programs;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the results of our efforts to discover,
develop, acquire or in-license additional product candidates;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">actual or anticipated changes in estimates
as to financial results, development timelines or recommendations by securities analysts;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our inability to obtain or delays in obtaining
adequate product supply for any approved product or inability to do so at acceptable prices;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">disputes or other developments relating
to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">significant lawsuits, including patent
or stockholder litigation;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">variations in our financial results or
those of companies that are perceived to be similar to us;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in the structure of healthcare
payment systems;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">market conditions in the pharmaceutical
and biotechnology sectors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the other factors described in this &ldquo;Risk
Factors&rdquo; section.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the use
of our cash, including the net proceeds from our financings, and might not use them effectively. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will
have broad discretion in the application of our cash, including the net proceeds from our December 2018 follow-on and July 2019
public offerings of common stock, and recent private placement, and could spend our cash in ways that do not improve our results
of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result
in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and
delay the development of our product candidates. Pending their use, we may invest our cash, including the net proceeds from our
financings, in a manner that does not produce income or that loses value.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is subject to changing
regulations regarding corporate governance, disclosure controls, internal control over financial reporting, and other compliance
areas that will increase both our costs and the risk of noncompliance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company,
we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, the
Dodd-Frank Act, and the rules and regulations of our stock exchange. The requirements of these rules and regulations will increase
our legal, accounting, and financial compliance costs, will make some activities more difficult, time-consuming, and costly, and
may also place undue strain on our personnel, systems, and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sarbanes-Oxley
Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial
reporting. Commencing with our fiscal year ending December 31, 2018, we performed system and process evaluation and testing of
our internal control over financial reporting so that management could report on the effectiveness of our internal control over
financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our compliance with Section 404 of the Sarbanes-Oxley
Act requires that we incur substantial accounting expense and expend significant management efforts. Prior to our IPO, we had never
been required to test our internal controls within a specified period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are required to
disclose changes made to our internal control and procedures on a quarterly basis. However, our independent registered public accounting
firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to
Section 404 of the Sarbanes-Oxley Act until we are no longer an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart
Our Business Startups Act of 2012 (JOBS Act), if we take advantage of the exemption available under the JOBS Act to the auditor
attestation requirement in Section 404(b) of the Sarbanes-Oxley Act. If we are not able to comply with the requirements of Section
404 of the Sarbanes-Oxley Act in a timely manner, the market price of our stock could decline and we could be subject to sanctions
or investigations by the stock exchange on which our common stock is listed, the SEC, or other regulatory authorities, which would
require additional financial and management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to develop and maintain adequate
financial controls could cause us to have material weaknesses, which could adversely affect our operations and financial position.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously reported,
in the fourth quarter of 2017, we identified certain material weaknesses in internal controls including regarding insufficient
segregation of duties in our finance and accounting function because of our limited personnel, properly identifying all related
party relationships and transactions so that they could be evaluated for disclosure in our public filings, properly communicating
the terms of certain agreements entered into by us to the Board of Directors in order for the Board to take the appropriate actions,
and adequately recording research and development expenses in our internal books and records to permit timely and accurate financial
reporting. While we have remedied these weaknesses, we might in the future discover other material weaknesses that require additional
remediation. In addition, an internal control system, no matter how well-designed, cannot provide absolute assurance that misstatements
due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we are not able to
comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper
and effective internal controls, we might not be able to produce timely and accurate financial statements. If that were to happen,
the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which
our common stock is listed, the SEC, or other regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any failure to develop
or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating
results or cause us to fail to meet our reporting obligations. Any failure to implement and maintain effective internal controls
also could adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control
over financial reporting that we are required to include in our periodic reports filed with the SEC under Section 404 of the Sarbanes-Oxley
Act. Ineffective disclosure controls and procedures or internal control over financial reporting could also cause investors to
lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price
of our common stock. Implementing any appropriate changes to our internal controls may require specific compliance training of
our directors, officers, and employees, entail substantial costs in order to modify our existing accounting systems, and take a
significant period of time to complete. Such changes may not be effective, however, in maintaining the adequacy of our internal
controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely
basis, could increase our operating costs and could materially impair our ability to operate our business. In the event that we
are not able to demonstrate compliance with Section 404 of the Sarbanes-Oxley Act in a timely manner, that our internal controls
are perceived as inadequate, or that we are unable to produce timely or accurate financial statements, investors may lose confidence
in our operating results and our stock price could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company&rdquo; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive
to investors. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging
growth company. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such
time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting
standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For as long as we continue
to be an emerging growth company, we intend to take advantage of certain other exemptions from various reporting requirements that
are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved, and exemptions from the requirements
of auditor attestation reports on the effectiveness of our internal control over financial reporting. We cannot predict if investors
will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of (i) the end of the fiscal year in which the market value of our common stock that is held
by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the end of the fiscal year in which we have total
annual gross revenue of $1.07 billion or more during such fiscal year, (iii) the date on which we issue more than $1 billion in
non-convertible debt in a three-year period, or (iv) December 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions in our corporate charter
documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and
may prevent attempts by our stockholders to replace or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in our certificate
of incorporation, and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders
may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing
the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of
our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">allow the authorized number of our directors
to be changed only by resolution adopted by a majority of our Board;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">limit the manner in which stockholders
can remove directors from the Board, as may be permitted by law;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establish advance notice requirements
for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">limit who may call stockholder meetings;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">authorize our Board to issue preferred
stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &ldquo;poison pill,&rdquo;
that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not
been approved by our Board; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">require all stockholder action to take
place at duly called stockholder meetings and disallow the ability of our stockholders to act by majority written consent.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, because we
are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits
a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years
after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger
or combination is approved in a prescribed manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our certificate
of incorporation provides that the Court of Chancery of the State of Delaware is, to the fullest extent permitted by law, the sole
and exclusive forum for substantially all disputes between us and our stockholders. These choice of forum provisions could limit
the ability of stockholders to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we consent to
the selection of an alternative forum, our certificate of incorporation provides that the Court of Chancery of the State of Delaware,
or the Court of Chancery, will be, to the fullest extent permitted by law, the sole and exclusive forum for any derivative action
or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers
or other employees or agent to the Company or our stockholders; any action asserting a claim against us arising pursuant to the
Delaware General Corporation Law, or DGCL, or our certificate of incorporation or bylaws; any action to enforce or determine the
validity of our certificate of incorporation or bylaws; or any action asserting a claim against us that is governed by the internal
affairs doctrine. Since the choice of forum provisions are only applicable to &ldquo;the fullest extent permitted by law,&rdquo;
as provided in our certificate of incorporation, the provisions do not designate the Court of Chancery as the exclusive forum for
any derivative action or other claim for which the applicable statute creates exclusive jurisdiction in another forum. As such,
the choice of forum provisions do not apply to any actions arising under the Securities Act of 1933, as amended or the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">These
choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors,
officers and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate
of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such
action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we do not anticipate paying
any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth
and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As
a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities analysts do not continue
to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock
could decline. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market
for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our
business. If securities analysts do not continue coverage of us, the trading price of our stock could decrease. Additionally, if
one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline.
If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn
could cause our stock price to decline.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="g1"></A><B>Item 1B.</B></TD><TD><B>Unresolved Staff Comments.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="g2"></A><B>Item 2.</B></TD><TD><B>Properties.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located in approximately 3,800 square feet of office space in New York City, NY. In addition, we lease approximately
1,000 square feet of office space in Reno, Nevada where we perform certain of our research and development activities. We also
lease approximately 120 square feet of office space in Newport Beach, California for clinical and marketing team offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in
the future on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="g3"></A><B>Item 3.</B></TD><TD><B>Legal Proceedings. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="g4"></A><B>Item 4.</B></TD><TD><B>Mine Safety Disclosures.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information concerning our executive officers as of March 25, 2020:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 37%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 55%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev, M.D., M.P.H.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Chief Medical Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Gandolfo</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer &ldquo;Ginger&rdquo; Clasby</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Clinical Operations</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luke Clauson</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Research &amp; Development, Manufacturing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Rowe</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Commercial</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Dr. Tsontcho Ianchulev</B>&nbsp;has
been serving as our Chief Executive Officer, Chief Medical Officer and a member of our Board of Directors since March&nbsp;2014.
From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical,
Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NYSE: DNA, before
going private in 2009), Dr.&nbsp;Ianchulev headed the ophthalmology research group and directed the development and the FDA approval
of Lucentis. Dr.&nbsp;Ianchulev currently serves as a director of the ASCRS Foundation, and is a member of the Board of Directors
of Iantrek, Inc. and AEye, Inc. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by
Carl Zeiss Meditec AG (ETR: AFX) in 2019. Dr.&nbsp;Ianchulev received his B.S. from the University of Rochester. He received both
his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr.&nbsp;Ianchulev
serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>John Gandolfo</B>&nbsp;has
been serving as our Chief Financial Officer and Secretary since December 2017. Mr. Gandolfo has approximately 30 years of experience
as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences,
healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings,
financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Prior to joining
Eyenovia, Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. (NYSE: XTNT) from July 2010 through September
2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell Therapy LLC, the global contract development
and manufacturing services platform of the Hitachi Chemical Regenerative Medicine Business Sector, represented in the United States
by Hitachi Chemical Advanced Therapeutics Solutions, LLC, a manufacturer of stem cell therapies, from January 2009 to June 2010.
Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. (acquired
by Covidien Public Limited Company (NYSE: COV, which was in turn acquired by Medtronic Public Limited Company (NYSE: MDT)), a publicly
held developer and manufacturer of computerized surgical stapling and cutter systems, from January 2007 to January 2009. Prior
to joining Power Medical Interventions, Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc., a then
publicly held supplier of needle-free drug delivery systems to the pharmaceutical and biotechnology industries, from September
2001 to May 2006, and served on the Bioject&rsquo;s board of directors from September 2006 through May 2007. Prior to joining Bioject,
Mr. Gandolfo was the Chief Financial Officer of Capital Access Network, Inc. (now known as CAN Capital, Inc.), a privately held
specialty finance company, from 2000 through September 2001, and Xceed Software, Inc. (OTC: EXDW), an Internet consulting firm,
from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc., a then
publicly held, cancer-focused healthcare information company. From 1987 through 1994, he was Chief Financial Officer of Medical
Resources, Inc., a then publicly held manager of diagnostic imaging centers throughout the United States. Mr. Gandolfo currently
serves on the board of directors and audit committee of Odyssey Group International, Inc. (OTC: ODYY). Mr. Gandolfo received his
B.A. in business administration from Rutgers University. He is a certified public accountant (inactive status) who began his professional
career at Price Waterhouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Jennifer &ldquo;Ginger&rdquo;
Clasby</B>&nbsp;has been serving as our Vice President, Clinical Operations since September 2017. From 2009 to September 2017,
she served as Vice President, Clinical &amp; Regulatory Affairs/Quality Assurance at Transcend Medical, Inc. In that position,
she was responsible for overseeing clinical operations and regulatory processes for the company&rsquo;s clinical trials in the
United States, Europe and Latin America, as well as worldwide regulatory affairs, quality assurance and compliance activities.
She was also a pivotal executive with Promedica International, a contract research organization, from 1994 to 2009. Prior to that,
Clasby worked with ophthalmic device companies American Medical Optics, Inc. (currently known as Johnson &amp; Johnson Vision Care,
Inc.) and Optical Radiation Corporation (now part of EssilorLuxottica (Euronext Paris: EL)) in various roles for approximately
14 years in the areas of clinical affairs, manufacturing operations, marketing and sales. She serves on the University of California-Irvine
Extension Life Science Advisory Committee. She holds an M.S. degree in Industrial Engineering from Arizona State University and
B.S. degrees in mathematics and physics from Guilford College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Luke Clauson</B>&nbsp;has
been serving as our Vice President, Research &amp; Development and Manufacturing since August 2017, as our Vice President, Research
 &amp; Development. He founded a medical device-focused engineering development company, Innovative Drive Corporation, that has
helped businesses of all sizes conceptualize and bring dozens of products to market, including several in ophthalmology, in 2004
and has been serving as its President since then. Mr. Clauson has been the President and a director of Inspire Products, Inc. since
2012 and also serves on the board of directors of Mimicmotion, Inc. From 2016 until 2018, he was Chief Operating Officer of ianTECH,
Inc.&nbsp;From 2009 to 2016, Mr. Clauson was Vice President, Research &amp; Development and Operations at Transcend Medical. He
started his engineering career at Cardica, Inc. (now Dex Liquidating Co.), where he ultimately directed product development for
the core anastomotic business. Mr. Clauson has extensive experience in designing, validating, achieving regulatory approval and
scaling for commercialization with multiple products. He holds a B.Sc. in mechanical engineering from the University of California,
Davis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Michael Rowe </B>has
been serving as our Vice President, Commercial since October 2019 and, prior to that, since July 2018, as our Vice President,
Marketing.&nbsp; From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie
Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization,
planning and execution for Rhopressa&reg;, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular
hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic
initiatives as well as strategic planning for the company&rsquo;s worldwide glaucoma franchise, including the development of
bimatoprost SR and the global launch of Ganfort&reg; UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare
Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an
M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State
University of New York at Stony Brook.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="b_001"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><A NAME="h1"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market for Common Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock trades
on the Nasdaq Capital Market under the symbol &ldquo;EYEN.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon information
furnished by our transfer agent, at March 25, 2020, we had approximately 125 holders of record of our common stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
dividends on our equity securities, and currently do not plan to declare dividends on shares of our common stock in the foreseeable
future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business. Subject to the
foregoing, the payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend
upon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant
by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Securities Authorized for Issuance under
Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Item 12 of this
report for disclosure regarding securities authorized for issuance under equity compensation plans required by Item 201(d) of Regulation
S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchases of Equity Securities by the
Issuer and Affiliated Purchasers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 13.5pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><A NAME="h2"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selected Financial Data.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h3"></A><B>Item 7.</B></TD><TD><B>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operation </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis is based on, and should be read in conjunction with our financial statements for the years ended December 31, 2019
and 2018, which are included elsewhere in this Annual Report on Form 10-K. This Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations contains statements that are forward-looking. These statements are based on current expectations
and assumptions that are subject to risk, uncertainties and other factors. These statements are often identified by the use of
words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; or &ldquo;continue,&rdquo; and similar expressions or variations. Actual results could
differ materially because of the factors discussed in &ldquo;Risk Factors&rdquo; elsewhere in this Annual Report on Form 10-K,
and other factors that we have not identified.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical
stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing our patented piezo-print
delivery technology, branded the Optejet<SUP>TM</SUP>. Eyenovia aims to achieve clinical microdosing of next-generation
formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system,
which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and
topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to
horizontally deliver opthalmic medication with a success rate significantly higher than traditional eye drops (~ 90% vs. ~
50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapeutics
which target new indications or new combinations where there are currently no comparable drug therapies approved by the
United States Food and Drug Administration, or the FDA. Eyenovia&rsquo;s microdose therapeutics follow the FDA-designated
pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices
or drug-device combination products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 29, 2019,
the Company announced that it is advancing the development of its MicroLine program for the improvement in near vision in patients
with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its MicroPine (progressive
myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular
hypertension) and MicroTears (red eye and itch relief lubrication) programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Presbyopia is a non-preventable,
age-related hardening of the lens, which causes the gradual loss of the eye&rsquo;s ability to focus on nearby objects. There currently
are no known FDA-approved drugs for the improvement of near vision in patients with presbyopia, although other companies have related
therapies in their pipeline. Eyenovia plans to initiate and complete its Phase III VISION trials for MicroLine in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroPine is the Company&rsquo;s
first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic
axial elongation and sclero-retinal stretching affecting approximately five million people in the United States. In February 2019,
the FDA accepted Eyenovia&rsquo;s investigational new drug application, or IND, to initiate its Phase III registration trial of
MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. Eyenovia enrolled its first patient in the CHAPERONE
study in June 2019 and expects to complete enrollment in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MicroStat is Eyenovia&rsquo;s
fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated 80
million office-based comprehensive and diabetic eye exams performed every year in the United States. Eyenovia has completed its
Phase III trials for MicroStat and announced positive results from these studies, known as MIST-1 and MIST-2. With the primary
objectives of its Phase III program for MicroStat met, Eyenovia plans to submit a new drug application, or NDA, to the FDA in 2020
for marketing approval in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Results from our previous
three Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating our mydriatic agents demonstrated
how the Optejet consistently delivered precision dosing at the volume of the eye&rsquo;s natural tear film capacity of 6-8 &micro;L,
which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional
eye drops with fewer side effects. In the third study, we evaluated usability, patient tolerability and IOP lowering of microdosed
latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent
with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in
more than 90% of cases. Based on the results from these clinical trials, we are advancing MicroLine, MicroPine, MicroStat, and
MicroProst (should we resume the program) utilizing the 505(b)(2) pathway. Where possible, we also intend to use this pathway for
future clinical trials in new indications with significant unmet needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not completed
development of any product candidate and we have therefore not generated any revenues from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have
financed our operations principally through stock offerings, including our initial public offering and follow-on public offering
that closed in January and December 2018, respectively and our public offering that closed in July 2019. Based upon our current
operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from the date
that the financial statements included elsewhere in this Annual Report on Form 10-K are issued exists. Our ability to continue
as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support
our future operations. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our net loss was $21.2
million for the&nbsp;year ended December&nbsp;31, 2019. As of December&nbsp;31, 2019, we had working capital of $11.4 million and
an accumulated deficit of&#8201;$57.7&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Revenue</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not generated
any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near
future. Our ability to generate revenues will depend heavily on the successful development, regulatory approval and commercialization
of our microdose therapeutic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses are incurred in connection with the research and development of our microdose- therapeutics and consist primarily of contract
service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project.
Our research and development expenses consist of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expense research
and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation
of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information
our vendors provide to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our
research and development expenses will increase with the continuation of the aforementioned initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of payroll and related expenses, legal and other professional services, and non-cash stock-based compensation
expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to
support our continued research and development and the potential commercialization of our product candidates. We also anticipate
increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange
listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with
being a public company are expected to increase in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Year Ended December&nbsp;31, 2019
Compared with Year Ended December&nbsp;31, 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December&nbsp;31, 2019 totaled $14.1&nbsp;million, an increase of $3.0&nbsp;million, or 27%, as compared
to $11.1&nbsp;million recorded for the year ended December&nbsp;31, 2018. Research and development expenses consisted of the following:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Direct clinical and non-clinical expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7,830,488</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,951,896</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Personnel-related expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,136,860</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,625,437</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Supplies and materials</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,666,284</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,702,229</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Non-cash stock-based compensation expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,459,055</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">821,568</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,762</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,966</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">14,102,449</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11,119,096</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in direct
clinical and non-clinical expenses and personnel-related expenses is primarily due to an increase in contracted services and the
hiring of three additional employees as we expanded our research and development activities for our microdose therapeutics. The
increase in non-cash stock-based compensation expense as compared to the 2018 period was primarily due to certain stock options
that were accelerated and immediately vested in February 2019 as well as due to additional stock option grants in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses for the year ended December&nbsp;31, 2019 totaled $7.2&nbsp;million, an increase of $1.1&nbsp;million, or 17%, as compared
to $6.1&nbsp;million recorded for the year ended December&nbsp;31, 2018. The increase was primarily attributable to an increase
in payroll related expenses of $0.7 million due to the hiring of an additional four employees, $0.3 million in incremental costs
related to being a public company, $0.3 million of incremental non-cash stock-based compensation, $0.2 million in incremental rent
expense related to the addition of our new leased office space in New York, NY in August 2018, and $0.2 million in incremental
advertising and marketing expenses related to marketing analysis upon potential commercialization. This was offset by approximately
$0.6 million less in professional fees due to higher expenses in 2018 related to the initial public offering and activities performed
to assess various financing opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we
have experienced negative cash flows from operations. At December&nbsp;31, 2019, our accumulated deficit since inception was $57.7&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December&nbsp;31,
2019, we had working capital of $11.4 million and stockholders&rsquo; equity of $11.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December&nbsp;31,
2019 and 2018, we had no debt outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At December&nbsp;31,
2019, we had a cash and cash equivalents balance of $14.2&nbsp;million. These conditions raise substantial doubt about our ability
to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere
in this Annual Report on Form 10-K are issued. Our financial statements do not include adjustments to the amounts and classification
of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as
a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities to support our
future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research
and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements
and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products
and services, competing technological and market developments, and the need to enter into collaborations with other companies or
acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to secure
additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce
costs in order to conserve our cash.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended
December&nbsp;31, 2019 and 2018, our sources and uses of cash were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December&nbsp;31, 2019 was $18.9&nbsp;million, which includes cash used to fund a net loss of $21.2&nbsp;million,
reduced by $2.5 million of non-cash expenses, partially offset by $0.2 million of net cash provided by changes in the levels of
operating assets and liabilities. Net cash used in operating activities for the year ended December&nbsp;31, 2018 was $13.1&nbsp;million,
which includes cash used to fund a net loss of $17.3&nbsp;million, reduced by $1.6 million of non-cash expenses and $2.5 million
of net cash used in changes in the levels of operating assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities was $0.2 million and less than $0.1&nbsp;million for the years ended December 31, 2019 and 2018 which was attributable
to purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by
financing activities for the year ended December 31, 2019 totaled $13.5&nbsp;million, which was primarily attributable to $13.0
million of net proceeds from the sale of common stock in our public offering and $0.5 million of net proceeds from the exercise
of stock options. Net cash provided by financing activities for the year ended December&nbsp;31, 2018 totaled $27.6&nbsp;million,
which was primarily attributable to $24.8 million of net proceeds from the sale of common stock in our initial public offering
and $2.8 million of net proceeds from the sale of common stock in our follow-on public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no off-balance
sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial
conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our critical accounting
policies are included in Note 2 &ndash; Summary of Significant Accounting Policies of our financial statements included within
this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recently Issued Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our recently issued
accounting standards are included in Note 2 &ndash; Summary of Significant Accounting Policies of our financial statements included
within this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h4"></A><B>Item 7A.</B></TD><TD><B>Quantitative and Qualitative Disclosures About Market Risk.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h5"></A><B>Item 8.</B></TD><TD><B>Financial Statements and Supplementary Data.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See the financial statements
included at the end of this report beginning on page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h6"></A><B>Item 9.</B></TD><TD><B>Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h7"></A><B>Item 9A.</B></TD><TD><B>Controls and Procedures.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Evaluation of Disclosure Controls and
Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the end of the
period covered by this Annual Report on Form 10-K, we carried out an evaluation, under the supervision and with the participation
of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness
of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In designing and evaluating
our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed
and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure
controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its
judgment in evaluating the benefits of possible controls and procedures relative to their costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on their evaluation,
our principal executive officer and principal financial and accounting officer concluded that as of December 31, 2019 our disclosure
controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we
are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management,
including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions
regarding required disclosures as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management's Report on Internal Control
over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our principal executive officer and principal financial officer, is responsible for establishing and maintaining adequate internal
control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes
those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made
only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the
supervision and with the participation of our management, including our principal executive officer and principal financial
officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31,
2019, based on the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO) (2013 Framework). Based on this evaluation under the 2013 Framework, our principal executive
officer and principal financial officer have concluded that our internal control over financial reporting was effective as of
December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Internal Control over Financial
Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been no change
in our internal control over financial reporting that occurred during the fourth quarter of 2019 that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Attestation Report of Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established
by the JOBS Act for emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><A NAME="h8"></A><B>Item 9B.</B></TD><TD><B>Other Information.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="i01"></A><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="i02"></A><B>Item 10.</B></TD><TD><B>Directors, Executive Officers, and Corporate Governance.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information required
by this Item concerning our directors is incorporated by reference from the sections captioned &ldquo;Election of Directors&rdquo;
and &ldquo;Corporate Governance Matters&rdquo; contained in our proxy statement related to the 2020 Annual Meeting of Stockholders
currently scheduled to be held on June 11, 2020, which we intend to file with the SEC within 120 days of the end of our fiscal
year pursuant to General Instruction G(3) of Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning our Audit Committee is incorporated by reference from the section captioned &ldquo;Corporate Governance
Matters&mdash;Board Committees&mdash;Audit Committee&rdquo; contained in our proxy statement related to the 2020 Annual Meeting
of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code
of business conduct and ethics relating to the conduct of our business by all of our employees, executive officers, and directors.
The policy is posted on our website, <U>www.eyenoviabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning our executive officers is set forth at the end of Part I of this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item concerning compliance with Section 16(a) of the Exchange Act is incorporated by reference from the section of the
proxy statement captioned &ldquo;Delinquent Section 16(a) Reports.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="i03"></A><B>Item 11.</B></TD><TD><B>Executive Compensation.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the sections captioned &ldquo;Executive Compensation,&rdquo;
and &ldquo;Director Compensation&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"><A NAME="i04"></A></TD><TD STYLE="width: 0.75in"><B>Item 12.</B></TD><TD><B>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
provides information as of December 31, 2019 about our common stock that may be issued upon the exercise of options, warrants and
rights under all of our existing equity compensation plans (including individual arrangements):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>Equity Compensation
Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan Category</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of securities<BR>
        to be issued upon<BR>
        exercise of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>outstanding<BR>
        options, warrants</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and<BR>
        rights</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Weighted-average<BR>
exercise price of<BR>
outstanding options,<BR>
warrants and rights</B></FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of<BR>
        securities remaining<BR>
        available for future</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>issuance<BR>
        under equity</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>compensation<BR>
        plans (excluding</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>securities<BR>
        reflected in column (a))</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 61%; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014 Equity Incentive Plan, as amended</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,167,367</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.86</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,333</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018 Omnibus Stock Incentive Plan, as amended</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,130,426</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">106,074</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,297,793</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.53</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,407</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other information
required by this Item is incorporated by reference to the information under the section captioned &ldquo;Security Ownership of
Certain Beneficial Owners and Management&rdquo; contained in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"><A NAME="i05"></A></TD><TD STYLE="width: 0.75in"><B>Item 13.</B></TD><TD><B>Certain Relationships and Related Transactions, and Director Independence. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the section captioned &ldquo;Certain Relationships and Related-Party
Transactions&rdquo; and &ldquo;Corporate Governance Matters&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><A NAME="i06"></A><B>Item 14.</B></TD><TD><B>Principal Accounting Fees and Services.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated by reference to the information under the section captioned &ldquo;Audit Committee Report&rdquo; in
the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="i07"></A><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"><A NAME="i08"></A></TD><TD STYLE="width: 0.75in"><B>Item 15.</B></TD><TD><B>Exhibits, Financial Statement Schedules.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>List of documents filed as part of this report:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Financial Statements:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The financial statements of the Company and the related
reports of the Company&rsquo;s independent registered public accounting firm thereon have been filed under Item 8 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Financial Statement Schedules:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>Exhibit Index</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">The following is a list of
exhibits filed as part of this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated by Reference (Unless Otherwise Indicated)</B></FONT></TD>
    </TR>
<TR>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; width: 39%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit Description</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File No.</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amended and Restated Certificate of Incorporation</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 29, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex3-1x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 14, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 12, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Securities</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement, dated March 18, 2015, between Eyenovia, Inc. and Senju Pharmaceuticals Co., Ltd. &#8203;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Tsontcho Ianchulev</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correction Letter, dated November 8, 2017, between Eyenovia, Inc. and Tsontcho Ianchulev</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Luke Clauson</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Jennifer G. Clasby</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-222162</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 19, 2017</FONT></A></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 8%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5*</FONT></A></TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="width: 39%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Engagement Letter for Professional Services, dated July 6, 2017, between Eyenovia, Inc. and Curt LaBelle</FONT></A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="width: 7%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
<TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 14%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD STYLE="width: 2%">&nbsp;</TD>
<TD STYLE="vertical-align: top; width: 7%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></A></TD>
<TD STYLE="width: 1%">&nbsp;</TD>
<TD STYLE="white-space: nowrap; width: 17%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Investors&rsquo; Rights Agreement, dated September 27, 2017, between Eyenovia, Inc. and investors party thereto</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Right of First Refusal and Co-Sale Agreement, dated September 27, 2017, between Eyenovia, Inc. and investors party thereto</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">10.7</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Voting Agreement, dated September 27, 2017, between Eyenovia, Inc. and investors party thereto</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">10.8</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9*</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Master Consulting Services Agreement, dated November 4, 2014, between Eyenovia, Inc. and Private Medical Equity, Inc.</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">10.10</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 19, 2017</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10*</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Engagement Letter for Professional Services, dated December 18, 2017, between Eyenovia, Inc. and John Gandolfo</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">S-1/A</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">333-222162</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"> 10.12</A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">January 9, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eyenovia, Inc. 2018 Omnibus Stock Incentive Plan</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 14, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11.1*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eyenovia, Inc. 2018 Omnibus Stock Incentive Plan, as amended</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11.1</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419030689/tv523178_ex10-11x1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 12, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12*</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Notice of Stock Option Grant and Award Agreement</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 14, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13*</FONT></A></TD>
<TD>&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Restricted Stock Award Agreement</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15</FONT></A></TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418034222/tv495935_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">June 14, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Employment Agreement, dated February 15, 2019, by and between the Company and Tsontcho Ianchulev.</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 19, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Employment Agreement, dated February 15, 2019, by and between the Company and John Gandolfo.</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 19, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Employment Agreement, dated February 15, 2019, by and between the Company and Luke Clauson.</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 19, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17*</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Employment Agreement, dated February 15, 2019, by and between the Company and Michael Rowe.</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8-K</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">001-38365</FONT></A></TD>
<TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19</FONT></A></TD>
<TD STYLE="text-align: center">&nbsp;</TD>
<TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 19, 2019</FONT></A></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*</FONT></A></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 39%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement, dated February 15, 2019, by and between the Company and Jennifer Clasby.</FONT></A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 17%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Nondisclosure, Assignment of Inventions and Noncompetition Agreement.</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419008865/tv512687_ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 19, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eyenovia, Inc. 2014 Equity Incentive Plan, as amended.</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Nonqualified Stock Option Agreement.</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-38365</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420419040097/tv527418_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 14, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Marcum LLP</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><A HREF="tm205388d1_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive data files pursuant to Rule&nbsp;405&nbsp;of&nbsp;Regulation S-T: (i) Balance Sheets as of December 31, 2019 and 2018; (ii) Statements of Operations for the Years Ended December 31, 2019 and 2018; (iii) Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December 31, 2019 and 2018; (iv) Statements of Cash Flows for the Years Ended December 31, 2019 and 2018; and (v) Notes to Financial Statements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">* Management contract or other compensatory plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.65in"><A NAME="i09"></A><B>Item 16.</B></TD><TD><B>Form 10-K Summary.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="i10"></A><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EYENOVIA, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 30, 2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsontcho Ianchulev</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer) and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Gandolfo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Gandolfo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fredric N. Eshelman</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board and Director</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fredric N. Eshelman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Curt H. LaBelle</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Curt H. LaBelle</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kenneth B. Lee, Jr.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth B. Lee, Jr.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ernest Mario</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ernest Mario</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Charles E. Mather IV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles E. Mather IV</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Anthony Y. Sun</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony Y. Sun</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page<BR>
 Number</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline">Years Ended December 31, 2019 and 2018</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><A HREF="#n_001">Report of Independent Registered Public Accounting Firm</A></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></A></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><A HREF="#n_002">Balance Sheets as of December 31, 2019 and 2018</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><A HREF="#n_003">Statements of Operations for the Years Ended December 31, 2019 and 2018</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><A HREF="#n_004">Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December 31, 2019 and 2018</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><A HREF="#n_005">Statements of Cash Flows for the Years Ended December 31, 2019 and 2018</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"><A HREF="#n_006">Notes to Financial Statements</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#n_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="n_001"></A><B><U>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheets of Eyenovia, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2019 and 2018, the related statements of operations, changes
in stockholders&rsquo; equity and cash flows for each of the two years in the period ended December 31, 2019, and the related notes
(collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations
and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Explanatory Paragraph &ndash; Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred
significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise
substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are
also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY<BR>
March 30, 2020</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="n_002"></A>EYENOVIA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>December
    31,</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2019</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Assets</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">Current Assets:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">14,152,601</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">19,728,200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt"><FONT STYLE="font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">196,680</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">132,756</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total Current Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,349,281</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,860,956</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">230,538</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,738</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117,800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117,800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,697,619</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,015,494</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders' Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,541,358</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,509,524</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">916,873</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">912,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accrued expenses and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">453,430</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">677,213</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 20pt">Total Current Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,911,661</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,098,841</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deferred rent</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">45,351</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,584</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,957,012</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,140,425</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Note 8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Preferred stock, $0.0001 par value, 6,000,000 shares authorized;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">0 shares issued and outstanding as of December 31, 2019 and 2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Common stock, $0.0001 par value, 90,000,000 shares authorized;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">17,100,726 and 11,468,996 shares issued and
    outstanding as of December 31, 2019 and 2018, respectively</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,710</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,147</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">69,409,949</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">53,388,216</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(57,671,052</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,514,294</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total Stockholders' Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,740,607</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,875,069</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,697,619</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,015,494</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The accompanying notes are an integral part of these financial statements.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="n_003"></A>EYENOVIA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Statements of Operations</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><B>For
    the Years Ended &nbsp;<BR>
    December 31,</B></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">14,102,449</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">11,119,096</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,206,095</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,137,347</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total Operating Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21,308,544</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">17,256,443</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Loss From Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(21,308,544</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,256,443</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">151,786</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,335</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,156,758</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,253,108</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Net Loss Per Share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">- Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.47</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(1.82</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Weighted Average Number of Common Shares Outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">- Basic and Diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,349,738</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,476,706</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The accompanying notes are an integral part of these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="n_004"></A>EYENOVIA,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Changes in Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the Years Ended December 31, 2019 and 2018</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="22" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Convertible
    Preferred Stock</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Additional</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Total</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Series
    A</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Series
    A-2</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Series
    B</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Paid-In</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Accumulated</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Stockholders'</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Shares</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Amount</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Shares</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Amount</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Shares</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Amount</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Shares</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Amount</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Capital</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Deficit</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 7pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Equity</FONT></TD><TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Balance
    - January 1, 2018</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,932,431</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">293</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">788,827</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">79</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">918,983</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">92</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,566,530</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">257</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">24,351,138</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(19,261,186</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">5,090,673</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Conversion
    of convertible preferred</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">stock
    into common stock upon</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">completion
    of initial public offering</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(2,932,431</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(293</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(788,827</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(79</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(918,983</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(92</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">4,702,116</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">470</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(6</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Issuance of common stock in initial public
offering [1]</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,730,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">273</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">24,547,530</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">24,547,803</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Issuance
    of common stock in follow-on public offering [2]</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1,380,000</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">138</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,817,611</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,817,749</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Exercise
    of warrants on a cashless basis</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">61,385</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">6</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(6</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Exercise
    of stock options</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">28,965</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">3</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">56,479</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">56,482</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1,615,470</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1,615,470</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Net
    loss</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(17,253,108</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(17,253,108</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Balance
    - December 31, 2018</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">11,468,996</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1,147</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">53,388,216</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(36,514,294</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">16,875,069</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Issuance
    of common stock in public offering [3]</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">5,046,763</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">505</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">12,958,070</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">12,958,575</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Exercise
    of stock options on a cashless basis</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">236,466</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">24</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(24</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Exercise
    of stock options</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">348,501</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">34</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">551,743</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">551,777</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Stock-based
    compensation</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,511,944</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">2,511,944</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Net
    loss</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(21,156,758</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(21,156,758</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">Balance
    - December 31, 2019</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">-</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">17,100,726</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">1,710</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">69,409,949</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">(57,671,052</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">)</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 7pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">11,740,607</FONT></TD><TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">[1]
Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">[2]
Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">[3]
Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,931.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The accompanying notes are an integral part of these financial statements. </FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="n_005"></A>EYENOVIA, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Cash Flows</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Years Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows From Operating Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; width: 74%; text-align: left">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,156,758</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,253,108</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Adjustments to reconcile net
    loss to net cash used in operating activities:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Depreciation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15,343</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,129</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,511,944</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,470</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(63,924</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(95,607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Due from related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,834</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,263,140</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,769</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">912,104</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Accrued expenses and other current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(266,283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">503,950</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Security deposit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(117,800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.625in">Deferred rent</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,767</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">41,584</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,919,308</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,111,138</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows From Investing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Purchases of property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(166,643</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,907</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left; padding-bottom: 1pt">Net Cash Used In Investing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(166,643</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,907</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows From Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Proceeds from sale of common stock in initial public offering [1]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,089,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Payment of initial public offering issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(345,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Proceeds from sale of common stock in follow-on public offering [2]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,084,330</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Payment of follow-on public offering issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(266,581</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Proceeds from sale of common stock in public offering [3]</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13,214,949</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Payment of public offering issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(256,374</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Proceeds from exercise of stock options</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">551,777</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">56,482</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left; padding-bottom: 1pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,510,352</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,617,734</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.625in; text-align: left">Net (Decrease) Increase in Cash and Cash Equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,575,599</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,478,689</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Cash and cash equivalents - Beginning of Year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,728,200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,249,511</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents - End of Year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14,152,601</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,728,200</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[1] Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[2] Includes gross proceeds of $3,381,000, less issuance costs of $296,670 deducted directly from the offering proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $815,052 deducted directly from the offering proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Supplemental Disclosure of Non-Cash Investing and Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left; width: 74%">Accrued purchases of leasehold improvements</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,500</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Exercise of warrants on a cashless basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Exercise of stock options on a cashless basis</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Conversion of convertible preferred stock into common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">470</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Reversal of previously accrued initial public offering issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(133,000</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.375in; text-align: left">Reclassification to additional
    paid-in capital for initial public offering issuance costs that were previously paid</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(195,700</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral
part of these financial statements.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="n_006"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 &ndash; Business Organization and Nature of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia, Inc. (&ldquo;Eyenovia&rdquo;
or the &ldquo;Company&rdquo;) was organized as a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under
the name, PGP Holdings V, Inc. On May&nbsp;5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October&nbsp;6,
2014, Eyenovia, Inc. reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia. Inc. (&ldquo;Eyenovia&rdquo;
or the &ldquo;Company&rdquo;) is a clinical stage ophthalmic&nbsp;biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet<SUP>TM</SUP>.&nbsp;Eyenovia aims to achieve
clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision
targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability,
patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the
ability to horizontally deliver opthalmic medication with a success rate significantly higher than that of traditional eye drops
(~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies
which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food
and Drug Administration (the &ldquo;FDA&rdquo;). Eyenovia&rsquo;s microdose therapeutics follow the FDA-designated pharmaceutical
registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
2 &ndash; Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Liquidity and Going Concern</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not yet generated
revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that
its research and development and general and administrative expenses will continue to increase and, as a result, it will
eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the financial
statements are issued. Implementation of the Company&rsquo;s plans and its ability to continue as a going concern will depend
upon the Company&rsquo;s ability to raise further capital, through the sale of additional equity or debt securities or
otherwise, to support its future operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s operating needs include
the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&rsquo;s
future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&rsquo;s
ability to successfully commercialize its products and services, competing technological and market developments, and the need
to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product
and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2019, the Company announced that it is advancing
its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result
of prioritizing MicroLine, in tandem with its Mircropine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred
development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication)
programs. The Company believes the re-prioritization of its programs will yield overall cost savings of approximately $1.5 million
to $1.9 million in 2020.<BR STYLE="clear: both">
 &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparation of financial statements in
conformity with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) requires management
to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed
in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on
various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported
in the Company&rsquo;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates
and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation
allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the
recovery of deferred costs. Certain of the Company&rsquo;s estimates could be affected by external conditions, including those
unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 2 - Summary of Significant Accounting
Policies&#8201;&mdash;&#8201;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair
value of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Cash and Cash Equivalents</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid
investments with an original maturity of three months or less to be cash equivalents in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has cash deposits and U.S.
treasury bills in a financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;)
insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its
financial institutions. As of December 31, 2019 and 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance
limits of $13,902,601 and $19,478,200, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Property and Equipment, Net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost,
net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient
to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5 years. Leasehold
improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and
repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment
when such betterment extends the useful life of the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Impairment of Long-lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews for the impairment
of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable.
An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual
disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December
31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Deferred Offering Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred offering costs, which primarily
consist of direct, incremental professional fees incurred in connection with the Company&rsquo;s IPO as well as other private equity
offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs
are offset against the offering proceeds. The Company had $0 in deferred offering costs at December 31, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the accounting standards
for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred
shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable
preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or
subject to redemption upon the occurrence of uncertain events not solely within the Company&rsquo;s control) are classified as
temporary equity. At all other times, preferred shares are classified as stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Fair Value of Financial Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the fair value of
financial assets and liabilities based on ASC 820 &ldquo;Fair Value Measurements and Disclosures&rdquo; (&ldquo;ASC 820&rdquo;),
which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 defines fair value as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes
a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &mdash; quoted prices in active
markets for identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &mdash; quoted prices for similar
assets and liabilities in active markets or inputs that are observable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &mdash; inputs that are unobservable
(for example, cash flow modeling inputs based on assumptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&rsquo;s
financial instruments, such as cash and cash equivalents, due from related party, accounts payable, accrued expenses and other
current liabilities approximate fair values due to the short-term nature of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to Federal, New
York State and City, and State of California income taxes and files tax returns in those jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes deferred tax assets
and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial
statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis
of assets and liabilities and their respective financial reporting amounts (&ldquo;temporary differences&rdquo;) at enacted tax
rates in effect for the years in which such temporary differences are expected to reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilizes a recognition threshold
and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in
a tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s policy is to classify
assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 81; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses are charged
to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development
expenses in advance of services being provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures the cost of services
received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured
on the grant date and the fair value amount is then recognized over the period during which services are required to be provided
in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common
stock out of the shares reserved for issuance under its equity plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Net Loss Per Common Share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects
the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following securities are excluded from
the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt">Options</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">2,237,438</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">2,220,868</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Restricted stock units</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">60,355</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,165</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total potentially dilutive shares</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,297,793</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,241,033</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Subsequent Events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events
through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized
or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
 &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently Issued Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) 2016-02, &ldquo;Leases (Topic 842)&rdquo; (&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 requires
that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement
of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right
to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting
policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors
are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach.
This amendment will be effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning
after December 15, 2021. The FASB issued ASU No. 2019-01 &ldquo;Leases (Topic 842) Codification Improvements&rdquo; in March 2019
and ASU No. 2018-10 &ldquo;Codification Improvements to Topic 842, Leases&rdquo; and ASU No. 2018-11 &ldquo;Leases (Topic 842)
Targeted Improvements&rdquo; in July 2018, and ASU No. 2018-20 &ldquo;Leases (Topic 842) - Narrow Scope Improvements for Lessors&rdquo;
in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance
issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method
of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect
adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02
and its impact on its financial position, results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2017, the FASB issued ASU No. 2017-11,
 &ldquo;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with
Down Round Features&rdquo; (&ldquo;ASU 2017-11&rdquo;). Equity-linked instruments, such as warrants and convertible instruments
may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings.
Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion
option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market).
However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether
liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share
(&quot;EPS&quot;) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered
by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this
ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15,
2019. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of
operations, and cash flows.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the FASB issued ASU No.
2018-13, &ldquo;Fair Value Measurement (Topic 820): Disclosure Framework&mdash;Changes to the Disclosure Requirements for Fair
Value Measurement&rdquo; (&ldquo;ASU 2018-13&rdquo;). The amendments in ASU 2018-13 modify the disclosure requirements on fair
value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The
amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to
develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively
for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should
be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning
after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating
ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2 &ndash; Summary of Significant
Accounting Policies &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Recently Issued Accounting Pronouncements
- Continued</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #1D1C1D"><FONT STYLE="background-color: white">In
December 2019, the FASB issued ASU 2019-12, &ldquo;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&rdquo;
which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to
the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12
is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact
financial position, results of operations, and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recently Adopted Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2016, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-15, &ldquo;Statement of Cash Flows
(Topic 230) Classification of Certain Cash Receipts and Cash Payments&rdquo; (&ldquo;ASU 2016-15&rdquo;). The new standard will
make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows.
The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective
basis unless it is impracticable to apply, in which case a company would be required to apply the amendments prospectively as of
the earliest date practicable. The Company adopted this standard on January 1, 2019 and it did not have a material impact on the
Company&rsquo;s financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,
 &ldquo;Compensation &mdash; Stock Compensation (Topic 718)&rdquo; (&ldquo;ASU 2018-07&rdquo;). ASU 2018-07 is intended to reduce
cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee
and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only
includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently,
the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic
505-50, &ldquo;Equity &mdash; Equity-Based Payments to Nonemployees.&rdquo; The amendments to ASU 2018 - 07 are effective for fiscal
years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption
is permitted, but no earlier than a company&rsquo;s adoption date of ASU No. 2014-09, (Topic 606), &ldquo;Revenue from Contracts
with Customers.&rdquo; The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&rsquo;s
financial position, results of operations or cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3 &ndash; Prepaid Expenses and
Other Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019 and 2018, prepaid
expenses and other current assets consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Payroll tax receivable</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">95,233</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid insurance expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,923</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">39,465</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid research and development expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,978</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid patent expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,404</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,562</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid conference expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,600</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Prepaid rent and security deposit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,463</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,729</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,079</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">196,680</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">132,756</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4 &ndash; Property and Equipment,
Net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019 and 2018, property
and equipment consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt">Equipment</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">229,529</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">62,886</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">82,500</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">312,029</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">102,886</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(81,491</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(66,148</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">230,538</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">36,738</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation and amortization expense was
$15,343 and $19,129 for the years ended December 31, 2019 and 2018, respectively, of which $9,762 and $17,966 was included within
research and development expenses and $5,581 and $1,163 was included in general and administrative expenses in the statements of
operations for the years ended December 31, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5 &ndash; Accrued Expenses and
Other Current Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019 and 2018, accrued
expenses and other current liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Accrued research and development expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">208,175</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">375,204</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued professional services</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">97,396</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">111,728</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Credit card payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">56,979</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,466</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Leasehold improvements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">42,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued franchise tax</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,995</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued travel and entertainment expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,385</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued legal expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">168,650</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">12,165</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">453,430</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">677,213</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6 &ndash; Accrued Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2019 and 2018, accrued compensation consisted
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Accrued bonus expenses</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">897,839</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">694,490</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued payroll expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19,034</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">217,614</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued compensation</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">916,873</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">912,104</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 85; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
7 &ndash; Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for income taxes consists
of the following expenses (benefits):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Deferred tax provision (benefit):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 64%; font-size: 10pt">Federal</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">(4,999,920</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">(3,516,722</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">State and local</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">68,762</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(47,238</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,931,158</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,563,960</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,931,158</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,563,960</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Provision for income taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for income taxes differs
from the United States Federal statutory rate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Years Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Federal statutory rate</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">21.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">21.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">State tax rate, net of federal benefit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.1</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.3</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Permanent differences</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.2</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.8</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Research &amp; development tax credits</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.8</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Prior period adjustments and other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(0.6</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2.6</TD><TD STYLE="font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23.3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(20.7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">0.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">9,479,512</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">5,453,854</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stock-based compensation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">943,370</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">616,207</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(14,030</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,486</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Intangibles</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">328,773</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">310,230</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research and development tax credits</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,584,753</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,008,443</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Deferred tax assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,322,378</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,391,220</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(12,322,378</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,391,220</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
7 &ndash; Income Taxes &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019, the Company had
approximately $45,000,000 of domestic Federal net operating loss carryforwards (&quot;NOLs&quot;) that may be available to offset
future Federal taxable income. Approximately $10,800,000 of those NOLs will expire during the years ranging from 2034 to 2037.
The remaining NOLs of approximately $34,200,000 have no expiration dates. Internal Revenue Code Section 382 limits the utilization
of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes that occurred
through July 15, 2019. As of December 31, 2019, the Company had minimal state net operating loss carryforwards that may be available
to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has assessed the likelihood
that deferred tax assets will be realized in accordance with the provisions of ASC 740 <I>Income Taxes</I> (&quot;ASC 740&quot;).
ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of
deferred tax liabilities, projected future taxable income, and tax planning strategies. ASC 740 requires that a valuation allowance
be established when it is &ldquo;more likely than not&rdquo; that all, or a portion of, deferred tax assets will not be realized.
After the performance of such reviews as of December 31, 2019 and 2018, management believes that uncertainty exists with respect
to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those dates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated and concluded
that there were no material uncertain tax positions requiring recognition in the Company&rsquo;s consolidated financial statements
as of December 31, 2019 and 2018. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No tax audits were commenced or were in
process during the years ended December 31, 2019 and 2018. No tax related interest or penalties were incurred during the years
ended December 31, 2019 and 2018. The Company's State of California income tax returns beginning with the year ended December 31,
2015 remain subject to examination. The Company's Federal and New York State and City income tax returns beginning with the year
ended December 31, 2016 remain subject to examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8 &ndash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Operating Leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2018, the Company entered
into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The monthly base rent ranges from
$19,633 to $22,486 per month over the term of the lease for a total base rent lease commitment of approximately $1,236,000. The
lease expires on September 30, 2023. The security deposit is approximately $118,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future minimum payments under this operating lease agreement
are as follows as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Year Ending<BR>
December 31,</TD>
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;<BR>
 &nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center"><B>Minimum Lease Payments</B></TD>
    <TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font-size: 10pt">&nbsp;<BR>
 &nbsp;</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: center; padding-left: 5.4pt">2020</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">244,853</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">251,586</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt">2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">258,505</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">198,157</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">953,101</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Note 9 &ndash; Related Party Transactions
 &ndash; Lease Agreements for details of a lease agreement with a related party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8 &ndash; Commitments and Contingencies
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Employment Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 15, 2019, the Company
entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer,
John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President,
Research and Development and Manufacturing (&ldquo;VP of R&amp;D&rdquo;), and Michael Rowe, now its Vice President, Commercial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the employment agreements provides
that if the executive&rsquo;s employment is terminated by the Company without &ldquo;Cause&rdquo; or the executive suffers an &ldquo;Involuntarily
Termination&rdquo; (each as defined in the employment agreements), provided that the executive has signed a full release of all
claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary
(currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under
COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible
for comparable insurance benefits from another employer, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the employment agreements also
provides that if, within 12 months following any &ldquo;Corporate Transaction&rdquo; (as defined in the employment agreements)
of the Company, the executive&rsquo;s employment is terminated by the Company without Cause or the executive suffers an Involuntary
Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in
lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently
estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for
the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable
insurance benefits from another employer, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Litigations, Claims and Assessments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal
costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its Chief Executive Officer
and members of its Board of Directors were named as defendants in a legal proceeding filed in the United States District Court
for the District of New Jersey on September 2, 2014 in connection with the Company&rsquo;s Asset Purchase Agreement with Corinthian
Ophthalmic, Inc. (&ldquo;Corinthian&rdquo;). A shareholder of Corinthian alleged a fraudulent transfer and sought to recover the
purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The court conducted
a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018. On October 29, 2018, the parties
entered into a Settlement Agreement pursuant to which the defendants agreed to pay the Corinthian shareholder $600,000 in exchange
for the release of all related claims. While the Company is indemnified by Corinthian and Corinthian's applicable insurance policy
provides coverage of $10 million, in an effort to avoid the additional legal costs and other resources required with a trial, the
Company contributed $150,000 of the settlement amount (the remaining $450,000 was paid by Corinthian's insurance carrier), which
was paid on October 29, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
9 &ndash; Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Consulting Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A company in which a member of the Company&rsquo;s
Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the
payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company
incurred expenses of $213,521 and $162,929 for the years ended December 31, 2019 and 2018, respectively, related to the agreement
which was included within general and administrative expenses on the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9 &ndash; Related Party Transactions
 &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Lease Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid $4,000 per month as of
January 2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for
its Chief Executive Officer (&ldquo;CEO&rdquo;). The Company left the space on August 31, 2018. The Company&rsquo;s rent expense
for this space amounted to $0 and $32,000 for the years ended December 31, 2019 and 2018, respectively, related to the office space,
which was included within general and administrative expenses on the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s Vice President of Research
and Development and Manufacturing (&ldquo;VP of R&amp;D&rdquo;) owns a company that entered into a lease agreement with the Company
on September 15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities.
The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September
15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and
security deposit to $4,012. The Company made $82,500 of leasehold improvements related to this lease which are included on the
balance sheet.&nbsp;The Company&rsquo;s rent expense for this space amounted to $48,144 and $47,270 for the years ended December
31, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Research and Development Activities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The VP of R&amp;D is the sole owner and
President of a company that performs contract engineering services for the Company. During the years ended December 31, 2019 and
2018, the Company recognized research and development expense of $851,746 and $863,355, respectively, related to services provided
by such vendor. The Company had a liability of $89,052 and $100,667 to the vendor as of December 31, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized $186,160 and $182,275
of compensation expense related to the VP of R&amp;D&rsquo;s salary during the years ended December 31, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>License Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2015, the Company entered into a
license agreement with Senju Pharmaceuticals Co., Ltd. (&ldquo;Senju&rdquo;) whereby the Company agreed to grant to Senju an exclusive,
royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use,
import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed
to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force
and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial
sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there
had been no commercial sales of a microdose product candidate in Asia, so no royalties had been earned. Senju is owned by the family
of a former member of the Company&rsquo;s Board of Directors and, together, they beneficially own greater than 5% of the Company&rsquo;s
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reverse Stock Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective January&nbsp;8, 2018, pursuant
to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&rsquo;s
issued and outstanding common stock and preferred stock (the &ldquo;Reverse Split&rdquo;). The number of authorized shares remained
unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented,
unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Authorized Capital</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is authorized to issue 90,000,000
shares of common stock, par value of&#8201;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&#8201;$0.0001
per share. The holders of the Company&rsquo;s common stock are entitled to one vote per share. The Board of Directors is empowered,
without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Equity Incentive Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 5, 2018, the Company&rsquo;s
Board of Directors and stockholders approved an amendment to the Company&rsquo;s 2014 Equity Incentive Plan (&ldquo;2014 Plan&rdquo;)
to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares. As of
December&nbsp;31, 2019, there were 15,333 shares available for future issuance under the 2014 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 6, 2018, the Company&rsquo;s Board
of Directors adopted the 2018 Omnibus Stock Incentive Plan (&ldquo;2018 Plan&rdquo;), which stockholders approved on June 11, 2018.
The 2018 Plan was subsequently amended by the Board on April 5, 2019 and approved by stockholders on June 11, 2019 (the &ldquo;2018
Plan, as amended&rdquo;). The 2018 Plan, as amended, provides for the issuance of incentive stock options, nonstatutory stock options,
rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&nbsp;units (&ldquo;RSUs&rdquo;)
to employees, directors and consultants of the Company and its affiliates. The 2018 Plan, as amended, terminates on June 11, 2028.
The 2018 Plan, as amended, requires the exercise price of stock options to be greater than or equal to the fair value of the Company&rsquo;s
common stock on the date of grant. There are 1,250,000 shares of common stock authorized under the 2018 Plan, as amended. As of
December&nbsp;31, 2019, there were 106,074 shares available for future issuance under the 2018 Plan, as amended.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Public Offerings</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2018, the Company consummated
its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million
in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8
million, which were recorded as a reduction of additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2018, the Company consummated
a follow-on public offering of 1,380,000 shares of its common stock at an offering price of $2.45 per share, generating $3.4 million
and $2.8 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were
approximately $0.6 million, which were recorded as a reduction of additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 15, 2019, the Company closed an
underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company
granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&rsquo;s common
stock at the same price, which was exercised in full on July 16, 2019. Including the over-allotment shares, the Company issued
a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and
net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses, which
were recorded as a reduction of additional paid-in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series A and Series A-2 Convertible
Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series A and Series A-2 Convertible
Preferred Stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined
that it was more akin to equity and, therefore, it has been classified within stockholders&rsquo; equity on the balance sheet.
While the embedded conversion option (&ldquo;ECO&rdquo;) was subject to an anti-dilution price adjustment, since the ECO was clearly
and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under
ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature because the conversion
price exceeded the estimated fair value of the Company&rsquo;s common stock as of the commitment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series&nbsp;A and Series&nbsp;A-2 Convertible
Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In
the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would
be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock
at the then effective conversion price: (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial public
offering provided that (A) the aggregate offering price, net of underwriters&rsquo; discounts and expenses, was at least $2.00
per share of common stock and (B) the aggregate proceeds of such offering were not less than $20,000,000; or (ii) the date specified
by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series
A and Series A-2 Convertible Preferred Stock converted immediately prior to the Company&rsquo;s IPO. See Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Conversion of Preferred Stock for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Series B Convertible Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series B Convertible Preferred did
not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more
akin to equity and therefore, has been classified within stockholders&rsquo; equity on the balance sheet. While the embedded conversion
option (&ldquo;ECO&rdquo;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the
equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined
that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the
estimated fair value of the Company&rsquo;s common stock as of the commitment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series B Convertible Preferred Stock
was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain
adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible
Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock
was automatically convertible into shares of common stock at the then effective conversion price: (i) immediately prior to the
closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters'
discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less
than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding
shares of preferred stock. All of the Series B Convertible Preferred Stock converted immediately prior to the Company&rsquo;s IPO.
See Note 10 &ndash; Stockholders&rsquo; Equity &ndash; Conversion of Preferred Stock for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Conversion of Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immediately prior to the closing of the
IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,702,116
shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 91; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock-Based Compensation Expense</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
expense related to stock options and RSUs. For the years ended December 31, 2019 and 2018, the Company recorded expense of $2,511,944
($1,459,055 of which was included within research and development expenses and $1,052,889 was included within general and administrative
expenses on the statements of operations) and $1,615,470 ($818,239 of which was included within research and development expenses
and $797,231 was included within general and administrative expenses on the statements of operations), respectively. As of December
31, 2019, there was $3,249,222 of unrecognized stock-based compensation expense which will be recognized over a weighted average
period of 1.9 years.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Restricted Stock Units</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2018, the Company granted an
aggregate of 20,165 RSUs to its directors under the 2018 Plan. The grants vest on the earlier of (i) the one-year anniversary of
the date of grant and (ii) the date of the 2019 annual stockholders meeting, subject to the grantee remaining on the Board until
then. The RSUs had a grant date fair value of $125,000, which was recognized over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2019, the Company granted
to members of its Board of Directors an aggregate of 40,190 restricted stock units (&ldquo;RSUs&rdquo;) under the 2018 Plan, as
amended. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2020 annual
stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000,
which will be recognized over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2018, the Compensation Committee
of the Board of Directors approved the grant of ten-year stock options to purchase 175,668 shares of common stock to Company employees
and consultants under the 2014 Plan. The stock options will vest in equal monthly increments over 36 months beginning on the one-month
anniversary of the date of grant, subject to continued service to the Company, and have an exercise price of $8.72 per share, which
was the closing stock price on the date of grant. The stock options had a grant date fair value of $1,412,700, which the Company
expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
the Company granted ten-year stock options to purchase an aggregate of 395,999 shares of common stock to its employees, consultants
and directors under the 2018 Plan. Of the 395,999 shares, (i) 313,674 vest over three years from the date of grant with one-third
vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject
to continued service to the Company, (ii) 60,000 vest monthly over 36 months beginning on the one-month anniversary of the date
of grant, subject to continued service to the Company, and (iii) 22,325 vest on the earlier of the one-year anniversary of the
date of grant and the date of the 2019 annual stockholders meeting, subject to continued service to the Company. The stock options
have exercise prices ranging from $5.10 per share to $6.30 per share, which represents the Company&rsquo;s closing stock price
on the date of grant. The stock options had a grant date value of $2,237,800, which the Company expects to recognize over the vesting
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 2, 2019, stock options to purchase
180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for
aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion of an employee&rsquo;s
payroll taxes of $62,193 to the Internal Revenue Service. The Company was reimbursed in full by the employee.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 14, 2019, the Company granted
ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000
shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and
the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an
exercise price of $2.74 per share, which represents the Company&rsquo;s closing stock price on the date of grant. The stock options
had a grant date value of $27,500, which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 92; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Options - Continued</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 6, 2019, stock options to purchase
an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which
resulted in the issuance of an aggregate of 236,466 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 13, 2019, the Board of Directors
of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr. Ianchulev on
July 24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized
$609,322 of stock-based compensation expense during the year ended December 31, 2019 , which represents the remaining unamortized
grant date fair value of the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2019, stock options to purchase
34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2019, the Company granted
ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors under
the 2018 Plan, as amended. Of the 681,572 shares, (i) 636,287 vest over three years from the date of grant with one-third vesting
on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued
service to the Company and (ii) 45,285 vest on the earlier of the one-year anniversary of the date of grant and the date of the
2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise price of $3.11
per share, which represents the Company&rsquo;s closing stock price on the date of grant. The stock options had a grant date value
of $1,909,700, which the Company expects to recognize over the vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In applying the Black-Scholes option pricing
model to stock options granted, the Company used the following approximate assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">For the Year Ended</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">December 31,</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">2018</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (years)</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.50 - 10.00</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.50 - 10.00</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free interest rate</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42 - 2.53</FONT>%</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.69 - 3.24</FONT>%</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">134 - 139</FONT>%</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">140 - 141</FONT>%</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; width: 66%; font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividends</TD><TD STYLE="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 15%; text-align: center">0.00%</TD><TD STYLE="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 15%; text-align: center">0.00%</TD><TD STYLE="white-space: nowrap; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has computed the fair
value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time
of occurrence. The expected term used for options issued is the estimated period of time that options granted are expected to
be outstanding. The Company utilizes the &ldquo;simplified&rdquo; method to develop an estimate of the expected term of &ldquo;plain
vanilla&rdquo; option grants. The Company does not currently have a sufficient trading history to support its historical volatility
calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility
of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free
interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with
the expected term of the instrument being valued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average estimated grant date
fair value of the stock options granted for the years ended December 31, 2019 and 2018 was approximately $3.10 and $6.39 per share,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 93; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10 &ndash; Stockholders&rsquo;
Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Options &ndash; Continued</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the option activity during
the year ended December 31, 2019 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Average</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Remaining</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Life</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Intrinsic</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif">Outstanding January 1, 2019</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,220,868</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3.01</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Granted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">692,572</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(668,502</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,500</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4.73</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,237,438</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.51</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8.1</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,559,915</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable December 31, 2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,183,637</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3.33</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7.3</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,222,680</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents information
related to stock options as of December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 59%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Average</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Remaining Life</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1.24</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">260,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5.2</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">260,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.95</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">700,281</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">545,170</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.74</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">681,572</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4.00</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.9</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">723</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,667</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.19</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,875</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26,668</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6.8</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21,249</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">311,499</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">224,438</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8.5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,333</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8.72</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">166,918</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8.3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">94,182</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,237,438</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,183,637</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2019
AND 2018</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 11 &ndash; Employee Benefit Plans&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>401(k) Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, the Company adopted the
Eyenovia 401(k) Plan (the &ldquo;Plan&rdquo;), which went into effect in May 2019. All Company employees are able to participate
in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees
are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue
Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company&rsquo;s Board of Directors has approved a matching
contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain
vesting requirements as outlined in the Plan documents. For the year ended December 31, 2019, the Company recorded expense of $71,285
associated with its matching contributions, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>Note
12 &ndash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Stock Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 31, 2020, the Company granted
ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 Plan, as amended. The shares vest
over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance
vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the
Company&rsquo;s closing stock price on the date of grant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Securities Purchase Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 24, 2020, the Company closed on
a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company&rsquo;s common stock,
(ii) a one-year warrant to purchase 0.5 of a share of common stock (&ldquo;Class A Warrant&rdquo;), and (iii) a five-year warrant
to purchase 0.75 of a share of common stock (&ldquo;Class B Warrant&rdquo;) (collectively, the Class A Warrants and Class B Warrants,
the &ldquo;Warrants&rdquo;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive
officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering after
deducting placement agent fees and offering expenses. In the offering, the Company issued an aggregate of 2,675,293 shares of common
stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares
of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of
the Class A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued
to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, on March
23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights
Agreement, the Company must file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K
for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued
in the offering and the shares of common stock underlying the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm205388d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF THE REGISTRANT&rsquo;S
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTERED PURSUANT TO SECTION 12 OF
THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of
90,000,000 shares of common stock, $0.0001 par value per share, and 6,000,000 shares of undesignated preferred stock, par value
$0.0001 per share. The following description summarizes the material terms of our capital stock. Because it is only a summary,
it does not contain all the information that may be important to you. For a complete description of our capital stock, you should
refer to our amended and restated certificate of incorporation, as amended (our &ldquo;restated certificate&rdquo;), and our amended
and restated bylaws (our &ldquo;restated bylaws&rdquo;), which are included as exhibits to this Annual Report on Form 10-K, and
to the provisions of applicable Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon information furnished by our
transfer agent, as of December 31, 2019, there were 17,100,726 shares of our common stock outstanding and held by approximately
44 stockholders of record. Holders of our common stock are entitled to the following rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dividend Rights</I>. Subject to preferences
that may apply to any shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock
are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may
determine. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Voting Rights</I>. The holders of our
common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of the stockholders,
including the election of directors. Our restated certificate and restated bylaws do not provide for cumulative voting rights.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>No Preemptive or Similar Rights</I>.
The holders of our common stock have no preemptive, conversion, or subscription rights, and there are no redemption provisions
applicable to our common stock.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Right to Receive Liquidation Distributions</I>.
Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable
ratably among the holders of our common stock and any participating preferred stock outstanding at that time after payment of liquidation
preferences, if any, on any outstanding shares of preferred stock and payment of other claims of creditors.&#9;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Fully Paid and Non-Assessable</I>.
All of the outstanding shares of our common stock are fully paid and non-assessable. &#9;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Potential Adverse Effect of Future
Preferred Stock</I>. The rights, preferences and privileges of the holders of common stock are subject to, and might be adversely
affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors is authorized, subject
to limitations prescribed by Delaware law, to issue up to 6,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each series, and to fix the designation, powers, preferences and rights
of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further action by
our stockholders. Our board may authorize the issuance of preferred stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring, or preventing a change in our control or the removal of management and might adversely affect the market price of our
common stock and the voting and other rights of the holders of our common stock. As of December 31, 2019, no shares of our preferred
stock were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Awards Available For Issuance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019, options to purchase
an aggregate of 2,237,438 shares of our common stock, with a weighted average exercise price of $3.51 per share, were outstanding
under our 2014 Equity Incentive Plan and 2018 Omnibus Stock Incentive Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2019, restricted stock
units representing a total of 60,355 shares of common stock were outstanding under our 2018 Omnibus Stock Incentive Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to an Investor&rsquo;s Rights
Agreement, as amended (the &ldquo;Rights Agreement&rdquo;), between us and the previous holders of our Series A preferred stock,
Series A-2 preferred stock and Series B preferred stock, which shares were all converted to shares of our common stock immediately
following the January 2018 initial public offering of our common stock. Under the Rights Agreement, beginning in July 2018, the
holders of approximately 4,825,216 shares of our common stock (as of December 31, 2019) are entitled to demand registration rights.
At any time, the holders of at least a majority of the converted shares of Series B preferred stock can, on not more than two occasions,
request that we register all or a portion of their shares. We will not be required to effect a demand registration during the period
beginning 60 days prior to our good faith estimate of the date of filing and 180 days following the effectiveness of a company-initiated
registration statement relating to a public offering of our securities, such as our registration statement on Form S-1, filed with
the SEC on December 12, 2018 and effective December 18, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in the event that we propose
to register any of our securities under the&nbsp;Securities Act of 1933, as amended, either for our own account or for the account
of other security holders, the holders of approximately 4,825,216 shares of our common stock (as of December 31, 2019) are entitled
to certain &ldquo;piggyback&rdquo; registration rights allowing such holders to include their shares in such registration, subject
to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the&nbsp;Securities
Act, other than with respect to a registration related to employee benefit plans, debt securities or corporate reorganizations,
the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters
may impose on the number of shares included in the registration, to include their shares in the registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay the registration
expenses of the holders of the shares registered pursuant to the registrations described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration rights
described above will expire upon the earlier of&thinsp;(i) January 2021, or (ii) with respect to any particular stockholder, the
date on which such stockholder can sell all of its shares under Rule&nbsp;144&nbsp;of the&nbsp;Securities Act&nbsp;during any 90-day
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN PROVISIONS OF DELAWARE LAW,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OUR RESTATED CERTIFICATE AND RESTATED
BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of Delaware law, our restated
certificate, and our restated bylaws may have the effect of delaying, deferring, or discouraging another person from acquiring
control of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Delaware Law</B>. We are governed by
the provisions of Section 203 of the Delaware General Corporation Law (&ldquo;DGCL&rdquo;). In general, Section 203 prohibits a
public Delaware corporation from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo;
for a period of three years after the date of the transaction in which the person became an interested stockholder unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">prior to such time, the board of directors
approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">upon consummation of the transaction that
resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock
of the corporation outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also
officers and by specified employee stock plans; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">at or subsequent to the date of the transaction,
the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by
the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;business combination&rdquo; includes
mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. In general, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of
the corporation&rsquo;s outstanding voting stock. These provisions may have the effect of delaying, deferring, or preventing a
change in our control. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our
board of directors does not approve in advance. We also anticipate that DGCL Section 203 may also discourage attempts that might
result in a premium over the market price for the shares of common stock held by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Restated Certificate and Restated Bylaw
Provisions</B>. Various provisions of our restated certificate and restated bylaws could deter hostile takeovers or delay or prevent
changes in control of our management team, including the following:&#9; &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board of Directors Vacancies. Our restated
certificate and restated bylaws authorize only our board fill vacant directorships. In addition, the number of directors constituting
our board is permitted to be set only by a resolution adopted by a majority of our board. These provisions would prevent a stockholder
from increasing the size of our board and then gaining control of our board by filling the resulting vacancies with its own nominees.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholder Action; Special Meeting of
Stockholders. Under our restated certificate, our stockholders may no longer take action by written consent, and may only take
action at annual or special meetings of our stockholders. Our restated bylaws further provide that special meetings of our stockholders
may be called only our board, President, Chief Executive Officer or by such other person the board expressly authorizes to call
a special meeting</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our restated bylaws provide advance notice
procedures for stockholders seeking to bring business before our annual meeting of stockholders. To be timely, a stockholder&rsquo;s
notice must be delivered to, or mailed and received at, our principal executive offices not less than 90 days nor more than 120
days prior to the one-year anniversary of the previous year&rsquo;s annual meeting of stockholders; provided, that if no annual
meeting of stockholders was held in the previous year or the date of the annual meeting of stockholders has been changed to be
more than 30 calendar days earlier or 60 days later than such anniversary, notice by the stockholder, to be timely, must be received
not earlier than the 120th day nor later to the 90th day prior to the date of such annual meeting or, if later, the 10th day following
the date we publicly disclose the date of the annual meeting. Our restated bylaws also specify certain requirements regarding the
form and content of a stockholder&rsquo;s notice. These provisions might preclude our stockholders from bringing matters before
our annual meeting of stockholders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our restated bylaws provide advance notice
procedures for stockholders to nominate candidates for election as directors at our annual meeting of stockholders. To be timely,
a stockholder&rsquo;s notice must be delivered to, or mailed and received at, our principal executive offices not less than 60
days nor more than 90 days prior to the annual meeting of stockholders. Our restated bylaws also provide advance notice procedures
for stockholders to nominate candidates for election as directors at a special meeting of stockholders. To be timely, a stockholder&rsquo;s
notice must be delivered to, or mailed and received at, our principal executive offices not later than the close of business on
the tenth business day following the date on which notice of such meeting is first given to stockholders. Our restated bylaws also
specify certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions might preclude our
stockholders from making nominations for directors at our annual and/or a special meeting of stockholders.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of Undesignated Preferred Stock.
Our board of directors has the authority, without further action by our stockholders, to issue up to 6,000,000 shares of undesignated
preferred stock with rights and preferences, including voting rights, designated from time to time by our board. Our board may
utilize these shares for a variety of corporate purposes, including future public offerings to raise additional capital, corporate
acquisitions and employee benefits plans. The existence of authorized but unissued shares of preferred stock would enable our board
to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest
or other means. If we issue such shares without stockholder approval and in violation of limitations imposed by any stock exchange
on which our stock may then be trading, our stock could be delisted.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our
common stock is American Stock Transfer and Trust Company, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Exchange Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq
Capital Market under the symbol &ldquo;EYEN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tm205388d1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in the Registration Statements of Eyenovia, Inc. (the &ldquo;Company&rdquo;) on Form S-3 (File No. 333-229365) and Forms S-8 (File
No. 333-227049, File No. 333-233278, and File No. 333-233280) of our report, which includes an explanatory paragraph as to the
Company&rsquo;s ability to continue as a going concern, dated March 30, 2020 with respect to our audits of the financial statements
of Eyenovia, Inc. as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019, which report
is included in this Annual Report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2020</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tm205388d1_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL EXECUTIVE
OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">I, Tsontcho Ianchulev, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2019;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.45in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 30, 2020</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Tsontcho
    Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tm205388d1_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL FINANCIAL
OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">I, John Gandolfo, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2019;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.48in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 30, 2020</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tm205388d1_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL EXECUTIVE
OFFICER<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the annual report of
Eyenovia, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Tsontcho Ianchulev, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my
knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: March 30, 2020</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tm205388d1_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE PRINCIPAL FINANCIAL
OFFICER<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the annual report of
Eyenovia, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, John Gandolfo, Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 30, 2020</P>



<FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>eyen-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:40 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:eyen="http://www.eyenoviabio.com/20191231" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="eyen-20191231.xsd" />
  <!--Context Section-->
  <context id="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2019_To_2_6_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-06</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_1_8_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-08</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-15</instant>
    </period>
  </context>
  <context id="As_Of_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-21</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_2_6_2019_To_2_6_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-06</startDate>
      <endDate>2019-02-06</endDate>
    </period>
  </context>
  <context id="Duration_1_2_2019_To_1_2_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EmployeesConsultantsAndDirectorsUnder2018PlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_6_2018_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-06</instant>
    </period>
  </context>
  <context id="As_Of_1_5_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-05</instant>
    </period>
  </context>
  <context id="As_Of_1_5_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-05</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_7_24_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-24</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_31_2020_To_1_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-31</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-16</startDate>
      <endDate>2019-08-16</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_1_14_2019_To_1_14_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-14</startDate>
      <endDate>2019-01-14</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2018_To_4_16_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-04-16</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2019_To_2_13_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-02-01</startDate>
      <endDate>2019-02-13</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-15</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_5_14_2019_To_5_14_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-05-14</startDate>
      <endDate>2019-05-14</endDate>
    </period>
  </context>
  <context id="Duration_1_2_2019_To_1_2_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-02</startDate>
      <endDate>2019-01-02</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_1_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="As_Of_8_8_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2018-08-08</instant>
    </period>
  </context>
  <context id="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-15</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:OwnershipAxis">eyen:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_10_1_2018_To_10_29_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-10-01</startDate>
      <endDate>2018-10-29</endDate>
    </period>
  </context>
  <context id="Duration_10_2_2018_To_10_29_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-10-02</startDate>
      <endDate>2018-10-29</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2019_To_4_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-04-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesAndSeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_1_29_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2018-01-29</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_29_2019_To_10_29_2019_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-10-29</startDate>
      <endDate>2019-10-29</endDate>
    </period>
  </context>
  <context id="Duration_10_29_2019_To_10_29_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-10-29</startDate>
      <endDate>2019-10-29</endDate>
    </period>
  </context>
  <context id="As_Of_1_2_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2019-01-02</instant>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-03-24</startDate>
      <endDate>2020-03-24</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:CommonStockOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2018_To_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-12-01</startDate>
      <endDate>2018-12-21</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:CommonStockOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-08</endDate>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-24</instant>
    </period>
  </context>
  <context id="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-01</startDate>
      <endDate>2016-09-15</endDate>
    </period>
  </context>
  <context id="Duration_7_15_2019_To_7_15_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-07-15</startDate>
      <endDate>2019-07-15</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_1_29_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-29</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-06</startDate>
      <endDate>2017-07-06</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="As_Of_3_25_2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <instant>2020-03-25</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit16">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="Unit15">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>eyen:item</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2019_To_12_31_2019">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2019_To_12_31_2019">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2019_To_12_31_2019">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2019_To_12_31_2019">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2019_To_12_31_2019">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2019_To_12_31_2019">0001682639</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_3_25_2020" unitRef="Unit1" decimals="0">19776019</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2019_To_12_31_2019">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2019_To_12_31_2019">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:EntityExTransitionPeriod>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2019_To_12_31_2019">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationDateOfIncorporation contextRef="Duration_1_1_2019_To_12_31_2019">2014-03-12</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityIncorporationStateCountryCode contextRef="Duration_1_1_2019_To_12_31_2019">FL</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2019_To_12_31_2019">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2019" unitRef="Unit12" decimals="0">31000000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2019_To_12_31_2019">EYENOVIA, INC.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="Duration_1_1_2019_To_12_31_2019">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2019_To_12_31_2019">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2019_To_12_31_2019">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="Duration_1_1_2019_To_12_31_2019">EYEN</dei:TradingSymbol>
  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">677213</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">453430</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
  <eyen:AccruedFranchiseTax contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:AccruedFranchiseTax>
  <eyen:AccruedFranchiseTax contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">40995</eyen:AccruedFranchiseTax>
  <eyen:AccruedLegalExpensesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">168650</eyen:AccruedLegalExpensesCurrent>
  <eyen:AccruedLegalExpensesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:AccruedLegalExpensesCurrent>
  <eyen:AccruedPurchasesOfLeaseholdImprovements contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:AccruedPurchasesOfLeaseholdImprovements>
  <eyen:AccruedPurchasesOfLeaseholdImprovements contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">42500</eyen:AccruedPurchasesOfLeaseholdImprovements>
  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">375204</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">208175</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
  <eyen:AccruedTravelAndEntertainmentExpenses contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:AccruedTravelAndEntertainmentExpenses>
  <eyen:AccruedTravelAndEntertainmentExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">7385</eyen:AccruedTravelAndEntertainmentExpenses>
  <eyen:ConsultingAgreementPaymentPerhour contextRef="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">250</eyen:ConsultingAgreementPaymentPerhour>
  <eyen:ConsultingAgreementPaymentPermonth contextRef="Duration_7_6_2017_To_7_6_2017_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">9567</eyen:ConsultingAgreementPaymentPermonth>
  <eyen:CostOfServicesEngineeringServices contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">863355</eyen:CostOfServicesEngineeringServices>
  <eyen:CostOfServicesEngineeringServices contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">851746</eyen:CostOfServicesEngineeringServices>
  <eyen:CreditCardPayable contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">9466</eyen:CreditCardPayable>
  <eyen:CreditCardPayable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">56979</eyen:CreditCardPayable>
  <eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-3563960</eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>
  <eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4931158</eyen:DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>
  <eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">2486</eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment>
  <eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">-14030</eyen:DeferredTaxAssetsLiabilityPropertyAndEquipment>
  <eyen:DisclosureOfAccruedCompensationTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2019 and 2018, accrued compensation consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued bonus expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 897,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 694,490&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued payroll expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 19,034&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 217,614&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 916,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 912,104&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:DisclosureOfAccruedCompensationTableTextBlock>
  <eyen:ExerciseOfWarrantsOnACashlessBasis contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">6</eyen:ExerciseOfWarrantsOnACashlessBasis>
  <eyen:ExerciseOfWarrantsOnACashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:ExerciseOfWarrantsOnACashlessBasis>
  <eyen:GrossProceedsOfStockValueIssuedDuringPeriod contextRef="Duration_1_1_2018_To_1_29_2018" unitRef="Unit12" decimals="-5">27300000</eyen:GrossProceedsOfStockValueIssuedDuringPeriod>
  <eyen:GrossProceedsOfStockValueIssuedDuringPeriod contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit12" decimals="-5">14000000</eyen:GrossProceedsOfStockValueIssuedDuringPeriod>
  <eyen:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">41584</eyen:IncreaseDecreaseInDeferredRent>
  <eyen:IncreaseDecreaseInDeferredRent contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">3767</eyen:IncreaseDecreaseInDeferredRent>
  <eyen:LeaseholdImprovements contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:LeaseholdImprovements>
  <eyen:LeaseholdImprovements contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">42500</eyen:LeaseholdImprovements>
  <eyen:LeaseMonthlyBaseRent contextRef="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">3895</eyen:LeaseMonthlyBaseRent>
  <eyen:LiquidityAndGoingConcernTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Liquidity and Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Implementation of the Company&amp;#x2019;s plans and its ability to continue as a going concern will depend upon the Company&amp;#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&amp;#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&amp;#x2019;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;On October 29, 2019, the Company announced that it is advancing its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its Mircropine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs. The Company believes the re-prioritization of its programs will yield overall cost savings of approximately $1.5 million to $1.9 million in 2020.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:LiquidityAndGoingConcernTextBlock>
  <eyen:MaximumNumberOfWarrantsToPurchaseCommonStock contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">2006495</eyen:MaximumNumberOfWarrantsToPurchaseCommonStock>
  <eyen:MaximumNumberOfWarrantsToPurchaseCommonStock contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">1337659</eyen:MaximumNumberOfWarrantsToPurchaseCommonStock>
  <eyen:NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">918000</eyen:NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode>
  <eyen:NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">35000000</eyen:NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode>
  <eyen:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2018_To_1_29_2018" unitRef="Unit12" decimals="-5">24500000</eyen:NetProceedsFromIssuanceOfCommonStock>
  <eyen:NetProceedsFromIssuanceOfCommonStock contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit12" decimals="-5">13000000</eyen:NetProceedsFromIssuanceOfCommonStock>
  <eyen:NumberOfShare contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="INF">1</eyen:NumberOfShare>
  <eyen:NumberOfUnitsSold contextRef="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember" unitRef="Unit14" decimals="5">2.42625</eyen:NumberOfUnitsSold>
  <eyen:NumberOfUnitsSold contextRef="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit14" decimals="5">2.21425</eyen:NumberOfUnitsSold>
  <eyen:OperatingLeasesMonthlyRentalPayments contextRef="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MaximumMember" unitRef="Unit12" decimals="0">22486</eyen:OperatingLeasesMonthlyRentalPayments>
  <eyen:OperatingLeasesMonthlyRentalPayments contextRef="Duration_8_1_2018_To_8_8_2018_srt_RangeAxis_srt_MinimumMember" unitRef="Unit12" decimals="0">19633</eyen:OperatingLeasesMonthlyRentalPayments>
  <eyen:OperatingLossCarryForwardsExpirationTerm contextRef="Duration_1_1_2019_To_12_31_2019">2034 to 2037</eyen:OperatingLossCarryForwardsExpirationTerm>
  <eyen:PaymentOfAccruedIssuanceCosts contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-133000</eyen:PaymentOfAccruedIssuanceCosts>
  <eyen:PaymentOfAccruedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:PaymentOfAccruedIssuanceCosts>
  <eyen:PaymentsForRepurchaseOfPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:PaymentsForRepurchaseOfPublicOffering>
  <eyen:PaymentsForRepurchaseOfPublicOffering contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">256374</eyen:PaymentsForRepurchaseOfPublicOffering>
  <eyen:PaymentsOfFollowOnRepurchaseOfInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">266581</eyen:PaymentsOfFollowOnRepurchaseOfInitialPublicOffering>
  <eyen:PaymentsOfFollowOnRepurchaseOfInitialPublicOffering contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:PaymentsOfFollowOnRepurchaseOfInitialPublicOffering>
  <eyen:PayrollTaxesReceivable contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:PayrollTaxesReceivable>
  <eyen:PayrollTaxesReceivable contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">95233</eyen:PayrollTaxesReceivable>
  <eyen:PrepaidConferenceExpenses contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">7000</eyen:PrepaidConferenceExpenses>
  <eyen:PrepaidConferenceExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">10600</eyen:PrepaidConferenceExpenses>
  <eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;3&amp;nbsp;&amp;#x2013; Prepaid Expenses and Other Current Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, prepaid expenses and other current assets consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Payroll tax receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 95,233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid insurance expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 33,923&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 39,465&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 17,978&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,404&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,562&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid conference expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid rent and security deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,463&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 75,729&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 24,079&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 196,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 132,756&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
  <eyen:PrepaidPatentExpense contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">10562</eyen:PrepaidPatentExpense>
  <eyen:PrepaidPatentExpense contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12404</eyen:PrepaidPatentExpense>
  <eyen:PrepaidRentAndSecurityDeposit contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">75729</eyen:PrepaidRentAndSecurityDeposit>
  <eyen:PrepaidRentAndSecurityDeposit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2463</eyen:PrepaidRentAndSecurityDeposit>
  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:PrepaidResearchAndDevelopmentExpenses>
  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">17978</eyen:PrepaidResearchAndDevelopmentExpenses>
  <eyen:ProceedsFromSaleOfCommonStockInIPO2 id="Item-0037" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">3084330</eyen:ProceedsFromSaleOfCommonStockInIPO2>
  <eyen:ProceedsFromSaleOfCommonStockInIPO2 id="Item-0036" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:ProceedsFromSaleOfCommonStockInIPO2>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">27300000</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">3381000</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_12_1_2018_To_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5">2800000</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">27300000</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">14030001</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">14030001</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">3381000</eyen:ProceedsOfStockIssuedDuringPeriodGross>
  <eyen:PurchaseTermOfWarrant contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P5Y</eyen:PurchaseTermOfWarrant>
  <eyen:PurchaseTermOfWarrant contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P1Y</eyen:PurchaseTermOfWarrant>
  <eyen:ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-195700</eyen:ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts>
  <eyen:ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts>
  <eyen:RemittanceOfEmployeeSPayrollTaxes contextRef="As_Of_1_2_2019" unitRef="Unit12" decimals="0">62193</eyen:RemittanceOfEmployeeSPayrollTaxes>
  <eyen:RePrioritizationOfOverallCostSavings contextRef="Duration_10_29_2019_To_10_29_2019" unitRef="Unit12" decimals="-5">1900000</eyen:RePrioritizationOfOverallCostSavings>
  <eyen:RePrioritizationOfOverallCostSavings contextRef="Duration_10_29_2019_To_10_29_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit12" decimals="-5">1500000</eyen:RePrioritizationOfOverallCostSavings>
  <eyen:RoyaltyPercentage contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember" unitRef="Unit15" decimals="2">0.05</eyen:RoyaltyPercentage>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">236466</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">-788827</eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">-918983</eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">-2932431</eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">4702116</eyen:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">61385</eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesOne id="Item-0003" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesOne>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesOne id="Item-0005" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesOne>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesOne id="Item-0001" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesOne>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesOne id="Item-0007" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">2730000</eyen:StockIssuedDuringPeriodSharesNewIssuesOne>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0025" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0027" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0023" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesThree id="Item-0029" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">5046763</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo id="Item-0014" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo id="Item-0016" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo id="Item-0012" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo id="Item-0018" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">1380000</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo contextRef="Duration_12_1_2018_To_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">1380000</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">-79</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">-92</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">-293</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">-6</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">470</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">-6</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">6</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueExercisesOfWarrants contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueExercisesOfWarrants>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0011" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">24547803</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0004" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0006" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0002" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0009" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">24547530</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0008" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">273</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesOne id="Item-0010" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesOne>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0033" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">12958575</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0026" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0028" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0024" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0031" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">12958070</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0030" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">505</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesThree id="Item-0032" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0022" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">2817749</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0015" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0017" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0013" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0020" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2817611</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0019" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">138</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueNewIssuesTwo id="Item-0021" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">-24</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">24</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</eyen:StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;5&amp;nbsp;&amp;#x2013; Accrued Expenses and Other Current Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 208,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 375,204&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,396&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 111,728&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Credit card payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,979&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,466&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 42,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued franchise tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,995&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued travel and entertainment expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 168,650&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,165&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,430&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 677,213&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">1509524</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1541358</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">694490</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">897839</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">677213</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">453430</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">111728</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">97396</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">217614</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">19034</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">66148</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">81491</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">53388216</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">69409949</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">1615470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">1615470</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2511944</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">2752197</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">563251</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">1071931</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="0">2241033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">2220868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">20165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="0">2297793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">2237438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">60355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">20015494</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14697619</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19860956</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14349281</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19728200</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14152601</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has cash deposits and U.S. treasury bills in a financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#x201C;FDIC&amp;#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&amp;nbsp;31, 2019 and 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $13,902,601 and $19,478,200,&amp;nbsp;respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="0">5249511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19728200</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19728200</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14152601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">14478689</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-5575599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashUninsuredAmount contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">19478200</us-gaap:CashUninsuredAmount>
  <us-gaap:CashUninsuredAmount contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">13902601</us-gaap:CashUninsuredAmount>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember" unitRef="Unit14" decimals="3">2.724</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit14" decimals="4">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_DirectorsAndExecutiveOfficersMember" unitRef="Unit14" decimals="2">2.27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit14" decimals="3">2.058</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;8&amp;nbsp;&amp;#x2013; Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August&amp;nbsp;8, 2018, the Company entered into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The&amp;nbsp;monthly base rent ranges from $19,633 to $22,486 per&amp;nbsp;month over the term of the lease for a total base rent lease commitment of approximately $1,236,000. The lease expires on September&amp;nbsp;30, 2023. The security deposit is approximately $118,000.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments under this operating lease agreement are as follows as:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Year Ending&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Minimum&amp;nbsp;Lease&amp;nbsp;Payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 244,853&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 251,586&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 258,505&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 198,157&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 953,101&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note&amp;nbsp;9&amp;nbsp;&amp;#x2013; Related Party Transactions&amp;nbsp;&amp;#x2013; Lease Agreements for details of a lease agreement with a related party.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Employment Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President, Research and Development and Manufacturing ("VP of R&amp;amp;D"), and Michael Rowe, now its Vice President, Commercial.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Each of the employment agreements provides that if the executive's employment is terminated by the Company without "Cause" or the executive suffers an "Involuntarily Termination" (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:none;"&gt;Each of the employment agreements also provides that if, within 12 months following any "Corporate Transaction" (as defined in the employment agreements) of the Company, the executive's employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Litigations, Claims and Assessments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company, its Chief Executive Officer and members of its Board of Directors were named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September&amp;nbsp;2, 2014 in connection with the Company&amp;#x2019;s Asset Purchase Agreement with Corinthian Ophthalmic,&amp;nbsp;Inc. (&amp;#x201C;Corinthian&amp;#x201D;). A shareholder of Corinthian alleged a fraudulent transfer and sought to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The court conducted a pretrial conference on January&amp;nbsp;22, 2018 and entered a final pretrial order on January&amp;nbsp;23, 2018. On October&amp;nbsp;29, 2018, the parties entered into a Settlement Agreement pursuant to which the defendants agreed to pay the Corinthian shareholder $600,000 in exchange for the release of all related claims. While the Company is indemnified by Corinthian and Corinthian&amp;#x2019;s applicable insurance policy provides coverage of $10 million, in an effort to avoid the additional legal costs and other resources required with a trial, the Company contributed $150,000 of the settlement amount (the remaining $450,000 was paid by Corinthian&amp;#x2019;s insurance carrier), which was paid on October&amp;nbsp;29, 2018.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2018" unitRef="Unit14" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">11468996</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">17100726</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">2675293</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">11468996</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">17100726</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">1147</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1710</us-gaap:CommonStockValue>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;11&amp;nbsp;&amp;#x2013; Employee Benefit Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;401(k) Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &amp;#x201C;Plan&amp;#x201D;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company&amp;#x2019;s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. For the year ended December 31, 2019, the Company recorded expense of $71,285 associated with its matching contributions, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CompensationRelatedCostsGeneralTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;6&amp;nbsp;&amp;#x2013; Accrued Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2019 and 2018, accrued compensation consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued bonus expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 897,839&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 694,490&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued payroll expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 19,034&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 217,614&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 916,873&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 912,104&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
  <us-gaap:ConversionOfStockAmountIssued1 contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">470</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:ConversionOfStockAmountIssued1 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="As_Of_1_29_2018" unitRef="Unit1" decimals="0">4702116</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember">The Series&#xA0;A and Series&#xA0;A-2 Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&#xA0;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&#xA0;the aggregate offering price, net of underwriters' discounts and expenses, was at least $2.00 per share of common stock and (B)&#xA0;the aggregate proceeds of such offering were not less than $20,000,000; or (ii)&#xA0;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember">The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders' equity on the balance sheet. While the embedded conversion option ("ECO") was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company's common stock as of the commitment date.The Series&#xA0;B Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series&#xA0;B Convertible Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series&#xA0;B Convertible Preferred Stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&#xA0;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&#xA0;the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B)&#xA0;the aggregate proceeds of such offering are not less than $20,000,000; or (ii)&#xA0;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred Offering Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&amp;#x2019;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs are offset against the offering proceeds. The Company had $0 in deferred offering costs at December 31, 2019 and 2018.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, prepaid expenses and other current assets consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Payroll tax receivable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 95,233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid insurance expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 33,923&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 39,465&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 17,978&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,404&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,562&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid conference expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 10,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prepaid rent and security deposit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,463&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 75,729&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 24,079&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 196,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 132,756&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:DeferredCostsCurrentAndNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:DeferredCostsCurrentAndNoncurrent>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-3516722</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4999920</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">41584</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">45351</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-47238</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">68762</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">310230</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">328773</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">7391220</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12322378</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">1008443</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1584753</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">5453854</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">9479512</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">34200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">10800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">616207</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">943370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">7391220</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">12322378</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="Duration_4_1_2019_To_4_30_2019" unitRef="Unit15" decimals="2">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage contextRef="Duration_4_1_2019_To_4_30_2019" unitRef="Unit15" decimals="2">0.04</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">71285</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">19129</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">19129</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">15343</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">15343</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="As_Of_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">100667</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="As_Of_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">89052</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit14" decimals="2">-1.82</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="2">-1.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Net Loss Per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,220,868&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 20,165&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,241,033&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.207</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="3">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="3">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">912104</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">916873</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2019_To_12_31_2019">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">3249222</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the fair value of financial assets and liabilities based on ASC 820 &amp;#x201C;Fair Value Measurements and Disclosures&amp;#x201D; (&amp;#x201C;ASC 820&amp;#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1&amp;nbsp;&amp;#x2014; quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2&amp;nbsp;&amp;#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3&amp;nbsp;&amp;#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of the Company&amp;#x2019;s financial instruments, such as cash and cash equivalents, due from related party, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">6137347</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">1163</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">7206095</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">5581</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;7&amp;nbsp;&amp;#x2013; Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes consists of the following expenses (benefits):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax provision (benefit):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,999,920)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,516,722)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State and local&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,762&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (47,238)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,931,158)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,563,960)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,931,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,563,960&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes differs from the United States Federal statutory rate as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research &amp;amp; development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prior period adjustments and other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (2.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23.3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (20.7)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred tax assets consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,479,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,453,854&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 943,370&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 616,207&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (14,030)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,486&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 328,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 310,230&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,584,753&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,008,443&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,322,378&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,391,220&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (12,322,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (7,391,220)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2019, the Company had approximately $45,000,000 of domestic Federal net operating loss carryforwards ("NOLs") that may be available to offset future Federal taxable income.&amp;nbsp;&amp;nbsp;Approximately $10,800,000 of those NOLs will expire during the years ranging from 2034 to 2037.&amp;nbsp;&amp;nbsp;The remaining NOLs of approximately $34,200,000 have no expiration dates.&amp;nbsp;&amp;nbsp;Internal Revenue Code Section 382 limits the utilization of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes that occurred through July 15, 2019.&amp;nbsp;&amp;nbsp;As of December 31, 2019, the Company had minimal state net operating loss carryforwards that may be available to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has assessed the likelihood that deferred tax assets will be realized in accordance with the provisions of ASC 740 &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt; ("ASC 740").&amp;nbsp;&amp;nbsp;ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies.&amp;nbsp;&amp;nbsp;ASC 740 requires that a valuation allowance be established when it is &amp;#x201C;more likely than not&amp;#x201D; that all, or a portion of, deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;After the performance of such reviews as of December 31, 2019 and 2018, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those dates. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&amp;#x2019;s consolidated financial statements as of December 31, 2019 and 2018.&amp;nbsp;&amp;nbsp;The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;No tax audits were commenced or were in process during the years ended December 31, 2019 and 2018.&amp;nbsp;&amp;nbsp;No tax related interest or penalties were incurred during the years ended December 31, 2019 and 2018.&amp;nbsp;&amp;nbsp;The Company's State of California income tax returns beginning with the year ended December 31, 2015 remain subject to examination.&amp;nbsp;&amp;nbsp;The Company's Federal and New York State and City income tax returns beginning with the year ended December 31, 2016 remain subject to examination.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&amp;nbsp;&amp;nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#x201C;temporary differences&amp;#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">1263140</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">31834</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">912104</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">4769</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">503950</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-266283</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">95607</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">63924</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-117800</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">3335</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">151786</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">32000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">47270</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">48144</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseExpirationDate1 contextRef="Duration_8_1_2018_To_8_8_2018">2023-09-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseholdImprovementsGross contextRef="As_Of_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">82500</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">3140425</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2957012</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">20015494</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">14697619</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">3098841</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">2911661</us-gaap:LiabilitiesCurrent>
  <us-gaap:LossContingencyAccrualPayments contextRef="Duration_10_2_2018_To_10_29_2018" unitRef="Unit12" decimals="0">150000</us-gaap:LossContingencyAccrualPayments>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_10_1_2018_To_10_29_2018" unitRef="Unit12" decimals="0">600000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5">1100000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod contextRef="Duration_10_1_2018_To_10_29_2018" unitRef="Unit12" decimals="0">450000</us-gaap:MalpracticeLossContingencyClaimsIncurredInPeriod>
  <us-gaap:MalpracticeLossContingencyInsuranceRecoveries contextRef="Duration_10_1_2018_To_10_29_2018" unitRef="Unit12" decimals="-6">10000000</us-gaap:MalpracticeLossContingencyInsuranceRecoveries>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember" unitRef="Unit15" decimals="2">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">27617734</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">13510352</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-27907</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-166643</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-13111138</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-18919308</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-17253108</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-17253108</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-17253108</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-17253108</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-21156758</us-gaap:NetIncomeLoss>
  <us-gaap:NetRentableArea contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit16" decimals="0">953</us-gaap:NetRentableArea>
  <us-gaap:NetRentableArea contextRef="As_Of_8_8_2018" unitRef="Unit16" decimals="0">3800</us-gaap:NetRentableArea>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the FASB issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2016&amp;#8209;02, &amp;#x201C;Leases (Topic 842)&amp;#x201D; (&amp;#x201C;ASU 2016&amp;#8209;02&amp;#x201D;). ASU 2016&amp;#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&amp;nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2020, and interim periods within fiscal years beginning after December 15, 2021. The FASB issued ASU No. 2019-01 &amp;#x201C;Leases (Topic 842) Codification Improvements&amp;#x201D; in March 2019 and ASU No. 2018-10 &amp;#x201C;Codification Improvements to Topic 842, Leases&amp;#x201D; and ASU No. 2018-11 &amp;#x201C;Leases (Topic 842) Targeted Improvements&amp;#x201D; in July 2018, and ASU No. 2018-20 &amp;#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&amp;#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In July 2017, the FASB issued ASU No. 2017-11, &amp;#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&amp;#x201D; (&amp;#x201C;ASU 2017-11&amp;#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &amp;#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&amp;#x201D; (&amp;#x201C;ASU 2018-13&amp;#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12, &amp;#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2016-15, &amp;#x201C;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&amp;#x201D; (&amp;#x201C;ASU 2016-15&amp;#x201D;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case a company would be required to apply the amendments prospectively as of the earliest date practicable. The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &amp;#x201C;Compensation &amp;#x2014; Stock Compensation (Topic 718)&amp;#x201D; (&amp;#x201C;ASU 2018-07&amp;#x201D;). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, &amp;#x201C;Equity &amp;#x2014; Equity-Based Payments to Nonemployees.&amp;#x201D; The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company&amp;#x2019;s adoption date of ASU No. 2014-09, (Topic 606), &amp;#x201C;Revenue from Contracts with Customers.&amp;#x201D; The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flow.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OfficersCompensation contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">182275</us-gaap:OfficersCompensation>
  <us-gaap:OfficersCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">186160</us-gaap:OfficersCompensation>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">17256443</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">21308544</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-17256443</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-21308544</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">953101</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">244853</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">198157</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">258505</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">251586</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_8_1_2018_To_8_8_2018" unitRef="Unit12" decimals="0">1236000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">45000000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;1&amp;nbsp;&amp;#x2013; Business Organization and Nature of Operations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Eyenovia,&amp;nbsp;Inc. (&amp;#x201C;Eyenovia&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) was organized as a corporation under the laws of the State of Florida on March&amp;nbsp;12, 2014 under the name, PGP Holdings V,&amp;nbsp;Inc. On May&amp;nbsp;5, 2014, PGP Holdings V,&amp;nbsp;Inc. changed its name to Eyenovia,&amp;nbsp;Inc. On October&amp;nbsp;6, 2014, Eyenovia,&amp;nbsp;Inc. reincorporated in the State of Delaware by merging into Eyenovia,&amp;nbsp;Inc., a Delaware corporation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Eyenovia. Inc. (&amp;#x201C;Eyenovia&amp;#x201D; or the &amp;#x201C;Company&amp;#x201D;) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;TM&lt;/font&gt;&lt;font style="display:inline;"&gt;. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver opthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &amp;#x201C;FDA&amp;#x201D;). Eyenovia&amp;#x2019;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">12165</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssets contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:OtherAssets>
  <us-gaap:OtherAssets contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">24079</us-gaap:OtherAssets>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="Duration_1_1_2018_To_1_29_2018" unitRef="Unit12" decimals="-5">2800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="Duration_12_1_2018_To_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5">600000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
  <us-gaap:PaymentsForRent contextRef="Duration_1_1_2018_To_1_31_2018" unitRef="Unit12" decimals="0">4000</us-gaap:PaymentsForRent>
  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">345497</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockOneMember" unitRef="Unit12" decimals="0">2211000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockThreeMember" unitRef="Unit12" decimals="0">815052</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_CommonStockTwoMember" unitRef="Unit12" decimals="0">296670</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">27907</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">166643</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2018" unitRef="Unit14" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit14" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">6000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:PreferredStockValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">132756</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">132756</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">196680</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">196680</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidInsurance contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">39465</us-gaap:PrepaidInsurance>
  <us-gaap:PrepaidInsurance contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">33923</us-gaap:PrepaidInsurance>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">5300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Item-0035" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">25089000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Item-0034" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-0039" contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_12_1_2018_To_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-5">3400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Item-0038" contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">13214949</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">56482</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">551777</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019" unitRef="Unit12" decimals="0">483888</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit12" decimals="0">67889</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;4&amp;nbsp;&amp;#x2013; Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, property and equipment consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 229,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 62,886&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 82,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 312,029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 102,886&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (81,491)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (66,148)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 230,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 36,738&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Depreciation and amortization expense was $15,343 and $19,129 for the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018, respectively, of which $9,762 and $17,966 was included within research and development expenses and $5,581 and $1,163&amp;nbsp;was included in general and administrative expenses in the statements of operations for the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">102886</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0">62886</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">40000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">312029</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" unitRef="Unit12" decimals="0">229529</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">82500</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">36738</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">36738</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">230538</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">230538</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5&amp;nbsp;years. Leasehold improvements are amortized over the lesser of (a)&amp;nbsp;the useful life of the asset; or (b)&amp;nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, property and equipment consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 229,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 62,886&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 82,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 312,029&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 102,886&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (81,491)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (66,148)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 230,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 36,738&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">162929</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionAxis_eyen_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eyen_CuraPartnersMember" unitRef="Unit12" decimals="0">213521</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;9&amp;nbsp;&amp;#x2013; Related Party Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Consulting Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A company in which a member of the Company&amp;#x2019;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $213,521 and $162,929 for the years ended December 31, 2019 and 2018, respectively, related to the agreement which was included within general and administrative expenses on the statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Lease Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company paid $4,000 per&amp;nbsp;month as of January&amp;nbsp;2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for its Chief Executive Officer (&amp;#x201C;CEO&amp;#x201D;). The Company left the space on August&amp;nbsp;31, 2018. The Company&amp;#x2019;s rent expense for this space amounted to $0 and $32,000 for the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018, respectively, related to the office space, which was included within general and administrative expenses on the statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s Vice President of Research and Development and Manufacturing (&amp;#x201C;VP of R&amp;amp;D&amp;#x201D;) owns a company that entered into a lease agreement with the Company on September&amp;nbsp;15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities. The initial&amp;nbsp;monthly base rent was $3,895 per&amp;nbsp;month over the term of the lease and the security deposit was $3,895. On September&amp;nbsp;15, 2018, the Company amended the lease agreement to extend it until September&amp;nbsp;14, 2020 and increase the&amp;nbsp;monthly base rent and security deposit to $4,012. The Company made $82,500 of leasehold improvements related to this lease which are included on the balance sheet.&amp;nbsp;The Company&amp;#x2019;s rent expense for this space amounted to $48,144 and $47,270 for the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development Activities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The VP of R&amp;amp;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2019 and 2018, the Company recognized research and development expense of $851,746 and $863,355, respectively, related to services provided by such vendor. The Company had a liability of $89,052 and $100,667 to the vendor as of December 31, 2019 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognized $186,160 and $182,275 of compensation expense related to the VP of R&amp;amp;D&amp;#x2019;s salary during the years ended December 31, 2019 and 2018, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;text-decoration:underline;"&gt;License Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During 2015, the Company entered into a license agreement with Senju Pharmaceuticals Co., Ltd. (&amp;#x201C;Senju&amp;#x201D;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, so no royalties had been earned. Senju is owned by the family of a former member of the Company&amp;#x2019;s Board of Directors and, together, they beneficially own greater than 5% of the Company&amp;#x2019;s common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">11119096</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">17966</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">14102449</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_FairValueByAssetClassAxis_us-gaap_PropertyPlantAndEquipmentMember" unitRef="Unit12" decimals="0">9762</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">-36514294</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">-57671052</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2019 and 2018, accrued expenses and other current liabilities consisted of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 208,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 375,204&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 97,396&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 111,728&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Credit card payable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 56,979&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,466&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 42,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued franchise tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 40,995&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued travel and entertainment expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Accrued legal expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 168,650&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,165&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total accrued expenses and other current liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 453,430&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 677,213&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,220,868&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 20,165&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,241,033&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes consists of the following expenses (benefits):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax provision (benefit):&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,999,920)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,516,722)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State and local&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 68,762&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (47,238)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (4,931,158)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (3,563,960)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4,931,158&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,563,960&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred tax assets consist of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;As of December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Net operating loss carryforwards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 9,479,512&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5,453,854&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 943,370&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 616,207&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (14,030)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,486&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Intangibles&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 328,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 310,230&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,584,753&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,008,443&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 12,322,378&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7,391,220&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (12,322,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (7,391,220)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Deferred tax assets, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The provision for income taxes differs from the United States Federal statutory rate as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Years&amp;nbsp;Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Federal statutory rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;State tax rate, net of federal benefit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Research &amp;amp; development tax credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Prior period adjustments and other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (0.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (2.6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (23.3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (20.7)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Effective income tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future minimum payments under this operating lease agreement are as follows as:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Year Ending&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Minimum&amp;nbsp;Lease&amp;nbsp;Payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 244,853&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 251,586&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 258,505&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 198,157&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 953,101&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to stock options as of December&amp;nbsp;31, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="3" valign="bottom" style="width:52.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:43.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&amp;nbsp;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&amp;nbsp;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;1.24
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;1.95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 700,281&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 545,170&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;2.74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;3.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 681,572&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;4.00
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 723&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,667&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,875&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21,249&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;6.20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 311,499&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 224,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;6.30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 28,333&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;8.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 166,918&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 94,182&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,183,637&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the option activity during the&amp;nbsp;year ended December&amp;nbsp;31, 2019 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,220,868&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.01&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 692,572&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (668,502)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (7,500)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.73&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,559,915&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,183,637&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.33&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,222,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;1.42 - 2.53&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2.69 - 3.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;134 - 139&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;140 &amp;nbsp;-141&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SecuritiesPurchasedUnderAgreementsToResellLiability contextRef="As_Of_3_24_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">6000000</us-gaap:SecuritiesPurchasedUnderAgreementsToResellLiability>
  <us-gaap:SecurityDeposit contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">3895</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_8_8_2018" unitRef="Unit12" decimals="0">118000</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember" unitRef="Unit12" decimals="0">4012</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">117800</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">117800</us-gaap:SecurityDeposit>
  <us-gaap:SeveranceCosts1 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">419000</us-gaap:SeveranceCosts1>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">1615470</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">1615470</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">797231</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">818239</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">2511944</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1052889</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">1459055</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">609322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="Duration_2_1_2019_To_2_13_2019" unitRef="Unit1" decimals="0">124210</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_4_1_2018_To_4_16_2018">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_14_2019_To_1_14_2019">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit15" decimals="4">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="Duration_1_1_2018_To_12_31_2018">vest over three&#xA0;years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting&#xA0;monthly over the remaining 24&#xA0;months</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_7_1_2018_To_7_24_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">20165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit1" decimals="0">40190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_7_1_2018_To_7_24_2018_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="0">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Unit14" decimals="0">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember" unitRef="Unit15" decimals="2">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember" unitRef="Unit15" decimals="2">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit15" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember" unitRef="Unit15" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember" unitRef="Unit15" decimals="4">0.0324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember" unitRef="Unit15" decimals="4">0.0269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit15" decimals="4">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2019_To_12_31_2019_srt_RangeAxis_srt_MinimumMember" unitRef="Unit15" decimals="4">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_1_5_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember" unitRef="Unit1" decimals="0">1866667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_1_5_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember" unitRef="Unit1" decimals="0">1733333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_1_5_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember" unitRef="Unit1" decimals="0">1733333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_3_6_2018_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member" unitRef="Unit1" decimals="0">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_eyen_EquityIncentivePlanMember" unitRef="Unit1" decimals="0">15333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member" unitRef="Unit1" decimals="0">106074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">2222680</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">1183637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Duration_4_1_2018_To_4_16_2018" unitRef="Unit14" decimals="0">1412700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">395999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit1" decimals="0">313674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" unitRef="Unit1" decimals="0">22325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Unit1" decimals="0">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_4_1_2018_To_4_16_2018" unitRef="Unit1" decimals="0">175668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">692572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_14_2019_To_1_14_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit1" decimals="0">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">681572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit1" decimals="0">681572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit1" decimals="0">636287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Unit1" decimals="0">45285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">3559915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2018_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">2220868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">2237438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2018_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">2237800</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_14_2019_To_1_14_2019" unitRef="Unit12" decimals="0">27500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit12" decimals="0">1909700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">1.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_2_6_2019_To_2_6_2019" unitRef="Unit14" decimals="2">1.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit14" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_8_16_2019_To_8_16_2019_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" unitRef="Unit14" decimals="2">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit14" decimals="2">6.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MaximumMember" unitRef="Unit14" decimals="2">6.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2018_To_12_31_2018_srt_RangeAxis_srt_MinimumMember" unitRef="Unit14" decimals="2">5.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_4_1_2018_To_4_16_2018" unitRef="Unit14" decimals="2">8.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit14" decimals="2">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit14" decimals="2">3.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_14_2019_To_1_14_2019" unitRef="Unit14" decimals="2">2.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_31_2020_To_1_31_2020_us-gaap_PlanNameAxis_eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit14" decimals="2">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit14" decimals="2">5.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit14" decimals="2">8.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit14" decimals="2">4.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit14" decimals="2">3.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit14" decimals="2">6.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit14" decimals="2">1.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit14" decimals="2">5.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit14" decimals="2">5.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit14" decimals="2">6.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit14" decimals="2">2.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit14" decimals="2">1.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">1183637</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit1" decimals="0">21249</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit1" decimals="0">94182</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit1" decimals="0">723</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit1" decimals="0">224438</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit1" decimals="0">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit1" decimals="0">6875</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit1" decimals="0">2667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit1" decimals="0">28333</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit1" decimals="0">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit1" decimals="0">545170</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="0">2237438</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember" unitRef="Unit1" decimals="0">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember" unitRef="Unit1" decimals="0">166918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember" unitRef="Unit1" decimals="0">2000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember" unitRef="Unit1" decimals="0">681572</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember" unitRef="Unit1" decimals="0">311499</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember" unitRef="Unit1" decimals="0">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember" unitRef="Unit1" decimals="0">16500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember" unitRef="Unit1" decimals="0">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember" unitRef="Unit1" decimals="0">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember" unitRef="Unit1" decimals="0">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="As_Of_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember" unitRef="Unit1" decimals="0">700281</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember">P8Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember">P8Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember">P8Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember">P5Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember">P8Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember">P8Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_1_29_2018" unitRef="Unit14" decimals="2">10.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_12_21_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">2.45</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit14" decimals="2">2.78</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">788827</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">918983</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">2932431</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">2566530</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">11468996</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">17100726</us-gaap:SharesOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;2&amp;nbsp;&amp;#x2013; Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Liquidity and Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Implementation of the Company&amp;#x2019;s plans and its ability to continue as a going concern will depend upon the Company&amp;#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&amp;#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&amp;#x2019;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October 29, 2019, the Company announced that it is advancing its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its Mircropine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs. The Company believes the re-prioritization of its programs will yield overall cost savings of approximately $1.5 million to $1.9 million in 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&amp;#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note 2 - Summary of Significant Accounting Policies&amp;#x2009;&amp;#x2014;&amp;#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#x2019;s common stock. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has cash deposits and U.S. treasury bills in a financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#x201C;FDIC&amp;#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&amp;nbsp;31, 2019 and 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $13,902,601 and $19,478,200,&amp;nbsp;respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and Equipment, Net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5&amp;nbsp;years. Leasehold improvements are amortized over the lesser of (a)&amp;nbsp;the useful life of the asset; or (b)&amp;nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Impairment of Long-lived Assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred Offering Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&amp;#x2019;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs are offset against the offering proceeds. The Company had $0 in deferred offering costs at December 31, 2019 and 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#x2019; equity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the fair value of financial assets and liabilities based on ASC 820 &amp;#x201C;Fair Value Measurements and Disclosures&amp;#x201D; (&amp;#x201C;ASC 820&amp;#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1&amp;nbsp;&amp;#x2014; quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2&amp;nbsp;&amp;#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3&amp;nbsp;&amp;#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of the Company&amp;#x2019;s financial instruments, such as cash and cash equivalents, due from related party, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&amp;nbsp;&amp;nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#x201C;temporary differences&amp;#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:none;"&gt;The Company&amp;#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and Development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Net Loss Per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,220,868&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,355&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 20,165&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Total potentially dilutive shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,297,793&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,241,033&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Issued Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the FASB issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2016&amp;#8209;02, &amp;#x201C;Leases (Topic 842)&amp;#x201D; (&amp;#x201C;ASU 2016&amp;#8209;02&amp;#x201D;). ASU 2016&amp;#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&amp;nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2020, and interim periods within fiscal years beginning after December 15, 2021. The FASB issued ASU No. 2019-01 &amp;#x201C;Leases (Topic 842) Codification Improvements&amp;#x201D; in March 2019 and ASU No. 2018-10 &amp;#x201C;Codification Improvements to Topic 842, Leases&amp;#x201D; and ASU No. 2018-11 &amp;#x201C;Leases (Topic 842) Targeted Improvements&amp;#x201D; in July 2018, and ASU No. 2018-20 &amp;#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&amp;#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In July 2017, the FASB issued ASU No. 2017-11, &amp;#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&amp;#x201D; (&amp;#x201C;ASU 2017-11&amp;#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &amp;#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&amp;#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&amp;#x201D; (&amp;#x201C;ASU 2018-13&amp;#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2019, the FASB issued ASU 2019-12, &amp;#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&amp;#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2016-15, &amp;#x201C;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&amp;#x201D; (&amp;#x201C;ASU 2016-15&amp;#x201D;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case a company would be required to apply the amendments prospectively as of the earliest date practicable. The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flows.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &amp;#x201C;Compensation &amp;#x2014; Stock Compensation (Topic 718)&amp;#x201D; (&amp;#x201C;ASU 2018-07&amp;#x201D;). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, &amp;#x201C;Equity &amp;#x2014; Equity-Based Payments to Nonemployees.&amp;#x201D; The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company&amp;#x2019;s adoption date of ASU No. 2014-09, (Topic 606), &amp;#x201C;Revenue from Contracts with Customers.&amp;#x201D; The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&amp;#x2019;s financial position, results of operations or cash flow.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="0">5090673</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">79</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">92</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">293</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">24351138</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">257</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-19261186</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">16875069</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">16875069</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">53388216</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">1147</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-36514294</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">11740607</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">11740607</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">69409949</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">1710</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-57671052</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Note&amp;nbsp;10&amp;nbsp;&amp;#x2013; Stockholders&amp;#x2019; Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Reverse Stock Split&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Effective January&amp;nbsp;8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&amp;#x2019;s issued and outstanding common stock and preferred stock (the &amp;#x201C;Reverse Split&amp;#x201D;). The number of authorized shares remained unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Authorized Capital&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is authorized to issue 90,000,000 shares of common stock, par value of&amp;#x2009;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&amp;#x2009;$0.0001 per share. The holders of the Company&amp;#x2019;s common stock are entitled to one vote per share. The Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Equity Incentive Plans&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January&amp;nbsp;5, 2018, the Company&amp;#x2019;s Board of Directors and stockholders approved an amendment to the Company&amp;#x2019;s 2014 Equity Incentive Plan (&amp;#x201C;2014 Plan&amp;#x201D;) to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares. As of December&amp;nbsp;31, 2019, there were 15,333 shares available for future issuance under the 2014 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March&amp;nbsp;6, 2018, the Company&amp;#x2019;s Board of Directors adopted the 2018 Omnibus Stock Incentive Plan (&amp;#x201C;2018 Plan&amp;#x201D;), which stockholders approved on June 11, 2018. The 2018 Plan was subsequently amended by the Board on April 5, 2019 and approved by stockholders on June 11, 2019 (the &amp;#x201C;2018 Plan, as amended&amp;#x201D;). The 2018 Plan, as amended, provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&amp;nbsp;units (&amp;#x201C;RSUs&amp;#x201D;) to employees, directors and consultants of the Company and its affiliates. The 2018 Plan, as amended, terminates on June&amp;nbsp;11, 2028. The 2018 Plan, as amended, requires the exercise price of stock options to be greater than or equal to the fair value of the Company&amp;#x2019;s common stock on the date of grant. There are 1,250,000 shares of common stock authorized under the 2018 Plan, as amended. As of December&amp;nbsp;31, 2019, there were 106,074 shares available for future issuance under the 2018 Plan, as amended.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Public Offerings&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January&amp;nbsp;29, 2018, the Company consummated its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, which were recorded as a reduction of additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On December&amp;nbsp;21, 2018, the Company consummated a follow-on public offering of 1,380,000 shares of its common stock at an offering price of $2.45 per share, generating $3.4 million and $2.8 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $0.6 million, which were recorded as a reduction of additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&amp;#x2019;s common stock at the same price, which was exercised in full on July 16, 2019.&amp;nbsp;&amp;nbsp;Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses, which were recorded as a reduction of additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Series&amp;nbsp;A and Series&amp;nbsp;A&amp;#8209;2 Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Series A and Series A-2 Convertible Preferred Stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and, therefore, it has been classified within stockholders&amp;#x2019; equity on the balance sheet. While the embedded conversion option (&amp;#x201C;ECO&amp;#x201D;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature because the conversion price exceeded the estimated fair value of the Company&amp;#x2019;s common stock as of the commitment date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Series&amp;nbsp;A and Series&amp;nbsp;A-2 Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&amp;nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&amp;nbsp;the aggregate offering price, net of underwriters&amp;#x2019; discounts and expenses, was at least $2.00 per share of common stock and (B)&amp;nbsp;the aggregate proceeds of such offering were not less than $20,000,000; or (ii)&amp;nbsp;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series&amp;nbsp;A and Series&amp;nbsp;A&amp;#8209;2 Convertible Preferred Stock converted immediately prior to the Company&amp;#x2019;s IPO. See Note&amp;nbsp;10&amp;nbsp;&amp;#x2013; Stockholders&amp;#x2019; Equity&amp;nbsp;&amp;#x2013; Conversion of Preferred Stock for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Series&amp;nbsp;B Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&amp;#x2019; equity on the balance sheet. While the embedded conversion option (&amp;#x201C;ECO&amp;#x201D;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&amp;#x2019;s common stock as of the commitment date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Series&amp;nbsp;B Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series&amp;nbsp;B Convertible Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series&amp;nbsp;B Convertible Preferred Stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&amp;nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&amp;nbsp;the aggregate offering price, net of underwriters&amp;#x2019; discounts and expenses, is at least $2.00 per share of common stock and (B)&amp;nbsp;the aggregate proceeds of such offering are not less than $20,000,000; or (ii)&amp;nbsp;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series&amp;nbsp;B Convertible Preferred Stock converted immediately prior to the Company&amp;#x2019;s IPO. See Note&amp;nbsp;10&amp;nbsp;&amp;#x2013; Stockholders&amp;#x2019; Equity&amp;nbsp;&amp;#x2013; Conversion of Preferred Stock for additional details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Conversion of Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Immediately prior to the closing of the IPO on January&amp;nbsp;29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,702,116 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-Based Compensation Expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company records stock-based compensation expense related to stock options and RSUs. For the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018, the Company recorded expense of $2,511,944 &amp;nbsp;($1,459,055 of which was included within research and development expenses and $1,052,889 was included within general and administrative expenses on the statements of operations) and $1,615,470 &amp;nbsp;($818,239 of which was included within research and development expenses and $797,231 was included within general and administrative expenses on the statements of operations), respectively. As of December&amp;nbsp;31, 2019, there was $3,249,222 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 1.9&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Restricted Stock Units&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July&amp;nbsp;24, 2018, the Company granted an aggregate of 20,165 RSUs to its directors under the 2018 Plan. The grants vest on the earlier of (i)&amp;nbsp;the one-year anniversary of the date of grant and (ii)&amp;nbsp;the date of the 2019 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which was recognized over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 16, 2019, the Company granted to members of its Board of Directors an aggregate of 40,190 restricted stock units (&amp;#x201C;RSUs&amp;#x201D;) under the 2018 Plan, as amended. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2020 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which will be recognized over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On April&amp;nbsp;16, 2018, the Compensation Committee of the Board of Directors approved the grant of ten-year stock options to purchase 175,668 shares of common stock to Company employees and consultants under the 2014 Plan. The stock options will vest in equal&amp;nbsp;monthly increments over 36&amp;nbsp;months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and have an exercise price of $8.72 per share, which was the closing stock price on the date of grant. The stock options had a grant date fair value of $1,412,700, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the&amp;nbsp;year ended December&amp;nbsp;31, 2018, the Company granted ten-year stock options to purchase an aggregate of 395,999 shares of common stock to its employees, consultants and directors under the 2018 Plan. Of the 395,999 shares, (i)&amp;nbsp;313,674&amp;nbsp;vest over three&amp;nbsp;years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting&amp;nbsp;monthly over the remaining 24&amp;nbsp;months, subject to continued service to the Company, (ii)&amp;nbsp;60,000 vest&amp;nbsp;monthly over 36&amp;nbsp;months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and (iii)&amp;nbsp;22,325 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2019 annual stockholders meeting, subject to continued service to the Company. The stock options have exercise prices ranging from $5.10 per share to $6.30 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $2,237,800, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January&amp;nbsp;2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion of an employee&amp;#x2019;s payroll taxes of $62,193 to the Internal Revenue Service.&amp;nbsp;&amp;nbsp;The Company was reimbursed in full by the employee.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On January 14, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On February&amp;nbsp;6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On February&amp;nbsp;13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr.&amp;nbsp;Ianchulev on July&amp;nbsp;24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the year ended December 31, 2019 , which represents the remaining unamortized grant date fair value of the award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 16, 2019, the Company granted ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors under the 2018 Plan, as amended.&amp;nbsp;&amp;nbsp;Of the 681,572 shares, (i) 636,287 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company and (ii) 45,285 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise price of $3.11 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant.&amp;nbsp;&amp;nbsp;The stock options had a grant date value of $1,909,700, which the Company expects to recognize over the vesting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;For&amp;nbsp;the&amp;nbsp;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;5.50 - 10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Risk free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;1.42 - 2.53&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;2.69 - 3.24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;134 - 139&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;140 &amp;nbsp;-141&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &amp;#x201C;simplified&amp;#x201D; method to develop an estimate of the expected term of &amp;#x201C;plain vanilla&amp;#x201D; option grants. The Company does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The weighted average estimated grant date fair value of the stock options granted for the&amp;nbsp;years ended December&amp;nbsp;31, 2019 and 2018 was approximately $3.10 and $6.39 per share, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the option activity during the&amp;nbsp;year ended December&amp;nbsp;31, 2019 is presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,220,868&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.01&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 692,572&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (668,502)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1.42&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; (7,500)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 4.73&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Outstanding December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.51&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3,559,915&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;Exercisable December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,183,637&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 3.33&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,222,680&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents information related to stock options as of December&amp;nbsp;31, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="3" valign="bottom" style="width:52.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:43.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&amp;nbsp;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercisable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Remaining&amp;nbsp;Life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;In&amp;nbsp;Years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;1.24
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 5.2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 260,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;1.95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 700,281&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 545,170&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;2.74
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;3.11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 681,572&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;4.00
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 723&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.10
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,667&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.19
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 16,500&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.7&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6,875&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;5.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 26,668&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 6.8&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 21,249&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;6.20
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 311,499&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.6&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 224,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;6.30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 60,000&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 28,333&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;$&lt;/div&gt;8.72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 166,918&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 8.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 94,182&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 2,237,438&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 7.3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"&gt; 1,183,637&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#x2019; equity.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="Duration_1_1_2018_To_1_8_2018">1-for-3.75</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssued1 contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">0</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">24</us-gaap:StockIssued1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2018_To_1_29_2018" unitRef="Unit1" decimals="0">2730000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_2_1_2019_To_2_6_2019" unitRef="Unit1" decimals="0">236466</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019" unitRef="Unit1" decimals="0">5046763</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="0">4388490</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_7_15_2019_To_7_15_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit1" decimals="0">658273</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">28965</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">34</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">668502</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">133686</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_2_2019_To_1_2_2019_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember" unitRef="Unit1" decimals="0">180000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_2_1_2019_To_2_6_2019" unitRef="Unit1" decimals="0">320001</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_5_14_2019_To_5_14_2019" unitRef="Unit1" decimals="0">34815</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">56482</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">56479</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">551777</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesA2ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesBConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_eyen_SeriesConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">551743</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">348501</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Note&amp;nbsp;12&amp;nbsp;&amp;#x2013; Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt; Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;Plan as amended.&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt; &amp;nbsp;The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company&amp;#x2019;s closing stock price on the date of grant.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Securities Purchase Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consisting of (i) one share of the Company&amp;#x2019;s&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;"&gt;common stock (ii) a one-year warrant to purchase 0.5 of a share of common stock (&amp;#x201C;Class A Warrant&amp;#x201D;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&amp;#x201C;Class B Warrant&amp;#x201D;) (collectively, Class A Warrants and Class B Warrants, the &amp;#x201C;Warrants&amp;#x201D;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering after deducting placement agent fees and offering expenses. In the offering the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share.&amp;nbsp;&amp;nbsp;The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;In connection with the offering, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company must file with the&amp;nbsp;SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common Stock issued in the offering and the shares of common Stock underlying the Warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 5pt;"&gt;
			&lt;font style="display:inline;font-size:5pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">1677000</us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&amp;#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;See Note 2 - Summary of Significant Accounting Policies&amp;#x2009;&amp;#x2014;&amp;#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#x2019;s common stock. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="0">-3563960</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="0">-4931158</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="0">9476706</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="0">14349738</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="0">912104</us-gaap:WorkersCompensationLiabilityCurrent>
  <us-gaap:WorkersCompensationLiabilityCurrent contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="0">916873</us-gaap:WorkersCompensationLiabilityCurrent>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0037" xlink:label="Item-0037_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0037_lbl" xlink:to="Footnote-05" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0036" xlink:label="Item-0036_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0036_lbl" xlink:to="Footnote-05" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0005" xlink:label="Item-0005_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0007" xlink:label="Item-0007_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0007_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0025" xlink:label="Item-0025_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0025_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0027" xlink:label="Item-0027_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0027_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0023" xlink:label="Item-0023_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0023_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0029" xlink:label="Item-0029_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0029_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0014" xlink:label="Item-0014_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0014_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0016" xlink:label="Item-0016_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0016_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0012" xlink:label="Item-0012_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0012_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0018" xlink:label="Item-0018_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0018_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0011" xlink:label="Item-0011_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0011_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0006" xlink:label="Item-0006_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0006_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0009" xlink:label="Item-0009_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0009_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0008" xlink:label="Item-0008_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0008_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0010" xlink:label="Item-0010_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0010_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0033" xlink:label="Item-0033_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0033_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0026" xlink:label="Item-0026_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0026_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0028" xlink:label="Item-0028_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0028_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0024" xlink:label="Item-0024_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0024_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0031" xlink:label="Item-0031_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0031_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0030" xlink:label="Item-0030_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0030_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0032" xlink:label="Item-0032_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0032_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0022" xlink:label="Item-0022_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0022_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0015" xlink:label="Item-0015_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0015_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0017" xlink:label="Item-0017_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0017_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0013" xlink:label="Item-0013_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0013_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0020" xlink:label="Item-0020_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0020_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0019" xlink:label="Item-0019_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0019_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0021" xlink:label="Item-0021_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0021_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0035" xlink:label="Item-0035_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0035_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0034" xlink:label="Item-0034_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0034_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0039" xlink:label="Item-0039_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0039_lbl" xlink:to="Footnote-06" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0038" xlink:label="Item-0038_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0038_lbl" xlink:to="Footnote-06" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">[2] Includes gross proceeds of $3,381,000, less issuance costs of $296,670 deducted directly from the offering proceeds.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">[1] Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,931.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">[2] Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">[1] Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $815,052 deducted directly from the offering proceeds.</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eyen-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:46 PM-->
<!--Modified on: 3/30/2020 8:33:46 PM-->
<schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:eyen="http://www.eyenoviabio.com/20191231" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.eyenoviabio.com/20191231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>00200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails">
        <link:definition>40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" id="DisclosureAccruedCompensationDetails">
        <link:definition>40601 - Disclosure - Accrued Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>40701 - Disclosure - Income Taxes - provision for income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>40703 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" id="DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails">
        <link:definition>40801 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" id="StatementStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" id="StatementStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" id="StatementCondensedStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" id="DisclosureBusinessOrganizationAndNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - Business Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>40702 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>40704 - Disclosure - Income Taxes - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40901 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>41001 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" id="DisclosureStockholdersEquitySummaryOfOptionActivityDetails">
        <link:definition>41002 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" id="DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails">
        <link:definition>41003 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>41004 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" id="DisclosureEmployeeBenefitPlansDetails">
        <link:definition>41101 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" id="DisclosureBusinessOrganizationAndNatureOfOperations">
        <link:definition>10101 - Disclosure - Business Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10301 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" id="DisclosureAccruedCompensation">
        <link:definition>10601 - Disclosure - Accrued Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10701 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10901 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11001 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11101 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" id="DisclosureAccruedCompensationTables">
        <link:definition>30603 - Disclosure - Accrued Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30703 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30803 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>31003 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <element name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="SeriesConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SeriesConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SeriesA2ConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SeriesBConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
  <element name="StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" name="StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_StockIssuedDuringPeriodValueNewIssuesOne" name="StockIssuedDuringPeriodValueNewIssuesOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesNewIssuesOne" name="StockIssuedDuringPeriodSharesNewIssuesOne" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" substitutionGroup="xbrli:item" />
  <element name="ProceedsOfStockIssuedDuringPeriodGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_ProceedsOfStockIssuedDuringPeriodGross" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_IncreaseDecreaseInDeferredRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOfAccruedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_PaymentOfAccruedIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_DisclosureOfAccruedCompensationTableTextBlock" name="DisclosureOfAccruedCompensationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidPatentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidPatentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidRentAndSecurityDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidRentAndSecurityDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PrepaidConferenceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidConferenceExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PayrollTaxesReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PayrollTaxesReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedResearchAndDevelopmentExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="AccruedLegalExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedLegalExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="eyen_CreditCardPayable" name="CreditCardPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element name="CuraPartnersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_CuraPartnersMember" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ConsultingAgreementMember" substitutionGroup="xbrli:item" />
  <element name="VicePresidentOfResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_VicePresidentOfResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
  <element name="SenjuPharmaceuticalCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SenjuPharmaceuticalCoMember" substitutionGroup="xbrli:item" />
  <element name="CostOfServicesEngineeringServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_CostOfServicesEngineeringServices" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element id="eyen_ConsultingAgreementPaymentPerhour" name="ConsultingAgreementPaymentPerhour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="LeaseMonthlyBaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_LeaseMonthlyBaseRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="RoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_RoyaltyPercentage" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceOneMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTwoMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceThreeMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFourMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFiveMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSixMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSevenMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceEightMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceNineMemberMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceNineMemberMember" substitutionGroup="xbrli:item" />
  <element name="ExercisePriceTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTenMember" substitutionGroup="xbrli:item" />
  <element id="eyen_AccruedFranchiseTax" name="AccruedFranchiseTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" name="GrossProceedsOfStockValueIssuedDuringPeriod" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_AccruedTravelAndEntertainmentExpenses" name="AccruedTravelAndEntertainmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" name="StockIssuedDuringPeriodValueExercisesOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" name="StockIssuedDuringPeriodSharesExercisesOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_CommonStockOneMember" name="CommonStockOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_CommonStockTwoMember" name="CommonStockTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ProceedsFromSaleOfCommonStockInIPO2" name="ProceedsFromSaleOfCommonStockInIPO2" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" name="PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_ExerciseOfWarrantsOnACashlessBasis" name="ExerciseOfWarrantsOnACashlessBasis" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" name="ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_OperatingLossCarryForwardsExpirationTerm" name="OperatingLossCarryForwardsExpirationTerm" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_OperatingLeasesMonthlyRentalPayments" name="OperatingLeasesMonthlyRentalPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_ConsultingAgreementPaymentPermonth" name="ConsultingAgreementPaymentPermonth" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" name="EmployeesConsultantsAndDirectorsUnder2018PlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_OmnibusStockIncentivePlan2018Member" name="OmnibusStockIncentivePlan2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" name="SeriesAndSeriesA2ConvertiblePreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_PaymentsForRepurchaseOfPublicOffering" name="PaymentsForRepurchaseOfPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_RePrioritizationOfOverallCostSavings" name="RePrioritizationOfOverallCostSavings" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_AccruedPurchasesOfLeaseholdImprovements" name="AccruedPurchasesOfLeaseholdImprovements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_CommonStockThreeMember" name="CommonStockThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_StockIssuedDuringPeriodValueNewIssuesThree" name="StockIssuedDuringPeriodValueNewIssuesThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" name="StockIssuedDuringPeriodSharesNewIssuesThree" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_LeaseholdImprovements" name="LeaseholdImprovements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" name="NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" name="NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_RemittanceOfEmployeeSPayrollTaxes" name="RemittanceOfEmployeeSPayrollTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_LiquidityAndGoingConcernTextBlock" name="LiquidityAndGoingConcernTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" name="DeferredTaxAssetsLiabilityPropertyAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" name="DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="eyen_NumberOfShare" name="NumberOfShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_PurchaseTermOfWarrant" name="PurchaseTermOfWarrant" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="eyen_ClassWarrantMember" name="ClassWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_ClassBWarrantMember" name="ClassBWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_NumberOfUnitsSold" name="NumberOfUnitsSold" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="eyen_DirectorsAndExecutiveOfficersMember" name="DirectorsAndExecutiveOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" name="MaximumNumberOfWarrantsToPurchaseCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eyen-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:46 PM-->
<!--Modified on: 3/30/2020 8:33:46 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" />
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637211972259243225" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637211972259243225" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637211972259253231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637211972259243225" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637211972259253231" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972259253231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637211972259243225" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972259253231" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637211972259253231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637211972259253231" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637211972259253231" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_637211972259253231" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637211972259343396" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637211972259343396" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637211972259343396" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637211972259343396" xlink:to="us-gaap_LiabilitiesCurrent_637211972259343396" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637211972259343396" xlink:to="us-gaap_AccountsPayableCurrent_637211972259353399" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637211972259343396" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637211972259353399" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637211972259343396" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637211972259353399" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637211972259343396" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637211972259353399" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637211972259353399" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637211972259353399" xlink:to="us-gaap_PreferredStockValue_637211972259353399" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637211972259353399" xlink:to="us-gaap_CommonStockValue_637211972259353399" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637211972259353399" xlink:to="us-gaap_AdditionalPaidInCapital_637211972259353399" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637211972259353399" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637211972259353399" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637211972259353399" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637211972259363407" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637211972259363407" xlink:to="us-gaap_OperatingExpenses_637211972259363407" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637211972259363407" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637211972259363407" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637211972259363407" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637211972259363407" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637211972259363407" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_NetIncomeLoss_637211972259363407" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637211972259363407" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_ShareBasedCompensation_637211972259363407" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637211972259363407" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637211972259363407" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637211972259363407" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637211972259363407" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637211972259363407" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972259363407" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637211972259363407" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637211972259363407" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637211972259363407" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637211972259363407" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637211972259373328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637211972259373328" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_637211972259393351" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972259393351" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637211972259393351" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637211972259393351" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsFromSaleOfCommonStockInIPO2" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="eyen_ProceedsFromSaleOfCommonStockInIPO2_637211972259393351" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972259363407" xlink:to="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_637211972259393351" order="7" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637211972259393351" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PayrollTaxesReceivable_637211972259393351" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637211972259393351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidConferenceExpenses_637211972259393351" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637211972259403359" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidPatentExpense_637211972259403359" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637211972259403359" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssets_637211972259403359" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637211972259403359" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637026734627435437" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637211972259403359" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637211972259403359" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_LeaseholdImprovements_637211972259403359" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_CreditCardPayable_637211972259403359" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedFranchiseTax_637211972259403359" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_637211972259403359" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637211972259403359" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="eyen_AccruedLegalExpensesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedLegalExpensesCurrent_637211972259403359" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637211972259403359" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637211972259403359" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637211972259403359" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637211972259403359" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Income Taxes - provision for income taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972259413356" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972259413356" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637211972259413356" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972259413356" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637211972259413356" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637026734627435437" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637211972259413356" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsGross_637211972259413356" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637211972259413356" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637211972259413356" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637211972259413356" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637211972259413356" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637211972259413356" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637211972259413356" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637211972259413356" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637211972259413356" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637211972259413356" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637211972259413356" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637211972259413356" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637211972259413356" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637211972259413356" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637211972259413356" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637211972259413356" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637211972259413356" order="4" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eyen-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:46 PM-->
<!--Modified on: 3/30/2020 8:33:46 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementCondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637211972259793615" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637211972259793615" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="eyen_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesA2ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="eyen_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637211972259793615" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637211972259793615" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_CommonStockThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_CommonStockThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637211972259933729" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637211972259933729" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972259933729" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972259933729" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637211972259943729" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637211972259943729" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RePrioritizationOfOverallCostSavings" xlink:label="eyen_RePrioritizationOfOverallCostSavings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RePrioritizationOfOverallCostSavings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972259943729" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972259943729" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637211972259953737" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637211972259953737" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="us-gaap_MalpracticeLossContingencyInsuranceRecoveries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MalpracticeLossContingencyInsuranceRecoveries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OperatingLeasesMonthlyRentalPayments" xlink:label="eyen_OperatingLeasesMonthlyRentalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_OperatingLeasesMonthlyRentalPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637211972259973743" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637211972259973743" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="eyen_CuraPartnersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637211972259983751" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637211972259983751" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637211972259983751" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_637211972259983751" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_ConsultingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_SenjuPharmaceuticalCoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637211972259993760" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_637211972259993760" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="eyen_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ConsultingAgreementPaymentPermonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ConsultingAgreementPaymentPerhour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_CostOfServicesEngineeringServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LeaseMonthlyBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OfficersCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RoyaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637211972260023780" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_637211972260023780" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260033785" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260033785" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceEightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceNineMemberMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceElevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="eyen_SeriesConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="eyen_SeriesBConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesBConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637211972260063814" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637211972260063814" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_OmnibusStockIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EquityIncentivePlanMember" xlink:label="eyen_EquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_EquityIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637211972260063814" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_637211972260063814" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260073814" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260073814" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637211972260163879" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637211972260163879" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassWarrantMember" xlink:label="eyen_ClassWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_ClassWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassBWarrantMember" xlink:label="eyen_ClassBWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_ClassBWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eyen_DirectorsAndExecutiveOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfShare" xlink:label="eyen_NumberOfShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NumberOfShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PurchaseTermOfWarrant" xlink:label="eyen_PurchaseTermOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_PurchaseTermOfWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfUnitsSold" xlink:label="eyen_NumberOfUnitsSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NumberOfUnitsSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" xlink:label="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eyen-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:46 PM-->
<!--Modified on: 3/30/2020 8:33:46 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Workers' Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2019 and 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 90,000,000 shares authorized; 17,100,726 and 11,468,996 shares issued and outstanding as of December 31, 2019 and 2018, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">- Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">- Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesOne" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Stock issuance of common stock one value on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne_lbl" xml:lang="en-US">Issuance of common stock in initial public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Stock issuance of common stock one shares on public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_lbl" xml:lang="en-US">Issuance of common stock in initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">This represents Stock Issued During Period Value New Issues three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">This represents common stock issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock one shares on public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock in follow-on public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock two value on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock in follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" xlink:to="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_lbl" xml:lang="en-US">Exercises of warrants on cash basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Value Exercises Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_lbl" xml:lang="en-US">Exercise of warrants on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Stock exercises of warrant on cashless basis shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Shares Exercises Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Exercise of warrants on a cashless basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options on cashless basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Number of share options (or share units) exercised on cashless basis during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Exercises in Period On Cashless Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised | Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:to="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Stock Issued During Period Value Conversion Of Convertible Securities upon initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Stock Issued During Period Value Conversion Of Convertible Securities upon initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon completion of initial public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:to="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Convertible Securities upon initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Convertible Securities upon initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_lbl" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon completion of initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockOneMember" xlink:to="eyen_CommonStockOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockOneMember_lbl" xml:lang="en-US">Common Stock One [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockTwoMember" xlink:to="eyen_CommonStockTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockTwoMember_lbl" xml:lang="en-US">Common Stock Two [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">Proceeds Of Stock Issued During Period Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IncreaseDecreaseInDeferredRent" xlink:to="eyen_IncreaseDecreaseInDeferredRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Increase Decrease in Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from sale of common stock in initial public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payment of initial public offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsFromSaleOfCommonStockInIPO2" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsFromSaleOfCommonStockInIPO2" xlink:to="eyen_ProceedsFromSaleOfCommonStockInIPO2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2_lbl" xml:lang="en-US">Cash inflow of sale of common stock in follow on IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2_lbl" xml:lang="en-US">Proceeds from sale of common stock In IPO 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2_lbl" xml:lang="en-US">Proceeds from sale of common stock in follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" xlink:to="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Cash out flows of follow on IPO issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payments Of Follow on Repurchase Of Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payment of follow-on public offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentsForRepurchaseOfPublicOffering" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payments for Repurchase of Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payment of public offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (Decrease) Increase in Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents - End of Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and Cash Equivalents - Beginning of Year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:to="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">This represents accrued purchases of leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">Accrued Purchases of Leasehold Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_lbl" xml:lang="en-US">Accrued purchases of leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExerciseOfWarrantsOnACashlessBasis" xlink:label="eyen_ExerciseOfWarrantsOnACashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExerciseOfWarrantsOnACashlessBasis" xlink:to="eyen_ExerciseOfWarrantsOnACashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExerciseOfWarrantsOnACashlessBasis_lbl" xml:lang="en-US">The value of the warrants exercised on a cashless basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExerciseOfWarrantsOnACashlessBasis_lbl" xml:lang="en-US">Exercise Of Warrants On A Cashless Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExerciseOfWarrantsOnACashlessBasis_lbl" xml:lang="en-US">Exercise of warrants on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Conversion of convertible preferred stock into common stock</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentOfAccruedIssuanceCosts" xlink:label="eyen_PaymentOfAccruedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentOfAccruedIssuanceCosts" xlink:to="eyen_PaymentOfAccruedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentOfAccruedIssuanceCosts_lbl" xml:lang="en-US">The amount of stock issuance costs that were incurred during a noncash or partial noncash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentOfAccruedIssuanceCosts_lbl" xml:lang="en-US">Payment Of Accrued Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PaymentOfAccruedIssuanceCosts_lbl" xml:lang="en-US">Reversal of previously accrued initial public offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" xlink:label="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" xlink:to="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_lbl" xml:lang="en-US">It represents of reclassified to additional paid in capital for IPO issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_lbl" xml:lang="en-US">Reclassification to additional paid in capital for IPO issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_lbl" xml:lang="en-US">Reclassification to additional paid-in capital for initial public offering issuance costs that were previously paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CommonStockThreeMember" xlink:to="eyen_CommonStockThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">This represents common stock three member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">Common Stock Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CommonStockThreeMember_lbl" xml:lang="en-US">Common Stock Three [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business Organization and Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Organization and Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, General [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LiquidityAndGoingConcernTextBlock" xlink:label="eyen_LiquidityAndGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LiquidityAndGoingConcernTextBlock" xlink:to="eyen_LiquidityAndGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for liquidity and going concern.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive weighted average diluted common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Disclosure of Accrued compensation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum operating lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes option pricing model to stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of the stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of information related to stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed To Issuers Equity Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RePrioritizationOfOverallCostSavings" xlink:label="eyen_RePrioritizationOfOverallCostSavings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RePrioritizationOfOverallCostSavings" xlink:to="eyen_RePrioritizationOfOverallCostSavings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RePrioritizationOfOverallCostSavings_lbl" xml:lang="en-US">Represent the re-prioritization of its programs will yield overall cost savings for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RePrioritizationOfOverallCostSavings_lbl" xml:lang="en-US">Re-Prioritization Of Overall Cost Savings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_RePrioritizationOfOverallCostSavings_lbl" xml:lang="en-US">Overall cost savings due to re-prioritization of programs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_lbl" xml:lang="en-US">Deferred Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PayrollTaxesReceivable" xlink:to="eyen_PayrollTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Amount of Payroll Taxes Receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidResearchAndDevelopmentExpenses" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research &amp; development expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidPatentExpense" xlink:to="eyen_PrepaidPatentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for patent expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Prepaid Patent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Prepaid patent expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidConferenceExpenses" xlink:to="eyen_PrepaidConferenceExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Amount of assets related to prepaid conference expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidRentAndSecurityDeposit" xlink:to="eyen_PrepaidRentAndSecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid Rent and Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid rent and security deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property Plant And Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Amount of accrued research and development expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional services</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CreditCardPayable" xlink:to="eyen_CreditCardPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Amount of credit card expenses payable by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit Card payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit card payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LeaseholdImprovements" xlink:to="eyen_LeaseholdImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">This represents accrued purchases balances of Leasehold improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LeaseholdImprovements_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedFranchiseTax" xlink:to="eyen_AccruedFranchiseTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Amount of accrued franchise tax expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued Franchise Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued franchise tax</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedTravelAndEntertainmentExpenses" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Amount of accrued travel and entertainment expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Accrued Travel And Entertainment Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_lbl" xml:lang="en-US">Accrued travel and entertainment expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="eyen_AccruedLegalExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedLegalExpensesCurrent" xlink:to="eyen_AccruedLegalExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedLegalExpensesCurrent_lbl" xml:lang="en-US">Amount of accrued legal expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedLegalExpensesCurrent_lbl" xml:lang="en-US">Accrued legal expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedLegalExpensesCurrent_lbl" xml:lang="en-US">Accrued legal expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonus expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred tax provision (benefit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State and local</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Amount of deferred income tax expense (benefit) before adjustments for change in valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit) Before Adjustments for Change in Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research &amp; development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Prior period adjustments and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Deferred Tax Assets (liability), Property and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:to="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" xml:lang="en-US">This represents amount of net operating loss limit of usage determined by the Internal revenue code.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_lbl" xml:lang="en-US">Net Operating Loss Limit for Utilization as per Internal Revenue Code</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:to="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" xml:lang="en-US">This represents Annual utilization limit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_lbl" xml:lang="en-US">Net Operating Loss Annual Utilization Limit as per Internal Revenue Code</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OperatingLossCarryForwardsExpirationTerm" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OperatingLossCarryForwardsExpirationTerm" xlink:to="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" xml:lang="en-US">The expiry term of carryforward operating losses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_lbl" xml:lang="en-US">Operating Loss Carry forwards Expiration Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="us-gaap_MalpracticeLossContingencyInsuranceRecoveries" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:to="us-gaap_MalpracticeLossContingencyInsuranceRecoveries_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MalpracticeLossContingencyInsuranceRecoveries_lbl" xml:lang="en-US">Malpractice Loss Contingency, Insurance Recoveries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualPayments" xlink:to="us-gaap_LossContingencyAccrualPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xml:lang="en-US">Loss Contingency Accrual, Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:to="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_lbl" xml:lang="en-US">Malpractice Loss Contingency, Claims Incurred in Period</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OperatingLeasesMonthlyRentalPayments" xlink:label="eyen_OperatingLeasesMonthlyRentalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OperatingLeasesMonthlyRentalPayments" xlink:to="eyen_OperatingLeasesMonthlyRentalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OperatingLeasesMonthlyRentalPayments_lbl" xml:lang="en-US">The amount of the monthly rental payments under operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OperatingLeasesMonthlyRentalPayments_lbl" xml:lang="en-US">Operating Leases Monthly Rental Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_lbl" xml:lang="en-US">Supplemental Unemployment Benefits, Salary Continuation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementPaymentPermonth" xlink:to="eyen_ConsultingAgreementPaymentPermonth_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">It represents monthly consulting fee expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">Consulting agreement payment, Permonth</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ConsultingAgreementPaymentPermonth_lbl" xml:lang="en-US">Consulting agreement payment, Per month</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementPaymentPerhour" xlink:to="eyen_ConsultingAgreementPaymentPerhour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">It represents hourly consulting fee expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">Consulting agreement payment, Per hour</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ConsultingAgreementPaymentPerhour_lbl" xml:lang="en-US">Consulting agreement payment, Per hour</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CostOfServicesEngineeringServices" xlink:to="eyen_CostOfServicesEngineeringServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CostOfServicesEngineeringServices_lbl" xml:lang="en-US">Represent the cost of services engineering services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CostOfServicesEngineeringServices_lbl" xml:lang="en-US">Cost Of Services Engineering Services</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LeaseMonthlyBaseRent" xlink:to="eyen_LeaseMonthlyBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">The base rent per month for lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">Lease, Monthly Base Rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Officers' Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Due to Related Parties</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RoyaltyPercentage" xlink:to="eyen_RoyaltyPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">It represents the percentage rate of royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Minority Interest Ownership Percentage In Company</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for Rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable | Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding | $</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceOneMember" xlink:to="eyen_ExercisePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price 1.24 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwoMember" xlink:to="eyen_ExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price 1.95 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceThreeMember" xlink:to="eyen_ExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price 2.74 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFourMember" xlink:to="eyen_ExercisePriceFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price 3.11 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFiveMember" xlink:to="eyen_ExercisePriceFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price 4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSixMember" xlink:to="eyen_ExercisePriceSixMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price 5.10 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSevenMember" xlink:to="eyen_ExercisePriceSevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price 5.19 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceEightMember" xlink:to="eyen_ExercisePriceEightMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price 5.25 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceNineMemberMember" xlink:to="eyen_ExercisePriceNineMemberMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceNineMemberMember_lbl" xml:lang="en-US">Exercise Price Nine Member [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceNineMemberMember_lbl" xml:lang="en-US">Exercise Price 6.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTenMember" xlink:to="eyen_ExercisePriceTenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price 6.30 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceElevenMember" xlink:to="eyen_ExercisePriceElevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price 8.72 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Outstanding, Outstanding Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Life In Years</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetProceedsFromIssuanceOfCommonStock" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The cash inflow from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_lbl" xml:lang="en-US">Gross Proceeds Of Stock Value Issued During Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" xml:lang="en-US">This represents company remitted portion of employee's payroll taxes to internal revenue service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_lbl" xml:lang="en-US">Remittance of employee's Payroll Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DirectorsAndExecutiveOfficersMember" xlink:to="eyen_DirectorsAndExecutiveOfficersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_lbl" xml:lang="en-US">The member stands for directors and executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_lbl" xml:lang="en-US">Directors And Executive Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_lbl" xml:lang="en-US">Directors and Executive Officers [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability_lbl" xml:lang="en-US">Securities Purchased under Agreements to Resell, Liability</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfShare" xlink:label="eyen_NumberOfShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfShare" xlink:to="eyen_NumberOfShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfShare_lbl" xml:lang="en-US">The value represents number of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfShare_lbl" xml:lang="en-US">Number of Share</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PurchaseTermOfWarrant" xlink:label="eyen_PurchaseTermOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PurchaseTermOfWarrant" xlink:to="eyen_PurchaseTermOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PurchaseTermOfWarrant_lbl" xml:lang="en-US">The Period Purchase term of warrant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PurchaseTermOfWarrant_lbl" xml:lang="en-US">Purchase Term of Warrant</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfUnitsSold" xlink:label="eyen_NumberOfUnitsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfUnitsSold" xlink:to="eyen_NumberOfUnitsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfUnitsSold_lbl" xml:lang="en-US">The value represents number of units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfUnitsSold_lbl" xml:lang="en-US">Number of Units Sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" xlink:label="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" xlink:to="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">The Value represents Maximum  Number of  Warrants To Purchase Common Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Maximum Number of Warrants To Purchase Common Stock</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="eyen_SeriesConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SeriesConvertiblePreferredStockMember" xlink:to="eyen_SeriesConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SeriesConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesA2ConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SeriesA2ConvertiblePreferredStockMember" xlink:to="eyen_SeriesA2ConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A-2 Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="eyen_SeriesBConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SeriesBConvertiblePreferredStockMember" xlink:to="eyen_SeriesBConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CuraPartnersMember" xlink:to="eyen_CuraPartnersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CuraPartnersMember_lbl" xml:lang="en-US">Cura Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_CuraPartnersMember_lbl" xml:lang="en-US">Cura Partners [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ConsultingAgreementMember" xlink:to="eyen_ConsultingAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President Of Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President of Research and Development [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SenjuPharmaceuticalCoMember" xlink:to="eyen_SenjuPharmaceuticalCoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SenjuPharmaceuticalCoMember_lbl" xml:lang="en-US">Senju Pharmaceutical Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SenjuPharmaceuticalCoMember_lbl" xml:lang="en-US">Senju Pharmaceutical Co [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementMember" xlink:to="eyen_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">This member stands for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:to="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series And Series A2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series And Series A2 Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">This member stands for employees consultants and directors under the 2018 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">Employees Consultants And Directors Under2018 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_lbl" xml:lang="en-US">Employees Consultants and Directors Under the 2018 Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OmnibusStockIncentivePlan2018Member" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">The member stands for omnibus stock incentive plan 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">Omnibus Stock Incentive Plan2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">Omnibus Stock Incentive Plan 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EquityIncentivePlanMember" xlink:label="eyen_EquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_EquityIncentivePlanMember" xlink:to="eyen_EquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_EquityIncentivePlanMember_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_EquityIncentivePlanMember_lbl" xml:lang="en-US">Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_EquityIncentivePlanMember_lbl" xml:lang="en-US">Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassWarrantMember" xlink:label="eyen_ClassWarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassWarrantMember" xlink:to="eyen_ClassWarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassWarrantMember_lbl" xml:lang="en-US">The member stands for Class A Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassWarrantMember_lbl" xml:lang="en-US">Class Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassWarrantMember_lbl" xml:lang="en-US">Class A Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassBWarrantMember" xlink:label="eyen_ClassBWarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassBWarrantMember" xlink:to="eyen_ClassBWarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassBWarrantMember_lbl" xml:lang="en-US">The member stands for Class B  Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassBWarrantMember_lbl" xml:lang="en-US">Class B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassBWarrantMember_lbl" xml:lang="en-US">Class B Warrant [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eyen-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.5.2.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2020 8:33:46 PM-->
<!--Modified on: 3/30/2020 8:33:46 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#StatementCondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureBusinessOrganizationAndNatureOfOperations" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedCompensation" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxes" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSubsequentEvents" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedCompensationTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureBusinessOrganizationAndNatureOfOperationsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20191231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637211972260374036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637211972260374036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637211972260394041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637211972260394041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637211972260394041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637211972260394041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637211972260404050" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637211972260404050" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637211972260404050" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637211972260404050" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637211972260404050" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637211972260404050" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637211972260404050" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637211972260404050" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637211972260404050" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637211972260404050" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637211972260404050" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637211972260404050" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637211972260404050" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637211972260404050" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637211972260404050" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637211972260404050" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637211972260404050" order="20" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_637211972260404050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637211972260404050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637211972260404050" xlink:to="us-gaap_AssetsCurrentAbstract_637211972260404050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637211972260404050" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637211972260414055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637211972260404050" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637211972260404050" xlink:to="us-gaap_AssetsCurrent_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637211972260404050" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637211972260404050" xlink:to="us-gaap_SecurityDeposit_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637211972260404050" xlink:to="us-gaap_Assets_637211972260414055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" xlink:to="us-gaap_AccountsPayableCurrent_637211972260414055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637211972260414055" xlink:to="us-gaap_LiabilitiesCurrent_637211972260414055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_Liabilities_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_StockholdersEquityAbstract_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_PreferredStockValue_637211972260414055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_CommonStockValue_637211972260414055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_AdditionalPaidInCapital_637211972260414055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637211972260414055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637211972260414055" xlink:to="us-gaap_StockholdersEquity_637211972260414055" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637211972260414055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637211972260414055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_98" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesAuthorized_637211972260424061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesIssued_637211972260424061" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesOutstanding_637211972260424061" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637211972260424061" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesAuthorized_637211972260424061" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesIssued_637211972260424061" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesOutstanding_637211972260424061" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_143" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingExpensesAbstract_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637211972260424061" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637211972260424061" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637211972260424061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637211972260424061" xlink:to="us-gaap_OperatingExpenses_637211972260424061" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingIncomeLoss_637211972260424061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637211972260424061" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637211972260424061" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NetIncomeLoss_637211972260424061" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637211972260424061" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637211972260424061" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637211972260424061" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637211972260424061" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260424061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" xlink:to="us-gaap_StatementTable_637211972260424061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260424061" xlink:to="us-gaap_StatementClassOfStockAxis_637211972260434070" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="eyen_SeriesConvertiblePreferredStockMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260434070" xlink:to="eyen_SeriesConvertiblePreferredStockMember_637211972260434070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesA2ConvertiblePreferredStockMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260434070" xlink:to="eyen_SeriesA2ConvertiblePreferredStockMember_637211972260434070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="eyen_SeriesBConvertiblePreferredStockMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260434070" xlink:to="eyen_SeriesBConvertiblePreferredStockMember_637211972260434070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260434070" xlink:to="us-gaap_ClassOfStockDomain_637211972260434070" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260424061" xlink:to="us-gaap_StatementEquityComponentsAxis_637211972260434070" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260434070" xlink:to="us-gaap_CommonStockMember_637211972260434070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260434070" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637211972260434070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260434070" xlink:to="us-gaap_RetainedEarningsMember_637211972260434070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260434070" xlink:to="us-gaap_EquityComponentDomain_637211972260434070" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260424061" xlink:to="us-gaap_StatementLineItems_637211972260434070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_StockholdersEquity_637211972260434070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_SharesOutstanding_637211972260434070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesOne_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesOne_637211972260434070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesOne" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesOne_637211972260434070" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637211972260434070" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637211972260434070" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637211972260434070" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637211972260434070" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueExercisesOfWarrants_637211972260434070" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_637211972260434070" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis" xlink:label="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_637211972260434070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis_637211972260434070" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637211972260444075" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637211972260444075" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_NetIncomeLoss_637211972260444075" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637211972260444075" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637211972260444075" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260444075" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_637211972260444075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering_637211972260444075" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering" xlink:label="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_637211972260454087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering_637211972260454087" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637211972260454087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_StockholdersEquity_637211972260454087" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637211972260454087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260434070" xlink:to="us-gaap_SharesOutstanding_637211972260454087" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" xlink:to="us-gaap_StatementTable_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260464095" xlink:to="us-gaap_StatementEquityComponentsAxis_637211972260464095" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260464095" xlink:to="us-gaap_EquityComponentDomain_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260464095" xlink:to="eyen_CommonStockOneMember_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260464095" xlink:to="eyen_CommonStockTwoMember_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260464095" xlink:to="eyen_CommonStockThreeMember_637211972260464095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260464095" xlink:to="us-gaap_StatementLineItems_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260464095" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260464095" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_247" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_NetIncomeLoss_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_ShareBasedCompensation_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637211972260464095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637211972260464095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637211972260464095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637211972260464095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637211972260464095" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637211972260464095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637211972260464095" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637211972260464095" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637211972260464095" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637211972260474101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637211972260474101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637211972260474101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637211972260474101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637211972260474101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_637211972260474101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsFromSaleOfCommonStockInIPO2" xlink:label="eyen_ProceedsFromSaleOfCommonStockInIPO2_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="eyen_ProceedsFromSaleOfCommonStockInIPO2_637211972260474101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering" xlink:label="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering_637211972260474101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972260474101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637211972260474101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637211972260474101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637211972260474101" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637211972260474101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637211972260474101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637211972260474101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6372119722604741011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6372119722604741011" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedPurchasesOfLeaseholdImprovements" xlink:label="eyen_AccruedPurchasesOfLeaseholdImprovements_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="eyen_AccruedPurchasesOfLeaseholdImprovements_637211972260484107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExerciseOfWarrantsOnACashlessBasis" xlink:label="eyen_ExerciseOfWarrantsOnACashlessBasis_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="eyen_ExerciseOfWarrantsOnACashlessBasis_637211972260484107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="us-gaap_StockIssued1_637211972260484107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="us-gaap_ConversionOfStockAmountIssued1_637211972260484107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PaymentOfAccruedIssuanceCosts" xlink:label="eyen_PaymentOfAccruedIssuanceCosts_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="eyen_PaymentOfAccruedIssuanceCosts_637211972260484107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts" xlink:label="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637211972260474101" xlink:to="eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts_637211972260484107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_277" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_277" xlink:to="us-gaap_StatementTable_637211972260484107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260484107" xlink:to="us-gaap_StatementClassOfStockAxis_637211972260484107" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260484107" xlink:to="us-gaap_ClassOfStockDomain_637211972260484107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockOneMember" xlink:label="eyen_CommonStockOneMember_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260484107" xlink:to="eyen_CommonStockOneMember_637211972260484107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockTwoMember" xlink:label="eyen_CommonStockTwoMember_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260484107" xlink:to="eyen_CommonStockTwoMember_637211972260484107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CommonStockThreeMember" xlink:label="eyen_CommonStockThreeMember_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260484107" xlink:to="eyen_CommonStockThreeMember_637211972260484107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260484107" xlink:to="us-gaap_StatementLineItems_637211972260484107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260484107" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260484107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637211972260484107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260484107" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637211972260484107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization and Nature of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment, Net">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627243880" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627243880" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses and Other Current Liabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368361" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368361" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10701 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627253889" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637211972260494115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627253889" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637211972260494115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10901 - Disclosure - Related Party Transactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_14" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_14" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11001 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_17" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11101 - Disclosure - Employee Benefit Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_20" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_20" xlink:to="us-gaap_SubsequentEventsTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LiquidityAndGoingConcernTextBlock" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="eyen_LiquidityAndGoingConcernTextBlock_637211972260504121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_UseOfEstimates_637211972260504121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637211972260504121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637211972260504121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637211972260504121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_637211972260504121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_637211972260504121" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_637211972260514124" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637211972260514124" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637211972260514124" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637211972260514124" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637211972260514124" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637211972260514124" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_637211972260514124" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637211972260514124" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637211972260514124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637211972260514124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637211972260524132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637211972260524132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment, Net (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627283917" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637211972260524132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627283917" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637211972260524132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_65" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637211972260524132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_65" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637211972260524132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368364" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368364" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_637211972260534144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637211972260534144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637211972260534144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637211972260534144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627293926" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627293926" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637211972260534144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224653" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637211972260534144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637211972260534144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637211972260534144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Business Organization and Nature of Operations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="dei_EntityIncorporationStateCountryCode_637211972260534144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation_637211972260534144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="dei_EntityIncorporationDateOfIncorporation_637211972260534144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68" xlink:to="us-gaap_StatementTable_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260544267" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637211972260544267" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637211972260544267" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637211972260544267" xlink:to="us-gaap_EmployeeStockOptionMember_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260544267" xlink:to="us-gaap_AwardTypeAxis_637211972260544267" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637211972260544267" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260544267" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260544267" xlink:to="us-gaap_StatementLineItems_637211972260544267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260544267" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83" xlink:to="us-gaap_StatementTable_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260544267" xlink:to="srt_RangeAxis_637211972260544267" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637211972260544267" xlink:to="srt_RangeMember_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260544267" xlink:to="srt_MaximumMember_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260544267" xlink:to="srt_MinimumMember_637211972260544267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260544267" xlink:to="us-gaap_StatementLineItems_637211972260544267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RePrioritizationOfOverallCostSavings" xlink:label="eyen_RePrioritizationOfOverallCostSavings_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260544267" xlink:to="eyen_RePrioritizationOfOverallCostSavings_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260544267" xlink:to="us-gaap_CashUninsuredAmount_637211972260544267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="us-gaap_DeferredCostsCurrentAndNoncurrent_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260544267" xlink:to="us-gaap_DeferredCostsCurrentAndNoncurrent_637211972260544267" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260544267" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637211972260544267" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PayrollTaxesReceivable_637211972260544267" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidInsurance_637211972260544267" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637211972260544267" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637211972260544267" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidPatentExpense_637211972260554269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidConferenceExpenses_637211972260554269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637211972260554269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_OtherAssets_637211972260554269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637211972260554269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627414064" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627414064" xlink:to="us-gaap_StatementTable_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260554269" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637211972260554269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637211972260554269" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972260554269" xlink:to="us-gaap_EquipmentMember_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637211972260554269" xlink:to="us-gaap_LeaseholdImprovementsMember_637211972260554269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260554269" xlink:to="us-gaap_StatementLineItems_637211972260554269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637211972260554269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637211972260554269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637026734627435437" xlink:to="us-gaap_StatementTable_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260554269" xlink:to="us-gaap_FairValueByAssetClassAxis_637211972260554269" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis_637211972260554269" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_637211972260554269" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260554269" xlink:to="us-gaap_StatementLineItems_637211972260554269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637211972260554269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637211972260554269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637211972260554269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260554269" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637211972260554269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_122" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637211972260564269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637211972260564269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_CreditCardPayable_637211972260564269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseholdImprovements" xlink:label="eyen_LeaseholdImprovements_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_LeaseholdImprovements_637211972260564269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedFranchiseTax_637211972260564269" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedTravelAndEntertainmentExpenses" xlink:label="eyen_AccruedTravelAndEntertainmentExpenses_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedTravelAndEntertainmentExpenses_637211972260564269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="eyen_AccruedLegalExpensesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedLegalExpensesCurrent_637211972260564269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637211972260564269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637211972260564269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368367" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedBonusesCurrent_637211972260564269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedSalariesCurrent_637211972260564269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637211972260564269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Income Taxes - provision for income taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637211972260564269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637211972260564269" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637211972260564269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637211972260564269" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637211972260564269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_637211972260564269" xlink:to="eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_637211972260564269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637211972260564269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637211972260564269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637211972260564269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637211972260564269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637211972260574281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_637211972260574281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637211972260574281" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_637211972260574281" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637211972260574281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637211972260574281" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637211972260574281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637211972260574281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment" xlink:label="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment_637211972260574281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637211972260574281" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_637211972260574281" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsGross_637211972260574281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637211972260574281" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637211972260574281" xlink:to="us-gaap_DeferredTaxAssetsNet_637211972260574281" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Income Taxes - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_OperatingLossCarryforwards_637211972260574281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode_637211972260574281" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode" xlink:label="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode_637211972260574281" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OperatingLossCarryForwardsExpirationTerm" xlink:label="eyen_OperatingLossCarryForwardsExpirationTerm_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="eyen_OperatingLossCarryForwardsExpirationTerm_637211972260574281" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_637211972260574281" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_637211972260574281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637026734627435437" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_637211972260574281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637211972260584280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637211972260584280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637211972260584280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_637211972260584280" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637211972260584280" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_StatementTable_637211972260584280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260584280" xlink:to="srt_RangeAxis_637211972260584280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637211972260584280" xlink:to="srt_RangeMember_637211972260584280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260584280" xlink:to="srt_MinimumMember_637211972260584280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260584280" xlink:to="srt_MaximumMember_637211972260584280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260584280" xlink:to="us-gaap_StatementLineItems_637211972260584280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_637211972260584280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="us-gaap_MalpracticeLossContingencyInsuranceRecoveries_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_MalpracticeLossContingencyInsuranceRecoveries_637211972260584280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_NetRentableArea_637211972260584280" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_637211972260584280" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_SecurityDeposit_637211972260584280" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_LeaseExpirationDate1_637211972260584280" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:label="us-gaap_LossContingencyAccrualPayments_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_LossContingencyAccrualPayments_637211972260584280" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod" xlink:label="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod_637211972260584280" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OperatingLeasesMonthlyRentalPayments" xlink:label="eyen_OperatingLeasesMonthlyRentalPayments_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="eyen_OperatingLeasesMonthlyRentalPayments_637211972260584280" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_637211972260584280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_SeveranceCosts1_637211972260584280" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260584280" xlink:to="us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_637211972260594292" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_161" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_161" xlink:to="us-gaap_StatementTable_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260594292" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637211972260594292" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637211972260594292" xlink:to="us-gaap_RelatedPartyDomain_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CuraPartnersMember" xlink:label="eyen_CuraPartnersMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637211972260594292" xlink:to="eyen_CuraPartnersMember_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260594292" xlink:to="us-gaap_IncomeStatementLocationAxis_637211972260594292" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637211972260594292" xlink:to="us-gaap_IncomeStatementLocationDomain_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637211972260594292" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637211972260594292" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637211972260594292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260594292" xlink:to="us-gaap_RelatedPartyTransactionAxis_637211972260594292" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637211972260594292" xlink:to="us-gaap_RelatedPartyTransactionDomain_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementMember" xlink:label="eyen_ConsultingAgreementMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637211972260594292" xlink:to="eyen_ConsultingAgreementMember_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637211972260594292" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_637211972260594292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637211972260594292" xlink:to="eyen_SenjuPharmaceuticalCoMember_637211972260594292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260594292" xlink:to="srt_OwnershipAxis_637211972260594292" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637211972260594292" xlink:to="srt_OwnershipDomain_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637211972260594292" xlink:to="eyen_LicenseAgreementMember_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260594292" xlink:to="us-gaap_StatementLineItems_637211972260594292" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637211972260594292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637211972260594292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="eyen_ConsultingAgreementPaymentPermonth_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="eyen_ConsultingAgreementPaymentPermonth_637211972260604289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="eyen_ConsultingAgreementPaymentPerhour_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="eyen_ConsultingAgreementPaymentPerhour_637211972260604289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_CostOfServicesEngineeringServices" xlink:label="eyen_CostOfServicesEngineeringServices_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="eyen_CostOfServicesEngineeringServices_637211972260604289" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_NetRentableArea_637211972260604289" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="eyen_LeaseMonthlyBaseRent_637211972260604289" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_LeaseAndRentalExpense_637211972260604289" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_SecurityDeposit_637211972260604289" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_OfficersCompensation_637211972260604289" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_LeaseholdImprovementsGross_637211972260604289" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_637211972260604289" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="eyen_RoyaltyPercentage_637211972260604289" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637211972260604289" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_637211972260604289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260594292" xlink:to="us-gaap_PaymentsForRent_637211972260604289" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224669" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224669" xlink:to="us-gaap_StatementTable_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260614297" xlink:to="srt_RangeAxis_637211972260614297" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637211972260614297" xlink:to="srt_RangeMember_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260614297" xlink:to="srt_MinimumMember_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260614297" xlink:to="srt_MaximumMember_637211972260614297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260614297" xlink:to="us-gaap_StatementLineItems_637211972260614297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637211972260614297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637211972260614297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637211972260614297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224721" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224721" xlink:to="us-gaap_StatementTable_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260614297" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_637211972260614297" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_637211972260614297" xlink:to="us-gaap_DerivativeContractTypeDomain_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_637211972260614297" xlink:to="us-gaap_StockOptionMember_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260614297" xlink:to="us-gaap_StatementLineItems_637211972260614297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637211972260614297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260614297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260614297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637211972260614297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637211972260614297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637211972260624326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637211972260624326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637211972260624326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260624326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637211972260624326" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637211972260624326" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6372119722606243261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6372119722606243261" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637211972260624326" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637211972260624326" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637211972260624326" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637211972260624326" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260614297" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637211972260624326" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_225356" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_225356" xlink:to="us-gaap_StatementTable_637211972260624326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260624326" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637211972260624326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637211972260624326" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceOneMember_637211972260624326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember_637211972260624326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceTwoMember_637211972260624326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceThreeMember_637211972260634338" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceFourMember_637211972260634338" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceFiveMember_637211972260634338" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceSixMember_637211972260634338" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceSevenMember_637211972260634338" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceEightMember_637211972260634338" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceNineMemberMember_637211972260634338" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceTenMember_637211972260634338" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637211972260624326" xlink:to="eyen_ExercisePriceElevenMember_637211972260634338" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260624326" xlink:to="us-gaap_StatementLineItems_637211972260634338" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637211972260634338" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260634338" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637211972260634338" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637211972260664346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260634338" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637211972260664346" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637211972260664346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260634338" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637211972260664346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637211972260664346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260634338" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637211972260664346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_202" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_202" xlink:to="us-gaap_StatementTable_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_StatementClassOfStockAxis_637211972260674357" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637211972260674357" xlink:to="us-gaap_ClassOfStockDomain_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="eyen_SeriesConvertiblePreferredStockMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260674357" xlink:to="eyen_SeriesConvertiblePreferredStockMember_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="eyen_SeriesBConvertiblePreferredStockMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260674357" xlink:to="eyen_SeriesBConvertiblePreferredStockMember_637211972260674357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637211972260674357" xlink:to="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_637211972260674357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_PlanNameAxis_637211972260674357" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637211972260674357" xlink:to="us-gaap_PlanNameDomain_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637211972260674357" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637211972260674357" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_637211972260674357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EquityIncentivePlanMember" xlink:label="eyen_EquityIncentivePlanMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637211972260674357" xlink:to="eyen_EquityIncentivePlanMember_637211972260674357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="srt_RangeAxis_637211972260674357" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637211972260674357" xlink:to="srt_RangeMember_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260674357" xlink:to="srt_MaximumMember_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637211972260674357" xlink:to="srt_MinimumMember_637211972260674357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_VestingAxis_637211972260674357" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637211972260674357" xlink:to="us-gaap_VestingDomain_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637211972260674357" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637211972260674357" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637211972260674357" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637211972260674357" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637211972260674357" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637211972260674357" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637211972260674357" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637211972260684360" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637211972260684360" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260684360" xlink:to="us-gaap_IPOMember_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260684360" xlink:to="us-gaap_OverAllotmentOptionMember_637211972260684360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_StatementEquityComponentsAxis_637211972260684360" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260684360" xlink:to="us-gaap_EquityComponentDomain_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260684360" xlink:to="us-gaap_CommonStockMember_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_AwardTypeAxis_637211972260684360" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637211972260684360" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_IncomeStatementLocationAxis_637211972260684360" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637211972260684360" xlink:to="us-gaap_IncomeStatementLocationDomain_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637211972260684360" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637211972260684360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637211972260684360" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637211972260684360" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260684360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260674357" xlink:to="us-gaap_StatementLineItems_637211972260684360" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637211972260694363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637211972260694363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_SharesIssuedPricePerShare_637211972260694363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637211972260694363" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637211972260694363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637211972260694363" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_637211972260694363" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_637211972260694363" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637211972260694363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637211972260694363" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_637211972260704260" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="eyen_GrossProceedsOfStockValueIssuedDuringPeriod_637211972260704260" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_637211972260704260" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637211972260704260" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260704260" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260704260" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensation_637211972260704260" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637211972260704260" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637211972260704260" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972260704260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637211972260704260" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260714266" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_637211972260714266" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637211972260714266" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637211972260714266" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637211972260714266" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637211972260714266" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_637211972260714266" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637211972260714266" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637211972260714266" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637211972260724397" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_637211972260724397" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_RemittanceOfEmployeeSPayrollTaxes" xlink:label="eyen_RemittanceOfEmployeeSPayrollTaxes_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="eyen_RemittanceOfEmployeeSPayrollTaxes_637211972260724397" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637211972260724397" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637211972260724397" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637211972260724397" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637211972260724397" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637211972260724397" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260684360" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_637211972260734394" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Employee Benefit Plans (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637211972260734394" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637211972260734394" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637211972260734394" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_233" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_233" xlink:to="us-gaap_StatementTable_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_SubsequentEventTypeAxis_637211972260734394" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637211972260734394" xlink:to="us-gaap_SubsequentEventTypeDomain_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637211972260734394" xlink:to="us-gaap_SubsequentEventMember_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_PlanNameAxis_637211972260734394" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637211972260734394" xlink:to="us-gaap_PlanNameDomain_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember" xlink:label="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637211972260734394" xlink:to="eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_VestingAxis_637211972260734394" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637211972260734394" xlink:to="us-gaap_VestingDomain_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637211972260734394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637211972260734394" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637211972260734394" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637211972260734394" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637211972260744412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_StatementEquityComponentsAxis_637211972260744412" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637211972260744412" xlink:to="us-gaap_EquityComponentDomain_637211972260744412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260744412" xlink:to="us-gaap_CommonStockMember_637211972260744412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassWarrantMember" xlink:label="eyen_ClassWarrantMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260744412" xlink:to="eyen_ClassWarrantMember_637211972260744412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_ClassBWarrantMember" xlink:label="eyen_ClassBWarrantMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637211972260744412" xlink:to="eyen_ClassBWarrantMember_637211972260744412" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637211972260744412" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637211972260744412" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260744412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260744412" xlink:to="us-gaap_IPOMember_637211972260744412" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637211972260744412" xlink:to="eyen_DirectorsAndExecutiveOfficersMember_637211972260744412" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637211972260734394" xlink:to="us-gaap_StatementLineItems_637211972260744412" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637211972260744412" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637211972260744412" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637211972260744412" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637211972260744412" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability" xlink:label="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability_637211972260744412" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfShare" xlink:label="eyen_NumberOfShare_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="eyen_NumberOfShare_637211972260744412" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_PurchaseTermOfWarrant" xlink:label="eyen_PurchaseTermOfWarrant_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="eyen_PurchaseTermOfWarrant_637211972260744412" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637211972260744412" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637211972260744412" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_NumberOfUnitsSold" xlink:label="eyen_NumberOfUnitsSold_637211972260754414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="eyen_NumberOfUnitsSold_637211972260754414" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637211972260754414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_637211972260754414" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637211972260754414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_CommonStockSharesIssued_637211972260754414" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20191231.xsd#eyen_MaximumNumberOfWarrantsToPurchaseCommonStock" xlink:label="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock_637211972260754414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="eyen_MaximumNumberOfWarrantsToPurchaseCommonStock_637211972260754414" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637211972260754414" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637211972260744412" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637211972260754414" order="13" use="optional" priority="2" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm205388-1_10kimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &, ;\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\]^(/[1FB>"[LV5OO
MU74\[?L]N,X/H6Z"O/KWQE\0?B),R^:GA^S<Y5$ ,F,CJ1SVK:%%OXG8PE72
MTCKZ'N>L>*=.T"$R7E[;VZC.2[@=*YB\_:'\)V<_E_VI&Y(ZQJ6'Z5Y79_ B
MSN[D3:G?7M_+G)+R?>K7T;]GKPH]\^Z"YWSD$_Z0W!'IS6RCAXZ2;9FWB'\*
M2/1M(^.7AG6YQ'#J*ACTWJ5&?J1760S+/&&1@RGH0:\(\??!"'P+$+JSDFEM
MI7PRN<F#T&>N*V?@[X\GTO45T^[G9K=\)&&7.T^F>O\ ^NMYX&,J7M:+N<E/
M'SC7]C71[!10#FBO,/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\R^,_C*_U._'AW196MYSA[NZ4_P"H3T'N:]*G
ME\B!W_N*6_*O#/AUJ?\ PD,^M:I(&+7M](-S 9P#M X^E7#3WB):M1[ESPKX
M T_PM!^X@4RNQ>21CDN3U.>M;N,'C I$.4%.J&W+6144H_")3X)#'=1D?WA3
M:1A\R^QS0,Z#XK:3#K?@:<2/(BQ;95V-C)!XKR;PX!+KEMRT9+KRO7KS_6O5
M?BAIE[K7PQNX-/>-+EXU*M)T &"?TKQ^WLVNF6+S6B=QMWJ.03W%?091K0G<
M^;SA6Q$&CZ-M6W0+]X\=2.34E4]!C\C3(8]Q?RT49..>!5RO >Y]''8****0
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AU
M!MEA.3T$;$_E7AGP:M_(\)R_[5U,P/KEC7L_C!BGA34B."+:0_\ CIKQ+X%.
M7^'=L2<DE_YU7V2?MH[(=*6J]UJ4&GQ;IY4B7U9L5EW'C>/#"UMKJ[95+8C3
MAL''4X%24;;#(IC?*/Q%<[KGBG7K/:;#P\UZ&4$AKM(BOL<T@\<:C864,U_H
M-W$9,^8L#K/Y('/.,9_"@#U35;@0>!II.RVQ/Z5X?:W:VDL<SG$:D.3GIC!K
MUB[NH_B!\,+ZQL;KRKF:T:+YE(:%BO&5/->26.G&UMH[:1_-V*(V;'W\#']*
M][)_@FCYO.])PDSZ \)ZE'K&A6UU"=T,\:LAQR1BM*LKP=#'::!:0Q#;&D*A
M5 Z<8K5KQ*FDFCZ"E\"] HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,WQB<>$]2_Z]9/\ T$UX%\#+FYNO $,$(,80
MG,K#C'M[U[]XO&?"FI?]>LG_ *":\/\ @*O_ !;>T]BU5]DRO:HCHK3PC;0?
M-*#=S$[C),=QS[#H/PK2B3R>P'L!TI^?W?X4@&ZI-1*:QPU.IK=: -K7=&W:
M/::E;0*U[ ,;\X/EG[P/K7DPE\V;S& !+$\'KR:]CUI9YOAK<BW_ ./AK9EB
M_P![! KP_P /6EW::):0Z@%%Y%'MF /1N]>]DV\D?/9\M(GO7PWUV+Q)X6M+
MN#/E.FT9]5.#705SGPUTR#2O#%I' @1 G ';/)_6NCKQ:O\ $DO,]VC_  X^
MB"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M***Y#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX W$ 9/UKTA/N#Z5YS\#_F2\_ UZ,GW!]*QS+_>)&^5_[M$6BBBN ] ****
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M^"$FR&\/;('2O25&%K#,O]X9OE?^[1%HHHK@/0"BBB@ HHHH **** "BBB@
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MK:XYCODR?4D&@#;M;W/7FM**[#@=JY>#0IXHLQ7P'T/^-6[2QU1,XF20>_-
M'2>>-O4?G3EE##J/SK <ZJK@>5"RXY.<&GM/>1\&$8]C0!N&0!NH_.CS%]1^
M=8!U"=3_ ,>TQ]ZC.M'S</%<KCKA: .ESFC.*Q[>\4C/GRC/8KR*)]3"Q?\
M'TOXT ?D%_P=5^*R5^'.AHQPZ3W#>^3@5\L?\$U/A2VH:W:&0>9\HZBO;_\
M@YRUQM7_ &B? MEO$BQ::"JJ<[<R$U-_P3&\-QM=:45B_>2A5Z=>E 'Z=_ /
M]G?3]7\&V<UY I7RPN-F*UM9_94L-#OFNM/!P3DKZ5ZUX"TK^P?"UE;8 VQK
M_+FMJ10Z8(R/2@!U%%% #'ZTE*_6DJ'N6.5L"EV@TRG*^!5$#J* <T4[@%,>
M0!.OM3GSM..N.*\S\<R^*]2OI+9!'96&<>9"3O=?Z47 [K4?$MAI8_TB[@B]
MF;G\JRI_BGH<#\W:,?55K@-(^',;N7N))9Y.YE;=6I_PA$,8P$ SZ**P=6R
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M6@V]V,/$GY5 /"T")\F^(^J,:U** /P8_;0^*2^%?^"QFNS;SBQU**,N3QC
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1,5W0A55  X'2@!U%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm205388-1_10kimg02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ B0'V P$1  (1 0,1 ?_$ +T  0  !@,!
M       ! P4&!P@"! D* 0$  04! 0$              P$"! 4&" <)$
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M,.G0* S<4;E 1"WX?ETH#E0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MYD>!X=-L5P#;;W(<4A'>48=%X?/08QN0!(HR,2D_;*3$O'BFL!S-0%/YR&*
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M\E.(GL-K?X_[J$AS*>Y@"W<P>OX_E5"%>)VAZ@(?&A0XE+XA:]_\/2@.5 *
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MH8&P_AMK$9Z&R%_S:Q/+&>/M83*MA0:1'2GO8WC_ +:"AH)K[YC@L#E+R)Y
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MTA*Y<+'1$IE$^I 'I6$G$H>I?'?B#B6 0D:B$8@S(S.4IB)MDRB9,J8%\R@
M%^4PAWM<?6MA'P*J;@9=K3!L]PR9P++,:BIO%9AH+!_$R"'NMG28IBE]2"8=
M4%R)F'P.'S%'J%2%#YJ.0GV2-IZ<RC(=O\"-QY1&R#]VL_:ZXR.7452:"DJ+
M@R;)\^,=.0*L<? J*I0 A; % =/BKGOW@'F;N=8;,PYIB\<421CM][J4FY6
M@F(I*'6CS_2MBF*(F @  A\* ^A_37'N-P5FG,Y4J7)<U?E3<2,DX PI(N!
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MO(:4%DHLM'NGC4H@HNS65N90E[>7>Q[@'0*\E[CP=EB+MZ8RJQ*NGZ40]_\
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M145_2Y$:B+T_#7E5*H9ETCMH8K#\U<NXXTY)2Z3E)BHH00<,17$1('N" %Z
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M9W)]A;^8V\DPN40H#:B-BF$0Q;QT<W(U9-4R)(((@!"%*3MT* 7$?7XT!4:
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M-]LY(7.1%^%>"\>16,8XWXUFV22&$M<C_:F6/-7JZ[ARZ< #E=JJ*?\ 3.8
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M\Q(JDFH4Q@\1$JJ95 Z?QKX6_'-LYEHO"J4Y'K.S8C;=KE7\QZ5IS*U53)%
M0,8"@(CZ?X_A0%#G9QE!0TE,/U?99QD<ZD')S"4A/:;)F4,7W#V*!S>/0+U8
M]53@5/FQG6FZ_N';&F<RS%S(--#0>4.8/"L&C5%/V.51CW)T@G)5$!*5VMY(
MC;R$P7&K.MP/7;0G%3&\$91BQ8=@@@BW1!)(B() 8A4RV*<@6"_B%NUZG1RT
M*&Z[1NUCDBH-VZ2!"$]LA4DRD I [ %@N%OC55<J@Z#V59M$5/=6(!T_(WB8
M0 1+UZ7N B(5&]C9/O UTRG94Q,/@QG!(XT].K*6$R:0_311#&]L7#MP("D
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MX&_EJYNX<PR1TB3+UNXF4W:^%6!D,L#5Z*TY<5J0_P#YD<+&X>3?2T(FIXG
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ML%G&:*A)5QC?[*9=LM'K$,W18)@IX%_FH#,FB]"[FWARSY-R6NC8Y@JNION
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M]/OMW[,P#"4<_?P,'@W]VS>G<&R1F82S>0.B*HACRTJP1$"LT53.5DR_*0:
MQJOS=X"8CALKIMQALO!:D1UC [+S")4U9-%P6"UGL605CX^;RQJFT4<-XR4E
M?<2>?5$ Q/F,>Q0H#)$IFO#+C[/GP+5^FV&2Y;E6K4\UFL2TY@C6;FFFEO8,
MDWG9DP>R=AC,@W\DVC(BH"Z*6Z9!$* D83NW@3D#OB9@VN,1QB9C=IJYC/\
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M2^\\>S24Q_$8;),-SQR5ID<W(XTDA";((V0*Q1?&5>-BCD;9%%$H(.! R8$
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MC<C OD2F0.X$R!T#CU : TZY>\4.1^Z.4W*S:6 8-L=EBI=.<:G3W3BI0@\
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M@YT!Q, B ^(V$;=?]OPH"6"9KW,:X? .E_@ _$* C[7S";R&]^@W&]K?&]
M2  L B =K!>WZ7H![5O4>G4 Z]P^'6@(6-W^:_:_7TO;]+T!#Q'O8;]NW^WQ
MH"/S?\7^- 0!.Q!\+IF$;CZ (_P]* B!1'Y1N #>_>W7O^M 1]H/_$/6_J/K
M:_\ J];4!#V0^/:]N_2_?U]: B*0&Z&$3!WZW'_,: "D VN(C8;A>_0?B'7H
M- 0]DO3KV[=^GY=>E /9+;QO\OPZV^/:]N] 0\/$/$H#;O8 &UQ&_P"/J% <
MO;N 7$?C;KT'X]PZVH![06 +C8.P=;!T$.G7IT&@'M^-Q*(];7M?KZ?$>U
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M'*6X!\H&'I62"NT H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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%0"@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm205388-1_10kimg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C@(% P$1  (1 0,1 ?_$ +,   $"!P$!
M       %!@$" P0'"0H("P$!  ,! 0$! 0$           $" P0%!@<("1
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MCSKM9&8+!?FDED*()^P"?A$#-=FO#*PA21,&0PY\H]3C_HV_QXC*MNN;:FT
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M* VM>C[O8WWS]/7;ON0MUO\ 4JVUL4%W0TXE:V+_ $S0IZE3J1BA1#$Y'(&
M]4"X58FE;A4ZD@.E2936<0H2.1$!$53[JP2I,QA++C/GS@+I;SN@ +3/'B.?
M]("@*BJU#S#YN1YP"K3U%0LA(4)G&7'A[Y2@'A2N5 ;0.H!\NH',@\N>< NJ
M>FV ."1JEG/C (%4^-2L1GX<)<)P"4+B$NDS$^&.9X #B3 +%'=<3_PF>1SR
MF?& >=HJD]-2B1YBF1YRU3^$X!XTBPL$S!F)#&9/]8!2IB)K$\=2L./" NX
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M/GEP1+B(ZL.ZZRLQ/W(E>(=0M"5 R"@#(SGC&FFHJ0! $ 0! $ 0%)U*2)$
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MNXN.W'W&&7+A25C8#;:T**5.CR"6!R$7Q4]2/FEZ^&>&7&<^0TR]HCT!- $
M0&..[CG2[<[M<TZM-GJ#IRGB@?S@-<%HJ;G7)IFF4_3:"EQ+J\9A*$>4<03
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M9ZY]D4RF%-.K25D2;(G,2&'" S'VKJK8*>@H7TH?JW'&TMI0D2"EJ2$JD!/
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M4C##,>'/* 6*!I17YAY3F9C++VP#D980@!23]DOXP@+C&9PPPD>><_A 1@"
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MX?/[?Q^MTVU^!<=[G=EUTBZYRZ6G]+W@]HJGRR\6ZFJ9?%&?U5T(5]#I4@)
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MUUNFS*%DO,7.@K*%QK65);J7#5L%M+8R493.' 0':[0(<;I:16I9<%,P%ZI
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MHI6JG;(2T5NU'TR4^3'$X^TF [%^SUD_0]DVFFZ:6U.M-O*DD D*0A8F9<C
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M<49@IPPRXQ00Q.)SXP! $ 0! $!6I2#4I(R"A]Y_K$V_5"F3Z)^1PQT.$0!
M$!AOU N%KLUW#<0<4;<KL93D0$$X>P0'.93W:MZ&MY0T%]<I2GY@%).&,I"
M\\^HZZJ/;V_*:)4L6^LF)2,DM**I>W[8#27L&HT5U;4+)*G'4!M$I_F/'2TU
M+%0<<.0D<X#JY_:W]--P[7=L'>ZV]K,:'??<(J>M[%73A%79]MC"GZ>L%:&Z
MUE07PGJ@-JP921.6$CP&.'L@$Y;2=*L#\QX<1[!A 0IF,3@<53RPR $ ZJ!D
M23@?A+_VP"H^A(R!\/*<^'W0$E%/6M)!G(\/9G *C%&VZM6I,S(2F/; *+%"
MPE1&F4CC('P^Z 4OIDH2)"2988"<O9+Q@%6WMI2Z"<B0!AG,\H#(=(D)93*
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M1@/R4*,N/Y*<\8#*<_)K\92_G 221S/\>Z.9J)(YG^/= 3)TXR).4_XD(">
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%/[X#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm205388-1_10kimg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ O0(% P$1  (1 0,1 ?_$ .$   $"!P$!
M       &!P$#! 4("0H""P$  00# 0$               ,$!08! @<("1
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M&OL.B&F!J$EUV=01XYEYT[S!PPY)T^,QTJ0:BN"AK"T1H0C0A/U:?_"OGO\
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MA&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"YP/\
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M12M1@FAS/N))O#;-GM2W(=FB%;;,8<>*R 1UA45JJFJ_?7]PYN!X)[::'&)
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MAQN8\V?L%*?8KSM_<T;(1'>Y1<4I3Y%8G+"@0EQ' )%%*\:;GZWL--4J.*4
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M&*&@Y*D7ELX2> 'C]ZKD!E*350I3P\SI*U:Y@.<46TDLT)I*,I[U1R([3R5
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M[=>U0\/_ '?]Y-0)E_JAOZJ'[EGS;^B7?HJ/O7VH#N"/=KE:Z.I!V-#X_P#
MZ$*8D4W/@1Y5/CO[-"%,K7V_F(_?T(1H0H%0&Q/[^A"*CW_F/Z-"%#DGV_N'
M]&A"C7Z?S$?OZ$*.A"A7Z?S$_O:$(J/;^?;]PZ$(J/?^8_HT(14>_P#,?T:$
M(J/?^8_HT(1R \:_F/Z-"%#FFH%=SX;'0A>M"$:$(T(1H0C0A&A"-"$:$(T(
M1H0C0A&A"-"$:$(T(1H0C0A&A"YP/\5G_N;^]?\ 3OM7_6EG0A?)W]FMYO\
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M%96[YD=RSNRVK"<TMMN%CL]F@8ZD2!<)""AAV%'35(:6/':N_CJ1TS4FR,#
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M]BKXT:'$L#MW>NZ;?*GM*6VZV@I5(%" A7\0FNYT_F9T&5.. 48^<NP5ZQ&
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M^'D-HMK*'%B*S-@&;PJV%!"$MBOEMJ,AU<ON>G4\4V>W<;_\E&VT$W#W8O\
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M5GM@T[+RU3ZDT;"92/DWHC944.K*$*!INH*TA#NG52\1D&BD+/9\.E'-;@.
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M&15996;&(S3"5EII(40D'B-JT'A2E1J2C8!XN0Q7$-7UJX=<EC'&A-%52;(
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M8D#BL4*F%0%-QO[QK6I/NXA:ES6X.(!*DOJHVO<"@!)KX;_N:4869O$0LDM
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M+ME+B%2H<>6IHS%06FVP E1\/+4UYK:U[N[3[%C6U$(Y?R._E[EKMO3]YO\
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M]P>EI[J>P?@M^/H-_$@QOLYVJQ?MQW'FS<I$1KYA%Z@J:?Z5OE*^PZM'%E'
M&E#N-<#W3Z<7&J2RW=L:E[W.Y<"2>U>J?2SUX?I5LV"_86-:T C'"F%.');S
M.SGJ3[6]](+4_M]ED2Y2$#F]8U41<6P*A04VK@I0'C45&N#:SM'5-(>YLP(A
MK0_*J]@[+]1M$W9;%K'#S+\ /D$^;<QPOU<Y(30I"5;?$3ML=]1;"+:/(5T^
M.RAE@SQXU"N"E.%*Z$)^$^'G4&GAX:9-FHXFO%0UO&8[E[3V#[5SD?XI\+3^
M#GWF#O\ V\[5D;^?[4-;;:6:.I@I"Z_MKY1Y)J:^-3^:II^YI[&1'$(^83*R
M Z IVG[4L,7D!*T-5^(24+X_\0>?L_AU<-%EJWCR49JW(\Z%9),H6_ ;EH07
M4I95SH-]AX4-"=7&S_MBJY-/>20293VI,Q+K;WGW>;0C+:4I'(CB5$;'>GCI
M&5V6<'DK&));C330<2$M+9<X;:4J0Z2JHH JA._A[!J<9,#%@<**@:GI%PZ0
MR92GAQVZPI+9 (0I+8Y$FIY>7A748UX>\D=JJM[:3$##@$Z-LN<UN,\ZRM3C
M+<<I)WX)-?A!)H*G4C%[O<JE>ME8[%.%BV7/6F;$>N,5\P9+#J7A&6#(?21]
M05/AO]&MC( :*,:Y\GAH4D+_ )+;H,Y$AMY++#LAQ]EKK)ZD<5JE+J@:(*CY
M&F@2M)H4\CTB=]'AIHGRP_N;!>LJ4%1ZB4A*'%KY  @>)]X\]+_T^U1U]97L
M$GA::IJ^[6=1!#=7\TTA086H;^)"#0;>9.D+A[(X\S3S4KH]G?ZE,VWE!Z;?
M$M=DWNG=#<W7DN"C;Y ^+924J/'Q(J"!J$N-2;&>*]":7LXWNG"-PXM687I\
M[_+@7J"[+D*:4B0PD@NT;^LFGPBNYUOIMS'<2=1QQX*FZQM9^W[@L8WP4#OI
M757Z,N_KES;L#T>Y,](RHP=;0X310"?AIX[Z@-Y:*W5(_#BK]L+=WDW",FA"
MZ=>R^?MY!$2VI]M*D1VE'XOU2V!7;VZ\ZZGITVG%P(\()7IMKH]3C:^,U):#
M]2R.5&;2J.6UI'-LOM*!!"E$$&H&XW.JO'(^2Y / E#Q)!";8CPNP4AFWMN,
MO*>0@EY:DO$)2HU'MKX_DU,L?T@BWF%N<<$TN2XA'GE]Q<5:D#D E#2 I2:$
M!0/B -.FWE>!X*9@U**X!#CBU,6.WLRQ,2'Y=M>?8=67H34=9ZU5N* #A!W0
M /HU(0W;3V)ZT0R#!6N=BLB5>1(8M+L:2M$%4L*YB/TVDU20GP(%16GGJ19?
MAK WFFLEK'G-%:,@L,BZPDQ[D_#8;>>6$MQ^*9SST9?!"0L;A+81YT\-;C4!
M5)^48I=DQ@KM\I+)D]&!"+L5$CDXZW>'WU-25M<>1"'62%&GT:6EU!H&"U^&
MCE1*''>T*E&(Q=TNS&OM)21U%<4./D%2>!/*M-1<^JMC87@XK22R$3<YIQ3_
M -C[;1F'(88C+C!)*0TXOQ0D @@$^>J_=:JY^ -4YMKJ&VIVIS;;B[<1YU:X
MQ2%H(2K8A1%1M3Z-,Q> V;W'B'?<F6HZ@R[O8VM/A#*?6K7E]RAXAC\R^3Y"
M8;4*-*4RTM(3R66U$KY^&Q&D]#DGO+C+%4K%ZZWMX<TA 7$W^,'ZMU(CY#"1
M=.L;B_)BI+3_ !=Z766&JC8T*=>J-O:0;.RAEDP<8VGZ15>8]WW;M4OYH8\6
MB9P'LJN,_+[T;E<+K/6XMPO2G5*+I));76A'GO726NF-S74I6BL^S=/;9VI>
M_!U*_.EE:9#7]U?/5\!3^\)VC/A_[N>]F_MKJDJX]8=6O=^"^YX% ^W]S].H
MS-4TQ38BBB30?DTJR@-20 M'.R-S$&@2:O;\6,AJ7(?2PTTVXMQ;SH8;0VV/
MB4M9(2/RZ59!-=OR0-))P[E'WVL6&G0&XNY&M8!7CBL,^[WK3[ 8E;9]B?[C
M6>+=76IT!3K$H27($LL+;0[Q1R/-MTBFU-7;0=@;IDOH[AD-+8&KJAWS<EPW
M>OK-Z="R?:7UR6R@'+BS'MI5RX?N\<KO9F7?//9+5S@KQ2=E,N1%R5V4A^9>
MH<F82E_IN#^;#H>%-]>U=LVDL6E,MW!C)@T5K5>$=S[WV#>:H]^>9\9<:4R'
M_B6SG$+!Z 8O;15GS*QW2_\ <W'A;KK>I$Z8OJY0'F6_F8%L?#H^790=ET
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M*\Q7;4IO?;>BQ;;AL[9[/,&@>:X'V)#T@U[>-W:7^D;NI)!(P]+)F)%:^]F
MPQ'"JDY=GB#D<JW*=?FNOO)$4<UF.A/*B76A\'$$;'W:QM/:&G:?MI]S))'T
MBRM <<./)4&?4O4&QW7#M:YG#=%=='+0NX$\'5%. Y*AR/NA9K*!;TS'&RAA
M'S+;*2I0>X_%\0Y>>H[1-IZ1K-R^ZM7QM:PU.8_@"K__ *@M6W/IVCZ98;6E
MEHPCJTX&@/"@^U);".ZBI+.0WU5PE1&("2RP]/%&E)23NVKE\?&GLVUG5=J6
M\^H$P2Q=(4&)-<!C3!6"UEU^3TMM-WZ43\<<QS7,?425C.6M&\C2HQQ"<7"\
M[M68/3)2[@9++ ;DFYOHHRJ4^YP4VT%J"2D*]FU-.]2VCI]_8-MNI&)!3$G#
M#YE6O2O>^^=YZK)INY&NAC96A?4# =]>849'<> <V78V5)F.M.,1XH=8:<AL
MM(6GJ+>?"*H)'A0'6]E#IECI3A)%": C"O(4[57MQ7NX-0W3'\'DG,H?0G"F
M!IA2O)7ONOE2K"VQ<7;PMNW+Z?R_R+;1^6="0%]-30/PD[;Z1T1VF/>Z2**$
M''C6OVI]ZJZANG1MM"ZL99AJHDB'>07-#N5>%4D8^0VV]V"?<3=3* @N/MVE
MQ"'5RFTH/.0I.Q;=*MOH.L2S:7>7N2.*)I!QK7E\Y5@TT;IU7:,=U/,_S197
M'C4?,I_:RSQ\[9D3\4;0GY*W+YL%I2%-O D.AL$C<J&L;JN=$#+:&S@C: PB
M2OZC44(Q[%&^GVK;TM-7N'WSG2VS&Y6C$D$]F ')4^)Y>DY=^SDUQQJZ1;NY
M#D,*:6MD-H;+96KDH)Y.*-3[AJ5=<;>CVNX6,$;;_(36F%?;6OU*,M-P;YM-
M[W0NFN=8SN(C S85)IFX4^:J4699X]BF:Q+8F6\QSAL(MZ&6U%J6^ZH@E*4J
MIOJG:)MVRN---[?OC\S,TN-#@#\XJI_=>^]XVEM'MV1CG-J&U%2W[CS[$N<]
M[@R+#:L:E2%QDPYQ49ZYD5N0I#S:.3498Z16@O.["GA72&V]IZ<+N;S#V9'-
M(&/VX*V[YW9NF'T]L=-T:-S=0:YI<2#1W.F%3Q/8O>=WV-C7;?'\J:M<>UR<
MC?C6V[S(:2I"HSE5I$J.0E(4KD*&AV\=-M$T70+?U,M[J>0&V@9D<!2I.5PJ
M*]Y'&B2T?=FZY=B3WT%N^+7[:,EY>"&$C^$@EWT@*5<.XMTLO:FQY$_<K=-M
M\&_-N0+//CH=@Q)(0ZE-T994A2&EAI-.= 05:G[[;6UKK?UYUG$VLD!>T"E0
M? ,>7:HK0=_;NW/Z8W^IWC0;]N>.F/-M:]M%DM:/Q >[&'=OL>O-UF63(FDW
M>-;[,]>8#$J*F.M(+$1J46JM)9;2>(! !III<[0T9DI%A*QO^(_@$XL/4_=5
MQL>T#X)/+V+B'BAJ:.'NXT/ST3*]T.^&'9]W3L7>GN%AN+93+OZVG)F.(91#
MM*Y%L068[BZA7S!% 5^1(TYLML7<;FVT$\+LK1XLQ/T^'BF0]9G7=T&1Z?<!
MCA4YV"M3QX/4GMSG/I1R3N)>6.[_ &;QR\(OMR9D.WV#+<AQ\-M? ERVPK<T
MM@OM.QP J@(J2=%UH^N23^5AG@;)PQ+J?[JF[3U"L;N7I2:?().W+A_OIL?5
MHWZ;<MM)N'I;LR.UDRU2XMG9MZG9(8O\=AUQ+4AL.K6EM*T("J'PKJ<VQI.\
MHWF*]R2,J0",V(Y<A@J'NO<WIQ)#)#IT-S%J!)S5:P-SU\5/&33-6E4X7X6W
M>3(.RW=F^Y1WER./:L?C6Y-OB)BO%Q$UYPT0IU(2D- U^L*Z1WAL'7M5M91'
M'&W,WB<W;["G?I5O6PT75X&OFRL,F!)%!ASQ75GVP]5'9+N^N/;L3S:QR;VV
ME*56UZ6VU)<6I(-&BL@/>/ZI)UY/W3LS7='N'":/,P<Q6GTD!?0;9OJEMN\A
M%F;@.G-.!;^*R5^:HRA#C7%RE04T4%(.P5RK3B3X:I?D;A[:X-+>WG[%TV,1
M79-Q YHC../-<Z/^*F=3_P#T[]Y-C56>=JCY?]J6O?I>UD;&<CL7'L6EQ1PZ
M;34KY1A\3])_?.GDT;I)"]E $TA!@9TW^\"?K5XLSA:DA8- * __ "5U,:==
MQV@I("3W)G?0.N:9* #M67F!2DNVA]I10KBTKB#0JJ4D;>(/CKI.G.$S*L[%
MRC=$++.Y:"*^Q-)D=N=A7-_IK(2\M;B@KX4_QAX5(WTSO9.E-D-:J[;?;;SZ
M4!3F%;HUT^1">J:[C?D2*CV?1IU'>,Z63%/[NSLWQ&-K2')Q+'EC+06L/])0
M;VWV5M6OCXZ1@F#"2ZO%4B\T-@=2@-:ISK5W.FBUKMBE%J',Y(<>5Q!"@NJ"
M#RV1J0COX6BA#OJ5-OMF75TXF(Q@'MK^"O\ =\FO,&TM2F9B9Z%MJ:B+;D=-
M3"UCX4\A2H3K=P>6]8$978CM5<M]IW$%Z8Y,ARNIA7\ F]<O-MO=EDPV[_$M
MEX9=;$[YQ]3KTE;JJ)6U0+KQ)\-M1\M\&>'Q5[5T?3-N,# '-:04WDON+F%H
M4XF/,G*BQE&$IY" VPYP&SJ %FH53Q.HY^J%CJ%Q4Y^PHKKQGIT^?\%9[AGU
MPR",!*FRWU)3Q6%GX*T(V/+<ZR[4*QYG$EI3^+:%G9T$+6B0<3W)LKPE;Q0I
MM);XI74HKN20:J.WEX:K>HW#GG^F2%=]+#+1@81X>Y0QO('K3-8<2^ZDMNA2
MB%FI"2"D@5'GIM8:C):X.K7,3@HO=FE1ZK9&2,#J4ICW?[5NI]$GJU7CLZVV
M=^XJ84B0P5..N;J654!!Y^S5]TZX;J3 *T/.JX);Z/?:5?.<[".N''\%V;^B
M'U4X\_:)R[_=7Y#TF$PB OK)4@K4E(3XD;!1&J-O7;_F(G= -!ISK^"])["W
M/:0/:R]<7  #"GWT6Y#MAW,A95'@?SE"S4L@E0!HHU21OX:X9)IQM)"UX&8'
MB%UVZOK"^H^V#A[:?<4_L%Q YI6E10B0L*6*%"JT/PFN^HV<DG(,"H&]M9'L
M+F/:!WE7B0S$>*.F$@N-K:">(VZ@%2K8[CCMI,6\\7B<YM'=G<JY ^XAE<0X
M.]BLS\%MVW=!3314PHH2_P  7"A*J\2%"E.1.G$<I8*'BK#::@Y@I(4GKCB[
MC[BI"&HRG'66F$(4@@=,?6)(WY'Z-*]<]I3PZBUSL#@K$_V[LSBHRW+:V9#"
MEJ#O3!(4X36@/C\1UCKGM*4;=YB/%A57:/@,*(E0C);2H)JXCHA/Q\A4UI2G
MY=8EO,,:\$Z?>MCQ)!2I@XM$0M3CK*5%"!NH\5)538IX@[ ZC9+GJ5C-:*/N
M=3;)'TXS1W%*ANW0VHZ7 V5.I4$]=:J\0: @[;>&EHH!+V!5#4+RX%0QV*E2
M>#:G$J=XLI:ZB#3ZRA6J4>_;W:;ZA:N+FV4#AF>VO=QIBGFWX[J2%][.00V2
MG_TU6DC\3'U@VCMUB%RLC=W9CL,Q9?S3A4E)3(0T4ABJ55YE7EKK/IKM1]E,
M+G4&M?&37PU)^L!4S?&Z 8S;VN9L@[>'VKYTWK4]04_O)GMW=$M;\6(\ZIMD
MN*X$(=6#0!1&XUW#4;Z$0]* . ;@.X#@J'H-HZ^>)74S.Q/SK7%=)WS#_!OD
ME)1]IRINL[ BE:ZYM>W,SY@QQP<5?A%):.;$"*$@8)YK2#_=3SU'G_>![1JK
MY4_L[[V#2'2->(3RA7W05K2$U"DCS-#O0>/B-,FF&3!M"EK>3J-S%44F:B,V
M5+4%$+2#P((0@BO)PF@3MY:2N-/N)XRR"N8_BF]QJ=A:ORW+PUE,2:4"UK?B
M,Y/EN3]A,QQGLU<A^VS$;K\8\]N*[(80A?5B,O)>0I#KCA2!2NKWM&UU72GM
MF?;.D:/Y2?\ A*X/ZG:CH&LP&SBO61NH1@\#_B"X\L5QKU$YMWLLG:W,[!,[
M2RKXX'KCDV7NM)0(#+K?SDN/*<>>9D+=!JBI2377HC2?46_ALI+46!ZN%#D/
M9_@7CR_](-I7NI-O-:U(F,DY://"N-:2K)WN)Z=.V&-Y+.L=M[H9%D#")J)=
MUN+DN.B&EQEI*768CK:3Q94X@D4/GJ.BW)N>6ZZTL,D<!/81_P (5YA],_12
MUM0ULXDGICXB<?\ \A6(N5XC:V[[/?QN;<[A)B-.6Z/)E3S\H+?(JD]#X@'G
MB20/ UU-OEO9&"_=6LF*B)-.])8)':8'4,1IQ=[?XN](E7:J0S9TQI,R1$A(
M=4Z^4N.#KE2N7&2U7[4[^W4U87=Y-;2"IH&.^PJJWFD^F4.I0/C<<9F<W?Q#
M^96@]LY4B.E/\Z;MPGM/.R7)3B6U*:_D3T%44&^(IQ%?'3%EA=MT@:B92,.W
M\U(;BN=LP[P++'IY,XX4[^].=BW;^QVU:,EOJ3,8C..K; ;<+#0; ^K'/P\C
M2M=-[71[J\TUVJ]0^]EK[?G[DGJM[MBTUF+4(1&;V.A/"N4<56*NUGR2Y)_9
M*TQ'?EG:RGU)0XRM*":$H4FB70*[5^'5HV]H-Y+:O/4/T_FE][[FVO#%;[JC
M8SK-RM!H*\E84Y-9YM]=LB;>B5<F)*6FST$J##BC0\5CX3P5JNZ7I%U!KK[#
MJ'QG-Q[33M3V36='W)IT6K7D;2]D6=I(_3Q[ EBW8F3= [D2$R78RA\E!F)#
MD9P\04U9"J'^#3C<&BW>AWPN,Y X\?S2FVMS;<W]<=+(QWE/8?N[DXC5T(@.
MHDPF"PHAIV*6RF-'81LT&&B*"B0!MY:WBVO=W&GOU?.<6Y^/;CVJMZ9Z@Z9?
M[IET&Z:.E'</C;[&O+1R[$I8>40KVU'MEKD(B"VMU>3%64!*$;J0I@$I&WMK
MJ'T+1+O7>M(R0ET KQK]ZLV]][:7M":"PC8UMG=.RN'+*:UY=RH9^76-E,J-
M#?;+[S?0?D1H[3?4<3LA#A1115R_/J$O-/O;^_&G22$T=V_FEM-W!8V5F=6M
M&#H%M<!^22F17EB"BW39UN 6II#*91X-\4^/5+BO/5TU72YK#;AM&24(;CCR
M^E1=EN/;VZ]5,9R-OVXLX5S5Y</O2&1/D9 W=_V;M<9]]F-(DO7"2E$D<64$
MG@D5!^$>W5>V%H]TVQGD,AX'G^:K&]]XMVMJD>F:W'G>\C)4=O#B"L.F^X"\
MDO1Q^--DP;F;A\H]%:2I$:2Z'"B@8/V92#];;6NFVL]SK#[5\F.;M_-7N/<5
M_I.U&ZXVW)L7M<1'3 ?-E/'V)W>XUTR;MWCELLN17=FTL7! >M[]OHR7%15A
MU+3Q:IR*QL3^YJQ[ATJ73H6OZE*]_P":HWI[OQ^\M??;P6WER'4)RY>>/Z6J
M\=L9V8YI:KW>+?);*&XZ%BX-J!6OBD\PLFAHH#VZ<:3MIM_HSWE]<">/=7M3
MKU+WE9>FN\H+?38Q/F+2:#-B:5Y.32G.\K<R^%C,>_OS&US4M2H,U\NQPYUJ
M*4@.5 &WAJGZ%I3(]=%@7TS%PX]Q[UU?6=0T/<VSOW+J#6LEC##D/.I X8</
M8GJR#*I_;O,\<M4YI+$'(XBP92%@);>5XME/Q)Z"DU--M]/MU: W1)V3!] \
M]OYJ&V9N*WU@/LK9@Z#!3 ?DLA.WF6W2+:+E+Q]Y-I>:?2DR(YHU,;;421Q2
M$H0EVOQ&IWU.ZMLUL^W8]3S\65X_FJEK?J#8;5W%'IT<0+YL3AV&G\)287<Y
M,[*EW!QU4:9/N)+JXA27"XH $A8W-3YZK^V]&9J,#[3J5H:<?S5CW!N:VL])
M_<?EQ@W-6G_VI5LLR(E\C7"^+>NS%JDLR67I%%R8D=A?,!5>1434^S3'6M*?
MI%PS3Q)05#>/YK.R-T:+OG3_ (Q-&TRM;F.'"A]@61F)9@S?I[+L>WP<ABAX
MO1[?=XC"VE-DU<H%(-'$IKQ-/'4IJFWY='TT7H>07MPQYGYT]L/430M7U8Z7
MD8[RSP:8?I/L[D^^29GVFG.1<3N=KBHDA$5*K8XT)$6*M_B%!2:!*5H6:I5Y
M4IJB:/M'4);XZOG)^7M4UJ_JAMR"Y&W3"R/SARTI3WOF"1&:6/!<>B,VK(&8
M#5@N#@1#A-E+BI"% N *9HHMM+"=S3;;3ZTT6]?N66[DD=E\N6\?YF]Z1U^Z
MVUZ?[>=I[,A-T2<N',4.%2K3<;_C6,8JW;I^.VF\8-(6TY!MDR&A33*]PE,(
MA/-$@;44-SIS-H.HRS4B>[$_+FG,6Z-J:=Z>"25C!UG?:Y54*=Z>,TM%L<OT
M6#:4VETM1([B3!^6?<XUHV?C7QVVIO[=-'LW%I&JMM(0]S#$'5Q/$GN/8F3+
MC9DV@0ZT!&TFC>7(*KR'L?V@D%GN'%E6)<-J.U!8<>EIC-.*1S2&_ED.H6M;
M@/UE;ZB3J>YOBV,<E >P_P#*I$C;$>D?%8LF [OQ377+LQV0C0F(L^%<H*KU
M-8N,%YJZ..-*>9>*EHBN+<4&FEJ5MML-M6!NJ>J%H_/$VD=:C!O#E^GL42[;
MWI+?,$TY'6>,SL7>\<3^KM3KSO2UV;R7M[FDK!^Y=QQWN7!@)NUMM=YN,5=H
MNK,)@N&  5-E+KJTTVWU(,W+ZE837S<UH/>  X=F#5&3[8]++QIT?391'?SC
M*QU2,KN-:E_=VK$[TIXOZL,O[BXG>+!B3]GM,')F&G\L^\(UNMK,:#.2S(<8
M:5(0MUMWI*!KL1OIMJVNSWMHYES;DS$<V_\ VJ&T+9C=NZZR6&^SPA_\=?\
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GX!?<MZ7]O_:;DK]E+#U0[_9UWJX (_;/B4D<JGD*$#8UV:I%?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm205388-1_10kimg05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ \@%5 P$1  (1 0,1 ?_$ .,   $#!0$!
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MTH%888/BZLQL:-8(I(U>Y(Y0FI"SL9!.F1DE%2AF:@-)5HNJ^.*)$CI[;ZB
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MQF0P.[DCJN@6C#,A$5$00333 %C&Y3@H(\.7;0'UPCCK6=Q3%U+1O39#R2Z
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MFC@'OUCJH'.;O /W1>7X=M )K\XN_?FE?CV]E:K^,'F&,& \;)^R?KH+T%.
MWCMO6_JSG$5=OC;\- /=T :MDJH'B9+F$P"(<AP](HAS /T 'T0'LX\=6=#*
MU*=T?<1$Q3<VP>D7XI0X[!R\IC )O()N'U-2+1%!L.(?XQ75=_?/$'^0(ZJ!
MTN@#0!H T : ![!_F]GZ.@&2Y5H,%E/JAI%,N#NRK5AEA"T6-"&AK78ZRT&<
M)<X6-)). KTI&F=+)L%CIE[SF  '0"I6Z/<$H\31=[$H 83&#*N2=@ H>0/:
MK<PCIIS>I9<NVK4'.[+II[&Z_(L'I"P.4HF-&WHA"\G.8V5<E%*7G,4H=MI
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M_(&K9R4(]3![#TB8%(J1(\?>$CJ 8Q2'RODDJHIE-R&4!'VI[T4RJ" ".VP
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M+S$$>(Z >6$G/^6K_2EV7R- 5]9SW\%Q^=V/R- 'K.>_@N/SNQ^1H"P\K/E
M-JL8PB8   EV._'R\2!P#RZ M-+6 O;5A$?2V )9EN(E 1 /B@&YMN'GT!Z>
MM)X2@/LP(;E =_6S+AN&_9R=H:H^# VPSM\OUE58'L9X ?S=K5L;Q*#KO?\
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M*1Z4BZ.N<3G!+B)A'MUJ_P#U+MZ.[+?;>/;_ )B=6TEJQUW?:.AY$!X"HEL
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MP-PM7+4MMR/3LJ5?H=4]6VY+32M>)=<A"-ORK4FKU[R8P: - &@#0!H T :
ML4^*/T#?UIM 1=?[O'_&C_3SH!A/O#*S%/.MJK8UJN(H>3"W81FLK6Z3QSA/
MIQMF3)FTMK6C7$)6SV;/QF$<^B%XA/D31BCJ.T5R[K!R" ZLV]JVFI:$DZU)
MYL',31N)<<,19/HWPE+@&PQ\FSKL?),S(,$2>'?,*B8U79.T]A!1-@(M"FX)
M^CJ>XZR^)CQ^KX&UA.4H@ F !'L 1V$> CP\_ !^EJ,D+._1Y^[[PO/N4.7?
MCN8#&*'FW$I1']#0#7L0B'YQ75?Q[)/$&_\ \@CH!TH" [[" [=NP[[?R;:
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M:962I5$$3'(50P&%,IC@ CJ+(=^-ASQX.=U-:>P<=%Q-!S>:,3XNP#CN.O\
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M-:T5RW7_ *E_>*/GQ$4O?(Q98J$.WE+"H)RIF]3-%%&Z8&YP,JJ^4[EJ")0
M-Q*<PAPV#CK2Q[D<LEXEB$KDG;ZJQ3:3K2E4G1DL(1E&M>9S!L>H'K0I'6;-
MQTQ0<_6:8N$];*QDB*L,E5J[0E*&ZC<E%Q3' X<Q*3=G'HMF_?,'B*YCN.4P
M&]+?7G_9>5W?N_>EVSDSN6L"W/J:FI14HQE5I)M5;6B2J3^DJ:"CSCTSY*RI
M+8"F(NI8N<HYVP=BVG(N;E)2*\[B25I-1D)B669K1#!<KI%RR 5DC-U$5!,
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M'4([Z@JNG9&V*+Q0*^4CR/:2EP<UI1*2DH22=0<HT;MX66D7!!;/6!R\Z@$
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M8F+_ !524\;TBU4^%R/C."NK/(M_IPY$8M2,EC'E6/@/ /\ F!N(D='%0#E
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MC,?9MAO^92CDO#C4MM6O)ZCY?F->PIT]83J75[G.9@L94QC8:]4,22D38F\
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M3/%EV=0K:P3T_5%XMJ672BSL3I+(LUC@L3F2Y2#N8- 2'D,!T"J 'QT0,',
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M]/N%V>5&_@LC-<85)"X,3>JR':SB4:@F\3.A"IHQ2"O,4.\3;$!LD;T$O0*
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M*82HY$/?[%6;'>+3E6YWB+&KKOE9Q-W7:U,OW<HHE4V\D#'O7!D$3N42@'>
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MJYZ7K+U,0$?4X^S8O@J^W=Q,FM[=8<C<ERR$M"SS&=9OH*0D)J.+#")V()'
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M*1WVS,?/$A]GT >RD=]LS'SQ(?9] 'LI&_;,Q\\2'V?0![*1OVS,?/$A]GT
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M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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MC9W^,OW53E*+9*W&5;TY> @<;MG;FCI(QRL,]772K2BB#]9R*Q52G IA  X
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M?YM33L$BK)+JIQ..@<LU%A;B*$:L-8 6C8OAP#D#AL(^?0'W'Z<\JEG$9O\
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MCVAOH&'1KCJSQ53A;%%W^->R<1=ZVP2JCH[J3J\/X=$"NIA!K*"X[SO4]^
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<)[7^FO<?7JA>&@#0!H T : - &@#0!H T!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm205388-1_10kimg06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!5@&Z P$1  (1 0,1 ?_$ /    (" 04! 0
M       (!PD& 0(#! 4*"P$!  $% 0$               8! @,$!0<($
M!@$# @,$!08$# P-#PT! @,$!08' !$((1(Q$PE!(A0546$R%A=Q@=265QB1
ML2,WH<'10C-3DR0T)B=W4F+3)355E3:VMS@*\.%RLF-S5+561Y=8&9)#1&1%
M=4;69]<H2'@I.?&"HM*#H[/#=+1VAH<1  (! P($ P4&!0($!@ '   ! A$#
M!"$%,4$2!E%Q$V&!(C(4D:&QP14'\-%"(S/A4O%B<B22HL)#-!:"TN)3<U4F
M_]H # ,!  (1 Q$ /P#[^- &@#0!H T : - &@#0!H T : - &@#0!H T :
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M35IG-?W2X+P_&?D/OT_\:CWV] _]A^W;0&T.)D )A*&:>0HF =A*&57@B [
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M = 6&<TP$.+&90'81^1, $>T"B8Q;%$%.<0*(@'><!$/#IH"4O\ YG] 3!H
MT!TWZJJ#1PJBB=PJ1(YDT$SE2.NH!#"FB10_ND,J< * CT#?0%3K[U,['$9#
MON*97BU>R7FL6FHX_@$&-TJ<E7[??;J20?1-4^<)%!.%DVM>CC/WI5_\'0.0
M.HFVT ]/'SD+4\[X;B<Q-&KJGQKD\S'V&)LZS-L\J<[5Y1U!6.)E79% :&)&
MRC-0A5@$"')L/3?0&?%S%B4Q>XN3:"8 ,!![;? &[3B7N INU^/:82]>OLT!
MM_&3$G[3J"'U#;H(!_. O@$- 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T
M?C)B/]I] _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B/]I]
M _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B/]I] _6Z!_3]
M 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B/]I] _6Z!_3] 'XR8C_:
M?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B/]I] _6Z!_3] 'XR8C_:?0/UN@?T
M_0!^,F(_VGT#];H']/T ?C)B/]I] _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_
MVGT#];H']/T ?C)B/]I] _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H'
M]/T ?C)B/]I] _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B
M/]I] _6Z!_3] 'XR8C_:?0/UN@?T_0!^,F(_VGT#];H']/T ?C)B/]I] _6Z
M!_3] 'XR8C_:?0/UN@?T_0&@YCQ(8! ,G4#Z?]]T#X;A_P"W] *\WM=6M/.N
MK*UFR0-A3;<:[.1=6$EV$J5N96\Q!DP6%BNN"?F%*(E[MN[8=O#0#FO9&.;*
M=KE\S27[ V!5=%$VVX[#VJ'*.V_MUSKMG!6:LC)O1A-0ITMI::ZZLR2M7;V.
M[<'2LA <\^HKQZP#DE'&%Q7MLI,-FL;)6B4J->-/0M"BYA3RX^3LL@BLF5H1
MR "82)E5.1(.\0 -1'<>^^RMCW-0S,B#NK_FC2O_ (B7;3^VO<6^[3*[AW'&
M+JEX_9TOW#R1%IK$G%L9%G.1CAC),FS]DY!ZW$B[1XB1=NL4W> ]JJ1P$/#Q
MU*;.Z6,ZW')QVG8N)2BZ\8O5/WHB\]LO8/\ VUU2]6U\,JJCK'1U]OB0MRJS
M!0,%\?,CY8R)5OOW0JE%MG4_544(A\G.M7KYG&M&@I39BQ2B2KQRD)CKF!$@
M;F,.P:WH)3:F:TJ)T$DQCS)X+W*D7LE_QW0L+P.,[Q'Q$S5K17Z-8:^]L4S"
MDFHZ1K;JD-YJ"G''R10QG (F%9J4!\TA0VUL%!AHGD'P&4M$HTA;I@D++'4T
MTU*R#!C!)?"T<D.W?JI/)\S(&GP*,$JB=1J*V_PQ@*!.NV@(O#F1PGCG]0K&
M.(>A6J$L32QOF[^K05;AH"MNH:7KS:89S"4DSCUHI^\---G29#ID%P4 ,!C
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M3BID"$ #$<BV27<%\A<A@$H[Z D/0!H T : - :".W4= : 8#;[>S0&[0!H
MT : VG-VE$=P#PZCX>/U .@.D=ZF4W9YJ/?VB8Y#+)E\H"AN.^X <.X.OO
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M?K@]T Y)_LC^;^,- )S*AOSNI_3_ .K9: _,-ZB-] -P9N5783HI' 0W$3D
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M50:^:4.SH8.\=@ 2B AMU$3 8 [0 /'0&\I@,4#%'<I@ 0$/ 0'J Z UT :
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M!N"93 F4PB(!N(Z AGC+_.OS'W$1_P NC+QZC_O!KVP?F#0#F: - &@#0!H
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MUY(\6W=V]SRYW7U1L];<5&3C2-=$Z4KI2KYEBYF-K,8J1GD(*0F((E%@\$!
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M<QOWKBLOSC3(Y47)H=8PG\Z:AE-VO<<R[=LH(]P%,(F#?8?#0#3U",LC*NP
M,5*VU1/"0@]J$0X1$0"+;A[_ )2I>\P"'CX[: 7SBN5Z&4>8HR"B"KH,Z,1,
M=NF=)$=J%71+VD4,8X; /M'V: =?0!H T : - &@#0"S\D,'8:S%3RK9B=/X
M-A2ROK'&W^'M4E19RC*(H&*O,QUJBG;)2,%-KW ?S!,0Q=]P'0"(<<\+<)<U
MVV'G*MRIR=RWDJJ)[/7*U?\ .L[;X"$2CI$T,69)6&JD6QE@82+,R)5W";@
M4VZ[[#H"X%-$B:94P*4   W* ;![I0*'0.G0  /R: W>4GXB0!'WNH^\( 80
M$0 1W$ $0\- :"FF!NA"AW[]^P?:\!W-])NGCXZ 4#COTR]S"V]N9(/?Z_\
M)]!?U-6O15Y@B'FW5J]8\V^GX2=@8N8*VY+2BS8\@Q0=JLU0QE:R@LT,LF<R
M!MO:7;;;?Q#7-R<".9\ZJBOX';R8#G#N4%7BJJJE1RA1+5059(2F[&TW'P4I
M(U5G)J?^L*+?RK5)<WVC=A->>8>9G[#WI;[?DZXE[5+E1JOLU-&_]%<?]C27
M!T\>9D7IQH%_<5XWI]G: X^[-B!L)@-+2AAZ= '<P;]>NO4YY-R.7<D^F-NT
MG1RK31I:FQ''MW\66*Y-=:I7FO(C.@X<Q56O4]R_<*_CFG0EKG>+-'?S%DB*
MY%,)R1?O;Y,M7CUU(-FR:ZCITV;)IJJ;@<Y2 !A'6?Z:_P!'ZBKD.F;I37[?
M(1G)0>WO*G1*G3U?Z>\]CU-L;T:W\7Y1U::A V5Y!73&HPKJ<C6[YU$&?Y!K
M;1Z+)T<OQ+9%XU4,FX*!P(HF(@8!#IKFY>%M^X04=XM6LFVF_2C1OIN-?,JT
MUH;VU;MW+VY?:[6OW'=R*0O*KUM+7E3GXG6YA6F=XM\4\YW^ATUCD"IU3$UA
M7C<8*K),F[5T:(*W:-(M0X%0"",JY 3()['   J0;[:@NX8V7VXWGY=QV=F5
M:I.B2]^GB2S;XX>\[C:Q\E);K<DM?%U_$I$]"KG9R^L\3FW!^:^.$W(VEHZ;
M96J$K$-F]?.NVN:92DC;$$L_[",42LBII."!WB4NYP 1U9@?N/VUW+BO:^S;
MWJ[BJJ4DTW7G7I?%:\B6]^_MWF=N7[.7F9D<>,K<)=#DUH^#IT\'YB)\N(KU
M'%O6"IU;C./[V+H>9<JX]M#&C2$8A)XWN#6JM&+R8LT]98=51,HPODE=/TTU
MD3'*W2*/4=<S#[*VN_N,KUSI7<<M:\T_'A7S)C;[UQ<3LB.W6MSC2W;I\^O/
M3A[CZBN2W"K'>8./F6G?)]PKR"D&F-[A,Q4=/-OE5*JDI&0#QU'N*K4V2OEQ
M[IBN4.QPJ<ZQ@#<PB(CKUR[9^FL1A=UG&*3\Z:OWGA"WC,QIN=BB4W5O75<5
M7SXDL\#L.8JHO##CM6Z?C^H0$%^%%1>*1;2"CA;K.I.)0=2#IT4S<PNG#QPH
M8ZAU!,8QA\=68\[4OB:5$<[+WC<+DI7VV[G'GRX<&+/@?B9QQJ_-_EJG$XEJ
M(-V5+Q3)13!VQ-,1L&XMR4\^LRL$QD_/:P9II\B55P#4J?<8H;"&VVN%MG9G
M;6S;O+N/9(*.^RDW*E*Z\]%77S.C>[K[Z6 GO]ZX^W):0JW33EKIH)IZN'HO
M\6^34OA'+:TC/XRG&61\>XPLK"CI,DH:UU.T60"K).&STJP1CQL;?L<(  @
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M  -P&UI@(?D$-5J_$L2272E\*&[. =J@[!N/?UVZ]"&VZ^/3V:MHBM6)3P'
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MZ4=SK+6CUBNUNP05A4D\25>R.(R)EF+]RG(N'$HW5*Z2;K*_"G66C.T#'
M1W'7D[M?I7<%K'>CO7:?;J<O9*>G>_CP)/J>1LZCZ@ETE7/&Z7:MGO'JE0CH
M_P!_:HM\NAT<@S($GE%"@!W *$+W>2 ]P!T'7KF)1V*2\4=,;#G8??C19-R=
MIS6?&7<7<HF X9!K1C%W#M*;M[1#<.@^S5KXE'Q&LD)V%KT,:8GI5A#Q3)LW
M6>R,DZ19LFB?84H'<N5SD11*)AV#<0U0"#<$\EX\F3<BX>'O%3EI61Y0Y<D&
M$;&S\8]?NV)SQ)@=MVB#D[A9N %$1,4H@'MT!DW($P#S&X,CL(;O\Z>(#OUH
M2 !O]'AH"3>6=(MMXPE?VE6R7+XY(VHUW5E5(B%B)<TY'FKCXAXUT$RGLR2-
MU_E$MC=?;H#!>"]!ME)X\8C"S93G<ALGN.*=\C9S,+!Q1*^U2A4^U!%:+;)*
MN4^S8"F4$/#0'3Q04X\Z>7(@&W=CS 0$,82["(1EC^O<.N@([Y\63.#*,QRQ
MI^+:W9*H7.F'W+>:DKRE"2:LJG8.]%J,<$>[,D@HJ&PJB;8"^S0#NP]W?PM+
M;V+,Z-5Q?)'4.21;+VMFY@6*BAE"MT_O(^)&,E55RAT >P1'H : 4?T]LAX_
MLF'IB$K]YJ,U-(Y7S7(+1,+8X>5DTF0Y"G#%>*L63MPN#8"K$,50 $@]Q=AZ
MZ B;(O'*<DN<>))(O(;-;!R_Q/EF0:%8S5?30BT#3=95&(9HN(%P<D28FX"!
MC&/U^UMX *AZI.7;#@C("6.:M!M)NS<GL7_*(*U6J6)"5J%GL8 ;YH_E'294
MR/IR6B90 *BGV"IV[B %#7D'[M;M;VG:K6\8R?ZC&XH*FKZ4Z5I[WR/9?VLV
M:._[E8V?):^@R/55VKHDHPZXUX<6ES1*_!GD35\WHU/*4K$O*!4^.6#G41=I
M6SI_ P)+C/2(H6&P0TPN<4I&O%BZ\94KH@%)VG$H=-2_LK<+6=VQB;K.-,^_
M2,_%5K^?L(UW?@2VK==RVV$E])CY+LV_;;A%-->SEQ?F2)Q(Y?\ %ZX\F>6]
M:J^=,:V&P9"R]3#4B$C[ U=OK2#7&T&DN:&;IB)G@)*MSEW+T Q>NI@>?F,<
M[$\;2&8L'C+<CLPU62A<S5J5L%:J3U_\MID:,#-(A/M2-*J_3:@!Q AE!.H
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M[M\JN<I1$IUSB8P:OV;M[9;%N&1MT(PQKF+".G!OC7B]?8:]V63CY\<[$?\
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M^W6AK\!$W2$=O7#N0B&JS=NN1FU.J*9A 1VZ==95<5SXJ4->M6-;40QOFVH
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M1\Z 2-B+-@0,HT*L( 5,QMBB(=!UD+1E4R"8VX]P$$H 4.@@7M]T2^\ B;O
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M#LDXE!J@BDR!J)2B91(R1A$XAN8!#?0&!\9=OQ8YD[!M_EV9_G'[@U[<?SZ
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MS"LU"OQ/JY>TQ.[-NI$W!@A8'COBVIE331;LL?5.5C6Z1"IHHQ\M'IJ BW3
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M==7U/1Z^XB3C3B;,L9R\Y*3<O5^+J;5*?Q$O.E@*-*-9&*%"FN (>HOUTB_
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MUEL;8XR-P5S CDBT3-?;U&*?WFOLHBR!7/O'::XW,YAX]^@=4 G8PK@2G,U
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M.HCW;;=.[?74V_(MYZQ[MI_VX12EYJE:F/@/LE<JR5-,H2B8 !"@':B\$.@
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MK4SA7C:@WESD2NVW,(V60?1\E-JR^5K5+,;*ZBD ;1Y)Y@_=.F[MFV1$2D3
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M,,@7U3&<+'5%=(#OYG[T)I+"S=1X)>8F?<HD, "'70%=WI7VBSRF<$X*/SG
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M\)03-9Z'8UG*'&;^R$_/_P!:;0";\9?YU^8_^?1E_P  :]H!S- &@#0!H T
M: - (%ZAIIN=XYW7%<5B+,64TLQ1$C3%SX>B*_,35)\X <M[.\96:7A6*S=H
MX3+VI]Q@4\#!MH!3_3?2Y'PV05:YENFY1@ZM"T)",C9.]\=L2XF:NWS(B#=N
M8E@H,_,OWTBLV2#S4S@1%0VYO'0%U!E=@W'8H!XB8>@![?HT!L%P7H4 W5,
MF(0?<%0I?$Q.[Q#8= :D4\S8VP@&^P;@(#U -]_IV'0"C<=/YWN8'U9DA/\
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M*5<H_P"F(LF/\.NQVKGO<=O5YZN'PDBNQ<75\S*0Z@ _3J3F(XC=%$OK$W]
MIA_IZ 3GC,&V6.8X?_+HR_X UW0#EZ - &@#0!H T : XQ2((@/O!VB)B[',
M&QAWW'QZ[@/@/30&IDRF'?J ].H#L([>P?I#0'D3BX-(UZN+I-@5)FZ4,_5(
M51)@!$%!%\H4X@44V8!YIMQV[2CH#Y?(KE3D"VVF9-0N:5UE.,\WE*J8SR;E
MB?F()K>XB35F; -IO] B$&(N,5XQ.\9MH9NX>E535/\ RI.AM] 7-\'\K9<O
M_#VNWFP@ZR1>&[Z_1E6DI@Z$#(9%K];M<M$4Z>E7)6QFC-:>A6J*QERD!-0#
M < V-H#I<1+-DN5N_+*1M^,FU4LJV9(<'M?;W".G$6P%H,"":A))NU134*N3
MJ!>W<OMT [835LV#_$\ Z!T^=-.G_P"[T!K\ZMG_ ((!_NRT_P!3T ?.K9_X
M(!_NRT_U/0&P\Q:SD$HU$A=_ RDPU%,HAU RG\GN! ]H@ B'T:#@)YRNQMR8
MS=3UZ)CD,4UBLR:D!(RKFZ#/2TH=Y7[ PG/*;&AEVS3Y8[)'@GL8 . &\-8;
MMW(A.%JS3T[K<)U5?A:Y>#]IDA<E"M%%U5-54BJ(>Y6X[Y%KUTR<PII*UD^:
M-#VV2J,BXCZA6K;()>7#2KDTT)S,FEA(V(1R8XD %R ;;J.O,^XL'(V+>[;V
M?_#<DNKJ^+GK2M*'-^FC:R/J/BJWXT7V<*#WQ^3491RE'PBM1FGBH"8B,7=H
M5ZN(" & P-$3G<JD[? 2?G ->EJ#M6H.V^I2BF_-K5&ZKL;LJ<SP\H7*PP..
M[[/.*\5%*+J-A>&7^<-0\E9&+>)ID @%, #YIOIUQ^ZIQP]LEEVO\JC[EH69
M%R5F+E'A0Q[CS'6NH8/Q;"'JQ57+2EPJCO\ UX:E$SA^@,@N.WE_:,9P C](
MB.MW:,:UC85MV:_'",G5UUDJO\2RS:A!*<.+U^W4FCYU;/\ P0#_ '9:?ZGK
MHJ*C6G,SU-#35M[3=M1*!MO<[IAJ(";<-BCLGN&_T^S50*-R'PCG_-CV'3@L
MJACFLPEDK=L80"=5KMA7+.UAT#]JX4E72Z2ZS7S@'N2$H=WTZS68VY-^K6E"
MUQC*4>JM$^1CW)+#W)_+7$[(F'JC>H)MFFTPSME"92DVC*&AVQEU  IG$"P:
MR )'3;&.&Y/> VQBB40WUS-PPK-WX5U>Y_F:V_6;F5@RM8].!2]Z/O'[E3QB
M=Y J&3L@Q,QCJ46G9W$5-A)V0=,'60Z?9G43D.98FF6@'!Y,?!J*';@?N,8X
MFVVW'7G/<&/#::;C9C-W5I5NJHB+]I_7[?B/!N/^WZLY:JK^*G.O#V'TO5ZX
MV":B(Z29P#1=N]0(=/MET""03!W"D8#)!VJ)?9, !L!@';IMJ:=N[QB;QML;
MEM_WTM5KQ^PG,HPZ.K^IGH*S=GZ?XMMMQ V^TTW >F_@/E]!#?77ZWC;==O1
M=+D5)I/74I:E6S*5SYE6GM%#PU(V&R<C>1%T;5]%X2%7J] ;G&51 #+QK TE
M(D24%/MV(JY*!@_T6O*^R<6-[N?-WZ2?UM^+C-U^&C:>D>3K%$<Q;L\O,E.Y
MP@]*?F.*28MX& 34\NW7PFFGT?\ :]>N'>.0TS;1#_>@7\\RU_I)ZHTG2O)E
M&DU1D990RLZQM7%9ZRTNPN&;KSHHB-892%KD17=(* CO'PC!R[!(ZFQ>X>TH
M".^^KI2<H]+X&*-B$)=2K7S$<XHNH/+. :7B^V8FO<59*7&R+Y<UIKEDH4E
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MH<@(D+'*+N'1DC/&CD3$.IW@!?;MKU*WD1A:M3:UG3[SMVU\*?,Q)E;JO?\
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M\Q6*)TW3=XW,=!1 P$'J ]!Z#L.@%CXZG*&7>8(B8/YY(3< $!$/\0(,NP@
MCL/NCT\=M -X"Q-B?:][< ';P[0-OO\ 0&Y=ORZ W^83;?N* ;;]1 -OR]>F
M@-H*D$1*&^X!N(]-@^UXCOMN %WT!O Q1\#!X;^(> ^ _D'V: #'*4-_$-P#
MIUVW^GZ- :>8781Z[AO[O]<.PCX%WZ[[;A](: /,+N =>I1-O[  /'<?IT!Q
MF%+N#N'WC_9#IN80#J ![1 - <H&*(B >P=OR]-^GT]-  '(.WO%ZB/;U#WM
MO'MZ]=M ;?-)TW'81WZ>([AX@(!N("&@-?,+]>WM'80 /K$1V - :]Y>@;^W
M8?#H/B(#UZ" : T!0@^T V$0$!$ $-A]H;^WQ#ZM ;#+ID[@$1$2E[Q  W$2
M]=A#Z=]NF@-_>4-M^F^P=1 /$=@Z"._LT  <!ZAX>._38>F_3KU^C\N@-I5B
M'\!\!V, [ )#; /:?K[I@W\- :F5(4 $3!X@'00';?VCU\ T!H58A@WZA[P%
M #!VB(B4#= 'KL #H#=WE^D?S (_T0 0T!M%8@=.HCN =H (FZB =VWL*'=N
M(^P- ;^X/'<!#?8=A#I^7Z- :>87Z1_]2;^F&V@#S"CX=>FX@&PB'AL40WZ&
M'Z/JT =X=/I$/#IO^3Q\= :"J4 W'?Q #>'N;[]3]=BAH !4A@W 1$!\! !$
M/Z #X: U\POM'8/'KTZ>&_7;H Z VF6(4=NH] 'IU#83=OCO_6^(_0'70&_O
M+^7ZMAT!P*'26**?VBB;81\ W(8-]C (" AX@/U: \12NP"IU%%H.$,NX5%9
M=16*CCG6.L;M4%43-Q.H=0I=A,([FWT![2)4VY?*(7M3)L0@!V[ !0V @ 78
M"@4-@ NW0 #0'.50AP[BF#;<0\0]@[#_  #H#89=,@B [B(=1[0[NFQA$>@^
M!=NOY0T!KYQ.\I-^IP$2C_6[  #U-X!N ]- 'G)^P1'ZNTW7^$-M :BJ0.N^
MX"&X"'4#![1 ?: ?T] :',GV[G'8/'PW'\NP 8=NN@.$XD  $IQ(']</O% -
M_LB.W:.W]/0&I! #%W,8=S#L(]P[^Z(!L/7<!T GO&7^=CF,'B)LY,#  >/:
M:AU\H&V'8>WN 0T YF@#0!H T : - &@#0!H#A7_ +&/01'P#8W:.^P_UW@7
M</:/0- 4<92X/7RI7[,%\Q1AV&M%.?\ *##>>?PO)-,T"Y5;UVD34)<W#M2=
M579_-&\O()KMTW7\D(D'8NX%T [W#+ ^0\7<3(G&-F?CCR\/9._3K9&&%C.'
MQJTNUPF+)%U>/,Y3-'O#5J-D4VX^[Y8F*/:': : ZU2X?9:IDW>K!#<O<A%D
M<AS[6RV%9>@T!4595K'IQ1%$B@S3(FE\ @0O;ML ET!YM]Q!RYB)W&S6G<J;
ME+Q4M<@C[XX<8YQ]WP]6-#2BWS%#=L F5+(I(E]W<=AT!FTI@SD0@P?F9\O[
MVL]*Q>'CD3XYQZ4CIZFW7.W;B86VQ 443+N([!L.@,+Q7AGEO,X\JLCD;E7=
M("\/([SK1$-<=X\4;L7P*+E%L10C<2 (HI$$=AZ=V@.JUP]R_-EZ5@7'*BZ)
MXQ0HL9)1MA+CG'GQ#FXKRRZ+Z-#N0 WPK:*3*KX=!-H#7+^'^8$'0I*2Q7RI
MN-EN97D*C&QKS'>/$VRC-S,LD)A<1.W*!E&D6=90"^.Y>F@)*0P3R!$B2BW,
M.\@90P**)?AQCXHE$PE Q0_O;N\LNW0/SZ C;%^'^7\XC=_Q$Y2W2 6C[_/Q
M=3!KCS'NTE369VX0DLIV-S;+/R&4$P#U#8-] <]IQ#RZ97W&T76>4UPD*5++
MV8N09=;'>/A<0B#*+*I7C,]VW<95Y*CV* '7MT!E-JPAR89UNP/:WRXO,A/-
MH25<0+ V-\>@1Y+-VBJK!LH)VY2]KET!2;CT !T!YM!PMREE:15)2Z\K[O!6
MYY78UU9H=/'>/C(Q\TJ@0TBS(H5N8@%37$2AL([ &@/$K6(.7;W)5^AYCE/<
M6>/HN+JBU'L!,=8[,ZF9%\B_&TH+E,V,;L8ND4@)N4 $#=- <V4,/\NH:)@5
ML?<J+G89)U=*S&3;5?'..2? U1Z]\NPRJ8 U3[EF#'WR!OOOX== 2&?!/($#
M].8=Z I0-T_#:@=NP"'9N<&O<)S$'KT\>N@(YQ5ASEY.U==]D;E1<ZY8"V.S
M,VS!OCK'ITUH%E,NFL _,8$!+YLA&)IJ"'C[WAH#K3.(>7;3*M2A6'*FZKXU
M?5:S.[1838YQ[\5'V)FYC4X%B@4&XJ"F]2<*FW -O<'?0'KY(PURJAZ';Y.A
M<L+K.72/@9-U6HIQCK'WP\A+%(F+1J83-NPPG, E+OT[AT![\)@_DF[A(AQ,
M<N;PSEW$=$JRK9/'=  K:15C$5I!NF(-1 "IOQ,3ITZ;: PRD8>Y>R-MR>QM
MO*>Y0]7AY^*;X\DT<=8],>>A'$$T>2;YV -OY-5O+**)>]MT#0&W(>'^7D6_
MQZE2N5-RFF$G>&$;?#KX]QVF,/4%F;M1Y)(F% H>>DX*B =?LFT!(B^#N0::
M"ATN8-[44\H_84<:X_W!7R_Y$A2@U]XZJA@#QZ%Z^&@,)Q/A[EK-X_@)/)/*
MNYUR[.@?A-P[;'..54&BR<F]29$3.+-0-U(U-$YMAV[C#H#I?@_R_'+CN"4Y
M3W0N+1H3>23LP8\QV#PMT)-G;N(H2D;%,F@,3VJ;[;;?7H#GRKA[EY!T.;DL
M;<J+C8[LT!B$5$.L=8\(V=IK2+9)ZH8YD"D 4&2BBA>[J($^O0$CIX'S^JF4
MP\Q[Z'<4-RCC;'0#N(![2L0'H;Z- 1KCK$/+R7>W]*\\IKA#M(>\2$9273;'
M>/1^=4Q%JS,QEW(E;"472[TZQ# /4 *&@.K<,1<Q(V[8MBJGRBNDO49B<G&V
M2)9SCS'A7%?BFT0Y<QCIN/D=YCNY(J:90* [%$=] 9Y.X0Y'MH&6>17+V[O9
MA"#DEH=B?&U 3(]EFS)PLR0.4S0!$%7)"%'PZ: \3&>&^54SC^H2U]Y872!N
MC^OQSRTP[?&^.#MXV96;$4?MDC?!G 4DEC" ;#MH#RX[$'+M?*-LA'O*:Y)8
MZ95>M.ZW8@QUCPR\C8WSIX2=8J$(V 2ILFB:1B^Z ;G\= =;*6'N8$-5V[S&
M_*>Z62Q_>BJMUXYUCS'J0$KSR<:MI]V.[<"&,UBE55 #??W=] 2B&!<]" #^
M^%D#[12B 8]H'<([AW  ?#= +[?JT!%>+,1\PIF$FG.3.4MQ@)M*W6IE%-6F
M.L??#+UAI)>17G_N-A '#QC[XE^T(B.@.>?Q!RZ0R31X:)Y4W)SCR4A+8[M\
M\;'./BO(F4;IM#5]NG_>W<5-<3* &WM)U\= >]?L*\HHRE6V2IW+.[2UK:UV
M2=5F+4QWCY,DA.-HX58]H;O; 0/BG*8 .X[== <]3POR7?5BNO+)RYO$;9'D
M+%N9V.3QOC\J+.879(K2;5$QFW:*;1<QP$0'M#;Z] 8O6,0<O']^R/&6#E3<
MV%,AUJT7'\RACK'IG,\D]BU'%A.X2!N)NUE(E(F41  V_+H#DO\ B#EW%FIQ
M*+RHN<R+N\0<9:Q<XZQZ4L92UEES3,P J-P$';?M*4A W,)1W\- 2:M@G/A"
M*B7F)?3&(41[/PXQT [B ]@"8& " "/B("&V@(VQ5A_EW-4N,D\D\J+C6[B=
MQ,$?PK7'&.U&Z35I,O6T:=,X-C%-\7&)(*&]H"8=] ;5\0<N_P 6XV":\I[J
M?&AZ9(24C8_PZQU\2G;B2K1!C$E*HU/NW4C#*JB(!L @ : [F4\-\L(2BV.3
MQSRMNUAO#-B5:N0SS'>.RM'[TZR9"HKC\&F0$2I"8YA'_0[!XZ S9A@CD.NS
M:.'O+Z]-WQV3=1PW)CG'OE(O%FQ!<$*)F1Q,FFN80#K[- 2+@G!"^&AR!(2=
M_G<CV3)5P"Y62PSS"-BEC/T8MK#MFK5A#II,D&B+1F0-BE#N-N(]1'0#"!N
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M5^P0TBT74;R<)-1$@FFY92<4\(=%<G4@*$'M$Q=A$"6/^G_1ZZ - &@#0!H
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ML"<;K$CEHN \CN$D6.*K0T1=NX)M'EF&"UGAHIV#@191S=Z=JJ10O:!B]H:
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MBAE*W0?#+/EPAZ"TN<C'1]-S)$V. 6FL8Y:_DTXNL3L/-)*F@UK3#+J()/5
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M4\F,CSV!Z11(3&L7D]AB?Y&TCG,CE>:J*<%6;'!M2K^=YKY=4AE3( 015WT
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M:IJ*-GB*Q%S$#N';0"8MI&X\.K@SXY8UG&G);EQR;EKEF"]7[,5FAL7,1JD
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M!LD&P[&$P;>^)C";H)A 1Z[&V$XCU = <X!L !U'8 #<?$=OI^O0&N@#0!H
MT : V"0IM]PWW$!'V=2^&^VPCM_!H#C.V1/]HOM(/01#;L/W@'3;W>[KMX:
MY] &@#0!H T : - =<6J(F W:(" "4-A\ $P'$-QW$"]P;[;[#]&@-46R2&P
M)@;8I0* &,)@#;?J&^_:80'KMMOH#GWV\= &X#X#OH T : - :"&X"&XAOTW
M#;?^B AH#B.@F<"E,'0H[EV'PW\0]O0?_P F@-$VZ:9_,)W=WE%2ZF$VY"B
MEW[MQW =_;[1T!SZ - &@#0!H T!L.0IPV,&X;@/01 =PZ@.X;" @.@.$6B7
M3[0;"(]! =QW,(".X#U*<W< ^.X==] <Y2@0-@#Z/RCMT#<?;TT!NT : - &
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
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J - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm205388-1_10kimg07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ XP$Y P$1  (1 0,1 ?_$ -0   $#! ,!
M       ("0H#! 8' 0(%"P$!   ' 0$               $" P0%!@<("1
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MA>>>UML[$&(S+5$;JGE?,ZCSWD>47#E2<QO,, D&<C)LL- Y4P69.5&U@.(
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MG^X,?Q?)\A<[/S"4R@[!ZO&H.E4(8LB=06;11943?*(=WQHB=;((B/41]/\
MFHBJ41(]YM.A@^*^_,J93#?$\AQ[5&;NH++SQZ3E_C;D\&[$#Q[@2&7;N5#
M%E$Q 0'XU0C<XTJ>JBH8OC-::'RC87%_,<JUSY5L@VI-3;4S[.9.<R*1T)*9
M"L[,963>D=.SMCXN_((J 4Q1)[9@"KV, YCJH=5/IC(F*BV8-8R-91S52ZIV
MS1JBU2%14H>X<Z2)"$]Q3]L-KB/K5(YGVHO1 A O8I>M@'H'7M  "_VV *@B
M (0.H%* W$;V"]S>H_KT1((\HQA3\>W+HQ![!+I/+>T2]+?XH/I^S1%2\5O]
MG1PX'[=$80(_>(Q]Q']<:(E_4145#@40 1$.GP'IZC]PU$-)Q"AY9?B#3WJU
M7< 0IQ,L"12$[Q5[R![07$.]3W.T@)A]H_&K::6YCPCCU$X"@)41$.KZ4[UV
M3<=X%$JA5""4!(HF<!!0+=3?+W%L/PM5"*[GH?.B<UP/])4'4:X &H58%.X2
M@(V ;AZB B:P"%O3X%&IXKATSJ:7-'L(4P2*^8/D!XQ<%HG#YODCG+K#6.?R
MHPV*$9P\K-O9>53*!OHVK.+267[K=1Z6&]7YC+6U[Z*9S:-!2<(CS7\ I?#<
MAV"39.51F&XM*1,5D603NO\ *8B.AW$VN5JS</%I!DB5)@5P8"F. V 1^RI%
M(MK\A/*1PQXQ_H*&VMO,(\VR\1-G6)HP4>]R!9_AB:";@^4'_+?<%C%F05 P
M'5L 41>\KY)^'Y-):EY"I;;C7FJ=W9=%X)KG)F:2KA*9RN8=_0L8E9LF)EF:
MXK!U ]A^T/2Y$NQLJ"R::I52JE5(14ABD4(4R:A.\A@ X].XHWHBNJ(BB(HB
M*(BB(HB*(BB(HB*(BB(HBIG-VV.)@*0EQ/>_6Y0 OI\ $:(HB_\ Q ;?RC<8
MX#/N9^@><4AK72$6OA..,M11D6R4<(2LP^;Q2SU%TLU44.151453W$;7MZ41
M.J^(K2?/#6^MG.=\RN6JO)-#:>*XKE."L%HQ-D?$6\G'(2+E%9RDFD10XD7
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M?Q7@-4Q?)G#]E[EY'93L79<RAA2#DK ^>2#)Q)9#CN)LRMDT4DH1);][*3L
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MWN7O6R<4@@*@!\Q0'Y>M$6!'R7S8\M2&1Q_%-1\#-=3+=,0E\D<J;(VPU06
M!'Z:.0(TBX]W[0V$#]_8?XC1%D>*^$S767/F^4<R]];OY=Y*;VEW49F&5/<?
MP))Z!@.K]'B<*\18D9"(=$U/<Z?&B)SO6'&G0&A,?7A]-ZBP'7S)!DNF8<<Q
MR,:N5BIM3 'O/B-_JEQ$ Z]QQN-6K!=1;S:F*73'(_%M.RG54KN,&WJ1B:J"
M[R_.)N!GEC4,(&.7DY@8E,(!<!3RXGMF#IT$@&L'V%Z>E>G?7;;-QVCC%E-Y
MQJYQ&7^UO>5KMA"1.IU?$\I#\8^/IQ*'>&G]>=0Z#<,7C?LMTZ^E>;Y()+=W
ME2NU2 "I[:@%;2YNDT[DH(;%]![0#K</F'J-Q#ML(^M2*56QEA$0[![C6[0
MR:A O?U[K?&I'-G.,?R^Y2NE:S YJV5>MD"J"HX12%(+K&74$B*72_SJ'$I2
MA:H&RN' /)H#W*/GM)H%JC,-Z:;Q-FZ/D6TL$AO;0=$5)(9/$MSD.5LH(]J)
MW +*@%K#VAT&K[;^-[G=W\/D-<]P<"!@*BH':K>\NV16LA=@--%\WWF5R;13
MU=RFX]XAK+/]F3^P^6V,[7A\AP2">3\*EC>*9([DW"BQX]-4R0+HV!(Q^AQ'
M[J]'>OFS;GM_%]L\T$>)PQIAX6=Y6L<9O6R7A)_U]BF\^)#R$XWSDU >-@]0
M[5U0ZT_ 8OC$LALS&WD :8=)1R#<SJ)!X@D9= #I#Z7Z5YFFEE=>NCD&4;3\
M0MYN7M>_4TUK_!.[5%6R*(M&\A-M(Z,TEL_;[N-<32.N,+F\G-#-NX32BD9'
MK.TF@G( G*FH9, $WP :HL>YV:B0HPG'?SS\J,KS;!/Y7=<Z-_0[8.VL%Q.-
M@]>Y2G*YI#X=L4PDA'RC %5%W<O&]Q?JDQ /;ZW]*NXV!U*J52QIJ/\ TB@)
M6%2D'4-^=P[ADD]9C[<BP!ZU,B+AH;T(JB12Y1^!JID4)'85%1=O&W@6N.$'
MDK\JR&29SD+C!\,Q# ,TRK8FRY5Y(OCIRHBO*.W[U?O'Z%LX5[4P3] J")O;
MR43NI&W.?9/-'7O(G6NU,^3+IAG@W&;.M:24NOEV-R$G'J%>X'(N$#&7> @I
M[@+M0[;&"_H-$3L?E.V-Y-)?B+O!SK+46CFO&><XZLY"?<Y+.O&F>P",AC[-
MSD;)&,;@"(*,U%3$2)ZIE* #UO1$ZMXJS&-XY^'!CE,4XZ(PCN*)#$ #?EX=
MP)]WS&3 U^T1ZB%$3@ A?H-$5N=JDIT. B7]S<;7^WI;K40:=BDD8V1NAV55
MY;YFS0*+@X_3$2*'<N*P)I%*!A$/>.8Y033 ?4WQJ?S#2E&_ *YBGDAB\B.@
MC]@^_-"3-FN +IG!4BH <CANOWI* -N[VSIB("0HA02%OR@#W!6%W:0WDC)9
MM0>P4&DEN>.-,_>KTR7:  7M* F*(F+<1[N\EB]0N%PO:I2]QS5>-HB;I;6G
M>:I%G,+D5PQXW(X'E_+S)<)Q;OG5":\E,MCTWSIM,I_,*D(((K.$7HE +F3#
MNJF&-::C-1T@.U#,K5$EY!?'!O706U-C3NX=7;!T-@A6#;;*4\@60C8I-^?V
M&!)R"?)&7$BS@0[1,G;N].M3**TIQ8Y!>''8&X\9B.+$;HPVYET':N*KXAKP
M(2< J;0!7.QE0C4?835:J% H]UK?JT1+SY08;Q/6PY_L_E?B.J9/#\!C73US
MDFSXN&?M8%AV%.Y305E"B"ACF"W8G\QA^%$27IK<WBSXMZKU5OYXIHG5VNYU
M4S_4N4L,?C6+APK+I"#MSC2+-N+RRK4P^\H0+=GJ-@HB\_)N1WBQT=D>L=^2
M$KHK%LJWZD9;!-EPF/L%9?)$)!<I"RII./;&7:M#+*66<J]O:H-A&B)3,+DG
M$O(]_P":Z^AFV%9!NW-]<1V0YX@WCT9-U*:^?H%+&)SKX052*S?HJ]Z2!A#W
M"&O:B+<FG= :7T'#/H#3&ML4UM$2<BK+R++%(IO&)OI!P8QUG#H42@98QA,/
MJ-@#H%$6Y:(BB+@?0;>MNE/9FB\5:2%)-5<ZJ*+=L41<.'!B(M2D+<RZHKJ"
M4I"M2$$3"80+;U&J3[2^#,)6!]#^7+L-.]5&LP\6:^>__P 4=L:9YO2C!YQE
ME,DV-I3B4"T3NW)8DZG\F;;.Y]Z"#")8O4S SF9MF;H<J8G*EZU=;7M&YRS?
M\V:/RO\ I(4WE@FC4Z'X)/!WK2-X>ZSVIS;@G.W,WS "9A@6'Y)E,S)X;@N)
M221%HQJVQTSH8M1RX 0.:Y1^RU2/;I>6]A(5%2M-?:EUCJN&;0.ML!Q+!XAL
M0@(LL8@(V'2+V%*4!$&;=,QC6*'41$:E19]V !C']#& "B8!'NL W +WJ25X
M8RO52@/U8_*J!A H_O8$3$36N<OXA^PI0];U;0WC'.TR _%5? WYEKO/,ZQ;
M \>FLFS;(XC&X*+CW[AP[E'K2-1*DBV.8W:=XJE[JZ@A8I"WO<*N;7:W[OO-
MHZ&&5TC)/ 0: DD9@9Y*UGW/;VM=;/IYHSQQQ'8OFL<I=E<DMTFY7<:.,^ L
M-B:ZY![</E\R]9L'LAD[5. GSO(9W&_3@9$C%QV%*H8_3K>O:'JUP&;DO&+'
M]0DT",U%2X4JT UH<5H5O>;D-U\N(CZ<G#PC+VJ2WP/YZ>7F%UE"Z^VOP 3F
MR8KC./8OA;Z$D!QTJ;*#CD(TBLRH^$$5EU$D"F/VA8!]*XIN?I_LUI!'6_@$
M[ -?B)U-H  !4T(IFMPNMS=;77T4D;WW&AIU# 8CL2\#[3\S.?/!/CNC]":D
MB7/:!5<HR!6>E&: A?O430'VSJ!W#T#XA6+AB].=O:/U1DLY%:N9,6@^P45>
M.'<IR'![(VGH6U5NYXK>4S9:@*YES>QC 6:Q_P#&6&NL)*)VY#=3D(N^^8RI
M;B &#I8 J,N]^G$;_.X_:73&@4(?)YE7=H)P HJ=S9W0<&R2->:9@$!53^(V
M9RLY5=P<T>2V?+'M]8DRR(^.L%2#U52(C&J)BFF<W7[0"K23G<4!_P"%;L;0
M8:PT_P#M5N+.7^I5\S\)O$=_KS*86%99@IF4G#.D([-,MS&<R)S'O01,H#HK
M5RY,E<YB?-5QM_J?NL-[%_\ 6#2\8")M<QW*6?;Q)92B6I(&&)":M\$G%Q[$
M\C^1&3*Y4S>8]J2=E]:S6*R$0T>MLM.#M9)D^,F[26!K]*HW$Q#!U#O&NY?N
M(YA-N7%]M9.6>-[CX6@4\+.HR6"XU8L9>.TUR[5+AAXJ*C2'".C(^,,<0,NG
M'LVS0@FM8H&^F22 _87H%[VKR ]S73&F+M(Q6]R-TN[E[514B*(DT\L\\C=7
M\;-W9W,8RUS&+QC7.3/W6*NBBNPFTDHAR<T?*I]IA)'KVLH;K8HU;18445\_
MKB!L'1^,\_M2\B--<6-1M,0:YCKW'\[CR95,S2#/9NS5_>;.]:L7+A5JO(8F
M@Y[UBE*H5#TL%JOXOQ4O5?21;@15NDKV&)[R1%!*/RG*"I ,*8^@E[>ZUOA5
M)V9]JBM5RFCM1S#O-7<IKG$Y%SL9BVBL[</(AJX6RV+:  -X^=46(<[]HG:X
M$.(ATJ"+$93BGQPF\DP_,);2.N'^4Z_9-8["IY?&8TTCC3%B %9-HM;V@]E)
MH  "8" ]MNE$6BO*$BFGX\>7 %*!;:0S$G:!2E+8[$"";M*4"]WRWO\ ;1%W
M\5UQ\='#<1$PC_(/A'4QA,/_ .'A\3"(T1+^HBTKR =;N9ZLRE?CNQQ.2VT1
MF XHSSA99MC)W8B:XR"R-CF)8/P@(410N_.+F/\ Q!C?C+ .\GQ[#L5P(,A.
M&6O>*\M,.\K^G!#Y/SGZ?O?$BQ,'0J86$WQHBRCPJ9Q_Q"COB.V7QS&M?Y5A
M9Y=P7#'W*!_+1F?BS*DH)A(FX!-TI&@>W;[P]QNEAHBF0Z+=[@<ZGPMQR 8X
MU'[?6BVQLW88>J=;'$)@YA!0(M0XF/\ 3@'4/F&B*-Q_Q'</F\WM'QL1.LL<
MP_,<_>;\.UQS&]@((N<0E7HHIB1"=(N4Q3,^X0[@ !O>B)N?G#XXM_<;>#'D
MIY<<D U+@V8;VB]8PC+56EHY=OKK&THK*F(GF7C5!$4/=*H4!.;LMVWHB<3\
M0\F:/V%I%#(^6G!+8QWFK(9.%UCJ3$(>+VZ1^KCS R39S,)(E='>LT$C?4>@
MF$!Z!1$XKYMN*FO^1_![<$IL2>RU"+U)KW*LSC<:QV169Q$W-L(Y1=C^D"*(
M]SML1T!;$$1 >OK>B*.9).-5Q2OA>EN3J6/DT(IQ1VBT:JYP0HX&.:*8N^38
MH.!/W,TY 0_>T/<*!@/8 ZT15..7 ;'M^>-G'.5&=;9=ZHUOIJ8W.Q8(R$8@
M\9Y;I0,X<SL3"XU^8"HI'.Y!TS3;-#I!W&]PO;TZ41;KXB<^ISA)N.//L#3?
MZ1Y7R1D-62N:Y'.3":.;8EK;*@)C^J<=QJ'6 [U\FRBTTEW2:8B!>\3" 6HB
MFHL')739!=,1$JR""_S%[1*"Z9%2$$!_; 0X7HBOZ(N!O8;6O8;7]+_"_P!U
M$7CR$PRBV3N0DGS-C'L6BSUX]=+)-VS9DW*8SEZX66.5-!LW HW,8:4)P&94
M1F/:HQ'.KR%2G*4F9:NT[FLSIWA!A>1,\/Y)\PHUHX..1BL8Q)#7VIU4@]Q^
MZ6*82.72 &[+]!&JL'#=WN]P9 V6I<1X:OU>Q1W&=MK\Q%:_!(*\D/*_QNM/
M%)F/$#AI(?ESI.3Q11BQ)$.F<AD$A'2)%9;*9N06(#B2F9+J9PLL)A-<; %=
M/W'T8Y7:;<;N1Q9'I!:?[OO%=(Z+'6^Z1/(HX$]<OXJ55X_'C%SPJXP-6SAJ
MNJRT[AB+A!JN5PHW51BT )WD(90Z8^X/[:N6.88W&-WS--#[1@5?UKBEH@MV
MB1,PB'<  F<0$PG[0L(&#U[QM4$6,Y5F>.83#O,ARN=A\;A6"2KA[)3K]"/:
M-T$2F,H85UCE(*@%+^'UI;;?=W4Y;&UTE<0&@D@=_<H&1E,32B:/V#Y1Y?:6
M2/=8<#-3S'(7-T159+9T=NZA]88ZY$XH*N'D\Z2*V?BV'Y@!$Q@, =!KH&T\
M/LFTN=[FBBLZ$D5TO%.\M5K+(7X1U+OL6 J^+S9?)^,E\CY_;ZR7/)&49*N&
M6L< ?KP> X>L0IW!#II)"5Q*.FIP AA.(%,)1Z6K-CU"V#8;ZUVO9;6.5\+O
MFD#078@X$#4:XT)"MXMB@UNO[ESJN&..'9]B0CX1^+V"P_)/E)F;:0F4'6CL
MYD<)QELX7(5G(XZH=RG:7:&*9%=.R8&((B!BF'J-=+]=>8WVY;#:Q6!,;7DX
M"M 0UIH=)R6M6<$UYO&BTR:X8TKW=%*30G<>(B5+\TC@,%B@D+ML8YPO<H#V
M',0+7MT"O*DUKNOGB6>1H<0#^8+HLFV7K7:C$Z0@"ITDY=*E9"043H"HF)3)
MJ !B^U;L +=!*( %1)\D5F!?]OWJRN+>>Y;Y-2P]]0?L7=B0ABJ& R@F[A+W
M"<PB 6 ;=1$*I%S;T^9&TQAN!&6/;@K>TL)=N88IGZRYU022<,NJOP* !\37
M]1-:X_WJG;;M_,2?>KJH[EX&123")CG#F0=,V#?Z=T N'SI!DW WTZH@4551
M*43&#X>M5;?:YKN^A-L'.<UXJ!4G$CH J-U(V.UD)(H6T4>#P@R\,AMOGF56
M8C[RN\I):.,Z?-2+O&YY*0!,C,IE"BY(!P^42!Z5Z*]=MFO;?C.UMD:[-W0_
MTL6J\>N&&Y=0BE%(W;C8#' !#N&PE,6P]!&P_:/3XUYOT%MT7=/+:/@MTE<"
M=/4*Z*81&PV]*KJBN]$28^7&=M=8<:]X; ?8NTS=KB^MLHDG.)OD>]A-M48A
MR=:.DD@"_P"6KE"RE[CVCT$*MGGROE45!/XN<E<LA]U\<FK_ (W<--5X,[WK
M@N2XU'8F=Q*94D.SU?\ %9_'63@5QF7#3W?:<&$IP:G 0"UJO+-WG8.P4%]$
M9N(&00,%@ R*8@ %[0 !(4>A1 HE#[K!:I3FBK5!$41(%\I/]GKR[_U)Y;_D
M@T14_%;_ &='#?\ U#X/_F\*(E_41<6ZWZ_9Z]/V/2XT16#Z+92;=9J_;HO&
MJX64;.TDG38P_:9NX(HD;T]! 0HB[-HYFR0*V9()LVY$P230:)IMT$RA;JF@
MD4J1!Z? *(KP2 ;UN/4!"]N@A\0Z?&B+5F=Z1U5LZ8P_(,_PB"RN<U_)_G.%
MRLRR2=O<;EOC(Q2QP[FKH; '<'P *(KW:6HM<;LPF:UQM;$HG.\&R)(B,WC&
M0MROXF233'N*5RU5N0X <.[X=:(DU:I\;O!O1V<Q6R]2\:M88%G<)[HQ>3X]
M I,I5F*S<6IQ1<$,(ENW$2V]+#1$K3*\-QO-\;E\1RN):S^-3S!:+EX:0(59
MB_CG  5=HY1,':LBH 6$#7]:(M"Y[PMXM[1UQC>H=@:/P'*-;8>9(^*8I*0;
M->.QPR74/R?Y 68E,/4P$, #\:(LKR+C3H_(]2L]&2.N<<#4D:G&),,!9,$6
M&.M21*Z2[ I&34J28D152 PE-<##ZWHBP/,^$7%G8NS\"W!F>EL.F]AZU;1[
M+#,B<,"D<0[6)1*C&(D22,1!8D>F0 1[RF]NW2U$2KR) 0"@ CVE+V@7H!>@
MAVC8 #J4 M^I1%4&]AMZV&W2_6W3I\:(L6R;,<?PR E\HRR7C<<Q^ CW,O.3
M$N[18Q\3%-$3K+O'SQ<Y$$"$(03=;]/MHBCWY/L_=?F5S^6U7I!SD>H?'?B4
MZI#['W*4KB)R7D2Y:J]K_#\%<?(LRQ!P)1[GA2F!8H_*8+TQ&(S2M,>J>6@.
M)7'K&M*0W'UAJS%#ZEQUDT1C\0<1K=>/.K'D[4)%V0R8?529NVZC@]U5!ZF$
M:AM^Y[Q:;VVX,A$@(TFIZ>WHK6XMOU&$ONJM]F'WJ&EKOPUZF\D7*3F/ATIM
M7-M)X_J?9$C&X_$Z_:-?IQ8+OEDS-S$>(JW3("8=O:);5ZR]2>?7^V\-@$!#
MWN :22<*M&)HX+7=JV^U=<F,ODIG@152*O'3XR\9\6D=G$U+<M=K;9Q"1A6;
M%%OM^<;-,=P^/C3@J0T64!23;_*4 -W',';\ KRC;Q7NXR5MHW/>XUH&DG'$
MX"I6T2W=A"VE7ZA[*+U-K>4D<DR=WJCA%J^<Y*;%!4[ V2QB:R.L<>554%)5
M[(9,)4T'1&:EQ,5-0+@'0:WG;.)V\<C9N1O?!M[FDG20V3X/%%C'[_MD?A+9
MB_N I]ZQW&_'-M[D7*Q^?^0'=$WGB0KH2,9H_!W;J!UK!JJ&!<(]\FV,+R:,
MU$?;,HJL8J@!<0J]GY/M>UL^CV*"-\;06ME>P:RWH7$9G[%=QV\5PT7+7/#'
MC4 3V]R=HUYJG7^I<>:8GK?$(/#L<8(IH-8F#CFK%LF"90 IQ]E,AS*?:(B-
MQKGFY[G>[F\MN9"<"*C"GLZ*Z8QK,&JWV)G>%:RQU_D6=91#XE"F*JU_-)MT
MDT:B\5;G*FF950?F$_V!5'9;"YFO@P1>;Y;FZ7!I=(036I-"HWP\RQ+&.(=0
MY%1E_%YF&O,KRSR(8"IMN$P:3VOLR5C<*G6$PBE*N?K%W*19& ^H*F"_S+7*
M4 -<0"U=R]7=DN[[9K:-AECQ.,9(TT:#4X8+ >FFYG:.2-DO(HY8V&I;(*AU
M#E0D56G8WA[N#^G8[XB$Y5;<38L<*99REF*<FJ$D[54<=XHF;%[VZ3<4^@_+
M<WK7AN>/D<W-G[7+>W7DL8W#S'TH!V'#%?76;?."0?MGM^<MV/:3NLEQ)&3]
M-%KJ#05=\U1UQ4M36.'K8)@&+X>ZG7^3.8",:QCB=DE/<?R:K=,"'=NC" ?O
MJI@$1"P!7:;=DEK"V*6KZ#-V)/O*^7.[[BW?]QFO&AMO5Y\,/@:.X#%;"01!
M,# %P#O$>G2_0.H]*O':1\H JL1$V0U$CGNHZ@)-315NS_QC?L__ "51+*]3
M\55T#M*1]S4XI1W+_5".K)3/\RUVU2FVD]^?86\*TE#*LBG(5FJ<Q3 =HN54
M>\OJ/VUG^.[H_9)W743622X4UBH%#7N[.U6<]NZZN8[1Y(LWAVLCYL!A0Y9]
MH35NHO!)JS3>R<;V#B_(C<1'L)/M\A=QOO%8Q\TX:J^^L65.DF'OIK"'43 (
M]1L-=%YAZM;MSO;8;'>K>TCMK<DM,+7-=B ,=3G=BQMIMFT;;O8MF&Y=&ZF%
M6DUI7,"F?<GYT99%H";45VJJA2HI=XNNTAB)I@0# 8Q!N<2A<?OKC,]Y;F<Q
MPG+$Y56T"SGEN9&V\<NEK :N:<>ZM%D2"WN"<"B4PE O4O4H@?J%A >MP"JD
M;XY!49JTC\YKRRX ![OYJYN?[ _8&IZ-5>C4G;E'GD;K/CQN38,OC"69L,:U
MUDLJ^Q!=O]0G/H-XIRH:'D$;&NT=D#M-<+@ U9SYJ50?N./+7',FY%Z S[8&
MC^)673D;M;!\4P3!]=()ERW \(V$O[\,,1'(J"H[FL/=*7=&$H@D<![JO-NS
M]ZE7T"4#=Z*)^T2=Z29NPP6,3N( ]I@^ EO8:@[ D=ZBJM01%$2!?*3_ &>O
M+O\ U)Y;_D@T14_%;_9T<-_]0^#_ .;PHB7]1$41%$11$41%$11$41%$11$4
M1%$74YA*0QBAW"!1$ O:X_J_"B+7VQ=H85J/#<CV'LO(XC#\)Q./6D9_(9=V
MFT8LFJ*)EA5%94Q2F%7M$B:874.>P!ZT1,%#&;F\UV>)OI<N5:=\9^'S'8C$
MJ?40^5<J9",>@<CQ2WM.6>OC&2M;H9<AK#<HT1/]8!KK"=68; 8!K['(S%,0
MQB,0B(2#AFJ3-DQ8-2@1%))%(A2]Q2EMW"'</VTRQ1>S(2#:,9O'SM=!LS9-
M57#YRY5(DBT1*0QQ,L8PE EBA]M8VVDO-PWN.&%CBT&F -3[NU0OIVQ6I(4/
MCB!S R[4?+GFW <?]3S&]-D;:V=*.,':1*A#8\U:MWRO_:4O)F']XC2G4'O,
M ] "O9'.^"0R<+M;C<)#'&QH<ZND5P&!KFM*XY(Z?<#IQ[TZOC7 7D'RIE6V
M=^0G<<@\C2KD?L>/6K7JT#@T.0#=Y6DZ[:G*M/E H@54AQ$#6'[:X==[_L/%
MFM?L31+.QE#(13VTI0G[EEHW3OD<VZMSIU'\KLJYIVO6.GM9:;QAKBNJ\*Q[
M"\>:(I)IL(2*;L"B!2%3!50Z:8*N3*@%S"<1$1ZUHDW([SE$CG74LA(J*FHI
M[!DLTQFTM;_<A:QW_3_%;?;)^VD0H!:Q"A8!'M#IZ%#T *PP=*)#"TDM::5.
M:N-,3!IB_P 0R]G17-K57T%@J5!)AY1\4]2\OM?JZQW%'RDAC/Y@A))IQ$HZ
MAW17*-A((.6AR','3XUGM@Y#-LUWY]MI+QT-0/B,50C!=,YC_P#&D#81X/N"
M.N<SQ;/(+%,N1G<+GV>10:Z^72IT0DFJI5DC.DDU2@\3 Y0N52X#6X[UZE[G
MN=B;>[CC$9'Y2XG[25BX]LKN7F6M0X&O8M#QRA0\WTX8I3)(ETE&D%9,X$3,
M0/D(D!"&[@-T#U]:\W,N89^>/>[!YB%?@OHQ%L^YP_LO@NK@%T9W2XTUQ&+Q
M0Y)_IJ8_:K[@@!N\1 H!^'KT#[;VZ_;UKIUT6Z6D+YV;2)1-(V7.I^]>F4P
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MD>XQAN 7]   'N^Y2X?,7[J(NOLFZ" D P (!<H"(7_<GMW$ /L#I1$@GRE
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M]/[%QG0&X,@U''KR>QX3764O,0:(%]]P$XC&+JQ_LM?F4<NQ5*':0 ]:QS9
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MJ]KK),G>E*YR3*YA2QW,Q,RJQ3O5G3A:XB'?VA?TK0.1<KN-PG(CP;4T8/E
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MQ5%$GCFX;$'L'LT/@Y>Y,ADR'$(X.Y0I#**F*!S7'J-$3@-$11$41<"(!ZB
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M52\5YBD\<_#?O,!;:(P@!N-NOY>%0'B.D8N5-\C(QJD(#>]+\%9(+74(%Q
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M\.0S.$R,D^29Y(LT7]UHU0CFPJ@S8M!"Q4DR=I@O>N8<S]2K#8X7[7M$38W
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M **9%_%U$1_7H>,W_> 3_P!%,B_BZB(_KT/&;_O )_Z*9%_%U$1_7H>,W_>
M3_T4R+^+J(K=SYW/&$S1.X><BF31NE85%W6-SK=!,#"!2BHJLQ(F0!,( %Q#
MK1%5+YT?&:H1-5/?Q5$E2@=)4F+Y 9-4ANH'3.#+M.4?M#I1%S_7G^,_^?S_
M +JY#_U&B(_KS_&=_/Y_W5R'_J-$1_7G^,[^?S_NKD/_ %&B+G^O.\9_^\"F
M7[AQ3(!$/U?\0&B*W=^=KQB,&YW;[D0T9M4S%(H[=X[--&Q#G$ (4RR[1)(A
MC"(  "("(T17!/.CXS3%*8O(!,2F #%,&*Y"<IBF"Y3%,6/,4Q3 -P$!]*(N
M?Z]#QFAZ[_3_ -$\B_BZB+@?.AXSOAOXIOO+BF0V_P @#K1%Q_7G^,[^?S_N
MKD/_ %&B+D/.AXS?0=_E*(^@&Q3(1$?U/\0&B*@[\[7C#8H_4/N1#1FW Q2"
MN[QR;:(@=0P%3(*KAFDGW*&&Q0O<1HBKE\YWC/,4#EW^3M, "4_Z*Y 8I@$+
MAVB#$P#<*(O6A/-EXXLDEXN A]]).96:D6,5'MQQ>>3%=V_<IM44@,=B4I>\
MZH (B-BAUHB<8_E7UO\ _P ECO\ ZM?_ -G1%LVB(HBUWLO H7:6OL[UGD(*
M?D>=8W-XK+&2*"KGZ">8*,'JJ('^7N31=_+]EJ(F$..G@]V1Q]S-_G;'EU/R
MF2ZXUIDVK.*#YSC#-;^1N"R.2.]7?.4#K 2:=-FI_: 3A</4*(K/;_@GR?;6
MUW.6.^4T^QP39ZNMISDKAB<"@139^9:Y<-7S6>9.RF-^5H33EJ J)%&P=PU1
MG'AJJXD\ 8GN\MXZ:BS/''$-*Z\PUT[4Q4V,M9^3Q6"D)UBS&,+$("5^[;'<
MG6;MTR@41-T[0"LELV[SV$K'1O(#7 D=H5N]NH&O49J.+R8_X972N>:EV1&X
MGM>?+G<E'R#C"AG09QV.Q^0O%3N&A7Y&PD1!LBH<2IC:X%KK=SZS[C)L XO$
MQS;<%Q'B_J/L_%:[NEE/$6WMN:Z2/BEQ^/OPJ<6>(^H=-M7NO\?R':N/P(*Y
MS.JD0F(W),E=%*677.=SWH+1R:B5TB]0+<:X+)L%I>WS]QO!XBZM%VG8?5;>
M[7C/Z/"[1$8RVN9;7.F&-?L3K3#CCH!1$PFT;J@;*& #C@>-* IZ")RB$<:P
M7&UA&]90PPP49  (Z=%S&"YENW2S35+S*[WUQ5^'&OCR-^_1NJ;_  MK_'/3
M_P#3*@KA<_T:N.W\QNJO]G^-A_\ M=$HN!XT<=Q]-&ZG_P#.P#&P_8O&!\ H
MB2-SIX'ZRWQQ7V_I_6&K-/8[L'-\9788K)+8KCL25"3(<ID5?K$(\%TRE$1"
MY>G7K1%L_CWQ,T1@.FM4ZYRC5.FI/,\+UYBN.Y&HCB6+/E'4Q&139I)."B=@
M9=8%'B!Q[Q#N&]$6[1XV<=S=!T=JG_9]C0?WHL*(NO\ 1JX[?S&ZJ_V?XY_%
ME$1_1JX[?S&ZJ_V?XY_%E$74_&KCQV&[=&ZH$P%$0 V 8X!;@%^HA%WHB1=S
M\X':YY%\3-XZ.T]K32V/;3S7% C\>>K8MCT>9A(&>,W!5U5FC KQN0S= Y0,
M !>]OC1%N7C_ ,2=%X'IC5.O\HU1IN5RW",$Q7&\F<M,0QIV*TQ&1C9B^.=1
M6-.Y,"SLHB'?8341;N_HU<=OYC=5?[/\<_BRB(_HU<=OYC=5?[/\<_BRB(_H
MU<=OYC=5?[/\<_BRB(_HU\=OYCM5?;__ )_C?\641(?\@G ;7'(?BML;3FIM
M8:?QW8V5MXY'&Y-WB6/QWM_1RK)^[,#IE')N.T&B8A</2B)1^IN+/'_&=;8'
MA<UJ33<ID>*X; Q$L9+#\8<F.\8QS9H]5N,>98Q57*1AN8+C?K1%M .-7':P
M?_ W5(=/0-?XY;];_LOTHBY_HU<=OYC=5?[/\<_BRB(_HU<=OYC=5?[/\<_B
MRB(_HU<=OYCM5?[/\;_BRB) 'DD\>^#\G>*V?:4T=KG2^,[,F9+%Y.+<KXUC
MD2HFE$R[1Y( NNWCP<H%68$$I1M8:(E@:VXO\?(/ L-QB0U!IV0F<:Q;'X*8
M7;X;C3L#R<9%-&CTQE@CC*G%1PD80$_4:(L])QHX[E#KH[5/41'Y<"QPX6'[
MQC!&]$7;^C5QV_F-U5_L_P <_BRB(_HU<=OYC=5?[/\ '/XLHBI*<;..9! 3
M:/U,6P"-SX!C86]/2\91$WOY'O'_ *]Y0<<SZPT=@VD\;SHFQ=>9,#X\%C,<
M887&LF9R4VR!5LR%2SMDD8HE]!M1$N3%N./'$D9$Q7\CFF'3^*@XIF_*WPW%
MG"A'"+-%,XBF6/,(D.9,1[A#N'XT198CQTT$T71=,M):K2<ME4UD5F^"8RBX
M05(/<FJBM^7$,DHF8+@(" ].E$6S?T>Q_P#_ "F,_P#N#/\ ]G1%D-$11$41
M%$5/NN82U*:/\)5/7XR N1L'WU1^GIDJP-?8H_7G2SC/3%X7\><;SS)-<81R
M<Y(P&NMHY-B4F>!R%MC?TBCGLCY\#E"*NH'S&N'=5RV2&!H,O^0*I!?6AG_3
MIA60BM<<C_KM6:>#G.<ZFM-\D=291G$]L>!X^<DL^U-KW+\HDAF)MWBD.L!F
M#=[+&,87ZC<.ZZH"/=W5(^;ZP$1G2.U326D-L\"/Y3C1/F-A**8B7T$QA_7&
MPC_?J2*W-LTQEVHDU5%S&L-&B@.*N*JJ5%$5F\]L"=QU )8I@+<0+83V)W >
MUTQ #6[@]+T11E,XE.7&!><[5,9M/=Y,BU=G>F]ISVLM5XP8(/'\0A(SW&[,
M)@KDP-Y&4(L3W%72GH T1(/X$NMYZ$\D>JGO,U[L/(,BY.[.VXYTQDF(;J1R
M_7QXV/DWYXQAD>+QRZC-L5"&(40)V@)3@ 4137&YA#M(85!,(K"/<%[V4Z"H
M-KD'YOE#[*(KNB(HBH.3&(W5,00 P$,("8!$/3XV].GQ'H'QHBA8<VW^T>$O
M-[7W([7W)G9^?8)GF2;(;YGL)UG#'(\+3RI''YAQ":9;:ZC%5/IORUTFFF#I
M0 [1 !'K1%Y?B]V7N''^47C_ -M.][["SV9YXP6])+?F!Y'D9YW&(QQC$LN&
M.+1D.*AOR-:)2*5(.@=M$4V8/Q$_\D/[PT15*(@>O2B+'IV<88W!RTY**B@P
MA8M_+O52!\Q646D==2W[H_MEZ!\1HB@XQ7EMR'D3Y;<)V&VW@GA&D'&/[HU9
MJ?3BCYS$N3S<3#NXN'RK.$7XDC&"\S- "Q#&Z 4 HBWGXFC[DX]\^, P#F=(
M[&F]Q\AX#865ZXR>%W)^GNJ9_'T)-VN@5[CR2RC=@^;MC% E@  M8*(IG11$
M2E$;W$H"-PL-Q#XA\!HB[41%$6.9.]=1\%//F27NNF$'+R#0HA<QWC5BJJ@F
MG?\ ='+^S1%\[767.#D?ALQGG-[:V4[H8Y!FVQN1NMM79A&9RG*X@[R3$TY!
MOBV*R^K%%!.A"12*( +L26!P4341.<^(W.]K8)S'XK-%MX;"VI'<R^,>1;8W
M-CF69-^D<9CN;I2RJJ4K$-TU!)!@D:Z8$Z=H  413+&W>"9@/VA8Y@(4#=XD
M(%@*!CW^8P_B_7HBN*(BB+P,EBDIV'D8959RW3E&+J/.X8*@A(M$WB0MSNV+
MB_<@N@4]RG#\(]:(H>.IN,,XCS]YD3'&W>^\7VM.'^L<BC7;?9&S7$AB^7[V
MS2 D#-8E2065%FVC<=6<>^<%.B?R6HB]CPKN-I<>^9L9Q^Y?.=FR'(W:>HIK
M9N.Y&3<)]C:YR;&ADW"ZSUPV;K*L(MX5!4"H 6Q@2#MHBF%MC$'\)A$QDRJ#
M>PF[# 'MBH8/4UKV^ZB*ZHB*(BB(HB*(BB(HB2+S$X:Z4YNZV#56[89X]A6D
MLPG8.8A7:D5DF-SS(3"C,0TLB8JS4Y4A[#"40]:*%!6O5>KQ,XF:9X<ZD9:<
MT;!+PV+,Y!])O7;]ZXDI>:FI%4%9*7E7[H17=OWA@ 3&$1#[*99*-2E1EL-[
M7M?X_J!Z?=1%VHB*(K5P B) L40'Y0*;K<_>0P=/LL0:(DM;!XC:9V/R!P/D
MEDT*L^V5K_#\AP*$>^Z(1RN/Y*4_YFPD$@ZJE<D5$H"7J6B)+&A?$+PWX\[\
M5Y%83 Y,]S=@^F)/#&.3Y3(SF,X$^R%0YY4^)Q;M4Z,=]2HH);E"X -@HB=-
M0$3]Q[V#M*0Q.SLLJ03=Y@^T#=P6HBN:(BB*DL4ITE"G*!R&(('()>X#$M\Y
M>WX]Q;A1$TA%>&#@Y&<AUN1"F%Y#*S2T](Y8TP::R61?:Y9Y1+D7+)9(CBRQ
MU&99!0CDX"!@M\UZ(LSXS^)OAWQ3WS.<A=58E,(9U,%EV\(C,SSV5@L&;Y [
M,\G$<+BG1Q;P+>4.8>XB90O\*(G0:(BB(HBL7+9N[0.T=D(Z;NBF3.FH4#)J
M$,%C$4+^$Y#%&P@/00]:(D*Y[XW.'6QMLXCN3)-)8=^F.&PL] QQHR"C8Z->
M-LG2,G(*N&R"*8+."E.(]X_, ]0&B+6G%[Q-<0N*&VG^[M:PN4R.;J)2;+&7
M669)(3[7 XV9646DHW#V<@=0(9BX.80$A;=/2B)T$@@)2B'H)0$/AT$ MT^'
M2B+M1$4163H 4(LD=(%R"F(&1L%E4E2F253-?U Q1ZT1-+07A;X(P.]YW>J.
MNI&1EIM[.21\%F)AQ(:ZB9K)DCA.3<;C*IQ9LWC_ -XXG.F6XJ"(^M$6?<1_
M%+Q'X8[3S'<.F\:G4\RRQL[C4'N2SCJ:2Q*#D'!W3F#P]%R8P1$8=8PA[9;%
M* V"B)S) !!, $.WK8"7 W84  "E[@_%T"]_OHBK41%$5%4H&$I1 ! 0, _N
M@^4;#?[*(D>:^X/<?];8WOG$X3%G"D)R/R*9RK:+=T[.J:7F9]$S=^=-8H@L
MVLD =H@/R]+41:6XA>*[BCPRSV8V5JV&R>8SN0C'D(PR'.\E?Y,^Q?%WKHSE
M7'\?.].H5E%E5,/:4@W .E$3E#4$^WO2 Q2B0B8%,7M$I4;D( @( -Q ;_J4
M175$11$41%$11$41%$7%@'U !^'I\!^%$7-$11$41%$11%QVEZ?*'0;AT#H/
MVA]@T1<"0HA82E$ Z@ @ @%AN'2WP&B+M1$41%$6)YBMD"&-9 MBJ+)UDZ,2
M^5QUK)K';QSB;314-&(/EB )DVBKP"%.(?M1HBC,P'D8\PTESF_H/2&@N-C7
M/XK$6NR)Z2+F+D8,N$*R?M*.FA@ 5?S$(\_<)1O\U$2U]=^7W4.%([47Y=;(
MUIA'Z.;?>:MPU+#%GTV\EY.):>^^8.&R2)C_ %95P$$RV[C?"B+/\?\ .1XU
M<GE,9BXKD+'@ZRS)&^((?6P4RR;Q.4KN"-4(C)G*S<J,&\>*G*5$JPE UZ(M
MLI^5?@H;>:/'QMO"&-L4\R;%R%,S>_HTED0>V5/'5LI,4(DLNL)P,1$3]YKV
M^-$5?R.<S7W#?1\%DN'0C;*=H[,SW%=7ZKQQ582IOLDRR11;).CE 1]Y%FB<
MRIK7^4*(L!V3Y=N%''2?<:KY!;NBL?W!AL/CR^R(&*AY.01QU[*L4U#O'CAN
MW.C'Q?N&$?<4$I:(L!S#S&<3<TUMNMYQMW)B.5;0UA@I,Z9L<J9R,1CLI%][
M=O\ F39PZ13%_&$ _P ZB-P#KUHBNW'F:X4ZTQG%V._-S8]!;05P+$\RS6$Q
M6*EYIE#QV3M".FDB"S5%0&\2)C7]Y40 I/C1%ZD+Y&57G/74_'TR4!,:$Y-Z
M/<;'X[;-@U3*AD,S'G15?L'AOPD 6BAS)AZC8*(G> ] OZV"]$7-$11%QVEO
MW=H7]+V"_7J/7UZC1$6#UL%[6O\ =]GZE$7-$11$41%$7%@Z] Z^O3U_5HB+
M!]@?9Z41<T1%$11$41%$11$41%$11$41%$11$41%$11$41%$11$41=#V HC:
MX]/3H/J'6_W41,EP_$W=C7S99=RR5@$6VDI7C.TP9KDY5_<77R(')>Y@+<;^
MV( '7IZ41,_1'BBY:+<HL<S'(]3Q<I@2/D&R/=4JD_7;.V3C7SM$Q6TFNV7
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0*(BB(HB*(BB(HB*(BB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm205388-1_10kimg08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg08.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!5@*& P$1  (1 0,1 ?_$ /H  0 ! P4! 0
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M0[,D5'7QHN)CH__:  P# 0 "$0,1 #\ ]_& P& P& P& P& P& P& P& P&
MP& P& P& P& P.JV>8- P<Y.';JNR1$)+2QFA%!2^:6+;*O3(?,*/U55$T!
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M45O$\#.Q"S!&=I$U DLP-XE=0_BM.,X@06.W ?(I0'XX&UH?W8.K/8J]]?\
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M^^)1[%]K(KH^YUY58K72'=E&)<[F2OL<J!G$=!/VBSRP+TR+(H9,@N%A WB
M@!0] #TX-1,*)0-R)RB)3F^OXF, \F,GYF,<4Q$?3D?A@<C 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@/N!\,"N P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M'<SW7A33/_X5,. @0#+$_E4U'YGS"J?71( T\2B4Z?'!L#>_EG>ZQ_FI(O\
M[UM0_P"IV _EF^ZQ_FI8O_O6U#_J=@/Y9ONL?YJ6+_[UM0_ZG8#^6;[K'^:E
MB_\ O6U#_J=@/Y9ONL?YJ6+_ .];4/\ J=@?,D^[WNH1+"2E)+VL8".C(MBY
MDG3YSVRIY"-VK- Z[A55,:9ZH-BD$Z@^11!,!'TP,C?;:]PZ@>XOHASMJGM6
M5:LU2M]AUYM.@HSC6QK4RZ5R069+M6TNT;-$96*D2I@JV< F4%$S!Q\!' D7
M(/("/EY?6,'PXXX$?J\?[GX8&O 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M !@?HZM3&.@F8Y3%,(#R4Y@.<OJ/U3F*  )@^G Y& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P&!LK@4R*A3_@&*(''R\>
M"C\1Y^CC PQ[H,*[/Z[@*C9-KS&JV5OO$-%)_B62-!.+_)@T<NF6N5;0D=%:
MJM+*JV*D=T!P'@P@4>3!@0,L0[$;:A8/61MD-8*-T'N#L?+WK6\_V#?U&46J
M,&Q36H]>@-D0)7LI?8N!:)F$YS>B2H@"HAZC@=A)O.6VQ0MW=@&U^V-KZXZ,
M9]?F_6B@.;B\47<1LFZ!"31D85)RD78*>Q95F=N+Y4J@F1XX\1-@3=]ENS6W
M- 5+74[0NJVV>RTC:FZ1+##:Q6ADI2IF(Q9."*RGXY<LT50<*N#E$2B @)!]
M,"-'VDMFW#<'>#W1=@WC4ELT?8YFZZ8(ZUW>%&:MEBTT**@FDL[^P*+-/!8H
M^GB<<#T&8# 8# 8%B>T7\VS?WYF]D_P0E\#$OV??Z-/I]^:EK_C>6P)*0^ ?
M>#]; K@,!@,!@,!@,!@;*_HF)O$3"3R.4H (\F AN XY /7]7D,#ST?I$JW?
MW7G3YQV)Z&;NN>NY?3GVI[MZC5>.B7H7+7LJ@#=_*%*_C'RI%Z^4QC',F("*
M9OHXP($_T4^^>Y%VAV/-S-N[!WMETET6ZF'CFEE81*4%>=CW)\O*?B9%V2)(
M\409NEE'+H4U2@ _5]/+ ]ENA.B^B-'V>QWQM4(6R[,L=[O-V=WV7CBN9B/?
MW>04D'K-B9<ZK= $TE03*J5,JH)AXB80$>0RHF]<T.R0\K7YVGUN4A)QHLPF
M(MU"QQVDDT7#A1!VF#8OS"\^H>O(&]0'GUP.B4[K;HK7T+#UVEZPJM>A8"<6
MLL4P8,1^6VGG"0H*RAE%U%G#IR9$1)^_'4+XCQQQ@=._D5]4QB;I!&T1KY2'
MV(]0?W.-5B/FLYQ=L_/*-RJH'6,FU:(22@N"-VX(MRK#Y@0#  X'9J5U>Z_:
MYK-KIE)U55*[5;PH92VP+)HJ:.GA,4"B5^@Y77*HD!2AP0."!QZ!@7IC8F.B
M(]E%1C5)E&1K-"/8,4"@1LT9-4R)-FZ! _ 3023 I0Y] # ^C@,!@,!@?.71
M+PY4 QRG HG*8AO$2F!$_(@(!SZCZ^O/K\.,"(CV4P,;K;NL3J*'-_++[,B)
MS&$3F$;T<3&.(<>9S#ZB(\B/.!,,4. X]1]1]1^(^H^H\<>N!JP& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P-)R%4*8A@
MY*8.# ( (" _$! 0'T' M]L#5= VG6W]2V'5HFX5^24;+NXN<:)/&QW+(Y5&
M;M(JA1%L\:&* IK)^*A!#D!YP+02/3'J]+U.NT:1T9KIU5:F\<R%<BU(!J 1
M3Y^H"LFZ1=D*#TZDLH4!=>:AOM'[?RP.Q2O5S0<]8Z=;9S4]%D;'04&C2HRQ
MX%DDX@V<<J"T:T9$1230(WCE"@*)!*()B'(>O.!?@6Q!*4HF,/C\.?$>>1#G
MD!*(>H<A^H CQ@0O]$4P_P#$X]V(1$P^%KT:B0.1 I4PH*)@*! ^J'K@348#
M 8# 8%B>T7\VS?WYF]D_P0E\#$OV??Z-/I]^:EK_ (WEL"2D/@'W@_6P*X#
M8# 8# 8# 8%#!Y (<B'/W/C][^K@=<ME3@KK69^GV2/;2M=L\+)5Z;BGB95F
MCZ)EVJK)^U62, @<BS=8P>OP^.!CATWZ6Z-Z)Z@;:/Z_5T*Y1F\]/6,Z*OR5
M'[N2L#TSUT9VY110*L1OR5-'DO)$B '/Q' RP*0 -Y<F$>!#U$>..>0Y . $
M0^Z/K@:\!@,!@,!@,!@,!@<1?^UNO[D;^\GP(@_92_FV[K_RR^S'\.3X$PP?
M#^J/ZXX%<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,"G'ZH_UO]@.<!Q]__7']G K@0M]$OZ3?W9?^>&C?_A^E@328
M# 8# 8%B>T7\VS?WYF]D_P $)? Q+]GW^C3Z??FI:_XWEL"2D/@'W@_6P*X#
M 8# 8# LWN_L#IOK?4D[]O/8]3U;2#/DHP]IN4H2*B4W[@!%LS^><A@,NX\1
M\0Y#X88F<&((>[][9 F\1[N]?R#X^7@>YH%.'UN 'ZR0>@A^IA&*IEN?^+Y[
M8_\ VWNOO_39K_\ >\82SBH/N^>V,'Q[O=?O^FS8?UDL&TTC[OOMD&X*GW=Z
M_G4.($3(6YHF,<YAX*0I2)>1C&'T  ^(X(JQE]6:]U[VY:Q)*P]F[BZ2@)9%
M%NZ4C9>SFCWJ3=VBDX:J*MW3=,_"Z"Q3E$ X,40$,)/EA[OWMC"/'\M_K]_T
MT;A_7%/!+5_XOGMC_P#;>Z^_]-FO_P![QA*.*@^[Y[8_ \=WNOPCQ\/RV;?[
M"0C@Q7NT3W?ZG]G9Z6K77OL!K3<$[!-TI"9BJ1/EE74;'*'^4#IT":?@4@*C
MQ\0_U\),L<!@,!@,!@,#B+_VMU_<C?WD^!$'[*7\VW=?^67V8_AR? F&#X?U
M1_7' K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@:3"(%$0#D0^CX8%B=^;XB]#4UG:GM3M=U?S5ABJK6:G4&(/9V>FYC
MS%JDD"@E;L&2)$CG7<N#$21(7DP\8&("7N=T"2@F)*WJ':UGV<20OK*U:BAF
M48[L],;ZR4\;E*RT@B[4A',6Q( B@JW64!T8/!/DWI@<EY[H>DQ<QDC7*K?+
MAKM&+HTIL'9L%'MSUO5@;"=_88!A;TEE4WR<HDY*<'B"13*-"D$QPXP)'$I$
MCE)%9MX*IN2-E4% /R51)P0BI3>)0%0.43>0>GTAS@0T]$CB7W-/=?$X!YJV
MO1ZHD#G][*%#1(7R,/U>3 //'QP)J,!@,!@,"Q/:+^;9O[\S>R?X(2^!B7[/
MO]&GT^_-2U_QO+8$E(? /O!^M@5P& P& P&!Y9OTO0H']J-4@_ =Y:\$0]/7
MZDL <^G/ ";GCZ>,Q*%? _++^S)>)?(A%//DQA4)R;S(/RQ,!@$! I@^CX!A
M7CQ*?9&W_J$?[ ?^%AG&>-4&S</4$$/ZJ?/ZYAPQC+[5<11"R5KA!#UL4$4>
M$@YX-*M $.>?I_6Q"5$Z4HGO5M6J??Z^))M6B1"ZXTH<2)-DTD1.;64!Y&(B
MF!4T_(?4>.>1]<RM10?9T!]/L[?^HD ?UP'G"-6H^R-O_4(_V _\+,*\9XU#
M-6X (_(1]/N$'_A#AFF9Q>TK]"O22_E>=L1*F0@)Z7@Q3 OD'@)K.W*80 3B
M')@-]S,K7Z0N P& P& P&!Q%_P"UNO[D;^\GP(@_92_FV[K_ ,LOLQ_#D^!,
M,'P_JC^N.!7 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8&DQ@+QZEY$>"@(\<C\> ]!$1XP-A1<2\>"8J"8?00'Q*4O')CJ"8
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M6@OX4M<UUC](' 8# 8# 8# XB_\ :W7]R-_>3X$0?LI?S;=U_P"67V8_AR?
MF&#X?U1_7' K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,#8<'$B0B4ICF,)2% I?,0$P@7S$OQ\" /(_J!@>;_P#2&'+%O0>G
M\NY>4*-:079!!Y*7#8E!F=QU6FL5*W+"1]9=90#=XO-Q[SS^4D*B0E1,8!']
M0,N_9>M4)9^MEHDH&[:7OD<&Q)1%*6T9HN4T!5$#%1*(Q[RI2S1DN_ET?PE'
M92"0P#QS@3%>8<>0^@<\"(_ /ZOW,#097C@0(8P#_M>!$1].   'U >1]?@
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MO[0&:0EDV?9XC8]IN9JA3-=Z^JR-HEF<:,>1RYV1>%7"J(1M(9.% !91(#N
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M)_(BJR:L3HS<A!*HNI1$"-N2%4$0()A$/7 C$]I32L?U\[Q^Z)JN%N%_OS"
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M$>?4P!ZC\0*' " ? N>=;/6Q$Q=X-7(^KHF9FJ9XW)RU88# 8# 8# 8# 8#
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MB8OJ'W<"@+I"H5+YA?F& P@GS]<2E$0$WC\?$!#X_# UE.0_/@8IO'CGQ'D
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M8Y"_A&*7X?$0#XCP'Q^Z.!0%"#^"8IO3R^J/E]7D0Y].?3D,!\U/DX>9>2
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M.,"-+VE=NN=\=X/=!V6[UQL#4CF;N&F$UJ3LN/)$6J,.TI"1"G?1)';U%O\
M.*4!*(&X$/A@>@O 8# 8#G L3VA'RZV;] OJ/\3>R0]/7XU"7X^'W<",3HOU
MWJ/:#V>NKFF;\NX2K$_KRJR<J#=-!4RR4+;'\LTCU6SQ)PW6:NU6WBJ' <E$
M<"577NF=8ZE@#UG65"JU2@%WIGSB+A8:/8-'4BN4HN914J+90BKA4OQ$0#GC
MC ^=L;06G-JA"&V'JRDW5:K.R/*T2=@(YR6-=)J Z [=51J<&R2JP 8X 7Q$
MP? <!8M)ZKN\3/P=LUK49Z&LZS%6PQ\G M%V\VO&-P:Q!W(&1* *Q:8>"*P
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MBF % O[X04Q X "2:IO'Y8AX)^G!$@X ..,"&KHJ(C[F_NQ\B(\6_18!Z\\
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ML50&]3;W)X*K9[%.GZA!3.3Y2HMC (J@0OK@2&)+?/*D=(Z:A%DBKI*) 4Q
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MJ4P<>GIA8W\!@>6?]+R_HI%/SY:\_<RF66]<HU/RSQ_!3^\I_?,M04P& P&
MP&!0WX(YBKHRS3K>TG]"N_G=]M/S+07\*6N:ZQ^D#@,!@0 _I*']%ALW\Y^I
MOX5!G)=BOM%R?SEOF:N\O4*^27BD1_M*7]R)^XS]4:_U?DIYH>:LS];U?&EJ
MR^KI3RE72GE,BB8# 8# T*?M?]7[8,HO^=RW[12CF/5OQO<2I>PY_2W4O_)O
MV/\ XUAL\=_>@_FG+?,Q\JIVIW=^KR_0#1_ #/+\><K^,[2N=)NY- P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& XP& P+;[7K9[AKR
M]U5!LS=NK%3;+",F[\B1V:KV3AW;-H1P"Q%" B9PJ4##P/I@1#0O5KLGH^K=
M:+11J;7=DW.A=8[IUQO]$;6MC"-8M>P.7;NOV. EG30\<K$P[M[XN$2) J=
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M%#T^.5_QCO+#IZ$OZ(]T>&'T;3^5_P#%\P="]93B)PH^N"@;ZP%!XT$  ?4
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M$1.$11&$8<.,1PON._;IUD>J?EJMJDZ5>19-I-4Z=KF4I8&;M3P1?$C!D0<
MW /NEX'XYR%&_+EO(3>BBB:]GAIA\GG^P_=AOCM=1N#)[USU-RW=F*HISU4<
M$8X[,>*)=PIE,K6O:^SK53C!BZ^Q.O\ 862BZ[HQ176,JNJ=5THLL8ZZIQ,/
M(CP(^F?$9K-UYZB<W<B(N53.J,(T:'JG);AW9V6W/8W/N.[<N[OM4^]KKN3<
MKF:M,XUZ)JTR[84 \?@'J _0'^VS6RFF]A/$YJW,W-WS->F<)UZ4IOZ/]_/7
M[P?J:OTSQ^I]>9STSW;1$=GIB(PCKZN:E^'GW^*8_K/;G",?HC+?+NO6TG^
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M</[75_RJD'I_PS_^<;]<<\FT]/\ &GG?T+6?^EB)\$<WL-)0    ]  >?'X
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M.! /0?00]?HP*@4H")@#@1#CT$>/['GCG]7XX&K A;Z)?TF_NS<?'\L-'?\
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M2I"&2^80"B<H*@H A\!$,"&;HF94?<N]V91$2JJ_EKI!,WU! B2A=>M#BBJ
M'\@-X&'Q'Z?IP3JT:TS*AC@80%-3ZP\_@A] A^KF8PZV):5=JOT>YCKVZ>=Y
MI_TD\%#:NZ7B8#%*7M-#K";Y0F "!7)CE, !4AE' _04N?,=KI_Z#".*KF>A
MONU[QIR'??V>QUSFYB.7JZHA!X<%!.<01-P)C"')%@'@1$0Y#Q]!SR+7DM[;
M=6$3AM3P1Q\K^C&BK?TT1,4:,(_NT\33XJ_^I'^Q6_X.1]"WMQ3XH\J6._O@
M?^VD^O\ 2GZ_^:K_ ,'-J,CO7"/>S[7E4S8WE,XU;LO5U<-47:8B?#$8Z,>+
M@5Y-_P"K_P!ZI_P<SZ#O7X$^UY3T?>'[JO\ Z6GRG)O_ %?^]4_X./0=Z_ G
MVO*>C[P_=5_]+3Y3DW_J_P#>J?\ !QZ#O7X$^UY3T?>'[JO_ *6GRG[Z(>B0
M_? BO_ RJ[DMZ13T9CQ>55U>=IKF*KD9/_ZJXVZH\.U&O'6WRE5\ *")A44(
MH #XJ@"?CP(&'ZGK\<KRF4WG-SHS/B\K1WA3F8M:,[;U_ E*+[ ?FGW8[R@'
MF)4]8:;(=4$_0BA%YD Y(/"G@)/I\1#TST]W8V[]OLY53F?.>D5^+"E^*OW^
M.L_K'EXN7:;L_0V7TQ&S_P 2]H>MI(YN!Y(/H;@ (8IR@ < 'J'B("/QX'U#
M.PWA/75[+<!3X_44^(_M?_+F%DJ_,_W"H?\ HA_L\X8>6G]+P\C>U(KP50"A
MO'7OF<R1A(0/&5'DRA?J)G'C@H&]#>OW,LMZY1J?EH^29A()!.)? _*?B(J)
M'!00X4, <<G#U /N9:A@K]7[BG]B/[& ^K]Q3^Q']C ?5^XI_8C^Q@/J_<4_
ML1_8P'U?N*?V(_L8#ZOW%/[$?V,"O"8^AQ.F7Z3B0P@7]40  $?7,5=&68UO
M:%^A9>27;KM<!P_?#:3KIUB%$3^ *6-$Y2@ %'@QA* CR/IFNL?I ?,_W"G]
MC_Y<!\S_ '"G]C_Y<!\S_<*?V/\ Y<#S^_I)QUA]K#9GB "979NIQ%)1,15*
M3\I4S'3'P43(58!'D $>.,Y/L3:RO]1,I7<F,>MHX^)J;QQKW?733JPEXLB(
MG,F@7@!#Y*7'/D!N/ OJ( 00 ?N^N?J;>WANNS.7VJHPV:>&>*/ \XW]S7KV
M]JICAJ_MPJBBJ B $#@!X#U/\ _]#+9WENJ9F=JGV_(UKF3WG1<JIB)PB9C5
M!\I7_:!_O_\ @9CZ1W5\*GV_(AZ)O3BGQ0?*5_V@?[__ (&/I'=7PJ?;\AZ)
MO3BGQ0?*5_V@?[__ (&/I'=7PJ?;\AZ)O3BGQ0?*5_V@?[__ (&/I'=7PJ?;
M\AZ)O3BGQ0?*5_V@?[__ (&/I'=7PJ?;\AZ)O3BGQ0&(8I/K)ASY>@\J?K>&
M8RN]-UQG]B*HTT>'CY'*4;OS->[9JOQ[_;GF2F>P^)Q]VNGF O\ :NN&QU#B
M5,Y^$PDHK][+P8O"BP_#ZH_@^F>.OO$U9&_O*)MS$SM>%V7V"RM5NSC/$]_Z
M9S<?63. #P). Y'Q$.?K!\2B'W!SS#%%%%,4V]6#L6(F)G%11;P$O)3E*8?'
MR\#&$#?$OU2E-\>/B/ 89:D5#*@)A+X>O'@;\,H@(AZCSQP(>H8&]@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@;#GR^0KX !C^
M(^)1#D!'Z $/]GZ/C@0F[\ZO]@Y&Z=J:#1*+'6JA=S+/K.;>[)>3L=')ZN-6
M%&S2SHS,.MS)O3)QJ/S(P[;DAUQ]>,#-SLMU(G.Q-:U_787LIOCK\:DD'YLS
MI&QM:[(6<R;%HP!.>7<-71GS=($!,F40 2CZX$?U7]CMC2KC>-@U3W!^\\'=
M=EKQCJ^V1CL:+2E+4YAVP-(U>87")X<J-&P 0H\!P4.,"XG_ (2]^'X^Y][@
MO/W?XSXG_D3,3$37M_WDYKF;%>7G#JZYB9X\8U83P+1[=]AJI;];UAINOO=W
M7V<UIDXA9:JUMM_BWZ$%/-VR[1*4CTRQ:().P0<'#R'GU'-;>&3L;SM]7FHQ
MI\&AR_9S?^\NRF_\OVFW-531O;*S5-NJJ-J(FJF:9G9G7.$SA/!.E;8?T;G0
M)A$1[:=MQ$1$1_\ WW8_$1Y'_P"@YPO\)[D_-3X_P.TY^\1WLS./TG<\=?\
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M/#PKY?\ A,; X O_ (G_ +@H\"8>1V=$<\G,)AY$(0/I'T^X&;3YC9C'$_\
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MJZ.>.6^8F10.0#,,LOO_  F-@?YS[W!?_>A%?\BX#_PF-@?YS[W!?_>A%?\
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M P& P& P& P& P& P& P& P& P& P& P&!00 0$!^ AP/WA^(>OW<#8!J@
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M?UQ_9P'@7[G]<?V<!X%^Y_7']G KX@'PY_UQ_9P-)OA]7\(0'QY$W'(?=X'
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M(A@;N[.A^W9!2=F.MSFK:A*>U+,8RIT^9D*&Q3J?V=0K*PN):O(+.7\NXGU
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M\W<MU? 3&9"V* >0_6'D!XP,V40X)Z_$1$1_?!4]1XY^L/K\?HP-W 8# 8#
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MUJ5(M-;UWNN[.Y>&MEEV?5*]5"K670M9HLZG6K78-FLS+ FRC8F;.*)E$3G
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MM.6+4=;U37=?3.O6TFY>]B5M5V9I952;HE4XZ,3)3;R+, .R40>"#E45#G,
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MMB*D]2*:F?T - 2&L2.K-,FJ=FJMS=SK65-+N7"<-,/9R"DTTQ!-JDLS%,!
M!/@6VO/LO;LL=+[<-VM:T>XN>X*+U1BM:'G&K5<OY1Z4:Q@W@DD_,P.XBPF%
MHX02<%%01*(>13X%LYCV1NS$QVAL5YEFNOGM'MFQ:]O!*VEV#(Q,AKZR15"3
MJZM,CZVPJWS9:-0DD?EMA*_;-CM3#Y-^0'D)0NK/MHRVF_:UMO2)X\J]%VML
M"C[&KUVV/K]F#7\86FW.)1Y%6.3D2D;/I8@%=IIN#''U3$Q X# BJG?94[F;
M>KD<>SUSK=H"7TQH&NZ6H]5U7(/5:QV1>U6RLY]"1W$FG%L4VS.;%CZD4!X=
M$5C?6-\,#)FZ>WIW4M=9U%MZLZ4Z=ZHW=K#L]7]S)Z8UT]FH&AV*OQ5.>5)T
MK9[4VC4C25D3</#+M3I,4/[6!3 8/7 L-3O9B[PUJJ4V2&QZ59["C-5]QX1X
MV4=/I.L$NG86Y?E37V(LUF1$WK-!J=1NNH<@_7'R^(<8%J==>PYVP4C;6AL2
M-TTC#WO:75B[2E')9U9Z#5AM+N"?EHP7;GK\*Q,D_0*8Z#8&X>("!!.?XX$W
M'N/=%+EV05Z6/M(0&L4?Y-.]X2ZO8"R-V\2@TH01KJ*79U9=LP7_ !<O'@HD
MNDD0H%.*0%$?IP(;KE[1_:JF:U)4;#7=,1>O.L0=G-M0V_=?N'KWL!V$6V)7
M;8>+UY:(UO%-U2\.),".2G=.RN"H)@4"#S@6NTK[3/<+M!UEU;:G^O-(]>P@
M^DRFHJ#&0*TI&6?:]@M=D9S;F8W1'DC&!XI_"MFA@1(<SL0.;D#%YP,\M?>V
M-VPU?N>[LV6O.J&P*#L:\T'; ;_V>UDY_;6KI"HZUC:NYIM7B0:IJ@@E+QPG
M8N2O42)H*&Y2' P=@?8L[X2[C;4I;5--1,[?] [5U"9S V5;[#+3MSV5%VR,
MF7$0UK<66"B2Q#,ODU.L^4*L83?-^L(8$MG<OH/V$V&7H#L+5%?U+MJT=2JT
M]IERTWM:0<,M:VYO.TQC5I"SLUS,9+YTA7W385&WFU$XE#ZIBB/.!C)TA]FG
M;FI-Q]<-E]@H33$M':BU;V7KSV(A"#-1]<NNXK>I.5M[3V<@Q$B#.'8J@4JP
M 4Z9R?5X' QRC_:*[G5JIQU0VG(:WJVFNOVL.Z=6KEWUY(SEGV3;6>]U92=K
MTQ^2+5@FJB_9"X^2=HW55,L'( ("/&!Q_9-K^R[+W\D-CIZFI]4U[JCI)3]!
MN;G0=?6>E5:6M,)+K*M3S2EC@:^I(VU<J8J27R"K@U'ZAU!' ^-8_8R[M[2W
MQ<+E<['J>GQ$C8^R9$+O3+"NSD)F'W%$N4:G(MZRU@V9XT[0RA4) 3OUSKDY
M, %P/NV+V8.[NV:S9F=FHG5K3KQOT_U_UFBX[6\H\.QOLO2MB04RO>[@4(!B
MF5S.04.*BO)%#F64, G'XX&2UB]E_9+NZ;.NM/K>F(!U9NX/5W>-/>L&249*
MPVOM3TUI#; B$%6;5#[ \E99$Q@12!/[27@QQ'D<"NH/9KVY7-GZ@LVSV>I;
M;3J2/>-23C)=%*?:$D.Q*C]?7#UHQ?LU2J+1R[@OVGGD$#>H?# L-4/8Q[,1
M.F-B:^M*.I+Z>;ZO:TT_'UB1ME@K[->P4_;D]?''XLFHJ.\X9LRB'[<&ZQDG
M!"N>0$@E#C [!J;V<.YM:UMUS=W,FD9VX:0[H2V\HJI2[MO(&K^I).M#7W%>
M>W%K661[78U' _:R*F9(E$Q2%-R(>>!SK9[,_92#Z?Z?U!K&K:%'83/L;M[:
MN]E70(1$I:X38+R7/5GL==%:[./4W$ B_)YHF14XX,4AB<^@=0I/LA=L:9KG
M2%:22T=*V>K=0^T'7*^2+MVZ(XC)#;\W*2]/GH*3-$BY>K,N2-RB/ROLZ:IA
M 0YXP/N6?V:NWD7 7K6M6@NO&R(+L3H'KIJRX[5V'(/ORXZQSNG(B(C9MSK$
M/Q8[<2,-(%CA>,BMEFBJ;H_)Q,&!WN&]DS<M=J#QDF\UC-["9^X%K;LC&[$E
M3%3M;[4-'C(]BY;.IQ-H9^C,R"K0QSH%.(<&]1,.!/6TG^W'\1\H]D*?JLF_
M!N"36!A$)^14HRM(+?F#=W-/946@.T)$-:&<.RI 00&1*5/GQ-S@?'[#>X/U
M ZJV.$J&^=WT[7UIL*1'D; 2CIPYE?Q2=?[-^/'S.+;/U8J&!;@/M#KY*?'(
M\\!@7HI_8'4FP;3(4JCW>#M5GBJK W9\PA'"KYN2KVA+YT!,H222 L'+*33$
M#)F(<?0?4,"[/VX/CX?5$P@4X& Q1*42^0B!0,;U PB @ AZ>H@.!\>Q6Z#J
M<!,V>Q/$XB"KL1(3TY)/#%(WBXB,05<NWSLQ!4$J*2")C#P!A  ]0P/AZYVG
M1MMT2M[+UQ8(^W4FX1Y9:K6")7 [&=C#G,F1ZP5<%;_.0$Z9@$0] \1P.A2_
M:30<%/LJO);.K))]]L!CJM.*;.E'[QML*19'D657DDF22XQ<@Z9$^8F#CY93
M%]><"]ZC\4U"$%NH/G\HH<&*8Q#J";^VD3^88J0 7\,.0Y],#6+Y(">? ^A3
M&.4!)Y)^(\#\P!,'B(!ZC](8&,W9;N1UGZC1E9G.Q^X*WJ>*N;]Q$59>PB^X
MG)5F@5\=NP!BS>*F530Y$?J\" _'TP+/67W/NA-/UG2-RSG9K7+/7.QY"2C:
M1:$';Q^UL$I'B09:+09L6:[X9".*( HD*8*)\\F* 8&1^B^PFG>R%(8[+T?>
M([85%=O5XU"Q1C>40;+/6Q_%1LD619L5CG05-P8WRQ  P+Q J %$2)F/R94%
M?#R*J0Q0'YG &\ ^8(B  /H)@'GX!@/M2)CB @)#E.41*<! P*<"!$B /U%.
M  1-XF'D0'TP*%634441\R^8B0QA(4OS2D$.1^?Y"*B?SBAR7DI?JX%N=J;D
MUMI:G*WK:EKB*;4R2L+#C+R_SBQXRLY(I1D-'IF3;G-]LDGZR:*7Q 5#!@:+
MGN'7>NY*B1]SM#2!=[-L*%6H:9TG2Y;-8W#51ZVCD :HKD^>=BF)P,H8A! H
M^H" 8'9+G=ZMKNH6.[7:895RHU&)>S5DG9-P0L?%PD<F99_)NC")E2-68%Y$
MW@8WT<8&W2[]5=C5&O7ND2S2SU&U0S*?KE@9& 6DQ"OTBNFT@U Q2J&!RB(&
M3*9,@B4.<#M)'"!1,/DF1,? QE?-(4S*+\B54BJGBF8JO($]!_"'CC ZDML[
M7Z%]CM6.[1#MMD2M?<6>,I:K]J2RO*VS5!!Y,-XI-4[D8UHX$"'4,4">7H'.
M!\C8VW]<ZJ/46]_M3"MK7JS-J53BNDGATIJQR/!646G]C0<D(X<G] %3P( ^
MO(8%QBGX\4@^A-(ROS!X6*F8G!3F\?F"HJ)@ #\^G X%E]_=CM*=8*&IL[L!
ML*#UC0D9..@3VB>44)'_ (XEO+[ Q0,BW<+JKNC)F(4I2B/(8&/!/<ZZ%FU&
M^WTGV7UT;5,=:6=*D;>F\?"W86IX7YL?6WL<#$)9M*/42B9) S?]] .0'C O
M1UP[7==^V$%-6GKGM"'V9 0$DK%3K^'0D4$6,DL0JPHKIR3-BN90A2CQXE$H
M<X'=[WNG46L9FF5V_P"Q*S4)[8LTG6:/ S<JV9R]KG%3J'(UA&(&^TNW"YDQ
M 1(42^(>N!;U#N'UB4W%-=>OX[]<EW-7&+^5FM>A/M"34,VBFAI&3,ND($21
M"/8<K+@<X&3+\2\8'-H7;/K=M6%+8]<[BHMN@3VY*BF=0THDL);D94Q&<%]G
M^7]H!V\^0(IB8ORU$R^9#"7UP,B%!*0A.#@DER   &.!@5*83<$*')E@.'H)
M><#2J<2"7Y1@\_0!#R+P!0Y5.10IS"/'C\1#R, >F!;396XM;Z<BH"8V9<(F
MF1EMM,#1:\ZF!6;-Y>UV58K.OPC J:2YP?2C]0"$\RE /IX .<#>N.X-;Z]G
MZ-5[I9VL%.[.F%:_2F+E%ZH-@F6C?[2NP;*M6[ANFZ33 3!Y&( E^G N2!4U
M#J& 0#@0*H8.>/F<<F'@1\@.0G <C\.<#I5KV/2*.[K#*YVF)KRMQGD:O56T
MJ\:M#6.RNB**,H*-3<J?.=R*Z"(G3(G^%XF^]@=N*X)XD(H!05$2B83 *9?E
M@/GY*&!/]Z$O/X)@(.!;_:FV-?Z@JJUWV186=7K2#^/B%7<BJ8AEY&6=I-(I
MBR13,=5T]D7:A2I)I@8Z@#Q@6OJ?<?JY?MIS.C:KO+7M@V]7V:CV>U]'6%LK
M/-&K9/YSLHMA,F1PM'I& [E%(QUD" ;S   <#4MW"ZRM*=LC83C>&N0I&H)A
M:M[*MB%BCW$!3[2W(D"E?DGJ"S@B4H8CE,4VQ/-8PF_!Y'C [SK3?NF=OZX_
MC<UILFIW76JK=T]"Z5Z5;.81)LP3.J\%ZZ*<GV%=BDF85B+_ "S$ /4H8'5=
M(]LNM_99.Q'T+N"C[5"K2@1=D+49IL_<1;DH^*?VI #$4(U<'*)2*>()J<"!
M1,.!]7=_970_6>ML[IO_ &G3M45R2>H1L?)W"83C4WLBN!?^)-$C"+ER5$%B
MB($(/RP$3& "@(X'2;GW;ZDZ[=:R8W+L-JZL+[F;,W6JTW]KC4D+DR>F K![
M#.044: S>K#X$7.H1(YQ /(!'C [GNGLGH7KE7F%TW?M2GZQK$JJ@E&S-KDV
M[!N[6=_+%-BP  %1Z*GD!^$OF>/X0_5]<"Y%0NM4V+68*\42QP]NI]B:(2=>
ML-??H2L1+1CA(BZ+MF^:J+(',(&XXY#CU*( .!V452E\BJ&$!\A(!B!P;R4*
M  )0$I0+R0?(> $H#Z?' V7*Z#1-P[<N2MF;)J9P\<**$ R"#4@K*F$PCP1$
MK=,QU1$ -Q@=(UGM.@[HI,7L+65@;6BF3:TDA%V%@D=-L]+#2#J.=JLA632,
MNT(]9'*4Y0.!@#T#@<#AWW=&J=52^OH"_76$JL[M:UA2]>QKY3Q>7&U"V.\&
M#BTDR*BN\(W(*AB\E H!R.!O/=NZ]CMG06G'UIBVFR;-79.S5NM.!*D[FH6)
M5!*2=1Y3% KHK(X_OQ2F\BAZX%ROEG(8GDJGS]40#P !4X^9Y%./D/*( ?Z@
M!P)1#Z<#0=0 *)DRE,0 Y$@G$2^I@$XK<_@*!^%R/WOC@<)9P04SK$()S)F%
M8X)F^80%0,"8%.0IA.*R(&\O'ZO'/.!T&I;CUK>+C?:!4K9#S]XU,]C8?84
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MAQ6]C:2A^G%WUG<YA?6,=IYG#MWMT_C0LKUR,&X!Y8"KC,F>IG=+)J 5(2B
MX%DX G?.Q3U*T'9=;]JWDMKO=O?5[M>XRL<_7UW9J/<ZI,#J&"),*NS-K)$J
M++@1JGX>!>0\>,#$W;^K^^U>UOU*HNOM.]K*5>=.];](JTXU-"TJ59G9 O\
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MEN+V[-P3I^SJMKO^W>U4-VE)>+38IBLQE!;2KY36K>?KK]PK'P<:J42"R4*
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M6S7^UZ437UT@Z,Z;RM75^<D\;HK2LBM"R,NU,8X,)N<C%RN7C<! &ZIO O
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ME%$1.8W #S@$W!5TQ^2<YDU@ R*A$P^H4H% WS%4RF(0XE]" 8/4/0,#DF$
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M=.XAH< #Q:.S)@90R1BB8 X,/'.!W"(:QD Q9Q39HUB(AFT(T9-6X),6B*"
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M=/14*:.3(X+\DK<4CAP<3#XX'3*O[U/:EM*4=786Y=&WJO;^ZU=A-A.-;4.
M&'V'I38L$]>UBB:VGGIGJSHLP1^LF @N@BJ8Y>0]/7 YKGN;[AO4Z*M6E]=;
M!UBC7>KMPZ@:EG8Z^U67L=FMMV[1-_M]OD9*<4F#+JC7)V=.OZ"8A"I 7X8'
M86/?O;=N[%]+DNUNW:I5D]">X9V.T)L'8D"__B[HE\KU9U^P?U]]:V"[Q:,(
M*3M82I_7%(W'/(#@2D[^WW",^_?MP[>Z][,AMATWL/8MJ=?M@M*794[)6)BJ
MQ4"-M)/II1CI=J:1K$P@7YBI $Q2F\1],"+/W<MN=FJ9W'[UTJ.[$.(#6 ^W
M&C=J'JYN_?1@C94[Q&,E)"O E)( E8&*P_.=.$" O]E'Q#GG W;-[G_=7JS!
MW_1.T-RZGG+FVU=U0L&H-H):Y=BXAB;J;J-'U<=1KR8*PGGK0L0;Y#N0<MDQ
M-ZJJ (\8&C0'NU>X7V;1Z_ZGJ%PT[2MA7FS=LJ[;-C25$&90D4.O<2K*PK\D
M-&6!>+:2,VDEXG!%T9 ##]03!@20,_<CWR[]CZ6[[&8TXG8"+K*,6F(1;G\D
M%;:MNZ/TV,X:&^=\_P"R@#T7OR?F<?,#CRXP)9;7UEZ\WZ_1>UK;I;74_M.#
M,U4B;M,U2+=6)FI'F*9DX*[52$YW++XHG.!S(F#ZHA@<1OU(ZV-[^^VB71FK
MDMAS4BK+R5U;U.+2LK^66;'9NI-S(_*!119XR.*2WTJE$0-R X&..^/;-ZQ[
M;TYMG5U(U_3=#OMP5-2AV>_ZNIL'&W!>CK/TGTU -7I&Q0:MYE1,05!/P$1-
MZ\X%\JUU#ZY0SS65F=:FHMDOVIJC7*94-A6&N1;VZ-HNL1J;"-72F#(BL#U-
M- "_-,'[V/(%$ ],#[%?ZO=:ZS;[;=J_I+5L+<MD-GC*[6!G3H9K*6Q@]2.:
M;;R[DC?AZW>^?[]^#\SXF\N<#Y+CI9U&DGE1?.NMFGG+N@%2"DN#TJ&4-744
M'*L@U"+$J %(DF]5%0B7'!#CY!QZ8&_V0ZMT;LC':T"P.Y>OV'3VQH39^N+?
M7U46\W4K'%$.W>(-SJE%!2)EXA95HZ2,!B'14\>/0,#CUCIWU2I%A=W&L==M
M0P=N>LYAN_L412X5A)2"%A$Y)]HLX3;E$49LBQA<%Y$IP,(" \X'=M;]<]$:
MKJUDI^L=2:^I%-NIGSJQURMUEC&1ED5E$?E.C3+=!$GVHQD#G3'R^K\LW
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M-Q(DT4.4#_)'DI5.#?$,#ZULZI]>;TK:%+EH[6%H6NZ42E=7DQ4H1=U:P@D
M:0XRR@-2G5/&MP J \\I%+XE$ ' [- Z(U?4-:.].T^@56L:PD8J4@7='KL8
MVB:_^*)IJLTDFR+%!/P2,Z36,)S!R)CCR/K@6KTGTZUGIG3^O=,J,D]E5;4L
M^^G]8_Q@M&<M(T<ZKY=]#LH%X*7_ !8M>^TG2;+<?-(GQZX%QOY-FC@VLMO5
M#4U!;;D6;_8_XRR5R--;RMO $%?&8% ')5W+7][%0!\P( !SZ8'U)71.IIQ*
MZA+:SI$D?9 L#7XTA!,7!KB$49)2++9%/D@>6/'G1+\HRHF$@D 0P+;!TJZM
M#<$]@*]>=.GNZ+L)-.V$I,.6PC)IH S1>EDC-Q52=$9!\H5>1-QQQP 8'UM?
M]0NLVJK2C=-;Z$U?2;6W3D"-[)7*S'QTRF26.*DFD+Q%(JIOMZAA,J(CP<1]
M?7 Y-@ZH]>+C5RT>WZ2UM8*@A97EN1KTM7(][$FLLJ8R\G/_ &$Z(HEEEW*A
MA%;CS'D?7 VZ]U+ZY52/8Q5;T;JV!CF,'.UA!C%U*-:LVU;LZQ5K%"H(I(E
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, P& P& P& P&!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm205388-1_10kimg09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg09.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ G@'4 P$1  (1 0,1 ?_$ -@   $#!0$!
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M/&[:8MN('V;*S&4"?FY*3HL''V_W/DJ'EMI(LF_U-=63YV@HLFB)2F,"B>P
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M8=679M5R9@_C/,LI[R" AN @/$0X?!HHQCDCF*DIKKYRO4@- &@#0!H T :
MB/ZG.B6?R7U]=-_4EC^D5F'3@,-]2V,LP950,S8VDGO]16-?QLW6("Q96;CV
M#XRYBE(!P: (FX;Z :CY7'1WU/XBSG1+7G##3+#E?Z<^C[_"0A+,+37)TN>I
M]OE:4N*.18]C7EE5VD+]4*$4(,CX;L5UU ,7??5N\Z69M>Z^@E9R>JKOG#QS
M8P=#S"RL;MBW_P" V3:,E$P'APW$X_+K2X2Y-R]O-4JU6LYN8B !N/ /2/8'
MQZWR3>DMMJ*K)I(3G+MOS!MZ=PT>3.2\F?,>1V8H@F4#!]+F, *^'ZH=NY@
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M*3EWW^B.^VLW!6)8Z7PXT<WP(T6V_$/Z58^-.W)6^-K)TC4ENN%FORIFQ[(
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MAC\MQD*>\@\KQR#=JM1LBLGC,BRT>8FQ$U-M]]6[O=2[+)CG1+-4 V>6\/\
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M.A])U?6 ;P- &@#0!H T : \;IJ1VV71,<Z7M#== RR)N10A5DCI"<AA[%"
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M<Y>M;WM=I>@G+Q7]WE*^S43^S$UP_$_6SY^D^S?#VZ+787I.BZMFX#0!H T
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MH[LN:&7;6][7:7H)S,5_=Y2OLU$_LQ-<0Q/UL^?I/LWP]NBUV%Z3HNK9N T
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M@-@3,)R%,8HE,(;B4>TH]X#V]F@*] &@#0%)_HC^'?J8YR'F&I]7_P!SKO\
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M49?P7Q,H$QM^T?QZE&->CJSIR%AZ(C'O $1$ 9O-@W]"91^<=26AW]95 *Y
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MD/B^LW@CP[OI=VKL]KXAR;EGTOUEZ?VZV0Y-Y/-^T7_"3AS_ +JD/]9O._\
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M,B8,4Z<XV@VXE#3R[EU]1[7:D<;2659>-AV5-L%E12AZ9&-7;ITY7=1Q$SN
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MP)#,+)]B>5LB&,@"!]J18W/&<+'"4KE,9L#QEAHTY8#<K<#<2.TQ/_%Y1VT
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M)'76J5:Y0JPKPEJKL/9(Q4P[JG9SC!O*LO$$ #?E:NRAL/9PT!MV@#0!H T
M: - 8H(AB1\[D4FC9)Z^! CQVFBDFY=HH)BDDBY6*0%%R(D^CS"(@' -@T!Z
M2MC  %,?<I>!=MP,0#;B<2B&WK"(\/\ >]V@+PICL(<#!L(;&$?6#;;8P[=_
M?H"P+8^P;"7?F*?<2DV Q0VW O)RB82#R;^@-] 5E1/R<AN00#FY1#<.4!'Z
M/>8VX#Q'<- 63LSB"GAJ%(8Q3 (B7U%#"7@)B$$@D #  "!1]8/AXZ ICXMG
M&BX,S:M6IGBQG;WV9$B/M3Y3E!5VMR  J+'*4"\QN8W*4H;[  : R6@#0!H
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M-\D94"Y?5\GC^J4NLL(ZPQ\87$C3*MD=V:0GK$SC$E64>58H'3$I3K$!)+F
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M$=M]@$=N ;[?"/ - ><[@"@;D+SF* CR (\QN3;G*4! /6X[%[A'0%1%R*&
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MF+%2.M&$Q#/6BB2/4,TIS>Z=.5(-"S;VY&G8+IXA,45]S=35."K[E*VC/KY
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M)T_I\P_E;,>36%RK]5C!M>?+%.5+&-,AJZ5HJ7Q7%J:HMWCWQ 009)J.!#Z
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M\)0;D46W#_@@(^C4O.47M35>OFH<0:ML+@Z8BE(2!C@Z8BU*J2R>$+@#E]D
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm205388-1_10kimg10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg10.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ Q $4 P$1  (1 0,1 ?_$ -(    %!0$!
M       ! @@) P4&!PH$"P$  @(# 0$!              $" P0'" 4)!A
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M")57"*9BT,<%%DR'*4YA33,8%-NTIQ^0!$  1TU'H2<H905(55GI245 +6E
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MN#\@G9IMDMB)+G9!<N<NA)%JV\.)0J^H22MU5=BH"B*B]^6S=D,]ZY;(J"&
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M/*/)YSZE;+' 6><:QI)+N'R++E&  +RU&\)<KO$XQ"__ --]/N->TNN\J7N
M0<7F7&D&:J0T/4\0:C1PH3SE\UF-MLLP^97,CY;B5;E^8D\BT_+6WF*Y.65]
MXR\A%AVY;SG$,M(1G$3"+&1C++ON2,BHZ3@E)!TD@YEG3QLLFJFB0H9]M[+=
MFQ=<!E^8.;).Z1YC0A!D&Y24V%QBBXP7+MUC0"X\N$S(&!V1TU'$2M0"OA 1
M3$XV7_+?R2@O(SB6P\2YAE9C 4CSBXF<0<@XFO\ Q9@FR(J"8YMQ7!W/=T*L
MO,WM(<JK]S3%N9Y&35GHJ+BK*BC$^@42<'^=:;&.??=;(8YKKU]H(4-'E R:
MD\H('$XH5""@B%UV2R'VRYKFVK+B#,_$<*FASM)1H"A"23AK;!OF2YM6SE#D
M6SS1?T#EZX&G'?R!9=P)CC&MAX4R'QKR7.\4W\_+6PUQ%F3"EZHYGLMM:UOQ
M";"YXC(46\D)%[O*T<-%Q2(?#:]?IKN8 !O"RUZDZRARD<+FC,$"9D"DUC*<
MT'GVV'$LM&\YA:$)D"0TK-KI54MG2D-=R_SQY@<EO'5RL@,^Y)BLDVF&/_%Y
MGVUK]3=<;;*R'9U\YEY4XN2NZP@M#C=DZ]E4<-S3-)-Y:,C<;=A/*(INVK\R
MQR@!,H6TOL;=".9SMI@-<[4!)<!PAP<"C0H<)[(KLN<_E[]RK'?3[SC1&ELI
M&K@0=0((252[O&_*_E*WY-QG&;C]E:R>/S7E'YM?+%A+(%ZP&'+.O>80@</8
M=L_(=L7&VBKO%Y&+WXA*HJ L\5#Z=R=8AW#=9-/VCUV!YEFRP$ GE[SJXLNN
M 05."C4LP4(+C0W/=0%+E@228=::2"4G_:$P0,%$:+<>:3R)WQ@'ABG$Y%MO
M'N0KPXE\V<Y7[FF&L/CK'V[E_*'%?D?>.![6@;C;<AK^QUC:PL6GB;50N"]O
MTT\4N))&1*,<D@W()^HNNL<QU^R)#E;-S*==P#,2Y0<N8$!&DSF2BPWVG6KG
MRUQWQ?FKUMSA.5OPH$3/4E2 0!*L=:/%SD3%9QQUC8MS3./(CD&YP;A3+&9\
M.6??%O7:_P ;.<N6J28CES%AI:64/9T[*L)$D)(F.=O)-6ICI**;3#U??9:M
MWKC+!5C'Y9U!(#LKL0X S43K2,7E[KKEMOG2NN:I$I@% 0AF#(RHJ&<<0=I0
M?$ZT.(EX\B,)W[;<%YED/++D.UN/T98N:)@,^9$6E.>REK?X=75B&,O!V>:Q
MC,X9>2GUJ;^&)'BQ0(L=3\(J/E0P.^F!M'M;YJ!>$NN!Y?(D , *UDW7%_/
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M 0J AZZ4TKU4A$QB.GV>F+0!(%4!2AT/H@AIVJ  %0VCN 0[4$0$1': ^H5
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M*[8B&X"FK%-=/8-=(54?4:T$V@"%0U$.PZ4&H: /0KDGIT],22<JC0RKI."
M--U-1$1J T[#7<7YBTIK4-?AT8HB+M&G7"4("3PCHT.[7M@#ZTV@/QW?PZ
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ML<URURXVXWS6H@) D&W'..WA8"T:R LU&-?N/8YS2"&AJA5XIM#1*8))*K1
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M.7C;YG%@K7 8F-66YY:LXR6.>.MV3?"J79W?R9N+(EE8ZL&&OP9^4?7IC-I
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MUN9G;]F6/;T1:-JP3,ZRBZC>(M^!:,(V.2.X4.<2(HD*)S"80W"(B\SG2)5
M@W:HCD:%R@ $J9)/7M/17=&5:]J" T&H#KIV$/6@FH/V?O#I :AIILB9!7&>
MB>U8':E0$.WX=QJ%$== * T$1"FFE/2G0 $@!=A.DMNVI&WME!B(Z!J(B):
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MT'9XVYF\F*!$T%D.HA[""7DM #29! 'N#6&LPYV<'*N7RR3(B&UMQSLH#:O
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MTTQ,H,\7&JG?G4C(]52612;2BBK)H<TB@D0Z2+=^8S<3OTD4U# 4BHF*4#"
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M)69F#&M[ V%6*;@:)!*Q+F,R^N$ETJG ())=VDY I%!%25;#W+N')Y0D\RP
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MBG+JA8WD'DN.D8V3C+>4>HIJ014?J"*72G'E5;N"&%$]8R_-6_,#2W+<\?\
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M<>C)EFA'_A0B!<_4?R=X]+9->J)$:].V)#1MS_RV93F#Z7PZ -35_P"*XFF
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MF$JXIP3LHXL+$D8!U)@CU<;0XWJ#&MTV<>$@]4(:P5".0MF*!A+BF &,8+B
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MX9(!6<$*J$^+4T^&XI1.6%'W0 ]"'YY!36F/BZB@P\/]Z4HX\#G!P <_.,H
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M=?EI4*UI7;I3O3\=.WIVZD@7;I)(?$F:55IVKV5IAA"1T,8:ZZ"/XO4*AM
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MP5&@#IWK2M/V](H=ATZ(2E9TTWGU80D #=J&H4_A !H(4$H"40  +\0'6M=
MTZ?#IZ]-TH*5IN[M->N:@I4 "G:H 42Z5*-::  #4:T[??TRG7OTG!(UZ:::
M\)IK@:;.P]J;=?P_#M\?2E:_OZ,%7ATT6"2H@K3!>[TP1@H(U #!KH81 0]*
M"(B(")M?MU[]+;IIZ8#*3C)1COUX=92.8OR/\6F/D0\A=TX#PCQ$X$7CEKC_
M ,><37AGGD_SAM')N01:0&3I_(!<18?QAC[&5W6>[D5VS>W)62D)60= U;$<
ME12)[PU-7987.N7!PVFO#2<7/+ =8"!J#6NZ=EQ[+?E67DFZ]CG +)K XM*B
MJERH"1KQAV'A4MRU\,Q_,3B<\XK\>>,&?N->:K+AL\H\5%+J5P5F']>XL@+T
MQ?EBSFUZ/Y*Y+;=3-E._IWT*]76<1Z[?YCB54H!E$VW\LR]:7)YCV.!()#V!
MA<1J:6N8BXJ%4&,=+C+Y:],Y8QP(Q:XN EK!:[8:TAL7D\)C*]/(_B>VKGPW
MCZ>G,;8SPW>!KRD<7\^LS.;I2N_(V18-G9^1K:X?NH_%\7 VZTB'BT:7(24@
MU?$D71@)]"D[24IY;.Z\[("HN,:E05 *E>',$" A1E:5HF1S#\O+-MJ\EUMQ
ME) '$90A#BTJ521)(JJ],9J[A':-?@(?,(B:@U[5].PAK^P>GCIV14%10O4.
MZ1ZZP51I\PT *_*- &A1I4=0_"-*UUZ)],/:%TV+AW;:17<U@IY"/#+4=0Y
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MD-NA>$@:$BVDB./;+?$E4UEGI5R/E?JMCZQ:#;[&6^:#W-:F0!SWMN28PA@
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MQ<E6C80<&/%*N53.7QW#A*%8@1ZNI)L7#M\E_P#>"0%;RTRFUETM0 K**7*
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MK0OS:@-:;NX5U]1'T^/?IT2D.M#H=BG&7H2 72@4H&GKZ4$=VT-*C7MKIT+
MHII^NM8*G\O]G^K_ !?B_P!;_12O49)2>F%4@0JGNJN/6J)MIM@&,%1"IM-
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M+E+29#]^JO\ >\28Y22D<?96YO <P QN30%7>$I,^9*5L,R!0Y8]1G4@#MV
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M"@+'4,SD"!F'NM%#+'62JR 2)AP/A\LS4<-LJI*+Q<69V8%?& UI0 );?&N
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MN2RL.Z!LZMV&!-:Z(P#/9$X'-1\0"[ J)NMG_BQKF_7+P<$/RSMTGL7$^$R
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M)D1^BU,VNG>1P]M])DT;[1*8'[-VL7=O.0#, A"9A,3;UTUK7!!":0"$X3(
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ME.I*](U"8[C2%  "/;XC0M/700 !J B(A0 [ /PZ84>&!)*4]'JZ(':@5_"
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M_0R$N86R@Q\;^9"R MO&*"<<069F8@)A$7KLPE#: ]<<.+<Y0$\1JD]6./H
MI'S>>GFN#0ISE%:$Q0&<C7,*(&O!+I"Z;Y+:F(O#JKF5<"LC^93AFOUII4@@
MS1 MMF.LP+=7_99/E3K"&$X /49&2=*#5OE*>L.EMB!:PK+A(E)I*)F"\0!.
M3C3WW<1F (4<98#. ;NBJ_.O]&*\K._S=Q71X\[P26T8HB\*#_ZC_> )F3.F
MX:T)8A&[AATX2E@I3&#A=,M/0 >HEW$LLO\ Q,S@Y$ BBH*HBL)IJ03;&37$
MRZ<C-"Z2:!$$_P"*32+;8@5V2V]DH&H@>9,)0  UZE-4RA=W?Q:Y(*!#!)?
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M"H9)K.S[-K<"%15.$7$.$! 3G*J6,J$N1 *]AX:@<*2F0=D+S&EA)4@ )QT
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M0FT[-LZ!B+5M*UX#GER(CX&V[:@F*$5"0$-'(7B5LPB8B+:I-VZ*8 5-%,I
M"@=>\1-5*[A'ZB3JDHFL%=\^_JUW[_*TQ;__ &I\D781 0\@/(^H 8:5K^M
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M8W1Z" *03/3&'O4KZA]] [?B"H;>YJ^M*B'W]&7"D$B<"3NW2K!T >]:]OF
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M(T$:4$ _A-41IK77[NHR"JB)2)3*$ J-4O3->S= $- 'O\.X5$0$: (&IV*
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M/](LL$FV?.MVD0FY;M.3W0ZXN1F82+B6G+KJ@Q37W+9<\*'M<\2J6L"/*5
M/$=]9QN>P_*EXZ+;Q+*R.,;IE('#V(;KM/!5GLK)P-DN(M"X;GD;@N'']HXX
MP1%15D-XR^G)9>RW[9*/@RJ_2MF1ESD3; "HNY<?<2_=S9GD(JYCPEPE5,H6
MB  *DA$&-8Q;;&C@54D!Q-:02J*7N F5)5%0D/[P;G/%_)/$MC9SPM=S>^,7
MY&B33%I7(U;/F0/6Z#YS%2#9S&RC1E*1DG%3#!PT>-7*2;AJZ0424*4Q!#H?
M;=;*$@R!"(004((.T%1H(8>TJX*"'$$' @D$$;")X5WQM6A@#YMI0H--PB&G
MQ^ T$:^H=^H*!B1 D_"._3UP=/7341K\M0W#WTKVH(_:-?V= )6O8FFDHDA]
MT2Z"/5V=,'V"E-!$1H ]P ?A0*@4/C\.G03I"*&@GJ1#VIU=$"GPIZ=O]FNT
M0$PB!MOI3M_>D6IGAIZ8<@$(";NC3""$0#N-/Q:!H&HZ4$HFVB(!H'V??TQT
MR$$Y20+U]1TV08]ZT M-:B "([@$ $0U^'I4?NZCF U#L[( "=O0O<=ZS4R6
M!4-G\.ZOXJAVIV[TI77O]O4DDLD3MU)I*#'%5TFNN=>R ;N(@(4K2@F].V@"
M %H%!&H]_P"]$#&!2'5GV[4TG!:@:@@74:=RB%*!K0   &HZ:="S48::]!":
M#E1!AI3 =.N"KH-=VNO8PFJ ::5 "!\N@ZC7UZ")2T]F$ ($R"';?;U[>B#$
M-?EJ'P"I@ 0&E1 !  VTI\>_ITB@.*Z8PPA,E3H'9/KKN@4 >U=:!0I0K2@4
M#32NG?M_9T\47J@ !H-^D@G9CJ@Z"%1"M!J ;1I6NH>H:AH Z4#[]>F2DL-V
MG3 BCA5=/8GK@M>X!\ #Y@^83:"%-P$#0/6OW] 4RKN3L@H92!TFNK5/9L B
M';0HC0!^4!W;M3%$!*)J4#4 &O[J=1VZ=4$LR4ZNHXJ>ZD 0#4:A4 _$8*Z
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M:ZX.H!I0:C4?XA]2@- H% K_ .OX],UET;O7 A GW'!,)=75K@N]!#700UJ
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B]L*^;;_\K?N^VF_?^_97_P!*]*73IIK2#WOXNBOK[%C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm205388-1_10kimg11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg11.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ SP(G P$1  (1 0,1 ?_$ /4   $#!0$! 0
M       !" D"!08'"@0#"P$!  (" P$!              $# @0%!P@&"1
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MNEST]*/H&)G''X>9C(L 2.;^L*J41*/&=9U63IO \, G+U>'$9GU<CA21'M
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M0B(&&1=O%Y)Z=!JA_P!E=R$D[6<NEU3'7=.53JJG.H<QASS9LF9@V0R0 !P
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M-4.NXN8$Q5N'L-CC<\V:S2M2@5E+%-RZY%9U[*./F6ZG@(H,!,:+C"3O0/<
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MY\^WGKZP 0UX;I%(I![.7O\ 5[>?OXCT4I>%*-?:'U<(I2CVC[Q^WW<2WK5
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MA'D4 *&HB(B'+0.WB:5YDW;18Z147394RZ N$"IKI',NW*)0%PB!#B*K<!.
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M]HDXC6[& CHA)P@@TBFB3-)ND1,VH&EVR'$G37&/%,+>Q9BS-!-B[DDZ"8
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M?Y@.)R]3A_['3_Q=DZK$:RQ]DU[D=K+ Z_C4W8]1_P##3-3/"+EWW;TPD?*
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MM-M]X_,WXG*$KU"SWXL(UTF_<T]G+VUK7)?3ZQ%GV<K4SGF_[JLOV"FMG,?
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M++M5>4;XDINN<WK=>_NEVB]?,GSGSD$@]1U_B>%E)YE#;B\-R;H7(5L,/J]
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MP<B>DNF19XQ'B$P.Z-*<SMMZ7^)-L.<JWG2AY%R0YEX#$+K%,C6UVF/X.LW
M9&4-+.[+:&=/I5>([78.E#!$L$ ;,85#PM6A$V2*#9+9Q1T^)L2;BA55NQ8P
MH0"[$DGD%_2-( KREL^09,D;PQ-@!<EB=.'.;>B_;)<(<M ^SZO=Q5^NII?3
MNX<:4O"E)PI7C?Q[&6CWT5*LF<E&2;-U'24<^;I/&$@P>H*-GC)ZT<$40=-7
M;=4R:J9RF*<AA 0$!X0"(-P:D,5(920P,@BN%'>K.[,,4;Z-TNWF;R/TF-A]
M3PI9\9P^,L:O>BS4]Y<O;*O:\3T^Y/+C;<D4J'*QJ%P_,\X]9*UUR@W<,V+9
MJX*4R:Y55+.GR$RS789"(N( B(/&9OV-(X5'4)M( D(<8:9!))W;I!N(@1]X
M$'C785N.MUJHFU"S9!HN8J+A9M1<<H7BRYCL>(93(T+4\<5:N#.VZPUG$L79
MJHH[GQ@6)S13%9PLW;*G*4[5UX0;GRZB1U#$@_B&1ZS&20%!XDM D]_IJOH]
MIPIMVLOAB#ZJP!,QJ%B3$B!QM3.NFQG?+>>9.TR<ENJMV:ZG6H.(&\8TS_M.
MJ. ,^8YLEH-)FJ;I&<Q38V="=0#X]<EFSN-<PSQ^U6:E(9\FHDJFK841>G+D
M3+;0P.A"H[*1H;9%N( -A-3N#/"F\3$6(W,H(FXNAUX7@2*W]OTWNI[2-MNX
M?+6+:(QW'Y9P'0)>]6'"M9R#2(*6J<'&UJ3M3BYY2/+S24O4:'%PL6=RLJ@R
M>23SQI(LFJRBY1+K,6QIXI')N"DW@%C:?3!@:GT218GAMD\-CS;20.) B8]$
MB3H/3 +&^HOO.VZVR!V>X =9=H$?N5N.]#IBY%+@TDV4]W2AY[<7B2[F=M(E
M5)-RYC4(8BRX+?\ YE(1'00TXV<V/P<S8M0K$3Z"15'3OXN''FB-Z!H](FIW
M1_I&]@CZO7KZN8<4%KVJV*B+ZN9G187I^BS400>?VDF%P:KND3N6R2XX>W"
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M,PE6MBV]7B1J]>,(RTJQA&T9%MW3LLN"K=1BMS?5YCB\[/4=-!S!.DVMN@
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M -8I,Q'0+I.#0]0.E%.4WZ4BC-JIJ3I$SEC9@YK*)O$5;RG!1 /F T'39"S
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M,9HL@F+')-F<>A(S;_RO-=+E12!98PG$H"(\99'W93D@"3,"P^@<*UXY8K(
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M=*JN0%NFF@4/$)C@)0 -1Y<?,?&LCX3ZZ-?#7_[$KXSYA8SF^"_,,8U.%?\
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MNS?+3MI7#[A-GF(=F%H)4_R?55TDX7'V&LFY3@;/7_Q=9T(3+IZW>'<BJV%
M$VZ9S[F1 F%8C=)T,_6!8=W;6FC%LK:[-JZB!QF";GA/9;OIWU_<;E"9#<)T
M]K6C8V%+&7D+M5C*6/[^4XI.^F,C(L08>>2ABY\XOFB4K8/$B/S&@<5(&).[
MU92/1N;=]D3]E7#;S2+^&\?O;3L_VH_EM3A9Z<A:Q"3%EL<M'0-=KL9(3D[.
M2[QO'Q,/"Q319])2LG(.CI-F4?'LD#JK+*&*1-,@F,(  CQ@; DV45*J78*M
MV--*GNH=L>J\;MYF+)NBP]!1FZ]*+<[=7LK:VK%'+#*;=1+")DJR+@J8_A,A
M(SS%JD[<@W;&=/$404\U0A!N\#+XW@$>^VAHXPPE3_$/5[=!>L=PV[O9DB>\
M6/U<:TMN: 0ZEO2WT_Y,[]P'LU_U5XMY<M!T\0>[ZN,1&V.-2-3VQ_**DR#M
M'GW_ * 'X\^?%=OII41/6H?-8O:SAR3?S9*TPC=^FQ!^]LBAV2:==9L]RM%<
MNITYY)%S'$)$()F<"+A-1  3U4*8NH#Q/GZE_(.M0+N)Z;((O>5-K7OI:ODO
MCT.WP1YLN-/$R'R_, E^8E#"VOS&UK]EZP&)G*J+%8@3-2:%CW3U!P@WD,>F
M;UI6+>Q[9XP2,C5T4"C4W%B:MB@<GC ;,<#CXQ3'CR]U&+(&L'((!T:\\=>,
M$_P6XU^?73-U>7(-R9"6 U&3G!!AO6]K:3_TQ%IK,HQU6W:TK&I/*M).C-U$
M5*N+VD"D]\R1D*D6,=E;UQ-8B*TU&K4O^M\P/(C--!6\S7C,IRJRM#@3K#?O
M6OV'Q/XNROJ^DZ5L@3(0P74-#_O6YNP^);BW9%-PAWD.^ZF731<0\K%32#BF
M[Z'Y9*+<UQP23;/\68^^5L:OY=BXMN"EC,U4U-X!(867W>8&'CN'Y2[_ ,YU
MPR JPQ)8@VYC:YX5WO\ (S$</FOFBL"",&(00;0YL))TG29OWUT RW^)Y7_)
MDAR__5%M?HX[J76O2%?F];2@F2;2L&F12R0UCTMO65G)!A(^C8]@@C7DHP86
M&79R3U0T]"L7)SE0E\A&TD+^82TV-* "H/'IOX?#+\-=$1X@7\D38!!!"ACK
M/IS6WSX:7)KSI\2E/]0=6/<E_P ZGK%\C2)*@@68\5P>K@_'>GG(,+62QMTR
MI9@^?+F"E,4DBU;$4',)S$-AH7$&SBJZ8#0=9L]=BP^9C()?2)VX,#FEI#SG
MJOAXY-'ZC\P$49B?$06509&/E 4P 0.95/+TUW>XKXUL^(K?\OX?Y9C.[*1M
M.:Y+>LR,;,XY_,&Y%A132-R0RZ.T?/JBY[L$8;95;U17EGM-JM8"'EI>QF37
M-<(DIK-#U2PV0"JD7T_$=Q%D(G+CY,.W4*-/FHR'X=ZQF\39_E>0RVU%@[_;
M',%9HCVNMR0]L0-?5^1>&WGG2_A^(/,$T#LT@+[)Y2P6T>KT..<8G(:_1-QS
M_J]H?;_Q+JO;R'_$,?VAZ^/*YUKTE69\1^G"E4]@Z\^8:?#GW?3P]%*7T[].
MW]?"E033>_GJ WS-.Z*JX QELU88RV]9]MV"6+[,EGW JWRQO*)2L>6N<L;M
MMCBE2\ S;/5;X1-JU3.9P)41#0X@(\?)>?\ QKY=\.=8.AZK#ER92BM*E0(:
M8%_1KI75WQ?\UO)?@WSI?).OZ7J<W4-B1]R,BK#E@!S7MMN=*TSEF<ZJ&;LE
M[9K[)1?3WA9;:YF6S9?@8QE,[L#1UJEI3%63]OSN$EWKS&Q"M(YLVRTX>IK-
MS',JHU3,4!;"HH'SK_-SR7&"/RW4%;>TG9/;^FE<-B^=WP_F09!T?5!8GU\9
M-P3:/T'IK?'\4G5L."7ETCIPF*LL@BGX[!N^3'S'#YY')>(%<;)F3(+M@H!C
M&T(1,"J&$$SIG-FOS7\E<P>EZ@']Y.P&J>H^>_PWTOK]%U9,'3)BX ']1^DV
MX5(/L"W*SV\/9MM[W,VFK0])LN7Z$WLT]5J](OI>!AI9.3DHA^WAI&4:,9)S
M&J.8PRB/S"1%BIG I]3 (CV8&7(BY$!", 1.MQ-=W)D7+C7*D['4,)UN ;Q;
MCPJ/[JV]0W<ALTREM.Q=M\4V[0G[]8#/MKNUSW#UF^6V(@8C#">+W)6=:@\?
M9 HE@EY^497=V+:.9)RTE*O46[5LV+YBBR?T/PWY$/B#S ]!XRX(QER[#< %
M(D!00S,0>55EF, "Y(X/XC\[/D'EWY\8&Z@^(J!%.TDM,'<05501S,Q5566)
ML 8:LD]63J@9<Q%?L:3EMZ93%OE/$YJ))M6-,SPQ>,YO-:<M4VL"QLSS.SJM
M,FU5H[T\Q8;0X!2MUB2 L.Z47D0.WX^J/R[S>K^=Q;B@/J&-S&RS.@7F=[A&
MY""0:^)__)^'Q2G^7]3L#OS;@3L199]NV99N7%C]?(OO0 ESX<=]7;J389QI
M1L85J\=-F4HN)J,I2X">EL6;E/S+)8UP]6HFCU6WS%?;YJ;22=SR?9(\C.,K
M*;9.95;F-,*M6L6('+M)\L\K2?S^(8Q)DXVG8! ;;NG<S<JH)8CG%I%;>#YA
MID"J>@SKD(01O6-[7*[H@JB\S9/4GD!W6J:/I#]03=+O)OFYO'.Z!GMV_',(
MT[;M:8N3VZ5V_P 56"R68CYA1M%6<S]TO5XC;Z-/>8V1;#+PBI(L[TSM!,Z_
MD>,/D/BCX;?X9ZY/+\V5<V9L"NQ4<H+%@4#20^W;!93MW2HNIK['R3SA/.ND
M;J\>-L:#*R ,>8@ $$K *3,A6O$$ZU.#R]-./F?TX5S%&@>FG#].%*7A2CA2
MD'LX4I UT] ]7T<(I2\_01X7I7$'U5*MCZ5W@[X+I XAZK3S!V)9M@;?$XVI
M7K:VGMMN,OEO;)CRE7V0_%<D/U[]C&3L> GT7#7L6OC!I#(D>+)QI%2O5)P%
M5&]@#TYRE=K6!9G0D;@0=C.J%AP,C<MQ665F5K$KU(Q*VY9D*%<*8-MP5F"]
MHBQJ7S,?49Q7;>FK;EVV!ZM@Z*;YF:].O,N#M\M]+A?'>$E7-6:-[1$9$R5C
MF0N1 JKO%,BT&O2L*^-\ZO+QYDUTC>+PNLZA<F09\A\0YLF28Y3OQ^(SK^R^
M[&0(GF*P(K# JHIPC5$Q@:,",FP(QUE=KAFXP&F(-6KH'9CH6:8K=E<ZJQP\
MI.7F>P/F::E<)Y]R5GJM5: S)CJ7L]5P)97V2)R<5J63L'N6\DA9&,:#&.<2
MDLHZ*S;'6.F&SDW?EAO,L,^0$@0I.W$TII"A6&,+HOAP(T%2J$S$"R>$L#B
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M;]/Y:FQ[!]HA[.[]//BG0U-1,=9+\0_AOP5^%(,W<I_:![ _PQI).%&<<YD
MW.T$63=^[0:OEVC%=SX2JJD06.F01,"9Q "CPWQ(5'PYUY:=HZ7),=FTZ:7^
MJOE/CM%R_!7FV-R0C>7YP2!) V&2 2 3&@)$GB*Q&.>NPCFQT7;Q9(3)!$JN
MYZ^G<OFQE9'\&4ES.J6F[07?MTY8STIR&\I1BP*(F!4AB>6'(9C/TV77C'-Z
M(])[+^ /R2X',BXUY5L8$A>>X!VQV[FTT-U0F3IMY@74A()0Y&2AUGZ$Q=%I
MENV"%*J=RT;GJB*J;LE%^5E"^2=13\?771 /-)YAZ3@#%;2TZ0(U_>^](O[,
M'NK;Q]9X3(MO$)TA8/- ON^_*WML .E@W5@]=/.ISTV1>G$79:WOV!VF$E-R
M3=O)ABS&A9-DS5FX6%5&+8_U'RIR%\!P54 "E NINWOE,@3J^MV^KX..+ 'U
MC$P3<]DUZ$^0.49O,O,R/4_+XHT!C>8F&82>/9]-3]2_^)Y7_)<A[/\ N1;U
M=FG'=*:UZ;K\U+:DA#+;6\'B5C5'L@OA?(K(IV="O61IY>Q1BS659QB#]RNE
M V;*43$&%ZE5=2UO&$!X[;X_Q,Y2\>FOATJWPYT4#&7_ "1@0^0[E@@=A=1S
M>%ZG3K.>9@5Y[^(3D/G_ %@EQC'5J;Y$QC:203 NN,GE\3\3J<D8/4FG4MG5
M3/*I%(UP^I&N[S2'!CHTO+,O67U?L-"!&*>(JKG">M>.[-8O$E!NU=)S<S8
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ML;Q-I@-N+;O9*R8@UGG1*\7]E1LJ$_@%3]U3H#"D'A3$PW6U:^6'<3Q=@#S
M./7V#_"XNSPU_4*_1?H_\'AU_!QZ_N#MJ+OK[?B">\/IGNH@TZA*L<;;[W;!
M]5XR'7LS Z=9P@#ES V^Q>&"PX_!B=4A[Z]-\M3VIUGPAXRDX[%^6Z[OB,$3
MN'39"-H&[@.5CRXS!CQ6Y4$SK-?'_,((?APIDVG&>HQ2&)VFYC<@OE$P?! G
M*872HBHY:T'@XEN1#(YD%*;MH9>0E0L=2$?^%.;8N]A6">.%#%?356<OS>;
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MUU83,S -R2)/K:& 1V &]9KYBZE0'AN!G36QY;1)G745YW41%)N2K*0'G/\
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M%F!R0X2ORV*R_(&),2;X)4QFDLH]$L8X7/<Q^X)_*FRB "OYJ1-3J1C#,5Q
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MT;\BJFG)51JDT<.TV[4D30B%K(,W;1)NP=$;VY9J9:J?BR[9?0X"*EF;\BB
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MU0B%CWJAF[PJ;1\8WE*F%%4 (81\!OZ(\3\0&/A_K220/RV2XU]4Z>BOD/F
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MO/[GLO[JU]PEL>[?$-NE>AFV&V&*8JOU,N0VV1EI)<[?(5Y6FI963:@D!Q!
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MB!.-#S@>)\/=;N]4>6\7WCU7./W8N(6_3I/N\<YNHG(!7/>3 GSSI6 8-_F
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M(CQG>L2#7G_=WCW_ )!4S_Z+07?V#_VCV<N,M[?I-(/:?LI?W>X])J(46F$
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M3B:0NSC:"4P&)M3VW%.40,4Q<&8O*8IBZ" @/Y6 2& 1U#LY\)/;42W;5/\
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G]FNG<'=P_52JN%*33F/K[]=->WOU'B*4OIVA^@>%*.)O2CA>E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm205388-1_10kimg12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "0 (X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** &;
MC2.^U<TR:0(/O8]Z@N;E5ZR^7]:&TE=D^KL6B_&ZJYO-C?-)MQUXKRK]HC]K
MWPC^S9HOVC7=2A-PW$=K'(#-)_P&OSN_:4_X*L^-OC6MSIWAQ!X6TM7.V1,F
M>=>1@G( XQ7S.<<69?ET?WDTY=C[CAKP]SG/&I82D^3^9['Z8?$#]I?P7\,(
M/,U[Q+I&FKN*XFN4!R/;->!?$3_@LE\*O"<QAT^\O->E+%5^PQ[D./\ :(_I
M7Y(^-]9N?$CJUS=237I<L[SN7RQZ\_6IM%LH8+N,372,JIP5QU[U^?XKQ&K5
M(.6'CIT/V[*? +#0:6/JMOJD?HWJG_!;R"8,VG>$=4D1<Y$MS%$P_ QFJVA_
M\%S[>63_ (F'A#5K6-2-S+=1/@?]^A7P-INJ6\D;HI7@X&1S5I$6*TE5@RB4
M8Z9S7R]+Q"S:$_>C^)]M4\!^'$M.9?,_4SX:?\%@/A9XR$2:AJ$^BRRD &Z4
M!/\ OH#%>[>!/VBO"OQ(:-M%\0:7J*2#(\JXC)_+.:_!N#18-/OU=6($7S8'
M&:ZS1_%3V5[;W%K=2Q3(<K) Q#ICG[RD5[U'Q.QE.RJTTT?*9K]'O"5$W@JT
MHOIS+3_AC]ZH]3\R0KGMG@5);7+3#KWQTK\M?@=_P5.\8_"-8+778D\4::KC
M.Z0K<HGH&7@G\*^\/V;OVQ/!O[3?A[[5X?U*-;I& FLIY0MQ"<9P5K]$R'B_
M+LTBE1G:?6+W/P;BKP[SG(9-XJFY0Z26WX'KS2$-]X?E4C-A:I1OYH^<!?0^
MM6P<Q5]99+8^'C*ZN2J<BEI$/RTM!0UR 1FF-)A?;ITIES(4D7Z'^E02W;B,
MY"@ ]2>M!/-OY$6KW8BMU8I\H.22.E?(/[7G_!4#3?A#J=[H?AF"TU;5X]J2
M3%]T4)(;)XZXPO3/WOK7&_\ !77_ (**W?P!BL/ OA.>U?5_$$3+J$J.7DL(
MF^0# /#')Z],9P:^ /!_PZUO6P(_,F8E22[+EFY!SG\:_,^->+I81?5\+\6I
M^[^%_AE1S!_VEF[_ '+LXQ?D7/'OCG6_B)XGO-:UB_GU2\NY"[-,?N9.=JCL
MM9RF6[E58;-WD ^;'.VNJ'[.>JI%Y[/?%,X^[U_"MCP#X&3P;?/-J32&,<98
M8S]:_!\57K5ZCJ5-6S^LL'CL%@\,J&"BE&.R1P=I\*Y]9G5XHF>7&6!4]:],
M\+_LR2:UX?DO3'ME0@#Y.G:O6/AYXQ\-7%PN)+- $ /(KVZ6#1[;PI]J2>&.
M)E)V!A6]'"5JL'J?$9YQ?B:,XPC3M=GY[^)_"*:1>R6YA"RQ,1N(QTK)-_<6
M\HCG@9N/D9!P:[_]J'Q=X?T#7L6LT5Q>3N245QA>>YKRR\^)D]S'-;PP1QN?
MN2 YQ65/"XG:3T/T3+,8JM!5*BLS3;0_[3B>5<H",?CZ55TQ3IL,D<N%*-GG
M@UGZ;KEQ?7!D:8V4\?#AA\D_OG-:<5G=>)+YY;H>5)&H"\?*Z^HK9\ZW/26*
M5N674OQZ[ EFYR)E_N XS[YK%\'?%;7?AGXNGUK0[R33]1TUEF2:)CS@YV[>
MX/O5C^P#)&_\*9Q]:P]3T;[+J=S'NVBZCX.>I]*VR^LZ$O:4':7<QQ.58;'4
M)8>NN:$MT?KE^P)_P4=L_P!HO3?[)\1_9-(\21!(DB\PA;O(^^H//_ZZ^MX)
M-T7^RW>OY_= O[GPI>VNHZ?-)%?6[*\;AOF4C'>OUL_X)\_MJ0_M(^"Y;#5&
MM+;Q'I(19X4D),B[>' //8U^W<&\81QO^R5W>:/XT\6_"QY-7EF.7Q?L>JWY
M=OGJ?3\8VC\!3ZABE\P?@#4BMBOT@_"EJKD5PX21<^A_I7D'[9_[25G^RS^S
M[KWBRYDC\^V@>.TB>3;YTS*0H'?@X/XUZY>MLV_C_2OR7_X+7?M P_$+XWZ)
MX.5H[G3?#L8FN$63@SR,,9'3@+^M>'G^:+!8*=1O7H?6<$\-U,ZS:GA8*Z6L
MO0X;]F/X)6O[4?B"\\6:]=-J5QJ;B:6:09D1_0U])CX(:7\--%\Q4!FC.U"[
M#H>/Y"OE7]DOXXVWPT^+5YI20O::1KACE3 ^6,@$'V%?1'QD^)-AJFGRV^GZ
MO&K<'!?.>N?YU_/->M"K^^JN[/Z<QF!QL<;'"X=?NH]%MT.0\2:WK&I:HMNL
M<JQQ28;R 3E>QK3B^'%AXDAFMI+>99"IWR,.#^=8_P /?C'!X>MY4O)89' V
M!CSGBL'7?VN;:RN+B.-HEPI^;/UKAJ5*;^$^B_LW,95.2A"T5U[G$>)+&7X;
M7%[#9V?EB-V5'9#\^"17CWC;]J+QM:6]QIE]>+&DO"*@(Z5H_&#]KN^\3V_V
M6QM_/DC<@R\]N*\6U+4[KQ)?+<7]Q\S':$V\"O9RW#RLI36A]YA\OC.C'ZU3
M3:&K<W$DGG27SN\F=YD&[!-=!X>@U*X=46[B4=?FBZUG:7:)/>\#,47!XSDU
MV7A>V, D9QDOT)'2M\=*E"/[L]CV*Z*QL:?X:OM;TZ2"6[@VE?O+%TXKJ?!<
M)-R-+UF14N(-J6LS#;O6J'@W3)9;<MD@;N1Z_6NKOM&DU_3S;N3N491^X/45
M\'C<>W/V:ZF%2H]B"ZT1XD>%ERQ;A\<-6#XM\&-?(LB#:]LV_I][':N_\%R?
M\);(VEW8\O4(RHB"#EE'I^-=AIG[/VM:IJ,=O+972QL1^]:/'&>3[UX2QSH5
M>5R/(GGM'!2]E7J*,GJK]CQS1;1-5T])$0 J-QP/NXZBN T7]IGQ!^SS^U/H
MFO>';EHK;1+B%YD!.+N/?^\B?';:6Q[U[M>_"R;P5INM6,<GG7$4TB#*X."3
MS7CNO?!N"1KV\NFD:X2/8@"YW'M7U/#.=4Z&+==NS1GF5.CF^"J82_-&=D_1
M]C]]OA'\4])^+_@;3_$&CWD%Y8ZA DB21ON )&2I]QFNJ3&W\:_-O_@AM\5)
M/"VE>)?AYJET9S%<K?::TF00C)AUP?0J.GK7Z0V_*'']XU_5&1YE3Q^$C7IN
MZ/X'XMX?J9+FM7+ZGV7IYK1K\S"^*/B=?!/@C5-6;;Y>G6DUPVXX&$0M_2OY
MS/B%\2K[XC?$'7?$>H._V[5;J25@3D* YQ_*OWD_X*.>,?\ A OV,_'VH94;
M=(N(1GUDC*?UK\!/AT8_$4"+.N)#@D9ZYYQ7QO'M>*Y:<]K-G[C]'_*8SJU<
M;;5-*_EV.Z\-^,KP2Q322QA%B"\K@D?6NNUB#6-8V3Z:)KE7  \O)'>KN@?!
MP>*?#LD\\#0&WCW*H'#8YYKT[X4:YI?AZUM8[AH;157:8V8 DY S7XOS0K+:
MQ_0LL1##U)3I1YOS^9X1)-K6B1%[DRIGC:P/%8-Y>S7LQ/\ K&8885[S\6O"
M:Z]%<W",NSS&V[.<UXU#X?:.\,?F-&=V5VKG)K.GR+W3ZC*<QI3PM]I(YB_T
M*2+8(U4;CD_+G%<\+*ZEO=LHBP'_ (CBOL+4/V<+S1_A):^)9+&>?HXCBB+;
MP1GG'2OG?7$U/Q/XJ8CP_<6\@!*J+=L >_%>S@\?."<9[+8\F>>8;&MK"RO;
M?U.<T"*5[^7Y%6'=AMG-=;8Z"K.KPRR>5W)Z USMF(M/NY/M$GV61F)<%L?-
MZ8KL/#>L?;6ALH1<74DY"H%A)Y/ Z5SXZ-6454@MSH>*5*"]M)1TOJ^AO?#_
M %6?RWB95D9&W9]17H/A=+G59M@MN20.E?0O["O_  3?M_B-X$N]2\66FJ:/
M=>;F)R=HD7&<@$=*['Q]^R!9? Z_(L[B\NUF!*M.1C-?)\49+CL!@EF$X:2_
M#S/S.MXH9-5QLLOHRO-?=<\N^!?PN;1M87Q!+;*T]G("B%1\V.>]?5W@K6(/
MB/)]J$)B@A0VC(P P6 .1]*^>/!%EJKQ3?96,LD,AW18X;VKWSX9YT#34N&7
MYKD#S8F& A'<5^(XKB"V*C"7S/R_CK$2KR]NY^^K6]#@KGX+:?>^(O$DD\,<
M(3Y5>0CY@%(S^E?/WB#X2VMQ#J5TDD;Q0*VQ5P<D'K7T/^T%XIU#Q.LD$=FM
MOIRK^^N5SN<BOF+Q/XK*23:9IHDCCD.&=N_TKW\IS!8B4E2E<^HX'K8^M0]J
MI[VT]"+]EO5M2^'?[3/A_5=CK";N.VE*J0GELP!R?QK]B-'?[1:!L_>Y!]1Q
M7Y#:3\06T/2[=+R)+=H")M^>248'^E?K)\+]5CUSP-IMU#)YD=Q CA_[V5!_
MK7]>>$..E+!/#2^S^NI^;^..%G+&4<9.-I---]SYQ_X+0WCV/_!/_P 8;,_O
MA!$2.P:50:_%[X.>&XM=UV" R"']\HRO>OVT_P""O7AV3Q-^P3XZMXU9F6U6
M8;1G&R16S^0K\'? /C34O#NLVL]JD<SB16  QGGOBO2X\A-U8RZ-6/J/ _%2
MIY=6M_,C] -7\)#X<>!UFADW;HBI23&'%?,GA?7SXF\>W5HND3W%W\VR9V)5
M2,=./?\ 6N@^*OC+Q%X\TW2S]NAC%JI!MX'SCGO7._!NYU+P5XMDG8K<,=Y5
M"O3(7!'TQFOR.%/4_:,MIUX7G/>6W^1Z[X6C2?X>![I9(KDS&$P$Y;=70_ K
M]F-O&OB=DOHY%S)N0K'D\UYQ\+OB+>>+?C*^FW5M!#;QR;RZL<YSUK[@^#-O
M-INLW(695;RP\8B&#@5-*BO:\S/'XDS>MEE&4*=E.2T\CMO%7A76?!7PVL=+
ML;6'R@_D S*?N@8!_2OG/XQ?LP:GK6BW%Y-JG]CZI%N*20H&0J?[W-:7Q1_;
M1UJWU6_T^^C\AM.=A&)"0)%#$ _6LWPMK\W[0'@^^>S\1PV]U<G=Y,DFX@]"
M,9Z4\;C;3C"E&^NI^?\ #^"S/ TUB:S482>K/C#X>_ SQ+IGQ&L;B>#3_$5J
MEX#<%I-S,N_DX!K]5_AC:>"_#2Z1<QZ'IEA<2% CLBY##''ZU\(_ /X:7_P6
M\?ZK_P 2R;5+F.9B2?EBSDDE1Z5]&?!KQ):_%9;_ %S4E_=Z2P-O;Q2A5+@;
MN_T%>KA<PFI-RCI'HSVN/*-3&0A[*3:4=;.U[Z+\3[=OOCC9^';V2WF@M[:&
MW R[28R#W KQK]JCXHZ?XG\,R7]C)%-/9HX6-6Y/IQ^-?(WC#]L3Q%XO\57:
M3V<,:0S;83&22O)Z^M:-E\4O^$BU:TAE:=?M#*TLCH5/';KTKYGC3C2MBZ'U
M31Q2V/A\I\+JV"K4\95336KUWMJ>A?LN:EJ%]XGNOM4$@3Y6^93\I.:^E]5T
MJ*/257^/;OSD=1VK@?AO;Z?IF@SZA:;&8)EBS9S@5S-W\:8O&D$ES]HFAC@?
MRV53CGVK^:<9.@N>=6#;Z6Z'EYQAZN9XWFI)QC#1G5_$;2;=_"-Y]I7/R'Y1
MTZ5\'_%O4IM)U*3R8R"KMM'I7W-=>+F_X12>2\M5^R_9B8Y/,RS'UKXE_:&E
M>/6'-O ?(;+!V'WB>U>QP+0E'$/LS]&\+?:QJSI5?D>0:_XJOK_"SW38R.@]
M<\5^W/[(%PUW^SIX5=GWEK"+G_@(K\1I-&?5(U\F1@T8#N-N<G/2OW-_9LT;
M_A'_ (*^';7G]S8Q#D8_@6O[,\)X^_64>EOR1Y'TAY45@L'"/Q7=_P"OF5?V
MJ?"G_"=?L]>,])"[VO\ 1;N%%QG+&%@/UQ7\XG@72/MOBAHDG6WR^%\S@@@[
M1P?I7]..KVXN(MIZ,K*?0@C!_2OY]_\ @H?^S6O[,_[5.M:>J31V6J3#4[,[
M-N$D<G ]@>_O7VW'&'DZ$:L5HC\_\&\ZC0K5L'-VYFFO.VYUOPK^$*WWA#5&
M>:;^T(T!P1GS,@\CVKS3QCX8USPYJ6;:XF$@3;D1GG(;->W? G]HW0[+1YM/
MFMW%TL"DROQGK\HX_P YJ/5_B=HMY([>5YLA/"GC^E?A4:[HXCF74_J/"U*T
MJ[C!>[=69'_P3D^&M]X@OM9U34X6MMLJHLUPGS-UZ5]O2K_9LGV[3[(R3V\>
MS"GAUQUKYC^"?QDL[[4$TT1+!:MAB,XP17UW\/Y;.^?]S<VR9CVD%@<Y KOI
M5E6O;<_+>.OK-/%<U9:?UV/BS]JC6F\4&.;R!;PS2M'(VW!!],FN?_8$\(ZC
MJG[1-E]EOXV@B#0RY&5"9],]:]__ &FOA2M_X9O-)AB%U<PSF4.BX&TD\]Z^
M5/V>-6UCX*_&<W"M']KRS8+;0H#>G>L*:=/$+GT/L<!BEF/#\\-ADN?E=K[W
M\O\ @GZGO\+?!/A_QK&+JX@:ZN4D#(74 9(&<5XA^UWX!T_X9VLVA^%=EG:Z
M]&96G3DQMTV\=,_UK:M[>;XRZHWV2XBEOKBS:<!!S"Y Z<^]?-_[0'C3Q=X
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M:,%"_7J<)X"^#^G>$-#L[,VUK-Y*+N)@&&8#E@.V<5UNGZ9%:QMY:A,MG"@
M5?$:9Z+^5.6)4%?<8'+,-@Z?)0@E_7<_',1BJU>I*I6DVY#1#C'3CVIX7!I:
**] YPHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm205388-1_10kimg17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "P ;D# 2(  A$! Q$!_\0
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M )%IEQ_P<'>'X,?\4/"V?^HX_P#\BU^5(TZ*:QZC.<X+?_6K%UF3[%=A2/\
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M,G!KTX<T)ZGGV3B07,$#121M\RR"O&?B3X8/A[6O.C7_ $=SGZ5[2]N$X K
M^(GAU?$/AR1 @:1>:[E+6[/&Q4#T;_@A/"/^'M/P3)/)\0QD<_[+5_9%L7^]
M7\;_ /P0QB,/_!7+X*QNN&CUU!S[*U?V*[F_O&MCSH^[H?@Q_P '@Q!^-OAI
M<\_\(C8G\/M^H5^7O[&7PT_M?57U:?\ U<(^3=W.:_4G_@\!LUG^,OAHXS(W
MA2QC _[?[^OB?]FOPC!X>^'VGPE0)9@KD8KR<TK^SI,^DX<P\:V(2D>N^ ?
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MY8D>,9-[8E8Y.2?6O1;_ ,0WUAK#M,FSNO85CWD%OXCE%Q/$LET6R??VKZ?
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MNK'Y]F%;EG9GGNM6C3WOF^C=#VK/CT8>(=3$D3!&CX*D]:T-<U)EE>W88/\
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MB!)"/<(U?UG;_P#9KJCMH>!6^(_ G_@\(3?\:/#1YV_\(G8@ >OV_4*_(?\
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ME'+ZB>QT4\^I2C=R_%'P=>.Z*<=>U9]W%-( :^\KO_@@O\8Y0?FLV_[=I?\
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M<A121L5G)R>?>OL1?^"%7QO4_P#'DO\ X S_ /Q-31_\$+_C=WLD_P# *?\
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JNSX<>/?$7DKIOAK54NI_+T^<94 ]688%?T-_9+__ *=_R/\ C4EIL__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm205388-1_10kimg13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %( =H# 2(  A$! Q$!_\0
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M 'R*<T@1<DX7UI5.10 S[-'_ ,\D_P"^11]FC_YY)_WR*DHH B:TC8?ZM/\
MOD51\2^$=-\7Z'>:;J5G!>6-^GE7$$B_+*OH:TG;:N:029(]Z /#=&_X)J_
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M'SX_"I,YKSOP%^U1\/OBBJ_V)XGTV_W=-DG^-=O'KUC(0JW=NY/0+(#_ "H
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MXU73=S36RD?>QCCKZU^JDUL'7:S/QSQ4&T7J_. \>=NUEST]: /R!_X(@_\
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M7XQ:%%YE]^T1>P1XW9DL+5?_ &E7!^(_"\ND3$>+?VG[9HX_OI(]M;C\U5:
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M!Z1\$?BN/BS\)M/\12*MLM[!YA#G&"<Y'X5H_#+4X+[[8T<BOF4J&7H:YCX
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M=$/^>@53CCKUI=7_ &=&C^$6I>*OA1\8/%\]I;VJ^1I"7B-"HR,X4J6Z9[T
M?=>G^/M&UK6&T^'5;">]CR?(AF!< >W6N@5O, Q]T'KZU^?/BRY\):=\./!5
MWX U1I/B9->00W4\<[-<RNV/,#KG  ;/:OHZ*P^.T=O&OVKPGGI\\39/UPP&
M: />'?>_!(QVI>K<$_3/%>)0V?QV"_Z[P;]3$_\ \73S9_'?'^O\&?\ ?E__
M (N@#V=XWZJV#[\TD]H#%N*H[>Z"O&/LOQV_Y^/!G_?E_P#XNFM9_';.[[1X
M/_[]O_\ %T =3\7_ (<0>*=*CG$UII-W:AG^U%>$48X;\ZX;P?\ LZ^$OB??
M2SZ_=:#XPCML&%4"NML??G.>]>9_M7Z[\4-"\/Z))XLU'2H/#-QJ:0ZK_9D9
M#F'!SDY)]*Y;Q3XQL?A5\=/"[_!.Q?5(+JV)U.SMG>192<A6.2<MC' H ^B-
M>_8,^%NN3JT/A#2[%F^9I+:/RVSV_K7)>)?^"6G@?7FWQ:UXNTP]A9:B8@OT
MXK+7]N/XD:!.T5_\!_'6H7("AY+="(@!G) VGVJ_:_\ !2.UTM-_B7P3XF\,
MK'\TOVI.(E'4GY>U &>/^":TW@]-WA3X@>*(+@?Q:A=M./Z4I_9V_:(T1/)T
MGXJZ+Y*=!-IS.3_X]6_;_P#!5CX(RNJ3>,[6WG;K"V,CZUVO@_\ ;2^&OC]U
M&D>*=-F9N@# 9H \CN+3]I;P9;M]HN]#\6&,_+'#%Y&\_4DU G[1'Q4\3ZQ!
MX=\;>!&\)6$JY:_CO5D,V/X1@<?CZU]0V_C#2[F-9DU*PPPX(=<5Q_QJ\3^%
M-*\#M?\ BJ_T^SL4DQ]J=^%]@<]Z /$K_P#:#^(?P^ODTOP9X+_X31)S@EKL
M1-:K[MM.?TJTU_\ M'_$)O\ 1HM,\'H1G;-BX*?D17>?L\?&_P"&OBF_O[7P
MGJ=E'>6S?Z2&E_UZ9X()/KCI7IFO>/\ 2-"L9;BXU2U@C7JSR(/YT ?/"?L_
M_M):E^[O_BIH0MVX98],;<1]=U2#_@GCJGC)?^*N\?:Y<EN7^PSM",^PKN_&
MO[?WPG^'%N'UCQ98VH[G>2!^M<C=?\%5/A7JD2GP_JO_  D6[^"V'7Z&@ T?
M_@EOX)TF<>=XD\:WB]0DVI%E/Z5UVB?L"_#/PV=\GAVWU=R-O^F 2;_S[UPA
M_P""A'B;4)/^)%\&?&FM6K?=N(%9D'U^6DN_C[\=/'$3-H_P_?P]N&8VU.%B
ML9]^G- &Q\4OAU\*_@M"MS]D'A:2=@&M=-B!FF/J$!Y [UM>"?V:OA'\3='C
MU2'0=*\0K.N?MUPBR,K>C'.0?:O%_"%YX[^%/QUU+7OC)H>F:\NI0!]+NM.C
M/DZ<H7F,@D@[N>?]JJWPCTKXU>#;C6]=\&:+HNG>#M5NC);Z->Q,UR[GI(OS
M=/PH ];\2?\ !.'X>^)YF^Q+K&A-DDMID_DA&[XK D_X)F0^&P9O#?C[QC!=
M@Y5KV^:=<^XP.*<W[7_Q7\$HD&J_!WQ#KDV 'DTV)U4GN>AJS;_\%()M*VKX
MB^'/BCPS_?%XAR@]>5Z4 41^S_\ M(>&75=,^)_A^XLXC\L4VF,TC#T+;JCN
M/BE^T9\.0Z3>!]/\;,@/S07"VQD^@((_6N@'_!5OX+6\BQ:AXJBTVX?CRI0
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MY&6/U%=-\)+Z*^&H/&C+ND).: .X P**13D4M !1110 4444 %%%% !1110
M4444 %%%% !33'D4ZB@",0[1@=!T]J<(QCI3J* &R1+*NUE##T-9_B#PGIOB
MG2Y+._LK>[MY%VM'(@8$>E:5(QP* /FCQQ_P3,\#:M-/=^$9+SP'JDS%VN-&
M)M6=O]HIBN.EO/VBOV7(-S)8_$O0+,[4A@;&H2KZL\@7)_&OL",M(CL>/IWI
MD5@J0MNW<\@$YVT ?,?A/_@J3X)M[:2U\<1ZAX#\1(N6TV_A9L8ST=<ID_[U
M=[^RA^V/X?\ VL=&U6XTF1(IM-N'BE@68.XC!(5_E) R,<>]<K^WG^RK-^T?
MX&M]/TS2-$NI?M0DN1/$$:X0#[K.,.!]"*^;?AM_P2K^)OP:^*O]L> =:L/A
MUI4J;[O3]/F:XBOI!_>,I9@.@ZT ?HNVI,N"JA^!N /*^E3Q7OF@95E)KX[T
MW]L/XO\ [.]Y]B^*_@)]4M&8I;:CX;@>8,@_CF)) _#'6O=?@U^U]X#^.4:I
MH6OV$VH#'FV,DP6>$^C#UH ]4J0=*K+="7F+#CNP/ J5925'RY^AH >R!NHI
M<<TBG(I,D#)P/6@ ,2G^&E9=PH!S]*6@ HHHH **** "BBB@ HHHH **** $
M*ANM+110 4444 %%%% !1110 4444 1W.6@;''U.*^(O^"E7PYL]$ET*_O;'
MQ#J.B74Y&IBQO)(O+SG9DJ1WVU]NW3;8&(('N1FOB?\ X+#>'/&&J?#[0]1\
M/M)/I=E,K:C:12B-[K)^0C/H2#^% '8?\$XM.\&Z=H&H1^$[;Q)%"K!F;4I9
M9AGN 7S7U!<6,.H0[)HUE3.[#\Y]*^*_^"1?ASQ5;:!JFIZMYEK93X6.SEN%
M=P?7 %?;8<-$/X=U 'DGQ!_8V\'_ ! \9#7+Q+V&X7#21V\[1Q38Z!U!PV.<
M9]33/%?[(?A7QMI]M;7IOHDM69HC;3/&=I)PIQZ"M+XE?M.>'_AM\4=$\,W7
MG/J.M,RQJO0;<9S_ -]"D^.G[02?!5M/M8=-NM<U'4&=XK:W'S!5!;^5 '3^
M!_A]I_PX\)0:'I\3?V?9Q%$WCYOSJ+X;J(IM02-0JAS4'PK^*-K\7? 5KK=O
M%);+=J=\3/S&1USQ4WPUE66YU':0?G/2@#L5&!10#D44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444  &T48R.:** (?L^&W!F^FXX'X4K
M09;/?IG%2T4 4GTQ9+;R'6.2%E*NI7 ;/^ST->&?&7_@G_X"^+,YF73SX=O
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M>(O!][J/@7PM_P (_8W) ,LC%A.?1<U]/^+=(N/$>AM:6E]<Z=(_2>)2'%?
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M0!V-%(OW:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X1\2M+'ISZ/>20G$BPRK(8S[@=*UX/!&D,Q']G6OR]\=: +)\?:/_T$K/\
M[^BC_A/]'_Z"%K_W\%1)X)TELXTVU_%:=_P@VE?] VT_*@!__"?Z/_T$+7_O
MX*!X_P!%*,RZG9,%ZXF4X_6HV\#Z7M^73[56[';TKQCQ7^T_\)/ 7Q,_X174
M)O)U=I/*<1V[/"C>CL.%/UH ]IC^(6BS1;UU2Q9?:9?\:&^(.BJ5_P")E9_/
MT_>CFN17Q%X#AF6&2ZT.V=D$BIYZ99?7&:UM#M_"OBF#S+*/2KV-#A7MY%D
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M3]XKC&,=J_2.\BCN(GCE0,C#!##(-9^I:3:ZI9BWN+6&:,=%= 0* /RWT/\
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MM%*QP*S]3\3Z?HI47E[:VN\X'G3*F?S-366I0ZA;B6"2.:)URLD;AE;Z$<4
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M=I=Q.4C=HV1?*)CQ_P".BO:]'\.Q>$OAM\'[.!IK74;,-#:Q2,2TOW=^[O\
MW:^DXM)M&B^6" )L\D#;UCZ8^E8?B'X6:/KFMZ5J5U&/,T-F>S4=(\XS_(4
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MD#H-U>L?$?X+^-?A)XL\2:3X<D\0OH,_A&UN9TBD<.\YDF\Q@<]=H''6@#]
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M JN%SC<"N.G:NVU/03X!\/PZ'XXUWQE9V%OH<6HZ#-'-,#<7S#<1N7D\@<4
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MF23@,\F[&-IQTK\_?BI\-(_COX8\8OHVEW]EX.\1>)5DM+6&U*0W*#/S1KC
M'TKC/%4?C#X]>%/"D/B'2+^TO/A5X@M;*V5K0H+VUD) P<<[?+_6@#]6+CQO
MX5U#QA<^'_MNF3:U)$KS6QQ)(4(')7Z5KR6%GI$(799Z?;1X"](U;V(Z8KY:
M\)_ FR^'/_!2[4M?TZVU.:35=/3SWEF:2%5*@97)P*9_P5N\0:EIOPET.UT^
M?4&>;4OWMM9.\;7:;3\K.F"O..<CI0!]*ZQXU\*_\)G8Z%>:AI3:M/&;BWMI
MRI?RU&2R'TP#71W1MYX=KFWF!(81L05P.A%?CSK.E:CXW\0^$]6N]-\46OB*
MV\*:O%:RI<W&;>11<""(-N_>$X0 G/6O4M;_ &G_ !9XZF\(:5X6EUS^TM)T
M0KK!,;8+XP0./O\ 6@#]#+KXC>%H_&K^'VN=.^WWD>^5 ZN&'O6S;^'M*TVQ
MDCAM+*W$N&V)&H.[.-V/QK\L_AK\,-/^(/[0'_%*:OXH^V77AU9=7$MS),;6
MX0LQY8G:?;M7TU^PU\<K_P"/WC74-?U]K_3X="F&DZ?'DF/43SF1O4C8/SH
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M$JJL@8*/F((/I[5+\6O&OQ?^!/BJQTO0_&VM:E/XC\,/J5XVH($BTXAV 8L
M.<=,T ?JAK'PS\-^*?#,.E3Z5I=QI=H1LMWB#)$5Z8'MBLSXG?$WPE\#O#5F
M^M74.GZ=*PMH(5 "NQX"A?QKXR_X(W^-_B!KVK>)SXF\<V/CW26@B\B6U.[R
M3M&XL02-V<YQWS71_P#!8?P2_C_2/ GV&[O?/L;FXN(8[8C:\BJA 88.>: /
MJG3_ (2^!DCW0Z'I>&438\M2^&^<L1VZUM0Z!HUY?I=+#9EK:-H8VC ^6)L?
M_$U^7/P0^/\ X@N?$'P\GTWQYK>L>.M2NC!XKT [66QMPIR<;<C"@?E7UQ_P
M2DT'5]0^!.I:[XCU_5M<NM4U6X01WH ^RQJWRJH !QS0!ZS/XP^&WPB\0:@A
M32M.U:Q87%TJ*!(BRMPY^H:NHN_#/A?XG00:I<6%EJZH-T$S(&89!R#[<U^:
M_P"V[X86T_;9^*2R:QJL%[J^EZ?#8VL:[A+_ *M3MX[5G^-[OXN?LXS^(?#?
MASQCJ=Y&_@^'4Q)?E1]DD:9%+ @ 8 )]Z /TRL/ASX3M(0EKHFEJ'B:%U6/C
M9SN4X!ZDFO(_VA_VLO@C\(-:MM%\=(JR:7L^SAM.>6*(MPH4X]>U>%?\$;O%
MWQ$\0:EXAA\1>-M+\<:3*ZO)=6KEOLDOEJQBSDX///UKV'_@JAH-G<_ K1[E
M=*M;N\;Q+IV9OLRO(J^;SSC)&/6@#6^%OPO^&'[0GQ8;XJZ7"VIW%Q9+ID,=
MY:F)8%BR054] =U>TQ>#_#LNUQ9696.?SQ,57 EP1G/K@G\Z_.W]JW5/B)I'
MB7XDZ]X-US6-/70=(MS8V%M&([,R$-EMJJ,G&,\UXW\,OVB/B9X,\$:I%X@^
M)BZ[X<O%$5QJ>F,K'1;EN@E/( !SG- 'ZN^/V\#:/IS7&O0:6+/6+A+>6:4
MB:3[J@_E72Z2NG6-I%#9"WM[6,8C$8 &!^-?BU!\6M3\?^$]=TG6OB+<>(-/
M\.^*],-K+;.!'(C(K,Q//<]J]BT71O'7CGP=JGB2S^)7BFWL8?&,FE6\,3)Y
M?D^>4!'RYQB@#]0+O2],M+R36BL!NDCV-=8&[;_<SZ=>*K:KX*\/:UH[VMW9
M6=S:%OM'E.@*^N17Y,_%KXI_&+P]\/\ 7O#NE>-KJQLM.\6?8I=8U;[H@\B%
MR<C ZN>E=K\%-7^+7Q/B\">&M7^)$KV5PS,NL:6Z#[8BL2-Q8,,8':@#])9]
M9\+6VIP>%O.LH9YXQ)!9JPW!1_$!6FGA#3'UU=2^Q0_:[>'R/M3J!(0.X-?E
MI^R'>7)_;%\*WWBSQ?JEWJBZMJ&EVC7+C9-'&8B ^ !_$<8Q7W7_ ,%"O$FM
M>$OV9-8NM"NKFQF4QK)=0\R6461N(^@SUH ]&^)?BSPOX4\&S:WXBDM3INF?
M.SG#)&>@^K<G\Z9X<L_"/Q$^&5K/;V-M)X=U1!= 21X5@W.['N:_+KX@ZU>_
M%O1;WP[X5\>ZYXO\%&TCN;_4"B_Z'=@C,)PN/7K7Z8?"?1(_#W[,&AVSR2/Y
M6@0JS. &!\@'D  #GF@#/^'_ ,6_A=XI\!ZIK.BRZ6-&\+3R073>4!]FD0?-
MC\,UO_#KQ+X/^+W@?2=:\-BTU#3;N1KFS?8.JN59Q[@J?RK\H++_ (2+P'H7
MQ+\ V<6I6NG?$N29],F6(_)/'N>3)QW6O6?AE\3_ !7^R/\ L/?#+6]"^U3S
MW5C)HUO8O'PLYGD!;'7)+9H _276_#^@^*;V%K^TL+J14_</+AB1_%Q4BZ'H
M8U*U'D68FM4+0,, P@]@/PK\LM3^*6J^'_%7B5?%/Q/U[P_XTB6*Z\/:.A3%
MX[J[-$ 5/' Z5S_@7X_^(==@N+SQ!\0O$&E_$!;V 6VAJJE902"5QMSWH _4
M_P "-X26]U:;1[6VL)[2X\B]E\L1%G!.?QS74C3K)M4CU!HX/M/E%4<X+!/0
M'T[_ (U^1WQ@_:<\2:GIGC71]<\7:AX-UB/Q)+<6LVU8DG41S;4?CH3@\=P*
M^H?^"8OQ;/QE_9C\'GQ1XYN+SQ5;/=0S!9%W3IY[[&((SC& /I0!]2_&SQQX
M/^#'A"X\2^+([>VT^)D$\YAWL6R-O ZG.,5PWP]_::^$?[6EQ'HMILU"6+][
M'!?630L!V*@CFN-_X*VW\>@?LKV]W>%C:V6OZ=<7+8R#"MU&6W>VW->8Z[\4
MO _[17[57P:;X7W%O<7?AZ9;O6I;$B!6M2% C?;@'D-U]: /MZ#P#H]AI*6,
M6GVL-I;/OAC$?RQGU H/@;2)G8&RMV\UQ(Q\D8+#H:P_CUXK\1^"/A_<7GA;
M2_[6U1?N0$%@WY<UYC^R]\</BQX_U^XMO&_@TZ# .8Y5C9=W_?6: /;+C3[&
MTU$W)C@25%"/.PP0H^Z,_7%>?W'Q8\ _$[5KK0;PPZC>:=>K;7,?D[TBF()'
M/T%>-?\ !2OXA:EX3U[P#:3>(+OPSX7U*\==:U&WV@P( Q4G((Z@=:^%O!7Q
MD\4>"4^(%[X#\1S^(Q-XC'DWDD*F2^0IC<"!V /(H _7R+P+X;NS!MTRQD2P
MR(7"J1#W(7TYS67-HG@KX;:9-K#66DV42MNFF0*"N[CYJ_,_4OV@=2\+:'K_
M /PA'Q,UCQ'>1^%;^[UN"X9-NB7?D2$X(4?<;U]*\\\<?$6[^(/P/\,V_A;X
MD:[XH@U6!)?%<A==NG8Y^7 'OUS0!^MG_"J/"'B'PM=G0X+'33KT9'VRU4(T
MP=>2I[]:K_ CX#>&_@1X"M/#NGR17D=@S3QR3$"5_4M^=?E!\3_BW\4K6[\-
MZ?H7Q0L_"N@Q6<":*MZX2:_!;[R9(RQZ#@CI7U=^RC9^)OBA\1OBIKGC?QAJ
M>DVWA^*"S C*K!$'RQ<9!Y.S]: /N:33+.">6\AMHI)Y]H>3')!&!S2V>FZ9
M:/((?L\+AMTKJP&YSUS[U@V92Q^$<+6=Y)>0KIPFAO5()N %RK'MDC%?FK<:
M/\1O$OQ)\-Q?\+$\46%OXH\4W=E-"BIB&%()W4\KZJ.M 'ZJM%%/A]D3!C]]
M0#G\:@UGPOIWB?39(;VUAO+2?[\4J;E;\*^?/^">FN^((/#_ (HT/6]4O-8_
ML/5#:VUS=C]Y+'A3N. !G)/051_:(_:$^-'@+XIWVG^%? ']N:'  8KL(Y!&
M0#G!]* /<S\(?"=KYT::#IVWRE\U1"/G7)P/PY_.K<G@K0(+&YT_[':""^8O
M<PA1^]8\DM4'PZUN^U_PA8ZCJ-OY&HW5LK7EN1@P,,\?K7YJ^/\ 3_B3XJ^.
MOCFXL/B/XNM;>7QPVE6MI;)'Y<5N2_'*$XP.QH ^]/B]^RAX+^+O@32=#N[6
MVTW2=,U)-2$=H%$;2)G&3^/-=DG@7PY9P6L%KI^GP6HRRIA1&%(/3ZU^6'B+
MXM>,OAW^TGXH\ >+_B'KNC?"S0A#,VO,H\Q9V4GRR^W;@^F.U:O@[Q+\0OCG
MXN^''ARU\?Z]'X5GN]3:/5(BBO?PI%.8#DKCLE 'Z2^)_%'@/PMJL.EW;Z=%
M=:<GGPV[ ?NU?.60?\!J+PUX5\$>-/"%U-HT-JUAK",TTT6W=/C(8-^1K\L-
M4N-3U_\ :1\SQ#XFUN*ZTZRDTZQ$Z?-?E<X)P ,_-7KG[+?A;7_@UJGA:SOO
M%_B%-&UBQN6OA-M\NP9I).<[>.,'F@#])/!7AJS\-:-;VMG&B01*-H7UK>KF
M_AA;P6?@ZU2#4#J<1^9+HL#YHXYR.*Z2@".>+S864C=GL:QTTVQT^R:WAM8%
MM;AB)$10 Y8]<=SD\_C5[Q#9_P!H:+<1>8T;,G#(V"".1S]17Y<_%?\ :7^+
M'A'QAJYM/[4;4/AW>W;7]J"3'>PS[UMV [X,D9_"@#]-K;PUIVEWWVFUL;>.
MX\KR&FC0*RH.0OTR36=+\+_#-[K#ZA)HFEMJ#8=KEH5:17(]>M>._![Q'XBL
M/V,[?Q)JFHW=OX@U.W%S(TZ><UNV3\NW'I4'[*WQ@UOQ[X\N;/5/%2ZR@7S$
MB72_LO;@,_?VH ]VO/"FFW8>>6SLW?9L<-$#NZ=:32M'TC2=3>YMK6SM;@1"
M,S!54A1_"37Y\_M8_&7XF>&?VDM<\$Z'J&JV&F6ICUH717>LD$9;SH@V/=.*
M\0^*'[17Q@^(6@B>ZGUW2_#.MWUQ?Z?-;YAG$7+1JQQTQC\* /V#;4/+@D<B
M-6S@9D S6-IWQ&TO4/$D^E_;8_[0L]IFMU<,8P0"&/M7Y,_%/]H#XM^+[+P)
MI=]?:U'I<.C/-/>V;&(RW:O'L#-_$<;N.]9>D_'#XIZ3\1=,U>2"^DTR[NX;
M77=2BC9)$@&T9/8<4 ?L:FFV\&I27T5I!'<3#RY9RH#N!TY]*J#X:Z%>W G;
M2=-DF68S^:8@6$A ^;IU_P !53X:^)-,UOPWI]M8WLE]'':(_FRMF1QC@M[U
MUEJNV/[H'TH Q+WX8:#J.BC3I](T^6P5_,%NT(,>[UQZUYMX[_8Y\->,/B?X
M/ULV5G!9^$1,(;)8QY4OFD%LKC':O::AD5C(IQ0!S]I\--#@A6%-)T](U.U5
M6,#"@Y';V%6M0\ :3?[O,TVRE+P&W8N@RR'^'..E:<5J4N-WZ59H Q?#?@#1
M_",;#3-+L=/\SA_L\83/Y5-?>%++4;A998(I)$^X67[OTK4HH YG3_A'X;T?
M5GO[30]-M[Y^3.D $C'W.*UM'T&'0K(6]K%##$N2JHFT GKQ6A10!SU[\-]'
MU/65U"YTVQGOXSN2YDB#2*<Y SZ"I[OP#I-]<233Z?9S32)Y3.T0RR?W2?2M
MJB@#'\.>!]*\(!QING6=GYIW/Y,83<?7@5:U70+37+00WEK!=1*X=4D7(!'0
M_6KU% &//X,T^<2 V=J1*I60-&#Y@/8UEV_P6\+VMI+;Q^'])C@E?>R"W7#G
MU(Q7644 <E;?!+PI90211>'='6.=Q),!;* [#HW3J*TD\!:3%IQM1I]CY&_S
M1'Y("[^S?6MNB@#G[SX9Z%J=E-;W&DZ?-!<OYLT3P@K(^ ,GWP!4FG?#_2=&
MLX;>RTZRM(;5"D"Q1 >4",<>E;E% '.Q?#+0H=0ANAI-@+BWD:6.41#<C$ $
MCCJ<?I6I?:#;:KI\EI=017%K*,/%(NY6'N*O44 <SHGPB\.>';.:WL]%TRUA
MN&S*D5NJK+]16TFDQ1VOD>5']GV>7Y8^ZJ@8  JY10!@_P#"OM'E$+2:7I^Z
M%S)'^Z!\MB,,0?<5Y[\7?V8K7XH>(_#4C7GV#2?#=R+R&QAC 627=G\CQ7K[
M+N%598'+YSDYX/I0!S^K?"S0_$&HI>WFC:=<7L1 CGEA!>( 8!!QUYKAOA1^
MQ[X9^'?BG6]9>SL[V\U6Z-PLDL(9H#G.037KT2N/O\T*A9MV,=L4 <WJ_P )
M_#?B2X<7^AZ5>;G\UC);JV]^>3[\U7MO@;X9LM3MKJVTFSMIK)2L/DQ",*"<
M]JZRWM_(_$U-CF@#-\0>&+'Q38/:ZC:V]];/UBF3>OY50\,?#+0/!=PTFDZ/
MINGNR[2T$(0GVKH:* &>5C^I[TUK?_@7UJ6B@#)U[P7IGBBT^SZC8V]]">L<
MZ!E_*J%A\+M T*V\BTT?3H8F.=J0*H%=+4<ZEOQ&* /-/B/^S5X=\:_#KQ)H
M-OIMCIS>(K.>TGN+>((S+*&4Y(Z\-5GX4_LW^&?AA\.]/T"VTC3FAL[=('80
M@&;&?O<<]:[Y8FABV8+>]31C"T <Q=?!WPSJ A$VAZ9(MO'Y468%_=+G("^E
M.U3X7:/K.C:A93:?:"'55Q>*B;?M!'3<>^,FNG'2B@#-\/>&;7PUH5OIUK&L
M=I:QK%'&.0J@ 8_2J[>!-):2-_[.LQ)#(98V\H9C8Y!(]SD_G6U10!3T_0K7
M2FD-O;PP^<V^0HN-[>IJ;[./,W?IGC%344 0BT42EL#GT'6LP>!=+CF>1+&T
M6225KAG\H9,AS\WUYK9HH YG5/A5X?UR.=+S1M-N%NF#S"2 ,)F X)SW'-6=
M,^'VCZ/]G6STZSMTM2QA"Q@>5D$':,<=36[10!SMQ\+= NKU+A]'TUIH\[',
M +#/7FC6_AGHVOZ+-87&GVCV\T30%?+ ^0CI7144 9?A7PE9^#=&AL+%/*M;
M?B-/[H]*U*** &RQ^:FVN9OOA5HNHZM?W\VFV<MY?*JRNR#][MP5W<=L"BB@
M#;L]*CM[%+?9&L*IM\I1\@I]OI4%J/W<,:'@91=N*** ,S6?A[I>NZI]LN+.
M&2X\IH3(R@DHW4?H*S-8^"?A_P 1^'+?2-0TJQN=-M-HBA9!A H ';VHHH /
M$OP+\,^*]*L;&]TJUFM-.P;>,H,1D=,4MQ\&=#N8IUDTVQ=98A$$,0VX ZGC
MK110!H^&_AWIOA3_ (\X1'^Z$7M@5MVZ&., XS[444 /HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm205388-1_10kimg14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "* 1X# 2(  A$! Q$!_\0
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M_=]: +E]_P %-O!NG@>9X9\>!B<;/L5KN^O_ !\4RZ_X*@>![,*9/#WCA=Q
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M;^>/*F/56C;(SU_"L/Q3^U*O@>X34&U&'^T-(V>;<M<C_3858X9E[2#(!_O
MG-? 5E\ _$NOZQ_Q);2[ A/F,D+$"+([C.!^%>J_#S_@GU\3OB#,+F70I)E9
MF5!+*V64YY],T ?H#\-?^"AGAZUF!UB^@LX7"7%O*URCQW"/U5"#P1G)!Z9K
MK?B!^VIX-F\.SQ6_B73YOM<JB,+,IQ@%^<9..G-?&/PW_P""3_C+2EN#JEY9
M:;;/'A4*J[@\\G(X_#KS6I<?L4:QX,L)M,T_Q%H[7-\# WF1_O&5N"0W11@]
MA0!]%ZQ_P43\+^&?#$%VU\EW)_9[0A;=]V'D0$-GV8UZ1\'/VJ?#W_"M=,MU
MN2G]F6J"XW<^;*W)]>>37QM\'?\ @G]XDMYVM'\2Z,MK 4Q'<9(<J<Y'!]OR
MKU?P'\ O''P<\'^*A=:3>7>F7NK?:5N!AD:,I@;3U4 \XQ0!]2ZQ^T9H=F+=
M3>01+(^PJT@!E)^[5WP_\5M-DE8FYB5W;;E95.T>G6O%OAMXGTR+P?;V]]IK
M#5IKQ(&N-2C5R1@[C&K#V(S[U]":1X%^''Q#TVW:\\/6%O(>("JB.67H,_+C
M/;K0!#+XELM6A+;N?]HX-5)9H94+JV$7KD]*Q?'G[#V)[B?P;XHN=/F!^6"X
M=GC)Q]T9/K7G&MV_Q,^#$K_\)'H\FHZ7"-OVRP.Y<#J2N,_SH ]<#PM(O\3;
MA@@^XKZ7TPYL4R-O7C/N:^'?AS\;+#QO/$L<V)1(J^6QPRC<.HZ@U]Q:1_R#
MH_Q_F: /@K_@X>M)M2_9+\(VL#!)+CQ; H9CA1^XGZGM7P7^R[X.;PAX<ENM
M2\ ZYJLEMF1[G3)XG7A2<DLZ;?7T]Z_33_@L9H9\1? 7PS:K8V^H-_PD49%M
M,X3S3Y$P^4G^/GCU[9-?F1\7_ ^LZ-I4T4VM7WAI88BCVC,P>8#^$E>H_P!_
M!'>@#,_:'_;FCMK%].TNT7PW:(S+/)#J*+,W;#M$"!VS\QZ5\-ZO-)\7?%%P
MEK=3WBG<))_)+PP$MG.X_>.!C'^T37HWB/X<V/C;Q/%"'>^BC?=<L@SGKP">
M?K@BOH_]C[]CC_A8&O1;=+^R:;$W^IB3"R\<,3U/XT >8_L[_L3ZIXSDM8M'
MTI=/L77$ER\67E]<'KBO3/VSM"\/?L,? :.&*.W_ +>UL-%%U\PG!Y)YXK]2
MO@E^R7IOA;P]!"ML842'G:O3 YKX*_;I_8VLOVO_ -I3QK+XJUR3PWX.^&>A
M+>Z9!&R!]>N^6-J"?NY7J1ZT ?CWHOP^O?B%KTDT]NU_<7,@,03G:W7]<UZ3
MX9^!>J)?M8SV;6R[<O!(NUQGIA>O-?I+^QA_P3O\!>.-+'BW18Y=,L=,"R?8
MYAYJ3L.61F;!XYY'(S[5ZKH?[%_A?Q_JLV+<VET(7<WC+Y@BV@;0/U/6@#\L
MKK]G4>')G1X'AE&-RR(054_Q'V_PK+TWP1;0I8Q3>3'=1LS2;SC"*1@_3!!_
M&N^_;N^.$WPG^(NHV*R>==6$/V2,PN%CN">C%3SVY^E?%.M_M2^((M:,C?9?
ME!5E"<>XZ]#0!]:ZA^SYJ.LV-C]CCAN8[ASYBQ'+ =03Z UD>._@)%H&F1PQ
MPJUZGS2(J8QD]#[UU?[#/[4ND_%+PG<V-ZT.FZO9"-=C*3YB9(RI'(.0!_P*
MO1_B'I-C?:@TT$TMSK$Z-F(QL$CYX ;')Q@GIUH ^3?"LEW\,O'2^<C"V69?
M,'\)&?\ "OL$_ _3O'G@JWU;09 K7"!VQT8D9_K7SW\9/!=Y+<F2Z=2RA4'D
MIQP>Y]:^C/\ @GQX@G\0^ +K3)6$BVC(H+')V[: /+X['4?"^HO97MO)$\!*
MB4 [2.QKK?#;6US$EK<Q*_FG/F=C7L_C_P"&5I?%WD@7YFV[BO)KP_Q';CPU
M?LL;?NPPP.ZGT% ':6/PLN]"OX;NRC6\M93F1(LG"CK7T1^Q%HUUI'[4?P\,
M4;O:2ZU:D$?PC><BO&_@/\4Q:7L=A<!0)@<&3GC/05]G?LD^#K67XW^#;VV:
M/,>J02/'CB+YN@_.@#S;]M6_\S]LKXFP.'R-:E90RG&-J=_SK@#<VEOI3SNT
M0DBC'S;FP@]_QK=_;L\1P6G[<WQ16;4/)VZS*NU<DCA:^>_B#\5-.L]#U)3?
M&1V!1(60_O1V]Z ,SXQ?M*K#<+I4/]GW:VVYIYQE=H],CG/%<CI_CF+3[-+F
MSU33].?!=EBDEGN"#TP",#\ZSO"&DVWC*^NK>.:Q1^'F*6KMM7J=SG: 1@\'
MZ5V7P>_9VTOQQJ$OEH_]F*V9;IAACCT'I0!0\)?"ZZ^)>O?:6A'V>]1=MRTI
MW$\9X'5B.WK7V7^S+_P3P36Y;.6YAFAACDW*]S/([$>RYQ7%?LWZ5IFJ^,U6
M*VMX;.V/EV\0'"[2!NQ[XK] O@_*MO#"H,:8')% '3?!3]C+P7\/[9#/IEM(
MX^;S'0_.1S4?QU_:)T'X26$MGH]O ]U;Y4+'A1&1SR>@J3XV_&L_#/P3^YD5
MKJX4I'N/W?4U^/W_  6$_;:UKP0A\%Z#<QV^I:Q$L][=Q2YGBC91E0>QR>M
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MVH.Y/GX#=O3FO._A[X)OM5U]6TRQ^V7E[/'IMLH4?O9BN]@/7 V_]]5]"?\
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MJY\-^%8&3PEX7T%[5Y5&/MUS(REII!W=L]?85^W'P6MFL_AGI43Y#1Q8((H
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MP?PSF@#V=;BPB\616R9GN;=BR+$3OG')^4^U=#X7\:Z?X;AO[Z\61209GAE
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M!6T<;?1I'Q7-:E^Q]X+N;T,-"@;;R1YKU]63^$ RE2O3@<5FMX +L64 <^E
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M6/ARR5(99]P50Q=5Y^][>IKI+'PO#&D'ES3+L1@^TXSDFK0E\R;?'( "NUE
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@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm205388-1_10kimg15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #\ 7,# 2(  A$! Q$!_\0
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MEQ]?S- $7]I6_P#SVA_[[%(M] [A5FC9F.  XR>]3[?<U1U 8U33_P#KJ_\
MZ+:@"_1110!E>-O^19N/JG_H:UJUE>-O^19N/JG_ *&M:M !7F_[2?P8'QX^
M%5_X>#>'4N)+F"ZM9]:TC^U+:TGAD62.81"6$^8CH&1TD5D9%(.17I%1F-2P
MXY'3/;_.: /.OV5/V<M'_9-^ ?AOX?Z#-=7=CX>BD62ZN-@FO;B:62XN+AU0
M!%:6>620JH"KOPH  %>@W.F0W;9DC#'ZFIPN#2T 4O["M?\ GB/S-']A6O\
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M %+^PK7_ )XC\S1_85K_ ,\1^9J[10!2_L*U_P">(_,T?V%:_P#/$?F:NT4
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M;CQ5X.\1>*?$[VMI;_90-,N=.C$SQS3+(\(CGG>2&V<SR$CRP=N*]O\ B/\
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M"33OLZ_W?U-"0*K9'\Z )*H:E_R%M._ZZO\ ^BVJ_5#4O^0MIW_75_\ T6U
M%^BBB@#*\;?\BS<?5/\ T-:U:RO&W_(LW'U3_P!#6M6@ HHKB/CMXI\1^#?A
M?K&J>&8?#LNK:=']I UV_FL[!($.Z5Y)8HI77$:N1B,\XH [>BO,?V2_BGXJ
M^-G[/GA'Q=XP\,Q>#]>\1V?]H7&CQW;W*V,<A8PAF>-'$C1>6S1LJF-F9#DK
MD^B:AJ4&G;?.D\OS,XZ\X^GUH M45F_\)38_\]A^3?X4?\)38_\ /8?DW^%
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MD2C<7QU8\%ORKS;XU^(;.;Q%\.2LZ\>*4)Z_\^-[[5WO_"3V.?\ 7+^3?X4
M:5%9O_"4V/\ SV'Y-_A1_P )38_\]A^3?X4 :5%9O_"4V/\ SV'Y-_A1_P )
M38_\]A^3?X4 :5%9O_"4V/\ SV'Y-_A1_P )38_\]A^3?X4 :5%9O_"4V/\
MSV'Y-_A1_P )38_\]A^3?X4 :5%9O_"4V/\ SV'Y-_A1_P )38_\]A^3?X4
M:5%9O_"4V/\ SV'Y-_A1_P )38_\]A^3?X4 :5%9O_"4V/\ SV'Y-_A4EKKM
MK>3K''*&=LX'//?TH O50U+_ )"VG?\ 75__ $6U7ZH:E_R%M._ZZO\ ^BVH
M OT444 97C;_ )%FX^J?^AK6K65XV_Y%FX^J?^AK5C6+R:QTZ::WM_M4\:,T
M<(<)YK!20NX\#)P,G@9S0!=K$\:^"K'QYX6U+1]4MTO--UBWDL[RW9F59X9%
M*O&=O.&!(/UKYBUG]LCXI:)KD>G:E-^S+X=\53/$L7@S5OB+-'JJF7'E123+
M:G;*^Y0 D#C)&"P.:^I/">H7VK>%]-NM4T\:5J=S:Q2W=DLXN%M)F0%XA(
MX5B5W8&<9P,T 7;:W\A0%QCL.RCL![5.1D444 )CV%&/84M% 'A__!13_DUN
M[_[&/PW_ .G[3Z^*F7/QB@/_ %!'_P#1ZU]I_P#!18X_99N_^QC\-_\ I^T^
MOBN32-<7XF0ZBMOI1T\6OV+/VQ_.VEU<OM\K YXQF@#['_X)L<_LPKW_ .*E
MU_\ ].UU7OV/85X!_P $U7W?LP(>N?$FOGC_ +"UU7T!0 F/848]A2T4 -(X
M^[7Y,^!#GX;_ !(SV\;>-!_Y<.I5^M!Z5^1OA/5?L'PZ\?J+2_NY+SQ[XSAB
M2UMVG8L?$.I=0O('O]/6@#T?X2+G_@I5\"/]SQ)_Z;DK]*5&$_QK\S?@5JB:
MS_P46^ -RD=Q#YL7B8F.>)HW0C3P.A [ ?G7Z:#I0 F/848]A2T4 )CV%>!?
MMC_MD7?[,/C+P!H6G^&+7Q#J/CRXOXX6NM6?3X+-+. 3,S,L$Q8MN  "COS7
MOU?#7_!6!?\ C)7]G'_KY\2'_P I\= "?#O]N_Q9HGB'QM-!X#\+R'4=;^UR
MJ_BZX3R'%E:1[%/]G'<"J(<D#EFXXR?L#X0^.5^*'PK\-^)X[4V<?B32K75$
M@+AS")XEE"%@!G 8#.!TK\X_!P']K^*>!_R$V_\ 22UK[\_9 ^7]DWX7_P#8
MHZ3_ .D<5 'HN/848]A2T4 )CV%9'B[Q=8^"/#6J:OJ$C16.CVDM]=NB%VCA
MC1G9MHRQX4X &3VK8KSW]JF+?^S/\1=W3_A%]2XR1TM93V- 'R]\2/\ @K/\
M-?%FH>#;VW\-_&*&#2=<349C<?#W5H3)%]END^0&#+MEP=@^;;EL8YKZ _9:
M_;<\%_M>:AXCLO"]OXJL=1\)F#^TK+7_  _=Z1<0K/YOE.$N$4LK&&4 C^X:
M^&==R+7P@<[L7L)&>.?LDPS\N,]/\GFO:_\ @F-'_P 97?&YN3MT#PJ@SZ"3
M6@.>N?<^IH ^W<>PHQ["EHH 3'L*,>PI:* $Q["C'L*6B@!,>PHQ["EHH 3'
ML*,>PI:* $Q["C'L*6B@!,>PH ]J6B@ JAJ7_(6T[_KJ_P#Z+:K]4-2_Y"VG
M?]=7_P#1;4 7Z*** ,KQM_R+-Q]4_P#0UJ_<D;,-M^8X^;\_Z?I5#QM_R+-Q
M]4_]#6KMV2JKU^^,X],>E 'YV^./CUJG[.__  4C\>:#J'BCQ7X.TSQQXJT>
M_P!/L-,B\+MI^M!]/LK62XD.H70OQ*SP>4_DQJ-D$9C5GWL?K;]L_P#:)U/]
MF3X&?\))I.E-JVI7.MZ/H-I;-$74R:CJ5K8K(5WKOV&X+;3)'O*A=Z[@U?,-
MW\%-7T3_ (*$?$S7-1\':A]B\1>,-*U'3K^#X;VVNQW4,6F:="\IU*63SH")
M(W3:JA(O+W)N)<U]P?$#X:Z)\6?!6H>'?$NF6>M:+JL1AN[.ZB#Q3J3G!'UP
M1W'K0!S/[,?QRM?VAO@[I/BBQN?ML=])<VD[_P!GM8^5<VUQ+;SH8FDEV[)8
M73B2125RK,OS5Z!/=^0V,2'Z1LW\@:Q_ /P[T7X5^%--T#PWI-AH>A:1$+>S
ML+*%8+>UC&3A$48').>A.223704 5?[4'_/.;_OS)_\ $T?VH/\ GG-_WYD_
M^)JU10!X/_P4-NA<?LLW@VR+_P 5%X;/*,N?^)]I_J!7RM%^Z7Y0%P1C:,=B
M?Z5]8?\ !1;_ )-7O/\ L8_#?_I^T^OD[_EF?J/Y&@#Z@_X)PW:Q?LRKGS&_
MXJ77QD(['_D+77?%>\?VH/\ GG-_WYD_^)KPO_@FW_R;,O\ V,NO_P#IVNJ]
M^H J_P!J#_GG-_WYD_\ B:/[4'_/.;_OS)_\35JB@"J-2!/W9O\ OR_^%?EI
M\#E_XE?C _-D_$'Q>V",$?\ %1ZC7ZJGI7Y6? [_ )!GC/\ [*'XP_\ 4BU&
M@#H_A))Y7_!2+X"'+<0^)/E"[B?^)<M?I*FI@J/EG'U@?/\ *OS?^#G_ "DE
M^ G_ %Q\2?\ IN6OTK'2@"K_ &H/^><W_?F3_P")H_M0?\\YO^_,G_Q-6J*
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M3_&G6]_--*JM9RQ*>K%E('Y&@"Y5#4O^0MIW_75__1;5?JAJ7_(6T[_KJ_\
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M110 5\-_\%8!C]I3]G/_ *^/$G_IOCK[DKX;_P""L'_)RG[.?_7?Q)_Z;XZ
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M.H?\^EM_X$M_\11]IU#_ )]+;_P);_XBKU% %'[3J'_/I;?^!+?_ !%?EO\
M H[M(\8YQN/Q"\7D@'('_%1ZCWK]5B,BORK^!S9TOQE_V4/Q@/\ RX]1H Z3
MX3M*G_!2+X!F*-9&\KQ)PS;1_P @Y>^#7Z0+=7^T?Z+;=/\ GY;_ .(K\X_@
MZ,_\%)O@)_UQ\2?^FY:_2I5PO_UZ *?VG4/^?2V_\"6_^(H^TZA_SZ6W_@2W
M_P 15ZB@"C]IU#_GTMO_  );_P"(KXA_X*J33R_M)_LY>=%''_I/B3[DA?\
MYA\?^R*^[*^&_P#@K",_M*?LX_\ 7QXD_P#3?'0!P3<JW^Z?Y5]G_LAW-[_P
MRC\,-MM;,/\ A$=)Y-P?^?.+_8KXQE_U3?[I_E7VU^R"/^,3OA?_ -BCI/\
MZ1Q4 =Q]IU#_ )]+;_P);_XBC[3J'_/I;?\ @2W_ ,15ZB@"C]IU#_GTMO\
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M@-+MR,3D?\LEQ_!7:L./Q'\ZYGX++CX0>&/^P5;=_P#IDM &W]IU#_GTMO\
MP);_ .(H^TZA_P ^EM_X$M_\15ZB@"C]IU#_ )]+;_P);_XBC[3J'_/I;?\
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M%(7 [K^=5_*NO^>UO_WX/_Q=9GB70+_7='FM8=4DTN:8!5N[.)1/!SU3S-Z
M]1RIX/2@#9\U6/#*<C(YZ_YS7Y7_  .;_B5^,_\ LH?C#_U(]1K]!/V8[77;
MSX2Z9J6K^)M0\0WFJ)]IDEU"&',1X7:@A2,!?ES@@\DFOS[^!J_\2GQC_>'Q
M"\7@D# _Y&/4?<T =3\'#_QLE^ G_7'Q)_Z;EK]*P<BOS1^$2LW_  4C^ NP
MKGR?$G++G_F'+[BOTD6"ZV_ZZWZ?\\#_ /%4 6=PIDS8Z#/]*A\JZ_Y[6_\
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MG\$X^\WBOP> 3_V,&F"@#]9J3<*K>1=;B?-M_;]R?_BJ/*NO^>UO_P!^#_\
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M"H^P^.GP-QE\!9('7_B=WE<9%$O7:O(R2!S0!]6?\$XVW?LHZ?\ ]C%XB_\
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MXYV/D:E=10O-&(OAKXO&Z21II&'E6 ^9W+,QSW)Z$5V7PD_Y%K6?^QP\4?\
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M:UU'^>HH ^X**9N^OY&C=]?R- 'RS^T]_P I$?A+_P!D^\5_^G#P_3/VDO\
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MS\?>,SX8U.!--M;HRQG2]1OQ(C3*Q5PUBJXR5*,_&<4 ?0!\*:;C_D'V?/\
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MJ6 ZD#/2H-5\(:3XA\+2:'J&C6>H:/<1?9YK"YM4FM9(_P"X8V!4J.RD8&,
M"NBHH Y&?X8^';O5])U";P[I<M]X?B>#2[AM/C:;38V4(R0N02@*C!"X!XR.
M*Z2*Z\M,>7<-UY*]:M44 5_M_P#TQN/^^*J:A:6^J- TUIYTEJYD@:2$,87*
ME"RYZ':S+D<X8C/)K3HH YU/"6FQZ;+9+I%E]CN+?['+!]C18G@!;;$R8PR
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm205388-1_10kimg16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm205388-1_10kimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #W ;4# 2(  A$! Q$!_\0
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MVY!_=N/_  'D_P#B:M>9]/SH\SZ?G0!5_MR#^[<?^ \G_P 31_;D']VX_P#
M>3_XFK7F?3\Z/,^GYT 5?[<@_NW'_@/)_P#$T?VY!_=N/_ >3_XFK7F?3\Z/
M,^GYT 5?[<@_NW'_ (#R?_$T?VY!_=N/_ >3_P")JUYGT_.CS/I^= %7^W(/
M[MQ_X#R?_$T?VY!_=N/_  'D_P#B:M>9]/SH\SZ?G0!5_MR#^[<?^ \G_P 3
M1_;D']VX_P# >3_XFK7F?3\Z/,^GYT 5?[<@_NW'_@/)_P#$T?VY!_=N/_ >
M3_XFK7F?3\Z/,^GYT 5?[<@_NW'_ (#R?_$T?VY!_=N/_ >3_P")JUYGT_.C
MS/I^= %7^W(/[MQ_X#R?_$T?VY!_=N/_  'D_P#B:M>9]/SH\SZ?G0!5_MR#
M^[<?^ \G_P 31_;D']VX_P# >3_XFK7F?3\Z/,^GYT 5?[<@_NW'_@/)_P#$
MT?VY!_=N/_ >3_XFK7F?3\Z/,^GYT 5?[<@_NW'_ (#R?_$T?VY!_=N/_ >3
M_P")JUYGT_.CS/I^= %7^W(/[MQ_X#R?_$T?VY!_=N/_  'D_P#B:M>9]/SH
M\SZ?G0!5_MR#^[<?^ \G_P 31_;D']VX_P# >3_XFK7F?3\Z/,^GYT 5?[<@
M_NW'_@/)_P#$T?VY!_=N/_ >3_XFK7F?3\Z/,^GYT 5?[<@_NW'_ (#R?_$T
M?VY!_=N/_ >3_P")JUYGT_.CS/I^= %7^W(/[MQ_X#R?_$T?VY!_=N/_  'D
M_P#B:M>9]/SH\SZ?G0!5_MR#^[<?^ \G_P 31_;D']VX_P# >3_XFK7F?3\Z
M/,^GYT 5?[<@_NW'_@/)_P#$T?VY!_=N/_ >3_XFK7F?3\Z56S0!4_MR#^[<
M?^ \G_Q-0W/B:SLK<R3--''T+-!)CT_NUI5A>/SCPU-_O+_Z%0!NT444 5-1
M_P"/RQ_Z[G_T6]6QTJIJ/_'Y8_\ 7<_^BWJV.E !4=Q]SWSQ4E#-@4 >,_&S
M]C_0_C_\5O"OB7Q#J6J2VGA.YM-1MM&B@LX[:>ZM;@7,$LLWD&[(694?R5G6
M)FC4LA(KV*W7$*CT&*/M";L;@3TP.M.1ED'!R,XX]J (/[*M_P#GWA_[X%']
ME6__ #[P_P#? JS10!6_LJW_ .?>'_O@4?V5;_\ /O#_ -\"K-% %;^RK?\
MY]X?^^!1_95O_P ^\/\ WP*LT4 5O[*M_P#GWA_[X%']E6__ #[P_P#? JS3
M0X8_K0!!_95O_P ^\/\ WP*/[*M_^?>'_O@59HH K?V5;_\ /O#_ -\"C^RK
M?_GWA_[X%6:* *W]E6__ #[P_P#? H_LJW_Y]X?^^!5FB@"M_95O_P ^\/\
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M_P )!#_SROO_  #E_P#B:N>6OI1Y:^E %/\ X2"'_GE??^ <O_Q-'_"00_\
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M>,?FP JQY:^E*J[: %K!^(/_ "*\W^^O_H5;U8/Q!_Y%>;_?7_T*@#>HHHH
MJ:C_ ,?EC_UW/_HMZMCI534?^/RQ_P"NY_\ 1;U;'2@ H)Q14=Q&9$QQU'49
MH <'!'4=,_A0&W#CH>AKYN_:HMM>\7_M)?"WPAX/U+Q#I.L75\GB'Q'J%OJ-
MQ%966@6,T;3P-#Y@AEFO)GAM@"A/E/.^08DKZ-M$\J!%;&5&./\ /Z=J )J*
MI_:)_P#GS;_OM:/M$_\ SYM_WVM %RBJ?VB?_GS;_OM:/M$__/FW_?:T 7*A
MN-Q.%;;QV'-0_:)_^?-O^^UH^U3=[5O?YUXH ^+?#_\ P69_X3#1+;4]$^ /
MQ?U32=0C\ZSO!J'AV(7,9^[($DU-74$<X90?4"L?PC_P5)U+1O'_ (LOQ\!/
MBM=?VO=6TIMXM1\/"2TV6R)B0MJ2KEL!AL9QAAD@C%>'?LBG/[,'@+_L#6__
M *#76>'_ /D;_$/_ %V@_P#2=* /IWX _P#!1]OCM\8]+\&WWPF^(?@>XUB"
MXEM;[6+O2)[65H8][1G['>SR*V#D'9C@\CO].1<Q\]^:^ _V>I&C_;"^&Y5#
M(V-6^4$#(^PGN:^\Q=7!_P"75_Q=: +=%4_M$_\ SYM_WVM'VB?_ )\V_P"^
MUH N453^T3_\^;?]]K1]HG_Y\V_[[6@"Y15/[1/_ ,^;?]]K1]HG_P"?-O\
MOM: +E>.?%7]MSX>_!+XG-X/\0:GK7_"1QZ;#J[V.G:!J.I>7:322Q13.\$#
MHNZ2WF4*6S\A)'(KU?[1/_SYM_WVM?GO^UO*S_\ !4#Q3N5HV_X5KX?P"0>/
M[2UKTH ]<^.G[>WP[\2W?@=K.;Q8W]F^*+6\G,WA'5XML2Q3!B@:V^=^1A1D
MGG%=?K'_  4R^%.@:->:A>7WC*WM=/B:>9F\%ZP J(A9R3]E^Z ,YS7R-\1'
M_?\ AOJ/^)W#T/\ TSEJK\>#_P 6-\;\M_R+^H<9_P"G=Z /TT\$>+]-^(?@
MW2=?TFY%YI.N64.HV5P$9!/!+&LD;[7 895@<, 1GD UL5Y+^Q/<3+^QM\),
M6K$#P7HX!WKS_H,->G?:)_\ GS;_ +[6@"Y15/[1/_SYM_WVM'VB?_GS;_OM
M: +E%4_M$_\ SYM_WVM'VB?_ )\V_P"^UH N453^T3_\^;?]]K1]HG_Y\V_[
M[6@"Y15/[1/_ ,^;?]]K1]HG_P"?-O\ OM: +E%4_M$__/FW_?:T?:)_^?-O
M^^UH N453^T3_P#/FW_?:T?:)_\ GS;_ +[6@"Y15/[1/_SYM_WVM'VB?_GS
M;_OM: +E%4_M$_\ SYM_WVM'VB?_ )\V_P"^UH N453^T3_\^;?]]K1]HG_Y
M\V_[[6@"Y15/[1/_ ,^;?]]K1]HG_P"?-O\ OM: +E%4_M$__/FW_?:T?:)_
M^?-O^^UH N49YJG]HG_Y\V_[[6I+:220_/ 8O<L#_*@"Q6#\0?\ D5YO]]?_
M $*MZL'X@_\ (KS?[Z_^A4 ;U%%% %34?^/RQ_Z[G_T6]6QTJIJ/_'Y8_P#7
M<_\ HMZMCI0!#]JPV" .2/O#M3A-D#H,^K5XK^WMX(T7Q1^S#XQU/Q%IVH:Y
MI7A32KW7Y]"@\0R:';:_]EMY)4M;JX5D'D.4 82'RQG+!@"*^<_^"77P4^'&
ML>+?^$S\&Z'\/?"%W%I]O>&U\ W>M6=M>I<+)E+VWNXXH;@8 *R&+S RM]WG
M(!]YD?:$X;T_#^H-/MXA#$%&>/K_ %JN;B&RVQM(L;28" D N0,< _2K:?=H
M 6BBB@ HHHH *;+]VG4V7[M 'Y-?LC?\FP> O^P-;_\ H-=%X1UJUU#QAKPA
MFW>;)$Z':P$@6%%8C(&<,"*YW]D;_DV#P%_V!K?_ -!KT@,3W)[\\T =+^SF
MN[]L3X;_ .[JW_I$:^^5^[7P+^SA_P GB_#CZ:M_Z1&OOL=* "BBB@ HHHH
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MK_Z%6]6#\0?^17F_WU_]"H WJ*** *FH_P#'Y8_]=S_Z+>K8Z54U'_C\L?\
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M/B/5M8MKWQ;/?6L3VU_HZQ7;22S,;;RXI;D;P4VB1FSQD 'Z!,]\H_X_K,9
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ML[.[EU^'PM_:<VO/++;96R>[0Q%Y"L2 AR.3%73?L,?''XF_$;]NZXTOQ/\
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M0!F_9]3_ .?RU_\  1O_ (Y4UG#>)+^^FMY(\=$@*'/UWG^57** "L'X@_\
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M_ J3_P"*K0HH S_^$<M_[UY_X%2?_%4?\(Y;_P!Z\_\  J3_ .*K0HH S_\
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M:X_^>B_]]4W^R[?_ )]XO^^11_9=O_S[Q?\ ?(H =]KC_P">B_\ ?5'VN/\
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M8JI(^H'TKRKX[_&7P3=?"C5XH/$OA5I&$8"1ZA [M^]7H%)ST_GZ5V$GQG\
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M&^_\!)/\*/\ A(8_^>-]_P" DG^% &C7RG^VMX1TGQM^V3\%+/7-)TO6K/\
ML'Q3(MOJ%G'=1!]^C@,%D4@, S $#(R>>:^G/^$@C_YY7@^MK(/Z5\V_M1WZ
M7O[;/P7V"4;?#OBG.^-E_P"6NC>M '-_%+X'>!K'X<ZI/!X'\%V\Z+$5EBT&
MTC=<S1 X81@],C\3ZFNFL_@%X 6\B/\ P@/@7[X_YEVS]?\ KG4?Q8T/Q!XE
M\&?V?X?_ +$66[VK</J32A0@:-UV^6"<Y0YSV-=1X=^UM9VOV_R3J!">=Y&?
M*WY^;;GG&.E 'R'JFFV^F?\ !%;2;:W@AMK>W^+T<,44*"-(D'Q&("J!@ #
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MVC/SQ,H_,T 6ZP?B#_R*\W^^O_H5;U8/Q!_Y%>;_ 'U_]"H WJ*** *FH_\
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M]GF5X_VPOAN41I&QJWR[@ ?]"/<U]X_:;C_GU;_OZM?"/[.'_)XOPX^FK?\
MI$:^^QTH H_:[K_GU;_OZM'VNZ_Y]6_[^K5ZB@"C]KNO^?5O^_JTOVFZ_P"?
M5O\ OZM7:* /E_X1D_\ "-ZL6 !/B[Q/Q_=_XGU_745R_P )_P#D7]6_[&_Q
M1_Z?K^NHH Y7XL,RV7AHHNYQXOT#:IXS_P 32V[UX7^US+(__!4'Q1YD;1M_
MPK7P_P ;@W_,2UKT%>[?%/\ U/A?_L<=!_\ 3I:UX;^V#_RE$\4_]DU\/_\
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M_P $Y_C[NMB%_P"%<>(<GS5X_P");<>U4/"''A'2_P#KR@Z_]<EK9_X*8_\
M*./X_?\ 9.?$/_IMN*Q?!_\ R*>D_P#7E!_Z*6@#2/2O,?AF[Q_\%4;4QHTC
M_P#"I+KY=P48_MJWKTX]*\U^%'_*5.U_[))=_P#IZMZ /(M28MXP\89&#_PE
M_B'C/3_B;75)3M4_Y'/QC_V-_B'_ -.UU3: %TY]GC?P9MR3_P )?H. ._\
MQ-+7VK]$UN+H#_CU?_OZM?G?I!_XKKP7_P!C=H7_ *<[:OT<'2@"E]INO^?5
MO^_JU+:R32.?,B:,8X)<'^56** "L'X@_P#(KS?[Z_\ H5;U8/Q!_P"17F_W
MU_\ 0J -ZBBB@"IJ/_'Y8_\ 7<_^BWJV.E5-1_X_+'_KN?\ T6]6QTH *1FV
MBEJ&Y5750>YX]^#G],T 4;GQ/9V6IV]G-=6L-Y>,PMX&F423[1D[5)#-@ YP
M#C!]*T()5GB5U*LK#((Z$5\D?MF?LPZU\7_C3'JVG^"8]9U:.[\(RZ#XF,]I
M&WA@6&MRW=^0SO\ :$W6[<B)"LP(1R!7UK;#;",?*.H!&,#Z=J )J*HFWOL?
M\?,7_?K_ .O1]GOO^?J/_OS_ /7H \&_X*:_\F_>'/\ LHO@W_U(M/K1E_UK
M?6NS^./P/M?CUX5LM$UK4+F&TL=9TW7$-HJI)YUC>PWD.2V1L,D"AAC)7=@@
M\U;'P8A?G[?-SSQ&* //ZJ?LC?\ )??C'_UVTG_TE>O2F^"\*D'[=.>>1L'-
M5OA]\%8/AKXO\1:U87TLEUXH:W-X)5!0- GEIL Y&03NR3SC&!0!^;?[(_\
MR;)X%_[ \'\J]&KZ1^'7_!-SP=\-/ ND^'['5?$$EIH]LEK"\S1F1E48&XA
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ME27R "!7(/\ \$L/!5YXMU'4[WQ/X\U"#4?MUV^GSW]O]ECU2^TI=*O-54+
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M/%E]X3U#3GL;SPZHL+/3KB1]'.C/<@6UK%)%(UH\@*0ND0=@RQJ57&S\-O\
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MM$LM#L[B6&66&$PP1S2+NMXMOVB67RU!";=S9]FC&Q<>E #J*** "L'X@_\
M(KS?[Z_^A5O5A^.H_.\.RKT^=><>] &Y1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6637392960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Accrued Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;6&nbsp;&#x2013; Accrued Compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2019 and 2018, accrued compensation consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued bonus expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 897,839</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 694,490</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued payroll expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 19,034</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 217,614</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 916,873</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 912,104</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6770452992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;2&nbsp;&#x2013; Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Liquidity and Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October 29, 2019, the Company announced that it is advancing its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its Mircropine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs. The Company believes the re-prioritization of its programs will yield overall cost savings of approximately $1.5 million to $1.9 million in 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note 2 - Summary of Significant Accounting Policies&#x2009;&#x2014;&#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#x2019;s common stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has cash deposits and U.S. treasury bills in a financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&nbsp;31, 2019 and 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $13,902,601 and $19,478,200,&nbsp;respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5&nbsp;years. Leasehold improvements are amortized over the lesser of (a)&nbsp;the useful life of the asset; or (b)&nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&nbsp;years ended December&nbsp;31, 2019 and 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred Offering Costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&#x2019;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs are offset against the offering proceeds. The Company had $0 in deferred offering costs at December 31, 2019 and 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#x2019; equity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of financial assets and liabilities based on ASC 820 &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1&nbsp;&#x2014; quoted prices in active markets for identical assets or liabilities;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2&nbsp;&#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3&nbsp;&#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of the Company&#x2019;s financial instruments, such as cash and cash equivalents, due from related party, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&nbsp;&nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#x201C;temporary differences&#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:none;">The Company&#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,220,868</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 20,165</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,241,033</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Issued Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2016&#8209;02, &#x201C;Leases (Topic 842)&#x201D; (&#x201C;ASU 2016&#8209;02&#x201D;). ASU 2016&#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal&nbsp;years beginning after December&nbsp;15, 2020, and interim periods within fiscal years beginning after December 15, 2021. The FASB issued ASU No. 2019-01 &#x201C;Leases (Topic 842) Codification Improvements&#x201D; in March 2019 and ASU No. 2018-10 &#x201C;Codification Improvements to Topic 842, Leases&#x201D; and ASU No. 2018-11 &#x201C;Leases (Topic 842) Targeted Improvements&#x201D; in July 2018, and ASU No. 2018-20 &#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In July 2017, the FASB issued ASU No. 2017-11, &#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#x201D; (&#x201C;ASU 2017-11&#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued ASU No. 2018-13, &#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201D; (&#x201C;ASU 2018-13&#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2019, the FASB issued ASU 2019-12, &#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2016-15, &#x201C;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&#x201D; (&#x201C;ASU 2016-15&#x201D;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case a company would be required to apply the amendments prospectively as of the earliest date practicable. The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2018, the FASB issued ASU No. 2018-07, &#x201C;Compensation &#x2014; Stock Compensation (Topic 718)&#x201D; (&#x201C;ASU 2018-07&#x201D;). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, &#x201C;Equity &#x2014; Equity-Based Payments to Nonemployees.&#x201D; The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company&#x2019;s adoption date of ASU No. 2014-09, (Topic 606), &#x201C;Revenue from Contracts with Customers.&#x201D; The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635009888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;10&nbsp;&#x2013; Stockholders&#x2019; Equity</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Reverse Stock Split</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Effective January&nbsp;8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&#x2019;s issued and outstanding common stock and preferred stock (the &#x201C;Reverse Split&#x201D;). The number of authorized shares remained unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Authorized Capital</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is authorized to issue 90,000,000 shares of common stock, par value of&#x2009;$0.0001 per share, and 6,000,000 shares of preferred stock, par value of&#x2009;$0.0001 per share. The holders of the Company&#x2019;s common stock are entitled to one vote per share. The Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Equity Incentive Plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January&nbsp;5, 2018, the Company&#x2019;s Board of Directors and stockholders approved an amendment to the Company&#x2019;s 2014 Equity Incentive Plan (&#x201C;2014 Plan&#x201D;) to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares. As of December&nbsp;31, 2019, there were 15,333 shares available for future issuance under the 2014 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March&nbsp;6, 2018, the Company&#x2019;s Board of Directors adopted the 2018 Omnibus Stock Incentive Plan (&#x201C;2018 Plan&#x201D;), which stockholders approved on June 11, 2018. The 2018 Plan was subsequently amended by the Board on April 5, 2019 and approved by stockholders on June 11, 2019 (the &#x201C;2018 Plan, as amended&#x201D;). The 2018 Plan, as amended, provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&nbsp;units (&#x201C;RSUs&#x201D;) to employees, directors and consultants of the Company and its affiliates. The 2018 Plan, as amended, terminates on June&nbsp;11, 2028. The 2018 Plan, as amended, requires the exercise price of stock options to be greater than or equal to the fair value of the Company&#x2019;s common stock on the date of grant. There are 1,250,000 shares of common stock authorized under the 2018 Plan, as amended. As of December&nbsp;31, 2019, there were 106,074 shares available for future issuance under the 2018 Plan, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Public Offerings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January&nbsp;29, 2018, the Company consummated its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, which were recorded as a reduction of additional paid-in capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On December&nbsp;21, 2018, the Company consummated a follow-on public offering of 1,380,000 shares of its common stock at an offering price of $2.45 per share, generating $3.4 million and $2.8 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $0.6 million, which were recorded as a reduction of additional paid-in capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July 15, 2019, the Company closed an underwritten public offering of 4,388,490 shares of its common stock at a public offering price of $2.78 per share. The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional 658,273 shares of the Company&#x2019;s common stock at the same price, which was exercised in full on July 16, 2019.&nbsp;&nbsp;Including the over-allotment shares, the Company issued a total of 5,046,763 shares in the underwritten public offering, and received gross proceeds of approximately $14.0 million and net proceeds of approximately $13.0 million, after deducting underwriting discounts, commissions and other offering expenses, which were recorded as a reduction of additional paid-in capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Series&nbsp;A and Series&nbsp;A&#8209;2 Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Series A and Series A-2 Convertible Preferred Stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and, therefore, it has been classified within stockholders&#x2019; equity on the balance sheet. While the embedded conversion option (&#x201C;ECO&#x201D;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature because the conversion price exceeded the estimated fair value of the Company&#x2019;s common stock as of the commitment date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Series&nbsp;A and Series&nbsp;A-2 Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&nbsp;the aggregate offering price, net of underwriters&#x2019; discounts and expenses, was at least $2.00 per share of common stock and (B)&nbsp;the aggregate proceeds of such offering were not less than $20,000,000; or (ii)&nbsp;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series&nbsp;A and Series&nbsp;A&#8209;2 Convertible Preferred Stock converted immediately prior to the Company&#x2019;s IPO. See Note&nbsp;10&nbsp;&#x2013; Stockholders&#x2019; Equity&nbsp;&#x2013; Conversion of Preferred Stock for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Series&nbsp;B Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&#x2019; equity on the balance sheet. While the embedded conversion option (&#x201C;ECO&#x201D;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&#x2019;s common stock as of the commitment date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Series&nbsp;B Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series&nbsp;B Convertible Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series&nbsp;B Convertible Preferred Stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&nbsp;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&nbsp;the aggregate offering price, net of underwriters&#x2019; discounts and expenses, is at least $2.00 per share of common stock and (B)&nbsp;the aggregate proceeds of such offering are not less than $20,000,000; or (ii)&nbsp;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock. All of the Series&nbsp;B Convertible Preferred Stock converted immediately prior to the Company&#x2019;s IPO. See Note&nbsp;10&nbsp;&#x2013; Stockholders&#x2019; Equity&nbsp;&#x2013; Conversion of Preferred Stock for additional details.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Conversion of Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Immediately prior to the closing of the IPO on January&nbsp;29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,702,116 shares of the Company&#x2019;s common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation Expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company records stock-based compensation expense related to stock options and RSUs. For the&nbsp;years ended December&nbsp;31, 2019 and 2018, the Company recorded expense of $2,511,944 &nbsp;($1,459,055 of which was included within research and development expenses and $1,052,889 was included within general and administrative expenses on the statements of operations) and $1,615,470 &nbsp;($818,239 of which was included within research and development expenses and $797,231 was included within general and administrative expenses on the statements of operations), respectively. As of December&nbsp;31, 2019, there was $3,249,222 of unrecognized stock-based compensation expense which will be recognized over a weighted average period of 1.9&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Restricted Stock Units</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July&nbsp;24, 2018, the Company granted an aggregate of 20,165 RSUs to its directors under the 2018 Plan. The grants vest on the earlier of (i)&nbsp;the one-year anniversary of the date of grant and (ii)&nbsp;the date of the 2019 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which was recognized over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 16, 2019, the Company granted to members of its Board of Directors an aggregate of 40,190 restricted stock units (&#x201C;RSUs&#x201D;) under the 2018 Plan, as amended. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2020 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which will be recognized over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock Options</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On April&nbsp;16, 2018, the Compensation Committee of the Board of Directors approved the grant of ten-year stock options to purchase 175,668 shares of common stock to Company employees and consultants under the 2014 Plan. The stock options will vest in equal&nbsp;monthly increments over 36&nbsp;months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and have an exercise price of $8.72 per share, which was the closing stock price on the date of grant. The stock options had a grant date fair value of $1,412,700, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the&nbsp;year ended December&nbsp;31, 2018, the Company granted ten-year stock options to purchase an aggregate of 395,999 shares of common stock to its employees, consultants and directors under the 2018 Plan. Of the 395,999 shares, (i)&nbsp;313,674&nbsp;vest over three&nbsp;years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting&nbsp;monthly over the remaining 24&nbsp;months, subject to continued service to the Company, (ii)&nbsp;60,000 vest&nbsp;monthly over 36&nbsp;months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and (iii)&nbsp;22,325 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2019 annual stockholders meeting, subject to continued service to the Company. The stock options have exercise prices ranging from $5.10 per share to $6.30 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $2,237,800, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January&nbsp;2, 2019, stock options to purchase 180,000 and 133,686 shares of common stock with an exercise price of $1.24 and $1.95 per share, respectively, were exercised for aggregate proceeds of $483,888. In connection with the exercise of the stock options, the Company remitted a portion of an employee&#x2019;s payroll taxes of $62,193 to the Internal Revenue Service.&nbsp;&nbsp;The Company was reimbursed in full by the employee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On January 14, 2019, the Company granted ten-year stock options to purchase an aggregate of 11,000 shares of common stock to its employees under the 2018 Plan. The 11,000 shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company. The stock options have an exercise price of $2.74 per share, which represents the Company&#x2019;s closing stock price on the date of grant. The stock options had a grant date value of $27,500, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February&nbsp;6, 2019, stock options to purchase an aggregate of 320,001 shares of common stock with an exercise price of $1.24 per share were exercised on a cashless basis, which resulted in the issuance of an aggregate of 236,466 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February&nbsp;13, 2019, the Board of Directors of the Company approved the acceleration and immediate vesting of 124,210 stock options originally granted to Dr.&nbsp;Ianchulev on July&nbsp;24, 2018 in connection with his employment. In connection with the acceleration and immediate vesting, the Company recognized $609,322 of stock-based compensation expense during the year ended December 31, 2019 , which represents the remaining unamortized grant date fair value of the award.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On May 14, 2019, stock options to purchase 34,815 shares of common stock with an exercise price of $1.95 per share were exercised for aggregate proceeds of $67,889.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 16, 2019, the Company granted ten-year stock options to purchase an aggregate of 681,572 shares of common stock to its employees, consultants and directors under the 2018 Plan, as amended.&nbsp;&nbsp;Of the 681,572 shares, (i) 636,287 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company and (ii) 45,285 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2020 annual stockholders meeting, subject to continued service to the Company. The stock options have an exercise price of $3.11 per share, which represents the Company&#x2019;s closing stock price on the date of grant.&nbsp;&nbsp;The stock options had a grant date value of $1,909,700, which the Company expects to recognize over the vesting period.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected term (years)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">1.42 - 2.53</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2.69 - 3.24</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">134 - 139</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">140 &nbsp;-141</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201C;simplified&#x201D; method to develop an estimate of the expected term of &#x201C;plain vanilla&#x201D; option grants. The Company does not currently have a sufficient trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted average estimated grant date fair value of the stock options granted for the&nbsp;years ended December&nbsp;31, 2019 and 2018 was approximately $3.10 and $6.39 per share, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the option activity during the&nbsp;year ended December&nbsp;31, 2019 is presented below:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,220,868</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.01</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 692,572</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.10</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (668,502)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.42</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (7,500)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.73</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.1
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,559,915</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,183,637</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.33</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,222,680</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to stock options as of December&nbsp;31, 2019:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:52.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:43.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options&nbsp;Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;Life</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>1.24
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.2</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>1.95
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 700,281</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.5</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 545,170</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>2.74
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>3.11
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 681,572</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>4.00
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.9</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 723</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.10
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.7</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,667</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.19
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,500</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.7</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,875</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.25
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21,249</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>6.20
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 311,499</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.6</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 224,438</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>6.30
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.5</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 28,333</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>8.72
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 166,918</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.3</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 94,182</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,183,637</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6770763152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PayrollTaxesReceivable', window );">Payroll tax receivable</a></td>
<td class="nump">$ 95,233<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">33,923<span></span>
</td>
<td class="nump">39,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research &amp; development expenses</a></td>
<td class="nump">17,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidPatentExpense', window );">Prepaid patent expenses</a></td>
<td class="nump">12,404<span></span>
</td>
<td class="nump">10,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidConferenceExpenses', window );">Prepaid conference expenses</a></td>
<td class="nump">10,600<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidRentAndSecurityDeposit', window );">Prepaid rent and security deposit</a></td>
<td class="nump">2,463<span></span>
</td>
<td class="nump">75,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other</a></td>
<td class="nump">24,079<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 196,680<span></span>
</td>
<td class="nump">$ 132,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PayrollTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Payroll Taxes Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PayrollTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidConferenceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets related to prepaid conference expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidConferenceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for patent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidRentAndSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidRentAndSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6648483024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expenses</a></td>
<td class="nump">$ 897,839<span></span>
</td>
<td class="nump">$ 694,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll expenses</a></td>
<td class="nump">19,034<span></span>
</td>
<td class="nump">217,614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total accrued compensation</a></td>
<td class="nump">$ 916,873<span></span>
</td>
<td class="nump">$ 912,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>36
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M\+L(6Z_-SOQCX[/@T,.ONQB^ %!+ P04    " !687Y0F5R<(Q &  "<)P
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M25A/'M23^WIR1T_N^4DA D6&G516/A"2-,LQOG-F)*B(^(J(HXAXCC[=D11
M?JRI"&HJ_'M8A/EED%_Z,3G7:UOZR<L@*9S#J'P80B@+:X$@7!B IZ8 ;F4
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M:%3.MR*1B$1*">V0*%E(10E-Z,Y5.581!?$('&DJ4B/E8UB!#54/E>F20;#
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M%?T7&!,B83!F_PVNP S<.C$:E6#*?0?516G!1Q9CA=/W86Q:-_;#"4%CF#\
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MSK]L['^-Z,!+V5SY$6K]!YL-";4+QQM_-N.8C8;#;OI!;/[&Q2]02P,$%
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M/]AL**A\.'["LQW';#2\Z:8?Q.9OG+\!4$L#!!0    ( %9A?E"A938JM $
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M2*A].![P;,<Q&PUONND'L?D;%V]02P,$%     @ 5F%^4%6\^4ZT 0  T@,
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M"KZ6XLC?P?DZ?+NJ<!OAVW\H_(M@MTJPBP2[_Y:X%O/Q31*VZ*D&4\=ILJ3
MOHV3O/#. WO+XYO\"1^G_4&86K:6G-'YEXW]KQ =>"F;*S]"C?]@LZ&@<N%X
MX\]F'+/1<-A-/XC-WSC_#5!+ P04    " !687Y0<'\3V[(!  #2 P  &0
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MP\NF_M>('H*4S4T8H39\L-E04/MXO UG.X[9:'CLIA_$YF]<_ 902P,$%
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MQB15OOA/:F\K]329!PV]2MU-5)^/]7D<2-9/;P]O?@ 5?P%02P,$%     @
M5F%^4"XG@QBW 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M;5/MCIP@%'T5P@,LRLQ.IQ,UV=FF:9,VF6S3]C>C5R4+8@''[=OW@JZU6_\
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M4]MNW" 0_17$!X0UZZ31RK:4316E4BNM4K5Y9NWQ1>'B EZG?]\!.XZ;NB_
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MPU3/+253\5_A"LK#0R8^1H'*QI44O76H)Q6?BA:OXR[;N _CS>W]1%LG\(G
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MAJ6>!*.E^*]P V[A+A.K44JN_1>5HS92+"PV%<'>YK7K_3K-)TF\A(4#Z!)
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M"?-Z!(EC3E/Z[GCLFM8%!RNR7C3P!.Y'?S+>8HM*U2G0MD--#-0YO4L/QWW
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M$69XYIEG&,9LDNI5MP &O0O>ZQRWQ@Q[0G39@F#Z2@[0VY-:*L&,-55#]*"
M53Y(<$*CZ)H(UO6XR+SOJ(I,CH9W/1P5TJ,03/TY )=3CF/\Z7CNFM8X!RFR
M@37P N;G<%36(BM+U0GH=2=[I*#.\5V\/Z0.[P&_.ICT9H]<)2<I7YWQK<IQ
MY 0!A](X!F:7,]P#YX[(RGA;./&:T@5N]Y_LC[YV6\N):;B7_'=7F3;'MQA5
M4+.1FV<Y/<%23XK14OQW. .W<*?$YB@EU_Z+RE$;*186*T6P]WGM>K].\TEZ
MLX2% ^@20-> ^-K7,B?RRA^8846FY(34?/<#<RV.]]3>3>F<_BK\F16OK?=<
MT"3*R-D1+9C#C*$;3+PBB&5?4]!0B@/])YR&PW=!A3L?OMMF3V_#!$F0(/$$
MR5\EQA<EAC#_49D&DZ0!@MU%DA FN4A"-HT3H!K_9#4JY=C[<=EXUZFXH[[Q
M7_!YI'XPU72]1B=I[//Q3:ZE-&"E1%=62VNG>#4XU,9M;^Q>S6]Y-HP<EC$E
MZ[^B^ !02P,$%     @ 5F%^4 @Q:0L5 @  R04  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&ULC53MCILP$'P5Q .<P>8C%P'2)5752JT47=7VMT,V
M 9V-J>V$Z]O7-H3+$:NZ/]B[S,[.&+S%(.2+:@!T\,I9I\JPT;I?(Z3J!CA5
M#Z*'SKPY"LFI-J$\(=5+H =7Q!G"490A3MLNK J7V\FJ$&?-V@YV,E!GSJG\
MNP$FAC*,PVOBN3TUVB905?3T!#] _^QWTD1H9CFT'#K5BBZ0<"S#IWB]S2W>
M 7ZU,*B;?6"=[(5XL<'70QE&5A PJ+5EH&:YP!88LT1&QI^),YQ;VL+;_97]
ML_-NO.RI@JU@O]N#;LIP%08'.-(ST\]B^ *3GS0,)O/?X +,P*T2TZ,63+EG
M4)^5%GQB,5(X?1W7MG/K,/%?R_P%>"K <T&<_;> 3 7DK2!QYD=ESNHGJFE5
M2#$$<OQ8/;7_1+PFYC!KFW1GY]X9M\ID+Q5.T@)=+-&$V8P8?(.)9P0R[',+
M[&NQP7?E^'V#[3TBB?P=B-<$<?7).Q/9PL2(21VF&S'X,<\?R4*+#Y?$$2%^
M08E74.(1E/L)4B]!^@%'Z9W2+"+IXN-M[U$XBK/4+R;SBLD\8E9^@MQ+D'_
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M[;63. $M8&H[8?OVM0V+J)GT)C[],_.-36:*D8M763.FO+>N[>7.KY4:GH-
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M'5U0RQ'!.$4M:[JP+%S?3I:%N&C>=+"3@;JT+9-_M\#%;1-&X4O'8W.NM>U
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M._--52O4[+U,<+&)[CK0I-F-FF2I^5]1N8HTGB61 I@I$B]%8OQPX0<(^0-
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M>5GF,'^;>&H.1^,FBM5BX ?Q4YA?PZ.RHV)VV36=Z'4C^TR)_3+_!!\V$+@
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M$T\U,?XB.@#IO5(RB-KOI!QW02#:#B@6#VR$09V<&:=8JB6_!&+D@$\FB)(
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M63L(H;B6C!^TY$D?OH9)R0_*##,];OL32#]1HK&GJV@XXBW_ 5!+ P04
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MK\PPU6,Q=)UAHG@W=E0RM?7B'U!+ P04    " !687Y0/QY_NFD#  #@#@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6R-5UUOFS 4_2N(]P'7QABJ
M)-+ZD:;2)E6=MCW3Q$E0 6= DN[?SX#+@KFD]*%@..>>>^WK$SP[R^*MW M1
M6>]9FI=S>U]5AQO7+==[D<6E(P\B5V^VLLCB2@V+G5L>"A%O&E*6NL3S C>+
MD]Q>S)IGS\5B)H]5FN3BN;#*8Y;%Q=];D<KSW ;[X\%+LMM7]0-W,3O$._%#
M5#\/SX4:N5V439*)O$QD;A5B.[>_PLT3(36A0?Q*Q+F\N+?J4EZE?*L'3YNY
M[=49B52LJSI$K"XG<2?2M(ZD\OBC@]J=9DV\O/^(OFR*5\6\QJ6XD^GO9%/M
MYW9H6QNQC8]I]2+/*Z$+8K:EJ_\F3B)5\#H3I;&6:=G\M];'LI*9CJ)2R>+W
M]IKDS?7<ON$?-)Q -(%T!*!7"503Z'^"?Y7@:X(_E< T@4TE!)H03"5P3>!3
M":$FA!V!L*N$2!,B0\%MUZ]IB/NXBA>S0IZMHNWI0UQO';B)5,NMZX=-AS7O
M5$^4ZNEI02,^<T]U((VY;3&DAPG[F#L,$_4Q]Q,P#T.,[WE]S!+#0!_SB&%(
M'[,:8@S$$Q:E@[AJ8KO9)>CLDH;O]_C4R+3%L :3-QC@+ A"7(>B.A31\8U5
MI .=+]0/@1D+B<&4=UY,<"\?'\W'1_(QA!Y:3'@A1!QN)/TX!(4.K]/I_HR%
M7PT9U#$P3T-,X- (+Y"A!3*DP,"8<#90 2<R9N$> Q$?3R5 4PF05#@>@*,!
M.!+ V-XK/N@*0H@7CG5IB J%G^^&53@0"B+".,%U(E0G^GPW+*-AFT-8]Y.1
M#X)3>Y-Y(PF!A[NLAZ04F7;D#;4X\T8,!T;\'":LI@;UEY-RGX:F_V' *^L.
MN T"XH-@SC0@1@@A#>A(,P-NA8!X(9@FH4%]EQBS., ]#B:8W$J#HA$[ZNO@
M5@,3O&8)G_B(SH8-L@'''VMEW&X \1L8_+(& R'?X71$"+<E0'QIN) <F5]F
M^KU&35QNW+P <2\PW4N#^D)TK&[<O0"Q+QBL) 9BN [!/8D@G@1&7ZU0T,B&
M)+@C$<21P'0D#0HN)XZQ*!JM:>1["S,:TV<U*.B;&@E"TVG=BX_H^NSW/2YV
M25Y:K[)2W^/-5_-6RDJHH)ZCMM9>'3>[02JV57W+U7W1GKG:024/^CSI=H?:
MQ3]02P,$%     @ 5F%^4$GO9&A1!   @Q@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#<N>&ULE9GMCJLV$(9O!7$! =MC(*LDTNZIJE9JI=6I>OJ;39P/
M'< ID,WIW9>O35G\CN3FQP:<\;SC&3_8>#=W6W]OSL:TP8^RJ)IM>&[;ZU,4
M-?NS*?-F9:^FZGXYVKK,V^ZV/D7-M3;Y8>A4%I&,XR0J\TL5[C9#VVN]V]A;
M6UPJ\UH'S:TL\_J?%U/8^S84X4?#U\OIW/8-T6YSS4_F#]/^>7VMN[OHX>5P
M*4W57&P5U.:X#9_%TXO.^@Z#Q;>+N3>SZZ ?RINUW_N;7P_;,.XC,H79M[V+
MO/MZ-U],4?2>NCC^GIR&#\V^X_SZP_O/P^"[P;SEC?EBB[\NA_:\#;,P.)AC
M?BO:K_;^BYD&I,-@&OUOYMT4G7D?2:>QMT4S_ WVMZ:UY>2E"Z7,?XS?EVKX
MOD_^/[KA#G+J(!\=U- A&H6&R'_*VWRWJ>T]J,?D7_.^QN))=KG9]XU#*H;?
MNN";KO5]1S+>1.^]H\GF9;21,QOQL(@Z[P\)B21>I-.=).- P1C5X( ^.9"+
M&$<;/=A4@XV4*B6582&"0@2$U$((V(@4BV@HHH$(+42T,QHA,I4H1BB!0@D0
MTMA!"AVDP$&RB'2TR>:1KF;#^:22097,H[J96]TD[CY89PUUUA[%139,SD6,
M>8H]RCL9^8Y',.@*(,7,=P'1?!;2H\23T><:KYF9)##"PH=AX4*<QK',F(>%
MP! +'XJAT9K1P1P+'Y"%2[(F+5*NTIAD 5!6G O,LO"!6;@TRU7*T"PPSL*'
M9^$"G?#3'_,L$*Q._M>.$*,B,<\2\*RXY0]S*A&GR]1/1O/4JY7@A##-$M&\
M3/UD]"GUF="I9*0PSQ+QO$R^='GFDH]1EH!2Q06**96(4B?YHU$R"Y29]!(#
M*M%:ZV0^<9_Z[*27&&.),%X^W)"14HP.IE@BBIWZNA2GDM/!$$L L6)RKS"A
M"JVXRPI/1G.\](K;A&*,%<+8V8:*__%@4QACA3!>UA@9*69-5LRVVH=A!3;6
M2<+LB13&6"&,$\8%QECY8#P9+8K,K.H*DZQ\2%8NR2+1;)DQRLH'963$EAFC
MK'Q05F!!SE)."+.L$,O,3"',,OFP3(AE[LV&,,SD S.Y,'=S/^%>*3'-Y$,S
M,F)?73'-Y$,S 9J%) 818MZ2$<Z<"XPS^>!,+L[)BEG]"=-,/C232[,2@M;<
MD##.Y(,S,B+FL4$89_+!F< +LR1^2F&@"0!-S**I,=#:!VCM IVLF'V$QCQK
M'YXU7IR9_&O,L_;A&1D1,W4UYEG[\*P!SYGB]GH:\ZP!S\2Y8,ZT?'C6+L_9
M*NVWP(\/-[DPW=J';HW6ZF0M&!0TIEO[T(V,B-G,:DRW]J%;NW2O263+^17-
MSH!+4Y^&T^\FV-M;-1R]SUH?)^S/<CA#_L]\/)[_/:]/EZH)WFS;VG(X+SY:
MVYHNFGC5Q7$V^>%Q4YACVU^FW74]'HN/-ZV]3D?^T>/_#KM_ 5!+ P04
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MPM*M3:LI96*Z(YX.%7X"9G.2BI8PSR+FL3X(H^R0XSP+&%77%#9G9V,$/W;
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MY4SB;%K.N!."$D]0XA$ R,AZDMM^2&Y[D+11.;F9O $Z1&,@,[G+<_:TBD#
M(P@8Z;I.MW=YEM/G")[DMQ]P<G_ETY-[/$[@A!^-4RH[.DX$*QYA1:XX'I[7
MLPE)J.(!55B)[ME#2%0=B;KQLT]W9]M-.XLJX8H'7,GE(UP/RJ/,9ZQX\ 0M
M'M0];!?@"5H\*D 2?],#:N6,(20,!"X!P87,O$#@$@!<9"R_! "-Z.L?@MU
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MU:A<F ]ND=@I$C\2!/Y*Q(7YQ[03ITCB( A7TQXQB<5T%K,-PEV\DL&+<\9
MU/9*2E3P2V>?@T5VOO7/H3VG[_#QR?A&1-UV$IVYTJ?=GLF*<P7:C/^D6V[T
M*S4'%"IEMEN]%^-='0/%^^D9PO-;F/\%4$L#!!0    ( %9A?E E6^:,?@0
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MFF$'*720WE!UZB0J)"76U-JX*A6-BYXDPR(\9:.?$_R 1"G9\_$&T0:&\W#
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M);?.41/7OR3%(BUID/NX0/4:+E,6Q"0JKT#5#*[A*M?5X2/?V[<GPMLN/'9
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MRS_ORBTO'BA#A>T'ENV'WM L7!.$SA%">]?^\3X_3ACY>%<D[=NL@!EM,J^
M7>V1PYUG7($70'*&VFB+D<.'2)$ .5VD0$HS82CX+7XFJ] .V1! *3=#Q^U#
M7R1 CA=I([MRT,89BTPU)!"O]MAED-717C_A:EYGC1L]!)S7P#3*0\"YW('.
M$J/9!HY@TVB9.KBXIHD.+>Y5F@&R'5J<WH,;?*6,5U\C[5W&#V0)W<,.?2+Q
MM-4<+7(YZVD7!;_%BHY?Q]?,GAPKA1GT@?<_ITM H1</C>C0].(),+@B 7P]
M129 GYBDB6&7/KQL-^RV/@@TYT5RFV89K@&V@%;ZQ[R,3H&6UZYV&Q#%$,:
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M45,&<]9"0V]O< \ LQ<DL!%5)XU@^5EL0SC26^3\;U"Z![#=%O&:Q$0<Q#$
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M20)1[KJ/4.L0%OWH)P+)X"?YBT.07M!IG3NG1>?KL'JD![NR=$3Z'9-6"U@
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MJ,QL O'9(4B&'CX8"D/J=;QZ#F[QA0Y7<3#I<AL.[J"9[SCJB7Q<.W$C+5.
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MMN.%6OK.@8^#N%7X,/UGH(2U(D3:%>JE&]/(G37V=WRB--6AJ4%T]#B=P[F
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M?D6YDAR]=C*+PM$\.NV<3"9A-)J=MF2D4OHIKG((N#.<P:?A))S"AXM]PYO
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MM381AA<F%+-FK:FV8(>;):H5EMD-8M-+V\MW',@I/G0&^T.S\#LW3,8)OD%
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M$A/"\_<O/IPYQ6<4!"2SVN67FWPGQ3JXW84A*K&3,%4M-XQ!(JO*P-<)LGQ
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M#.Z:B]NX;*+I.)Q,9FU"+CQJ G^]7A6N5[\IE(0+TGC3$I0(03!KD1SJFBU
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M.+UQ7Q5J^/N8D'>_MJ=;Z(P*&CA=FCE9D%K5H3"\(Y=RID5:!2)>;U*M=&F
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MW3'IDQ()"=,8$3E 8P?$ T4(]5I9-^EIC?MNS5MO*4* T9(+19C*F2E1+RM
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MF%T$G/QVY9K[*#/G%2G+JC -06$Z]P5'?% PB5Y $*0;X2/TS:58 MOLH+
MGVF2.TKU7Q) .*62#8%JZEA8)GZ7W_,Q%.[D](TQ0R*1<W+V\'=7MJU;.YUS
MK:_JJW 4[2*U$6W,EY'$N+ZO:WECY6N745@Y2[IXLS"$::&2*E7\#FW,PH(L
MCB)=/[B!=]9^2.^P'&C9@L\";=MI8S=<<O5_,[M_\VQ!R=0Q9^19M8*K7#_C
MNV@7-O?'/!VB]GE1-R9DR3&"9W\:6F.>DW"G\5]<7L;[2?E -&LS_^.P-<,_
M?EDE_DZJOVC[&$KV19+;FB)A;L3-H\7Z6&N1!$^]$+W@7.EB6 WM+JI2L#<:
MQ8GN&YK3GJQPM[*1,EM_JQIN2I>/+(RP)0,Z#8>T!)QD,(EP*IOGQIH/MO4#
MEY.AFA]M3[M[X]W>YBA)8?"@N.DIY%O<9 W@HCC#HT9W05<:<[E38 8OV@H@
MQV$AHCZ6NPV&$N&6KW;76P+/N#_NCOO6R.5T9!YH@V:)PKATEO,NS\S\/<7,
MBC@(C^D9!=T 3NGKY$.4H[Z52?^0J,FYU*8O!27>&-)G2YYXME11>.6VC[I]
M6*]<WTE_<FI K#56R95VCE'P\4(M?>? QT'<*GR8_C-0PJ^J?O41J7Z]]M75
MX@YHEI3Z<?W[+=$#DN%H@@>JX_TK8N&I$0N7$D7VTHW6?4]*IE!_R?0[ZBQK
M,6GUV-^X,<WP<+;OT4,;#6*IXHC!C-:SN+1-\"2VC*J7/^_,QW Z6*I;ZX0K
MO&SBL"ZH,QR&\\&P,YR'(S@=??!@M%TGFH;SZ:PV Y:Y]AX;A*/^J!/UP_%D
M8)["HB82-VN?[(>3?K\SI8+C=AV95C):<.*[Y*4#;HPFP\YT'$X'\PX=?6<P
M"OO3N5F28-JQ)X"5S><3JE4/GX:#<#J>/")5^DA,:TJ4?0I:-2;</@&'S":P
M+/Q@'HX'6 Q^@KWJ)YWFC.;.;$ 5Y4=<&WX(1]R'MZ*^OE26/[:F@8M&3>G0
M'#]Y,L/"\]$I=C (H]'LM"7IG#+,<95#P"5N43 )I\-9#7H2R;^'-KQQ@DF.
M(O:/2@YX_'$^,OG@"<>L0#E\KP' _5D849^ (9:7A=NK;WO)K2I$=H!8#^>3
M3A1%<!=GG7,JF8#)'4M-K^B,)T LYAVD,:U8-6*LTMNK<]X@O;K#6!\@<XAS
M\_FX]A#(+&A")7Q!<0S5=G];L,99_;U5<JNU[/ A_3F:S,+)N"]DQ7P[<!C8
MXXX,8#D:#X%=4I.'Z30<1#6>IFNJZ%O'8^=B3_3R\3CH]03\"DR[SK-=Z:+5
M#/!D-B3J,A_!C>];M!(^9EG!')C^J /R7SB)1A6(NPM$7A=A5XLA?8(#ZH_V
M)=0<2Z2ET%O5X-@DP+4_K= K:\"S6'.B'HE3OZ%8N;^CF)>^8E>@H^%@G!\$
M8#D982MO8/+]4_QK&(X!8M/!X+1C,X96.0B7'<#Z*3#IDQ'@YQ#H,+X)\T9C
M_ SO34!4F, H[&8*J U5K1Y3Q[S4,:\@16\!DB.DF$_[#L?J:W84;K^$GE70
M$U9IXP4X<%2LQSO%^_VR:5JJ!@UI.TZ_YGYP<J;EHTZO>31 ]QYV7Y-_^'!T
M=Z:\RHV\*R?=Z?<B:MR&'>$N06&,,\K2M D\G9-^#\[Z!_QWAO^:]([_B->;
MGSPF0,E81+Y+[#E$3>9F.#!6W5,/D W <8@>CCZA60;\[WX<.1D,>T-^O-^;
MXH>7;>>*3>FX-5WGAWV(T9"$UEK[P4GZ<LHY5.A;G60Z1X@"GQ-VBB'RE,T(
MB$7U'Y$<A:,IR%/1 #Z/0R3_L_&(^USL:;_:F8^&X7#:[TS@E@[ZTQ9AJ',2
M@; [A,L(<C (7:^S+3911]K6&0[@'@-%'()$#<)2>SZ/>]Q1.)Z-0.3%[CU]
M$ !&HV&G 5[(!(?8A1Y$?V3[$2I_U,VJ=L3VR5/L027/GC:-JJ+=04J "1.I
M@WOG5.?W%FL('4G<)9R',HEWM=!A8^*JY=;[KQE+F!;V2\O:4+&IA4X5@ RI
M@(_UYI'PFD\MWLI,)"P94U<';44HHHU&@$U#_#/J#,9X>!/\8P!_8!<PU+9!
MJ8OF(,F-IZ01#H$W1HU)31+V\1N-C3D&C%_1<;/.G__5S//[-?/<=XCL&K)P
M-)WT:M+COSKO_?-VWMN' <?TW=MOM?Q7([__/S;R>R%EY(/WQ6V<:35FY,CO
M3*F#]]8P?W*!\=BK.DMYR5'CJ**9BH^A5BW _,@=7.<':O]6X\AOCAOL0GPA
MWM?55]_&12\ @:7S;_^&OI*O\!UT@[,G> 8LA&" 9F<!#FM&=5IGO?3\!.>4
M(6I\!/48\3 XH]3>AFQPM=VSVY=[-9U\N/H$B_J?MW15_T_U+;V<;;\_#G V
M%>&U0T9<T'RZN@A.GM?0Z/UBVS,UX&L_-A4"ESH=C17%M9IX4VG7$.&2<1AU
M,R"->-M8?NXMUKH!L:X-8"KMA]1X;ENU,W_B@HE(N:IO2AG*VH0B1[9-.&A^
M[1$.EL/'T^RG:)NR[J-H>[)HUV0/O5IQ4[0]UN"G:%],BZ>BAH\(Q1I3?9RO
MXC%^B6[0_.M1)[<?'7\N0/&MM?UYG/W_D5/"CL* H%4C_V9C;;AN#<]>OM>A
MN]@,U*=3JPNO*B[\M4H,9,[V0*:M8(=>TNKS/SN51L[\2B,M;^R%?2N<'NMP
M.0RAH[T5;2\V.BIJ]+SNJ&C'&-=5T3:KYZIH>^B@JZ+M1=]7T4Q OM)1U>B!
M./ZX?)-_Z]E4K/W[=[+/J>%9]KO[S+M'W<H#)O6: ,J6V+I)Q3.JUY!NGUVT
MX3X>Z8FH@*+5FEJQDK=+YLTVZIKT$/7Z_;J-X2C3=?6M/FC5M:'ZO6']RT8[
M=_4A-'OW?ZCM"ZW@#5\?9Q2OOC5LVOT )ZB?Y"$+>L-")TWK'[1\/41(-7S?
M[TT;OF]%D/H!-&RQ@FU-=O7'W#@81Z3)VB4[9&=OKM+4;E[?R^-; S(<Z_I>
MIGPDVC3 J_I(@T7]B%'HJATX+$=N29ODEKJ*I]"GLD7G^Z"/IU5Y_@TV*"#R
M]8EJQ,FF.(>RL<_[$8.><4J2.R+/\YAQFS86Z,Y0F$DE@^PCD)O:)>\/1]3T
MME\WCC3@=5C=@0?&$'NH8 BL%G>TDW^#L8\:=[]CI1N(_T.UR4O?_^$L(/&Z
M>+>C%3HR&KZK>2C0J='P72UZHME?\MAM'A+J:S+-[K87]&><_"!D[F;['_\>
M36<UWY5KI)BUDL1%3^VA;<_P&9N%/Z"):QUCQL@5YG&#@D(F[KKE824I#4E0
M'\+V7OG ?0<:Q$.\B!\ =&3Q/2N2./C?H'6S/D8 &GYP-!72H6JD6_7FBV:]
MF4_6N9<7#>SJ*MD  /MLR*MC277C 0FE6$:U#6/V@^U\%:?K$FV+IL3_)?'X
M^KK0"L6];1K,0E>[C?8[!;(FH>QT@5Y(? C<XW@5DRV46ILVWN(JU(.W6!!H
M]<#'MFK=Y >QU%]B==S@HZT.O<=T^X?="E!_0J@Z;4'5/\39072F$Y.(^LF!
M*^1>C_&^@=HFVX^6#78KFRKRH4$N> -8D;GTKH$JY04;I<7W]_X>E/+R+MT@
MHF!2'=J$7V?JM*Q9]9K$KU\0&2]A."J'AJ)UJVE@KRDD-/B!"16-.WPO;<5_
ML[<V9K-AI<4^=)5D?]YA?TR@KHMDQW6PS_/6I7[('^(5@-#"Z[&&$3,T$*QO
M #N\P<'[F^!*BUV^!-DP2[B'Q56+L>&"#<[N36L@L>= A.DW1!)WV9BGLUMQ
MAJ=AKNT+- _;( 0)60C)%4"%PA[_VEV^J^DIK4L^;'YZ\@9;Z55HC5#D#O%(
M&66T>*\V:@^U<(A6YU7-]=[ZA!LK4+OBDB,TD?)MM<TV!Q!4'T/?<X,N.IG7
MOFR(+J@--APU$9YHU*@.1OUF)P+&-M0>QA"'^@C#>?-\+?:%AF/R^@]6XQ..
MT$;?Q@]!-&IV(;U*K@VOJ_U(3*[M3?H1JR@V_7BV0:\C#UL+8S>.Z4"=;!*&
M )?EJM%#6'_#Q"BTOJ.>]$"\Y^:5@-SAH3/I\^"W3QW$K*/Q)(-#7L3ZQMQ@
MBN/!82(S'@]"DGF?#$1_N5\!2'<'7W\>LJE'#.0'3P0:).'ML#K(3.A;Q/0-
MZ-PR?OB*J9S%5P>9RE1#K809S1HG,V%$@0D78J6I=E2/>'//N@X3K*/B9EHY
MD2L7S_$X.82@.9"@X0[YVZY=@K81G!V'P;$'>-1@+H(>7(Z/W4$$#.9@P$+K
MYBN#\>UH!J0R;E-W-1HT8EMM??-QZ_JF!X2!REB#WK1]KY5GA[TH.O99Y/ZM
MSYH+W=>- \"/V/BX%QT>=/8X8,*8\V,W->X-V@$_D?GG!TA'9<Q);W!X3U,=
MLYGTU88<'A[R2/R8]::#@V,=HI8MU.OI#G"RFD5MXA3:%33#OEF<FC5+3"2E
M83&UIC>)1 ZBYC=ISL&HY4><4^UV=:FQ,))A\YO]<?./+/I(>>\+CI]EVU$H
MW)A[^] 3]3/AL#%^/933-D%>-:S0JA:BG?)3XB9Q%7NT1%/[::3C8C_VO,%H
MJ'X@.Z!66@\#3XC[?E.3VMTT/T--C#2F;4Q-E^#(Y(-$"ZV<E]*Z,GB%2N1K
M[04!.K]V;&CL-6F;E4C!(]2D,PVH,\,T6@#/G5JGE::5B@^*+%0 [=R4SFQ$
MC08 !V<%E:VC-5X_> >A2S_C-AP7MKI<=70\(>T! CKI?_Q[-.G_Q'3$Y$YI
M^0EN,4)J=YXEW>U=6BQ-6P_MW0@_T,'$69;BCIPH<W\<+8*G97YE(%[!6@Q9
MICN)[9,\&#F/U.!.)BI[X&C6H=/BTHA-U_,[P%ONCFA;I34CRS<<Q%J1.+_#
M.NB?X!<YH>;M#IMU_6$;1_K>X&FR,!XQ9?GT.0^H5\>NIO&Y(^'4L&3?3. L
MV$4A6_6S1KST!MQX)"_?3_*^^G#1 9.LT"A?'0&IY/?$)3VT<H_3YEOB4<-\
MCT>E!DDL)"=W :\PX;K:K.J^LZ@+W+$[[$UK7A/0TM+M5L]::RC]I@PT:/=C
M4[B1CRV^%:?=V/,-")2#+4*F0E$0G^P4J'&$X^W6WV&'(EZ[-=<YE))J/CV&
M*AUU[?]^*SY>'E;QQTK#P<?[O/H^MDUOU?H!)-VSU2KGO@&\IB><(F_X(X5Y
M@CB8/043_#%@(^VA^:-'L]3*X-39ME4[-O7:Q/=BZNY?4%][[,?R2=);N9P@
M106W WF=I=>[4J7=#)UU>&GH)7K].UX;:R029#G;;>_R A6$O\ELIJ0Z:B&$
MZC5PZS7QX-)Z.'N?#OXW.)1(<GB  XDA>Q42#(DJ63AH4T,P3?"*XDB"%T'S
M8%H/3GLYQ&YW=QN"2QD#&8GVF,<39_'J07HU4%UD;3VP20HT0R1+[81GZL+;
M)J[<#0&4DKB$RX5YV;]BC=1<NP>(D@%+S#%7"GN?47$TIZ:JU/<K/5ZL[2$R
M3T6A9I:]X(]WZ4KJ_;=V/L!. N?OGYW2RIP^O[%7F$TRH1,GA#0,RI2*$</P
M, *]OU@E7$V0JL'F)=8Y=:S*MD%#< =25J@ P;.H-&V\3F]VQ2+6TK)2'#*1
MKN;4<\#T&'':,>RD-\8Y]ABI%.FO',;V*7C"(<14%-"!I&"""Q'G5P8<5H5.
MEI(8CA+$FIL&UQIGRGI_4_I-"6VYV(6))>/JXQ;A6=]LVPW31SHF^WNH_7!L
MMP+\B_&+?D38P6H3;GW8UM42@8,J-8I[\"\7U@U=A#)]B&P0,K?FHO9[8K_0
M'IHQM0"N7*<;Z2_&#)YKP..$BSJX0^=XCX%*[;B<JKZF6TM<3ZJD;6(-3>Q!
M2HTY\IM''D:\V^9HPEQ034*_]4P[P.74MMBAPY:FJ6[CQ^ D/>6%I&L@4-B*
M!":AU$.]D'A/I>5,'-RDQ=I%,+I/]P56 \U,Q?W-[GJ5+DQ+&MM@E>[5R9G,
M2$5=C=O*>9K.1V+SS01$S;!Q S>=IK!H":D(J9G*ELI;;(/G _01V$XH-<C
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V<U.PD 4AN%;(;T
MA_-3_(FX<N-6O8$&!DJ$MNF,4>_>RL:::#\7Y&-#0TK.>5</S?3V,>ZKO&N;
M5.^Z-'L_[)NT+.J<NYL0TJJ.ARI=M%ULACN;MC]4>?C:;T-7K5ZJ;0PZGR]"
M/YY1W-V.9\X>ULNB?UA+,7NN^FW,RR*\[\-;V[^D.L:<PO$B%\."X2<?7?S/
M^G:SV:WB?;MZ/<0F_U+QO: (OP?I=)#2@VPZR.A!/AWD]*!R.JBD!RVF@Q;T
MH,OIH$MZT-5TT!4]Z'HZZ)H>)',@XYR?A+#F:RV :^%[+0!LX8LM@&SAFRT
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M+GAM;%!+ 0(4 Q0    ( %9A?E S1( ![@   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %9A?E"97)PC$ 8
M )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ 5F%^4-=):\O< @  _@L  !@              ( !]P@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %9A?E!+B:,O;0,
M  <.   8              "  0D,  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " !687Y0R$6\"3X"  "T!P  &               @ &L
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 5F%^4.H>
M)#JY @  +0D  !@              ( !(!(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( %9A?E RM# _ 08  & C   8
M  "  0\5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !6
M87Y0DZ_=)3\"  #9!@  &               @ %&&P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ 5F%^4#ZA64;W!   Y1<  !@
M         ( !NQT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( %9A?E#"?S$,) (  &X&   8              "  >@B  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !687Y0.E.8K+0!  #2 P
M&               @ %")0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ 5F%^4+R<GKJS 0  T@,  !D              ( !+"<  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !687Y08[VZ4;,!
M  #2 P  &0              @ $6*0  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( %9A?E"\%+AJM $  -(#   9              "
M 0 K  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 5F%^
M4*%E-BJT 0  T@,  !D              ( !ZRP  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " !687Y05;SY3K0!  #2 P  &0
M        @ '6+@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( %9A?E!P?Q/;L@$  -(#   9              "  <$P  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 5F%^4*+'.VJS 0  T@,
M !D              ( !JC(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " !687Y0?$Z>7;0!  #2 P  &0              @ &4-
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( %9A?E">\@_
MM $  -(#   9              "  7\V  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ 5F%^4!@_9BVT 0  T@,  !D
M ( !:C@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !6
M87Y0RC+;&K(!  #2 P  &0              @ %5.@  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( %9A?E#5KZNY;P(   P)   9
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M970R-2YX;6Q02P$"% ,4    " !687Y0JXH!%+8!  #2 P  &0
M    @ &<1@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M %9A?E!/@B]WTP$  )P$   9              "  8E(  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ 5F%^4(H>2TRV 0  T@,  !D
M             ( !DTH  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " !687Y032?-8M,!  "<!   &0              @ & 3   >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %9A?E SU3R.Q@$
M #<$   9              "  8I.  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ 5F%^4 @Q:0L5 @  R04  !D              ( !
MAU   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !687Y0
M00"4JA,"  "1!@  &0              @ '34@  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( %9A?E!U"-@^6 (  *@'   9
M      "  1U5  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ 5F%^4!2&0Q0@ @  3P8  !D              ( !K%<  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !687Y0WW7*'54"   N!P
M&0              @ $#6@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( %9A?E!F\@+>; (  #4(   9              "  8]<  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 5F%^4!V8C27M
M 0  \P0  !D              ( !,E\  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " !687Y0H<K'F4 "  "B!@  &0
M@ %680  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %9A
M?E 4JSGU20(  )T'   9              "  <UC  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ 5F%^4#8A4CQ> @  H0<  !D
M         ( !368  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " !687Y05K_$DP\"  #D!0  &0              @ 'B:   >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %9A?E F/H"^Z0$  /T$
M   9              "  2AK  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ 5F%^4&TN/CJ? @  [@D  !D              ( !2&T
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !687Y0R9L%
MBV$#  #B#@  &0              @ $><   >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( %9A?E >$7AR1@(  .('   9
M  "  ;9S  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M5F%^4#\>?[II P  X X  !D              ( !,W8  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " !687Y02>]D:%$$  "#&   &0
M            @ '3>0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( %9A?E!^TC-E\P<  .8N   9              "  5M^  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 5F%^4%UL;++Q 0
M%P4  !D              ( !A88  'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " !687Y0)5OFC'X$  ":%@  &0              @ &M
MB   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %9A?E#$
MZ@?!>6H  *&F 0 4              "  6*-  !X;"]S:&%R9613=')I;F=S
M+GAM;%!+ 0(4 Q0    ( %9A?E!N\6,1= (  &8.   -              "
M 0WX  !X;"]S='EL97,N>&UL4$L! A0#%     @ 5F%^4'O0 (%+!   I"$
M  \              ( !K/H  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M %9A?E 6_TPVV@$  )L>   :              "  23_  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %9A?E!*E27=QP$  (@>   3
M              "  38! 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     [
- #L #Q   "X# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758583520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember', window );">Common Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 27,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">2,211,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember', window );">Common Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">3,381,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">296,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember', window );">Common Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">14,030,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">$ 815,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771110832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,102,449<span></span>
</td>
<td class="nump">$ 11,119,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,206,095<span></span>
</td>
<td class="nump">6,137,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">21,308,544<span></span>
</td>
<td class="nump">17,256,443<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(21,308,544)<span></span>
</td>
<td class="num">(17,256,443)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">151,786<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (21,156,758)<span></span>
</td>
<td class="num">$ (17,253,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="num">$ (1.47)<span></span>
</td>
<td class="num">$ (1.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="nump">14,349,738<span></span>
</td>
<td class="nump">9,476,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640163824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DisclosureOfAccruedCompensationTableTextBlock', window );">Schedule of accrued compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2019 and 2018, accrued compensation consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued bonus expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 897,839</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 694,490</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued payroll expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 19,034</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 217,614</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 916,873</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 912,104</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DisclosureOfAccruedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DisclosureOfAccruedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760829184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive weighted average diluted common shares</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,220,868</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 20,165</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,241,033</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771305504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 08, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyInsuranceRecoveries', window );">Malpractice Loss Contingency, Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="nump">$ 1,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,800<span></span>
</td>
<td class="nump">$ 117,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod', window );">Malpractice Loss Contingency, Claims Incurred in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation', window );">Supplemental Unemployment Benefits, Salary Continuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OperatingLeasesMonthlyRentalPayments', window );">Operating Leases Monthly Rental Payments</a></td>
<td class="nump">$ 19,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OperatingLeasesMonthlyRentalPayments', window );">Operating Leases Monthly Rental Payments</a></td>
<td class="nump">$ 22,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OperatingLeasesMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the monthly rental payments under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OperatingLeasesMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss recognized for asserted and unasserted malpractice claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68049836&amp;loc=d3e5870-115623<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyClaimsIncurredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of insurance recoveries recognized from insurance and similar arrangements for reimbursement and payment of malpractice claims recognized during an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060100&amp;loc=d3e8578-115644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6770879104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of information related to stock options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">2,237,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,183,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember', window );">Exercise Price 1.24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember', window );">Exercise Price 1.95 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">700,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">545,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember', window );">Exercise Price 2.74 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember', window );">Exercise Price 3.11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">681,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember', window );">Exercise Price 4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember', window );">Exercise Price 5.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember', window );">Exercise Price 5.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">6,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember', window );">Exercise Price 5.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">21,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember', window );">Exercise Price 6.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">311,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">224,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember', window );">Exercise Price 6.30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">28,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember', window );">Exercise Price 8.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">166,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">94,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>43
<FILENAME>0001104659-20-040118-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-20-040118-xbrl.zip
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M/57VM.KVU#1JG59[EUQ&?A3-1.*7;?:2_'4)I>=H!VE-@M9_A#Q@_;'\*OH
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MB+L38]<CI,7QAKO38I^GSLM%"F.O.<!N22'8C+:><G$L=]'8:Y*<V0'J9O?
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M&"1TU 5@L1</<N>_(1T&/4_P1C*G*S4O6E:0C8:<Z2!B;7KY^Z9\OZ[= "]
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M*H6 ZTX/3E :Q>@ -MJ[>=RTY(>?WX7\_)F0T<4GVJ<0^-M7'@_X%1DQ2!,
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MI"6GEY443E&/)P:W*SM\5-"/%H[O9?.6!OQN>R%V*-G40A>.YE4[Y9UKRG(
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M$;Q/Z=)G(C[ .S8%TM10TIS0CHT:MP;4#AV@( P+@X'NH-E.DMQAY EL1\"
M^4C0/ZB0]T@W9K6B)F;%MP!I5Q@]'J" /[,51FPYJ@0#S/FC"\AP\"8P'>,
M-2@4=5$'P?),8YBK]T//CX1HC(.YJ&W3WS^]CV9PG)KF^3 3:&!D%6NK90TU
M-B%ORU'I@RY)L:,^V)BA !K(*1@GV2:,Y#);)@B'S1=K8)!<\DS%'=@GT 3@
M2T25$,;S W FP1@\!.,"N "'YB-@"AJNB"L2SHFU1YNT##6<$_1/V%&? LC
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M\F&/1YXLK\XQCI*&IIOJ"DE [8VXREU>TKQ7(X2JD+XJQ&ZZ!"C$5HB]LGQ
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M%ZH(:7/%I$II3A,^=X+DT2.'E+56^UY;ER'M#/1N1Y4AK;73=^P,Z465M,9
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MU7;(%R_/[+0I>5Y.LH<"?7)77Z.[P'/M^4Y0_#/O%9EVA]RR"Z9A+K3!;/_
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M;)NM=E\Q<V]FYEES*#<,HS4P%3=*P@VE&V7BAM*-,W&#O0ZK[2,\6O;?3V$
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M9"4Q?38GBXIQ6N/S*7$=6@2)RX/KIXA\W39;TL &:]+.V@'3,OJT.HJ#M9E
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M/#O$BWX"]-E3H:+88&^05A6CC]M. A/.C0GG3I\*3!")50$17$/$N5.N'9*
MWB=C!5R+-&VOMD_.)Q ?@W!.7%$QVG,V=RWENEN[%Y%9;<NLCF5S-.IC7I4[
M_>YB]O1DFM8WQ>I:DO2XC!Z:(RT9RE@7F"H4G)^,IU!PKB)EH>_=Y7@GTI<=
M]]RZF*44$,L5Q/8B&=FAC87SB4JYX>A[XI#J!9.Z*A<O1!/2X8I)E]*<&GP^
M"Y);CSRGK;78]]JZ#:D^E@U=M"'MM=-WZ SI696TQT#=@4:D I]/B<^Z8HI6
MI ,%@RXE6@^*"NMHLQ/7* U324J?KZ^#BPN8TF-H+]]>L/]?9/2=N0\9O>9>
M8,>OD0CYIZ_@8_Q[HJA""?OB'QTT#RG\H\[X1R)^[; \2+ILFE-YJIK#2Y#V
M Q9.Z?.<.U?)'<>ZN-<D*,ZU4SD\BI_[Z/;P*'[NH]+#H[A E1Y<]2PH+F2<
M*XJ?^^SJX"@N_/$#4KP72021==R^,Y^-.3U1927$1%19B2SU3EEJ558GNFSI
M8[&5WU%C+ZJL>J2/HLI*X'.MRDKOXZ%5 0:BRDJ@PMZH ) N0*'G_IJH^NJ
M)HJJ+X',]5-+FB9;D]VNIJLE;-E+3.KE/T[K>K-/U]"Z1CUP^4O4_E<2Q>[\
MB;V5OH#5QR $[HP$=Z&]O#\ J3?0N<VKR=>][,DZ?[LGTCSPO. 1C\!2;DK+
MD$3$CR/)]>=!N+!C-_"ED'AV3&92',!P@?.G%"SQ_4BR(RF8KT_K2IC-?=UO
M NXD**6R^!1&<6%Y73PCOT,\+T6PMQ>C"_HZ6MI.]CJ%98?@>G-83L$2E-^S
MEQ%YG?WQACU(F@# 9<_:>[M%5Y6)<4[G*Y,'6$MQ0F$?$_\<$*].(G@@X1ST
MY_6].YL1OR1.SZCG/$EP92CJ63=%.L[, V\M6XHAN,$+-X1N\,0-35,L879X
MX8;0#9ZX(>S&B;BQ9;D2^-W@K .W](MVQIF:8IZW%^N:!(J=Q,&!VEZS^.0X
MN9/)D5(G]'N/;'JW@3=KS*7D$_B<1L&E1E(]]-2/("G<9KRW5F!#/W<S9:'
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MKEN3;5T_7DAQ%*%0)SOX[2>DQ![^O*[!2E3^EF)^4XU\+?F+C: U48\/X/_
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MO<CH>CDR+R3:..[MA5J?Y6X$L!H(8/%  .OX!!CIZPDPTCD@0#:)=010#T4
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M$,?#4IK;;,Q&$+Y^(>0>4_>:G>,E5=B[X@+,=F-/3QA]W(Y'-YM!>#T\F]V
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MME0(VK]PM4S;N^>@Z$NOT-DLFO7#2RNP!.W+SUX457&)*_0SBUXC[Z0"-]"
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MB>%QB, .QYT8A'.+11AJ4 Y%RU\WO?@Y+E".=X0[MNET6;9+2C?$J,0DL(N
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M<O<AD**G>CTL+2*C;Q OROV?=7WH M4<(,%"Y1@E)J"*J@#-*PNWQ62M)*+
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M*K]%-4%TI C>&FPRX8]6BJZ)'BFE!6S<WE@=Z4L,$KDFN-$W]R&;QL3G&2J
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M#S16>LZ2]<V6UB+@+6Q4A[S6J #W*(YBU3<IEG@P=RE.S"EN4^)"[J47B5)
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M:^90O-LG**#%;U)1(R&J89E+QK7ZT90'.*[*M1SRA931WH80 "@;,$C$NH2
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MK!(2KM>UANEV9^L6&$@?:R4/RF;."U3#CEABYBAPQRN*D%W:1_)Y^']H)+;
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MP@*F N@8[^0"M %AD@'47#AFC@!F(VTVQ*OFA=P@4)<PHP0%RCTRL-U(.5+
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MXIIVK![$^W0]BW-RG$#^([T!%HCR-*#_S2=NGN=3?![NRR@O3W<F3L=5_TP
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MZ[1;;+@Z[CU%1P7!A_'=?>P?_3>#1/<*3CUV"9(Z(%WAQ_(C+I<;JP9!%HA
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M=E$*J"9!2RUIM[N -C.YG)DD9WOW.TN*;OJ?^]OG*-]&*[POXQ6M VS*RS6
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MQ\3NJ98!$)GY 4@D\O+K?[TOW<$K0 'TO=\^#;\<?!H S_8=Z"U^^Q0%GZW
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M'K(K6FH#@88RK'R!Y"+2$%-#+HR*Z<.PU<P\N7-1:(@!<I.^[M:"SI5W9KW
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M'::UHZ)E_P$A2IS*%=]%=L@T\Z?GW/B>G?P'1?RU_<P!0S-2&;927<MD_@S
M/'*OX9QFF^#H:8[8FQ(KJ3:FNWTB#'=DJN3)"BQFDQR7W3T%T@*KM#SN(B_P
M<"@<H$Y1]FZM%9:E&^=,N@,V@*\5=D9&2VW6;C,>;NEU C1V')JIJ&IZRKDK
MHL58GDW?U(O-C$&!$(&=Q$7*6=7)])DUQ"KO<%P=C9%V2Y([KH@NO 6PP7"+
M=9HU00S9%]H5Z3[$=)_T7]3U%'9<JURR9,]\#T\*X&V*8VF7&QLI8TXR)14,
M[W(+CR\2J3/$ZAR\^ '<UA_K.Q@I8P%2)17^;B-G23$8&Q;1 BTV+8R1.B]M
MDLIMT_;M1G':W=XHSY@6-XZ>QF&D*<VRJF[[H>7N,OL#I5!*U<]B)IA)E0F&
M7CV%]E?5UIA=U%69#"<'XEG5-?$04[CFVW&;\>A*)U,[IS%YD#ZM"[CEZ*D=
M-#A$*F"'KR%4JW!;>O&?NEA;CI[:R;FIR 2$7T.]GNY3XD&V&;GLT-IBJ_[
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M,C,Q+GAS9%!+ 0(4 Q0    ( %9A?E#AV^'S  T  *RO   5
M  "  =$* 0!E>65N+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4    " !687Y0
MCY;KNB(?  !;)@( %0              @ $$& $ 97EE;BTR,#$Y,3(S,5]D
M968N>&UL4$L! A0#%     @ 5F%^4._:EQ-$6   #2D% !4
M ( !63<! &5Y96XM,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( %9A?E#)
MMV^KXCX  #64!  5              "  ="/ 0!E>65N+3(P,3DQ,C,Q7W!R
;92YX;6Q02P4&      8 !@"* 0  Y<X!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771178016">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series A-2 Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 24,351,138<span></span>
</td>
<td class="num">$ (19,261,186)<span></span>
</td>
<td class="nump">$ 5,090,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,932,431<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">2,566,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesOne', window );">Issuance of common stock in initial public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">24,547,530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,547,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesOne', window );">Issuance of common stock in initial public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of common stock in follow-on public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of common stock in follow-on public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">2,817,611<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,817,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueExercisesOfWarrants', window );">Exercise of warrants on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants', window );">Exercise of warrants on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,615,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,615,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,253,108)<span></span>
</td>
<td class="num">(17,253,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">56,479<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering', window );">Conversion of convertible preferred stock into common stock upon completion of initial public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (293)<span></span>
</td>
<td class="num">$ (79)<span></span>
</td>
<td class="num">$ (92)<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering', window );">Conversion of convertible preferred stock into common stock upon completion of initial public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,932,431)<span></span>
</td>
<td class="num">(788,827)<span></span>
</td>
<td class="num">(918,983)<span></span>
</td>
<td class="nump">4,702,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">53,388,216<span></span>
</td>
<td class="num">(36,514,294)<span></span>
</td>
<td class="nump">16,875,069<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,468,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree', window );">Issuance of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">12,958,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,958,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree', window );">Issuance of common stock in public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,046,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis', window );">Exercise of stock options on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis', window );">Exercise of stock options on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,511,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,156,758)<span></span>
</td>
<td class="num">(21,156,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 348,501<span></span>
</td>
<td class="nump">551,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">551,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">$ 69,409,949<span></span>
</td>
<td class="num">$ (57,671,052)<span></span>
</td>
<td class="nump">$ 11,740,607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,100,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">[1] Includes gross proceeds of $27,300,000, less total issuance costs of $2,752,197.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">[2] Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $1,071,931.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised on cashless basis during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Conversion Of Convertible Securities upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock exercises of warrant on cashless basis shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one shares on public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents common stock issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one shares on public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Conversion Of Convertible Securities upon initial public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueExercisesOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercises of warrants on cash basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueExercisesOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one value on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents Stock Issued During Period Value New Issues three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock two value on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options on cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueStockOptionsExercisedOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768275344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EYENOVIA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,776,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760855056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization and Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Organization and Nature of Operations</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;1&nbsp;&#x2013; Business Organization and Nature of Operations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Eyenovia,&nbsp;Inc. (&#x201C;Eyenovia&#x201D; or the &#x201C;Company&#x201D;) was organized as a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under the name, PGP Holdings V,&nbsp;Inc. On May&nbsp;5, 2014, PGP Holdings V,&nbsp;Inc. changed its name to Eyenovia,&nbsp;Inc. On October&nbsp;6, 2014, Eyenovia,&nbsp;Inc. reincorporated in the State of Delaware by merging into Eyenovia,&nbsp;Inc., a Delaware corporation.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Eyenovia. Inc. (&#x201C;Eyenovia&#x201D; or the &#x201C;Company&#x201D;) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">TM</font><font style="display:inline;">. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver opthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;). Eyenovia&#x2019;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Its products are classified by the FDA as drugs, and not medical devices or drug-device combination products. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6753583056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for income taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes consists of the following expenses (benefits):</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax provision (benefit):</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,999,920)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,516,722)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State and local</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,762</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (47,238)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,931,158)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,563,960)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,931,158</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,563,960</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes differs from the United States Federal statutory rate as follows: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Years&nbsp;Ended</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State tax rate, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.1</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.3</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.2)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.8)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research &amp; development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.8</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prior period adjustments and other</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.6)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (2.6)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23.3)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (20.7)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred tax assets consist of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,479,512</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,453,854</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 943,370</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 616,207</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (14,030)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,486</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 328,773</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 310,230</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,584,753</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,008,443</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,322,378</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,391,220</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (12,322,378)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (7,391,220)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6637112944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, prepaid expenses and other current assets consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Payroll tax receivable</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 95,233</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid insurance expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 33,923</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 39,465</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 17,978</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,404</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,562</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid conference expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,600</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid rent and security deposit</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,463</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 75,729</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 24,079</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 196,680</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 132,756</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635461984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="nump">$ 244,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">251,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">258,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">198,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum Lease Payments</a></td>
<td class="nump">$ 953,101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767856576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jan. 14, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Apr. 16, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised | Shares</a></td>
<td class="num">(34,815)<span></span>
</td>
<td class="num">(320,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,220,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(668,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237,438<span></span>
</td>
<td class="nump">2,220,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable | Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.51<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,559,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640092000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;11&nbsp;&#x2013; Employee Benefit Plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">401(k) Plan</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &#x201C;Plan&#x201D;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2019, the Company&#x2019;s Board of Directors has approved a matching contribution equal to 100% of elective deferrals up to 4% of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. For the year ended December 31, 2019, the Company recorded expense of $71,285 associated with its matching contributions, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>350</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations</Role>
      <ShortName>Business Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</Role>
      <ShortName>Accrued Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</Role>
      <ShortName>Accrued Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Business Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperationsDetails</Role>
      <ShortName>Business Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationAndNatureOfOperations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment, Net - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails</Role>
      <ShortName>Accrued Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Income Taxes - provision for income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - provision for income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Income Taxes - Effective income tax rate reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective income tax rate reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Income Taxes - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumPaymentsUnderOperatingLeaseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Payments under Operating Lease Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of information related to stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="eyen-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eyen-20191231.xml</File>
    <File>eyen-20191231.xsd</File>
    <File>eyen-20191231_cal.xml</File>
    <File>eyen-20191231_def.xml</File>
    <File>eyen-20191231_lab.xml</File>
    <File>eyen-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760821472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;7&nbsp;&#x2013; Income Taxes</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes consists of the following expenses (benefits):</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Years&nbsp;Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:30.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax provision (benefit):</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,999,920)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,516,722)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State and local</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 68,762</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (47,238)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (4,931,158)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (3,563,960)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4,931,158</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,563,960</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The provision for income taxes differs from the United States Federal statutory rate as follows: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Years&nbsp;Ended</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Federal statutory rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21.0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">State tax rate, net of federal benefit</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.1</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.3</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.2)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.8)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research &amp; development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2.8</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prior period adjustments and other</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (0.6)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (2.6)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (23.3)</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (20.7)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Effective income tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.0</font></p>
				</td>
				<td valign="bottom" style="width:03.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred tax assets consist of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Net operating loss carryforwards</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,479,512</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5,453,854</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 943,370</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 616,207</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (14,030)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,486</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Intangibles</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 328,773</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 310,230</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Research and development tax credits</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,584,753</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,008,443</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,322,378</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,391,220</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (12,322,378)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (7,391,220)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Deferred tax assets, net</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2019, the Company had approximately $45,000,000 of domestic Federal net operating loss carryforwards ("NOLs") that may be available to offset future Federal taxable income.&nbsp;&nbsp;Approximately $10,800,000 of those NOLs will expire during the years ranging from 2034 to 2037.&nbsp;&nbsp;The remaining NOLs of approximately $34,200,000 have no expiration dates.&nbsp;&nbsp;Internal Revenue Code Section 382 limits the utilization of approximately $35,000,000 of those NOLs to approximately $918,000 on an annual basis as a result of ownership changes that occurred through July 15, 2019.&nbsp;&nbsp;As of December 31, 2019, the Company had minimal state net operating loss carryforwards that may be available to offset future state taxable income as it conducted most of its operations in Nevada which does not tax corporate income.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has assessed the likelihood that deferred tax assets will be realized in accordance with the provisions of ASC 740 </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;"> ("ASC 740").&nbsp;&nbsp;ASC 740 requires that such a review considers all available positive and negative evidence, including the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies.&nbsp;&nbsp;ASC 740 requires that a valuation allowance be established when it is &#x201C;more likely than not&#x201D; that all, or a portion of, deferred tax assets will not be realized.&nbsp;&nbsp;After the performance of such reviews as of December 31, 2019 and 2018, management believes that uncertainty exists with respect to future realization of its deferred tax assets and has, therefore, established a full valuation allowance as of those dates. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated financial statements as of December 31, 2019 and 2018.&nbsp;&nbsp;The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">No tax audits were commenced or were in process during the years ended December 31, 2019 and 2018.&nbsp;&nbsp;No tax related interest or penalties were incurred during the years ended December 31, 2019 and 2018.&nbsp;&nbsp;The Company's State of California income tax returns beginning with the year ended December 31, 2015 remain subject to examination.&nbsp;&nbsp;The Company's Federal and New York State and City income tax returns beginning with the year ended December 31, 2016 remain subject to examination.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760916016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;3&nbsp;&#x2013; Prepaid Expenses and Other Current Assets</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, prepaid expenses and other current assets consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Payroll tax receivable</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 95,233</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid insurance expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 33,923</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 39,465</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 17,978</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,404</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,562</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid conference expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 10,600</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Prepaid rent and security deposit</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,463</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 75,729</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 24,079</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 196,680</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 132,756</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6756307216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RePrioritizationOfOverallCostSavings', window );">Overall cost savings due to re-prioritization of programs</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,902,601<span></span>
</td>
<td class="nump">$ 19,478,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrentAndNoncurrent', window );">Deferred Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RePrioritizationOfOverallCostSavings', window );">Overall cost savings due to re-prioritization of programs</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RePrioritizationOfOverallCostSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the re-prioritization of its programs will yield overall cost savings for the particular period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RePrioritizationOfOverallCostSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758932608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 208,175<span></span>
</td>
<td class="nump">$ 375,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">97,396<span></span>
</td>
<td class="nump">111,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_CreditCardPayable', window );">Credit card payable</a></td>
<td class="nump">56,979<span></span>
</td>
<td class="nump">9,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseholdImprovements', window );">Leasehold improvements</a></td>
<td class="nump">42,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedFranchiseTax', window );">Accrued franchise tax</a></td>
<td class="nump">40,995<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedTravelAndEntertainmentExpenses', window );">Accrued travel and entertainment expenses</a></td>
<td class="nump">7,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedLegalExpensesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">168,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 453,430<span></span>
</td>
<td class="nump">$ 677,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedFranchiseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued franchise tax expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedFranchiseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedLegalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued legal expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedLegalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedTravelAndEntertainmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued travel and entertainment expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedTravelAndEntertainmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_CreditCardPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit card expenses payable by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_CreditCardPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents accrued purchases balances of Leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760946720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, accrued expenses and other current liabilities consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 208,175</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 375,204</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued professional services</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,396</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 111,728</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Credit card payable</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,979</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,466</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 42,500</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued franchise tax</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,995</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued travel and entertainment expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,385</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued legal expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 168,650</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,165</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued expenses and other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,430</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 677,213</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6756315392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Liquidity and Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">On October 29, 2019, the Company announced that it is advancing its MicroLine program for the improvement in near vision in patients with presbyopia towards Phase III clinical studies. As a result of prioritizing MicroLine, in tandem with its Mircropine (progressive myopia) and MicroStat (mydriasis) programs, the Company deferred development activities for its MicroProst (glaucoma and ocular hypertension) and MicroTears (red eye and itch relief lubrication) programs. The Company believes the re-prioritization of its programs will yield overall cost savings of approximately $1.5 million to $1.9 million in 2020.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&#x2019;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note 2 - Summary of Significant Accounting Policies&#x2009;&#x2014;&#x2009;Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#x2019;s common stock. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has cash deposits and U.S. treasury bills in a financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of December&nbsp;31, 2019 and 2018, the Company had cash and cash equivalent balances in excess of FDIC insurance limits of $13,902,601 and $19,478,200,&nbsp;respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5&nbsp;years. Leasehold improvements are amortized over the lesser of (a)&nbsp;the useful life of the asset; or (b)&nbsp;the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Impairment of Long-lived Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the&nbsp;years ended December&nbsp;31, 2019 and 2018.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred Offering Costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&#x2019;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. Upon the closing of the offering, the deferred offering costs are offset against the offering proceeds. The Company had $0 in deferred offering costs at December 31, 2019 and 2018.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#x2019; equity.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of financial assets and liabilities based on ASC 820 &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1&nbsp;&#x2014; quoted prices in active markets for identical assets or liabilities;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2&nbsp;&#x2014; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3&nbsp;&#x2014; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of the Company&#x2019;s financial instruments, such as cash and cash equivalents, due from related party, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is subject to Federal, New York State and City, and State of California income taxes and files tax returns in those jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the consolidated financial statements or tax returns.&nbsp;&nbsp;Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#x201C;temporary differences&#x201D;) at enacted tax rates in effect for the years in which such temporary differences are expected to reverse. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">The Company&#x2019;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the consolidated statements of operations.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and the fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Upon the exercise of an option, the Company issues new shares of common stock out of the shares reserved for issuance under its equity plans.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,220,868</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,355</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 20,165</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total potentially dilutive shares</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,297,793</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,241,033</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Issued Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the FASB issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2016&#8209;02, &#x201C;Leases (Topic 842)&#x201D; (&#x201C;ASU 2016&#8209;02&#x201D;). ASU 2016&#8209;02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal&nbsp;years beginning after December&nbsp;15, 2020, and interim periods within fiscal years beginning after December 15, 2021. The FASB issued ASU No. 2019-01 &#x201C;Leases (Topic 842) Codification Improvements&#x201D; in March 2019 and ASU No. 2018-10 &#x201C;Codification Improvements to Topic 842, Leases&#x201D; and ASU No. 2018-11 &#x201C;Leases (Topic 842) Targeted Improvements&#x201D; in July 2018, and ASU No. 2018-20 &#x201C;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201D; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In July 2017, the FASB issued ASU No. 2017-11, &#x201C;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815)- Accounting for Certain Financial Instruments with Down Round Features&#x201D; (&#x201C;ASU 2017-11&#x201D;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2018, the FASB issued ASU No. 2018-13, &#x201C;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201D; (&#x201C;ASU 2018-13&#x201D;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2019, the FASB issued ASU 2019-12, &#x201C;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,&#x201D; which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact financial position, results of operations, and cash flows.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recently Adopted Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2016-15, &#x201C;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments&#x201D; (&#x201C;ASU 2016-15&#x201D;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The new standard requires adoption on a retrospective basis unless it is impracticable to apply, in which case a company would be required to apply the amendments prospectively as of the earliest date practicable. The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2018, the FASB issued ASU No. 2018-07, &#x201C;Compensation &#x2014; Stock Compensation (Topic 718)&#x201D; (&#x201C;ASU 2018-07&#x201D;). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, &#x201C;Equity &#x2014; Equity-Based Payments to Nonemployees.&#x201D; The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company&#x2019;s adoption date of ASU No. 2014-09, (Topic 606), &#x201C;Revenue from Contracts with Customers.&#x201D; The Company adopted this standard on January 1, 2019 and it did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760785792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option pricing model to stock options granted</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:29.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected term (years)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">5.50 - 10.00</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Risk free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">1.42 - 2.53</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2.69 - 3.24</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">134 - 139</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">140 &nbsp;-141</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the stock option activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the option activity during the&nbsp;year ended December&nbsp;31, 2019 is presented below:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Life</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,220,868</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.01</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 692,572</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.10</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (668,502)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1.42</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (7,500)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 4.73</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Outstanding December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.51</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.1
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3,559,915</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Exercisable December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,183,637</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 3.33</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,222,680</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of information related to stock options</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents information related to stock options as of December&nbsp;31, 2019:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="bottom" style="width:52.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:43.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options&nbsp;Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercisable</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Remaining&nbsp;Life</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Number&nbsp;of</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">In&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Options</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>1.24
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 5.2</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 260,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>1.95
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 700,281</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.5</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 545,170</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>2.74
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>3.11
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 681,572</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>4.00
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.9</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 723</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.10
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.7</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,667</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.19
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 16,500</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.7</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6,875</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>5.25
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 26,668</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 6.8</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 21,249</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>6.20
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 311,499</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.6</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 224,438</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>6.30
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 60,000</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.5</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 28,333</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left">$</div>8.72
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 166,918</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 8.3</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 94,182</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 2,237,438</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:22.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7.3</font></p>
				</td>
				<td valign="bottom" style="width:04.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 1,183,637</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771146256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (21,156,758)<span></span>
</td>
<td class="num">$ (17,253,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,343<span></span>
</td>
<td class="nump">19,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,511,944<span></span>
</td>
<td class="nump">1,615,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(63,924)<span></span>
</td>
<td class="num">(95,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,834<span></span>
</td>
<td class="nump">1,263,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,769<span></span>
</td>
<td class="nump">912,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(266,283)<span></span>
</td>
<td class="nump">503,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,767<span></span>
</td>
<td class="nump">41,584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,919,308)<span></span>
</td>
<td class="num">(13,111,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(166,643)<span></span>
</td>
<td class="num">(27,907)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(166,643)<span></span>
</td>
<td class="num">(27,907)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in initial public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,089,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of initial public offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(345,497)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsFromSaleOfCommonStockInIPO2', window );">Proceeds from sale of common stock in follow-on public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,084,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering', window );">Payment of follow-on public offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(266,581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">13,214,949<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentsForRepurchaseOfPublicOffering', window );">Payment of public offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(256,374)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">551,777<span></span>
</td>
<td class="nump">56,482<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,510,352<span></span>
</td>
<td class="nump">27,617,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,575,599)<span></span>
</td>
<td class="nump">14,478,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - Beginning of Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,728,200<span></span>
</td>
<td class="nump">5,249,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents - End of Year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,152,601<span></span>
</td>
<td class="nump">19,728,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedPurchasesOfLeaseholdImprovements', window );">Accrued purchases of leasehold improvements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ExerciseOfWarrantsOnACashlessBasis', window );">Exercise of warrants on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Exercise of stock options on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentOfAccruedIssuanceCosts', window );">Reversal of previously accrued initial public offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(133,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts', window );">Reclassification to additional paid-in capital for initial public offering issuance costs that were previously paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (195,700)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">[1] Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">[2] Includes gross proceeds of $3,381,000, less issuance costs of $296,670 deducted directly from the offering proceeds.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $815,052 deducted directly from the offering proceeds.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedPurchasesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents accrued purchases of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedPurchasesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ExerciseOfWarrantsOnACashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the warrants exercised on a cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ExerciseOfWarrantsOnACashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentOfAccruedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentOfAccruedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentsForRepurchaseOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentsForRepurchaseOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash out flows of follow on IPO issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentsOfFollowOnRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsFromSaleOfCommonStockInIPO2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow of sale of common stock in follow on IPO</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsFromSaleOfCommonStockInIPO2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of reclassified to additional paid in capital for IPO issuance costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ReclassificationToAdditionalPaidInCapitalForIPOIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6756201152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">17,100,726<span></span>
</td>
<td class="nump">11,468,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">17,100,726<span></span>
</td>
<td class="nump">11,468,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6780146416">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2019</div></th>
<th class="th"><div>Jul. 15, 2019</div></th>
<th class="th"><div>May 14, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Jan. 14, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Feb. 13, 2019</div></th>
<th class="th"><div>Dec. 21, 2018</div></th>
<th class="th"><div>Jul. 24, 2018</div></th>
<th class="th"><div>Apr. 16, 2018</div></th>
<th class="th"><div>Jan. 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 06, 2018</div></th>
<th class="th"><div>Jan. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,249,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfCommonStock', window );">Net Proceeds From Issuance Of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,702,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest over three&#160;years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting&#160;monthly over the remaining 24&#160;months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds Of Stock Value Issued During Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,412,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,511,944<span></span>
</td>
<td class="nump">$ 1,615,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,214,949<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,815<span></span>
</td>
<td class="nump">320,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RemittanceOfEmployeeSPayrollTaxes', window );">Remittance of employee's Payroll Taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">551,777<span></span>
</td>
<td class="nump">56,482<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,459,055<span></span>
</td>
<td class="nump">818,239<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,052,889<span></span>
</td>
<td class="nump">$ 797,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">28,965<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Stock Issued During Period Shares New Issues Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,388,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">636,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">636,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,674<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-based Compensation Award, Tranche Three [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,325<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember', window );">Employees Consultants and Directors Under the 2018 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">681,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,999<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,909,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">681,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,999<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member', window );">Omnibus Stock Incentive Plan 2018 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,866,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Stock Issued During Period Shares New Issues Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders' equity on the balance sheet. While the embedded conversion option ("ECO") was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company's common stock as of the commitment date.The Series&#160;B Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series&#160;B Convertible Preferred Stock conversion price would be reduced on a weighted average basis. Each share of Series&#160;B Convertible Preferred Stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&#160;the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B)&#160;the aggregate proceeds of such offering are not less than $20,000,000; or (ii)&#160;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Stock Issued During Period Shares New Issues Two</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember', window );">Series And Series A2 Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series&#160;A and Series&#160;A-2 Convertible Preferred Stock was convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price would be reduced on a weighted average basis. Each share of preferred stock was automatically convertible into shares of common stock at the then effective conversion price: (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A)&#160;the aggregate offering price, net of underwriters' discounts and expenses, was at least $2.00 per share of common stock and (B)&#160;the aggregate proceeds of such offering were not less than $20,000,000; or (ii)&#160;the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">[3] Includes gross proceeds of $14,030,001, less total issuance costs of $815,052 deducted directly from the offering proceeds.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">[2] Includes gross proceeds of $3,381,000, less total issuance costs of $563,251.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_GrossProceedsOfStockValueIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RemittanceOfEmployeeSPayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents company remitted portion of employee's payroll taxes to internal revenue service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RemittanceOfEmployeeSPayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one shares on public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758916336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 9,479,512<span></span>
</td>
<td class="nump">$ 5,453,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">943,370<span></span>
</td>
<td class="nump">616,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment', window );">Property and equipment</a></td>
<td class="num">(14,030)<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">328,773<span></span>
</td>
<td class="nump">310,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">1,584,753<span></span>
</td>
<td class="nump">1,008,443<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">12,322,378<span></span>
</td>
<td class="nump">7,391,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (12,322,378)<span></span>
</td>
<td class="num">(7,391,220)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredTaxAssetsLiabilityPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772071024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>Sep. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,800<span></span>
</td>
<td class="nump">117,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=eyen_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority Interest Ownership Percentage In Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember', window );">Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,144<span></span>
</td>
<td class="nump">47,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,160<span></span>
</td>
<td class="nump">182,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember', window );">Senju Pharmaceutical Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_CostOfServicesEngineeringServices', window );">Cost Of Services Engineering Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,746<span></span>
</td>
<td class="nump">863,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,052<span></span>
</td>
<td class="nump">100,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPermonth', window );">Consulting agreement payment, Per month</a></td>
<td class="nump">$ 9,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPerhour', window );">Consulting agreement payment, Per hour</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,521<span></span>
</td>
<td class="nump">$ 162,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPerhour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents hourly consulting fee expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPerhour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPermonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents monthly consulting fee expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPermonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_CostOfServicesEngineeringServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the cost of services engineering services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_CostOfServicesEngineeringServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base rent per month for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage rate of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eyen_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eyen_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760916016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - provision for income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (4,999,920)<span></span>
</td>
<td class="num">$ (3,516,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">68,762<span></span>
</td>
<td class="num">(47,238)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance', window );">Total</a></td>
<td class="num">(4,931,158)<span></span>
</td>
<td class="num">(3,563,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">4,931,158<span></span>
</td>
<td class="nump">3,563,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) before adjustments for change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760816400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization and Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Mar. 12,  2014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758545888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 312,029<span></span>
</td>
<td class="nump">$ 102,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(81,491)<span></span>
</td>
<td class="num">(66,148)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net, Total</a></td>
<td class="nump">230,538<span></span>
</td>
<td class="nump">36,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">229,529<span></span>
</td>
<td class="nump">62,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760822016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;9&nbsp;&#x2013; Related Party Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Consulting Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A company in which a member of the Company&#x2019;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $213,521 and $162,929 for the years ended December 31, 2019 and 2018, respectively, related to the agreement which was included within general and administrative expenses on the statements of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Lease Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company paid $4,000 per&nbsp;month as of January&nbsp;2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, NY for its Chief Executive Officer (&#x201C;CEO&#x201D;). The Company left the space on August&nbsp;31, 2018. The Company&#x2019;s rent expense for this space amounted to $0 and $32,000 for the&nbsp;years ended December&nbsp;31, 2019 and 2018, respectively, related to the office space, which was included within general and administrative expenses on the statements of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s Vice President of Research and Development and Manufacturing (&#x201C;VP of R&amp;D&#x201D;) owns a company that entered into a lease agreement with the Company on September&nbsp;15, 2016 to lease 953 square feet of space located in Reno, Nevada with respect to its research and development activities. The initial&nbsp;monthly base rent was $3,895 per&nbsp;month over the term of the lease and the security deposit was $3,895. On September&nbsp;15, 2018, the Company amended the lease agreement to extend it until September&nbsp;14, 2020 and increase the&nbsp;monthly base rent and security deposit to $4,012. The Company made $82,500 of leasehold improvements related to this lease which are included on the balance sheet.&nbsp;The Company&#x2019;s rent expense for this space amounted to $48,144 and $47,270 for the&nbsp;years ended December&nbsp;31, 2019 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and Development Activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The VP of R&amp;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2019 and 2018, the Company recognized research and development expense of $851,746 and $863,355, respectively, related to services provided by such vendor. The Company had a liability of $89,052 and $100,667 to the vendor as of December 31, 2019 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognized $186,160 and $182,275 of compensation expense related to the VP of R&amp;D&#x2019;s salary during the years ended December 31, 2019 and 2018, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:underline;">License Agreement</font>
		</p>
		<p style="margin:0pt;text-align:left;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During 2015, the Company entered into a license agreement with Senju Pharmaceuticals Co., Ltd. (&#x201C;Senju&#x201D;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, so no royalties had been earned. Senju is owned by the family of a former member of the Company&#x2019;s Board of Directors and, together, they beneficially own greater than 5% of the Company&#x2019;s common stock.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760821472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;5&nbsp;&#x2013; Accrued Expenses and Other Current Liabilities</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, accrued expenses and other current liabilities consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 208,175</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 375,204</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued professional services</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 97,396</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 111,728</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Credit card payable</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 56,979</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 9,466</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 42,500</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued franchise tax</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,995</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued travel and entertainment expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 7,385</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Accrued legal expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 168,650</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 12,165</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Total accrued expenses and other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 453,430</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 677,213</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779257392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 24, 2020 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 14, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="nump">$ 8.72<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100,726<span></span>
</td>
<td class="nump">11,468,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,287<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember', window );">Employees Consultants and Directors Under the 2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">681,572<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability', window );">Securities Purchased under Agreements to Resell, Liability | $</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from Debt, Net of Issuance Costs | $</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfUnitsSold', window );">Number of Units Sold | $ / shares</a></td>
<td class="nump">$ 2.21425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Directors and Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfUnitsSold', window );">Number of Units Sold | $ / shares</a></td>
<td class="nump">$ 2.42625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfShare', window );">Number of Share | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PurchaseTermOfWarrant', window );">Purchase Term of Warrant</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MaximumNumberOfWarrantsToPurchaseCommonStock', window );">Maximum Number of Warrants To Purchase Common Stock</a></td>
<td class="nump">1,337,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class A Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class A Warrant [Member] | Directors and Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PurchaseTermOfWarrant', window );">Purchase Term of Warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MaximumNumberOfWarrantsToPurchaseCommonStock', window );">Maximum Number of Warrants To Purchase Common Stock</a></td>
<td class="nump">2,006,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class B Warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Class B Warrant [Member] | Directors and Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 2.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Employees Consultants and Directors Under the 2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MaximumNumberOfWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Value represents Maximum  Number of  Warrants To Purchase Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MaximumNumberOfWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents number of units sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PurchaseTermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Period Purchase term of warrant, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PurchaseTermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability associated with funds outstanding loaned in the form of a security resale agreement between the entity and another party for the purchase and resale of identical or substantially the same securities at a date certain for a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesPurchasedUnderAgreementsToResellLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EmployeesConsultantsAndDirectorsUnder2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_DirectorsAndExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyen_DirectorsAndExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760752416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">2,297,793<span></span>
</td>
<td class="nump">2,241,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">60,355<span></span>
</td>
<td class="nump">20,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">2,237,438<span></span>
</td>
<td class="nump">2,220,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758144016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 15,343<span></span>
</td>
<td class="nump">$ 19,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">14,102,449<span></span>
</td>
<td class="nump">11,119,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="nump">7,206,095<span></span>
</td>
<td class="nump">6,137,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">15,343<span></span>
</td>
<td class="nump">19,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">9,762<span></span>
</td>
<td class="nump">17,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expense</a></td>
<td class="nump">$ 5,581<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6753701872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective income tax rate reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent differences</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research &amp; development tax credits</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior period adjustments and other</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.30%)<span></span>
</td>
<td class="num">(20.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768298880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;8&nbsp;&#x2013; Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August&nbsp;8, 2018, the Company entered into a lease agreement to lease approximately 3,800 square feet of office space in New York, NY. The&nbsp;monthly base rent ranges from $19,633 to $22,486 per&nbsp;month over the term of the lease for a total base rent lease commitment of approximately $1,236,000. The lease expires on September&nbsp;30, 2023. The security deposit is approximately $118,000.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments under this operating lease agreement are as follows as:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For the Year Ending</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Minimum&nbsp;Lease&nbsp;Payments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 244,853</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 251,586</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 258,505</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 198,157</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 953,101</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See Note&nbsp;9&nbsp;&#x2013; Related Party Transactions&nbsp;&#x2013; Lease Agreements for details of a lease agreement with a related party.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Employment Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Effective February 15, 2019, the Company entered into at-will executive employment agreements with Tsontcho Ianchulev, its Chief Executive Officer and Chief Medical Officer, John Gandolfo, its Chief Financial Officer, Jennifer Clasby, its Vice President, Clinical Operations, Luke Clauson, its Vice President, Research and Development and Manufacturing ("VP of R&amp;D"), and Michael Rowe, now its Vice President, Commercial.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Each of the employment agreements provides that if the executive's employment is terminated by the Company without "Cause" or the executive suffers an "Involuntarily Termination" (each as defined in the employment agreements), provided that the executive has signed a full release of all claims, the executive will be entitled to receive: (i) severance pay equal to three months of his or her then-current base salary (currently estimated at approximately $419,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of three months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;text-decoration:none;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;text-decoration:none;">Each of the employment agreements also provides that if, within 12 months following any "Corporate Transaction" (as defined in the employment agreements) of the Company, the executive's employment is terminated by the Company without Cause or the executive suffers an Involuntary Termination, provided that the executive has signed a full release of all claims, the executive will be entitled to receive, in lieu of what is described in the above paragraph: (i) severance pay equal to 12 months of his or her then-current base salary (currently estimated at approximately $1,677,000 in the aggregate), and (ii) a reimbursement for health insurance benefits under COBRA for the executive and his or her spouse and dependents for a period of 12 months or until the executive becomes eligible for comparable insurance benefits from another employer, whichever is earlier.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Litigations, Claims and Assessments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company, its Chief Executive Officer and members of its Board of Directors were named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September&nbsp;2, 2014 in connection with the Company&#x2019;s Asset Purchase Agreement with Corinthian Ophthalmic,&nbsp;Inc. (&#x201C;Corinthian&#x201D;). A shareholder of Corinthian alleged a fraudulent transfer and sought to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The court conducted a pretrial conference on January&nbsp;22, 2018 and entered a final pretrial order on January&nbsp;23, 2018. On October&nbsp;29, 2018, the parties entered into a Settlement Agreement pursuant to which the defendants agreed to pay the Corinthian shareholder $600,000 in exchange for the release of all related claims. While the Company is indemnified by Corinthian and Corinthian&#x2019;s applicable insurance policy provides coverage of $10 million, in an effort to avoid the additional legal costs and other resources required with a trial, the Company contributed $150,000 of the settlement amount (the remaining $450,000 was paid by Corinthian&#x2019;s insurance carrier), which was paid on October&nbsp;29, 2018.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636132288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">Note&nbsp;4&nbsp;&#x2013; Property and Equipment, Net</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, property and equipment consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 229,529</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 62,886</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 82,500</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 312,029</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 102,886</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (81,491)</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (66,148)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 230,538</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 36,738</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depreciation and amortization expense was $15,343 and $19,129 for the&nbsp;years ended December&nbsp;31, 2019 and 2018, respectively, of which $9,762 and $17,966 was included within research and development expenses and $5,581 and $1,163&nbsp;was included in general and administrative expenses in the statements of operations for the&nbsp;years ended December&nbsp;31, 2019 and 2018, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636132288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum operating lease payments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Future minimum payments under this operating lease agreement are as follows as:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">For the Year Ending</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:23.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Minimum&nbsp;Lease&nbsp;Payments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 244,853</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 251,586</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 258,505</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 198,157</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:21.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 953,101</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640592880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019 and 2018, property and equipment consisted of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:24.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Equipment</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 229,529</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 62,886</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 82,500</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 40,000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 312,029</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 102,886</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Less: accumulated depreciation and amortization</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (81,491)</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> (66,148)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 230,538</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:10pt;"> 36,738</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760916016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Note&nbsp;12&nbsp;&#x2013; Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;"> Stock Options</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On January 31, 2020, the Company granted ten-year stock options to purchase 25,000 shares of common stock to its employees under the 2018 </font><font style="display:inline;color:#000000;font-size:10pt;">Plan as amended.</font><font style="display:inline;font-size:10pt;"> &nbsp;The shares vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months. The stock options have an exercise price of $4.68 per share, which represents the Company&#x2019;s closing stock price on the date of grant.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Securities Purchase Agreement</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consisting of (i) one share of the Company&#x2019;s</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font><font style="display:inline;font-size:10pt;">common stock (ii) a one-year warrant to purchase 0.5 of a share of common stock (&#x201C;Class A Warrant&#x201D;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&#x201C;Class B Warrant&#x201D;) (collectively, Class A Warrants and Class B Warrants, the &#x201C;Warrants&#x201D;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.3 million of net proceeds in the offering after deducting placement agent fees and offering expenses. In the offering the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share.&nbsp;&nbsp;The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share.</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In connection with the offering, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company must file with the&nbsp;SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common Stock issued in the offering and the shares of common Stock underlying the Warrants. </font>
		</p>
		<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6756300672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember', window );">Common Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,752,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember', window );">Common Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember', window );">Common Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 14,030,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 1,071,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_CommonStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768206256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,152,601<span></span>
</td>
<td class="nump">$ 19,728,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">196,680<span></span>
</td>
<td class="nump">132,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">14,349,281<span></span>
</td>
<td class="nump">19,860,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">230,538<span></span>
</td>
<td class="nump">36,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">117,800<span></span>
</td>
<td class="nump">117,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">14,697,619<span></span>
</td>
<td class="nump">20,015,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,541,358<span></span>
</td>
<td class="nump">1,509,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">916,873<span></span>
</td>
<td class="nump">912,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">453,430<span></span>
</td>
<td class="nump">677,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,911,661<span></span>
</td>
<td class="nump">3,098,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">45,351<span></span>
</td>
<td class="nump">41,584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">2,957,012<span></span>
</td>
<td class="nump">3,140,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2019 and 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 90,000,000 shares authorized; 17,100,726 and 11,468,996 shares issued and outstanding as of December 31, 2019 and 2018, respectively</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">69,409,949<span></span>
</td>
<td class="nump">53,388,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(57,671,052)<span></span>
</td>
<td class="num">(36,514,294)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">11,740,607<span></span>
</td>
<td class="nump">16,875,069<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 14,697,619<span></span>
</td>
<td class="nump">$ 20,015,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641263312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode', window );">Net Operating Loss Limit for Utilization as per Internal Revenue Code</a></td>
<td class="nump">35,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode', window );">Net Operating Loss Annual Utilization Limit as per Internal Revenue Code</a></td>
<td class="nump">$ 918,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OperatingLossCarryForwardsExpirationTerm', window );">Operating Loss Carry forwards Expiration Term</a></td>
<td class="text">2034 to 2037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</a></td>
<td class="nump">$ 34,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents Annual utilization limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents amount of net operating loss limit of usage determined by the Internal revenue code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OperatingLossCarryForwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiry term of carryforward operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OperatingLossCarryForwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6770507680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.42%<span></span>
</td>
<td class="nump">2.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">134.00%<span></span>
</td>
<td class="nump">140.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">139.00%<span></span>
</td>
<td class="nump">141.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758808688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
